

Scientific Programme

Sunday, 12. July 2020

Plenary Session
07:30 - 08:30

Virtual Meeting Room 1

PL 01, Plenary Session

Chair: Flora Peyvandi (Italy)
Chair: Marco Cattaneo (Italy)

ISTH 2020 Virtual Congress Welcome and Introduction	07:30
Speaker: Flora Peyvandi (Italy)	
Speaker: Marco Cattaneo (Italy)	
Advances in Gene Therapy and Ethical Aspects	08:00
Speaker: Luigi Naldini (Italy)	

SSC Session
08:00 - 09:30

Main Foyer

Test session

Test Presentation	08:00
--------------------------	--------------

Virtual Exhibition
08:00 - 14:00

Virtual Meeting Room 7

Virtual Exhibition

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 1

SOA 01, State-of-the-Art on Hemophilia and Rare Bleeding Disorders

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: David Lillicrap (Canada)

Progress and Obstacles to Hemophilia Gene Therapy	08:45
Speaker: Amit Nathwani (United Kingdom)	
Q&A	09:05
Immunogenicity of Adeno-Associated Vectors	09:10
Speaker: Federico Mingozzi (United States)	
Q&A	09:30
Immune Responses to Factor VIII in Hemophilia	09:35
Speaker: Sebastien Lacroix-Desmazes (France)	

Scientific Programme

Q&A

09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 2

SOA 02, State-of-the-Art on Thrombotic Microangiopathies

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Marina Noris (Italy)

Differential Diagnosis of Thrombotic Microangiopathies

08:45

Speaker: Giuseppe Remuzzi (Italy)

Q&A

09:05

First Guideline of ISTH on Diagnosis and Treatment of Thrombotic Thrombocytopenic Purpura

09:10

Speaker: X. Long Zheng (United States)

Q&A

09:30

Drug-Associated Thrombotic Microangiopathies: Emerging Toxicities of Novel Drugs

09:35

Speaker: Marcel M. Levi (United Kingdom)

Q&A

09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 3

SOA 03, State-of-the-Art on Fibrinolysis and Proteolysis

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: José A. Páramo (Spain)

Visualizing Thrombosis to Improve Thrombolysis

08:45

Speaker: John W. Weisel (United States)

Q&A

09:05

PAI-1 and the Multi-Morbidity of Aging

09:10

Speaker: Douglas E. Vaughan (United States)

Q&A

09:30

Fibrinolysis and Bleeding of Unknown Cause

09:35

Speaker: Ingrid Pabinger (Austria)

Q&A

09:55

Scientific Programme

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 4

SOA 04, State-of-the-Art on Role of Hemostatic System in Cancer, Inflammation and Immunity

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Suzanne Cannegieter (the Netherlands)

The Role of Platelets in Sepsis	08:45
Speaker: Oonagh Shannon (Sweden)	
Q&A	09:05
Fibrinolytic Factors in Cancer Progression	09:10
Speaker: Marie Ranson (Australia)	
Q&A	09:30
Inflammatory Roles of Platelets	09:35
Speaker: John W. Semple (Sweden)	
Q&A	09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 5

SOA 05, State-of-the-Art on Arterial Thromboembolism

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Francesco Violi (Italy)

120 Years of Aspirin: Retiring, Recombining, or Repurposing?	08:45
Speaker: Carlo Patrono (Italy)	
Q&A	09:05
Triple or Double Therapy for Patients with Atrial Fibrillation and Acute Coronary Syndrome/Percutaneous Coronary Intervention? With What Drugs?	09:30
Speaker: Renato D. Lopes (United States)	
Q&A	09:50

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 6

SOA 06, State-of-the-Art on Platelets and Megakaryocytes

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Alessandra Balduini (Italy)

Scientific Programme

Inherited Thrombocytopenias as a Model to Study the Mechanisms of Platelet Formation	08:45
Speaker: Hana Raslova (France)	
Q&A	09:05
Small GTPases in Megakaryocyte and Platelet Biology	09:10
Speaker: Wolfgang Bergmeier (United States)	
Q&A	09:30
Gp1bα- Drive Force for Liver Thrombopoietin Generation	09:35
Speaker: Heyu Ni (Canada)	
Q&A	09:55

SSC Session
10:00 - 12:00

Main Foyer

Test SSC

test pres	10:00
------------------	--------------

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 1

OC 01, Arterial Thromboembolism Oral Communication Session

Chair: Filippo Crea (Italy)

von Willebrand Factor as a Predictor of Mortality and its Target Concentration Dependent Inhibition by BT200 Aptamer in Patients Treated with Potent ADP Receptor Blockers	10:15
Speaker: Katarina D. Kovacevic (Austria)	
Low-grade Endotoxaemia Enhances Artery Thrombus Growth via Toll-like Receptor 4: Implication for Myocardial Infarction	10:27
Speaker: Cristina Nocella (Italy)	
Unraveling the Protective Effects of Factor Xa Inhibition by Rivaroxaban on Atherosclerosis by RNA Sequencing	10:39
Speaker: Jens JN Posma (the Netherlands)	
Reduction of Intracellular Sodium Protects from Inflammation and Atherosclerotic Plaque Progression	10:51
Speaker: Philipp Hohensinner (Austria)	
Impact of Platelet-Selective TGF-β1-Deficiency in Atherogenesis and CD4+ T Effector Responses Using a No-Germline Genetic Engineering Atherosclerosis Mouse Model	11:03
Speaker: Shuai Tan (Sweden)	
Q&A	11:15

Scientific Programme

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 2

OC 02, Fibrinolysis and Proteolysis Oral Communication Session

Chair: Ton Lisman (the Netherlands)

Fibrin γ-chain Crosslinking Plays an Important Role in Preventing Thrombus Breakdown and Embolisation in-vivo	10:15
Speaker: Cédric Duval (United Kingdom)	
Chemical Modulation of Fibrinogen Production and its Impact on Venous Thrombosis	10:27
Speaker: Rui Vilar (Switzerland)	
FXIII Catalyses Histone-Fibrin Crosslinking to Inhibit Fibrinolysis	10:39
Speaker: Matthew Locke (United Kingdom)	
Fibrinogen Is Citrullinated in Venous Thrombi and Forms Fragile Clots with Increased Resistance to Lysis	10:51
Speaker: Imre Varju (Hungary)	
Low $\alpha 2$-plasmin Inhibitor Antigen Levels on Admission Predict Unfavorable Outcomes in Acute Ischemic Stroke Patients Treated with Intravenous Thrombolysis	11:03
Speaker: Zsuzsa Bagoly (Hungary)	
Q&A	11:15

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 3

OC 03, Hemophilia and Rare Bleeding Disorders Oral Communication Session 1

Chair: Sebastien Lacroix-Desmazes (France)

Immune Profiling of Previously Untreated Patients with Severe Haemophilia A by High-throughput Mimotope Variation Analysis	10:15
Speaker: Guido Baselli (Italy)	
Final Results of PUPs A-LONG Study: Evaluating Safety and Efficacy of rFVIII Fc in Previously Untreated Patients with Haemophilia A	10:27
Speaker: Christoph Königs (Germany)	
Deciphering the Ets-1/2-mediated Transcriptional Regulation of F8 Gene Identifies a Minimal F8 Promoter for Hemophilia A Gene Therapy	10:39
Speaker: Ester Borroni (Italy)	
First In Human Liver Biopsy Study Following Gene Therapy for Hemophilia A	10:51
Speaker: Sylvia Fong (United States)	
Phase I/II Trial of SPK-8011: Stable and Durable FVIII Expression for >2 Years with Significant ABR Improvements in Initial Dose Cohorts Following AAV-Mediated FVIII Gene Transfer for Hemophilia A	11:03
Speaker: Lindsey A George (United States)	
Q&A	11:15

Scientific Programme

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 4

OC 04, Platelets and Megakaryocytes Oral Communication Session

Chair: Mauro Torti (Italy)

Moderate Platelet Defects but Efficiently Restored Thrombopoietin Production Early after Partial Hepatectomy via JAK2-STAT3 Signaling in Mice	10:15
Speaker: Friedrich Reusswig (Germany)	
GPR56 is a Platelet Collagen-Responsive GPCR and Hemostatic Sensor of Shear Force	10:27
Speaker: Gregory Tall (United States)	
CD84 Links T Cell and Platelet Activity in Cerebral Thrombo-inflammation in Acute Stroke	10:39
Speaker: David Stegner (Germany)	
Hemostasis vs. Homeostasis: Platelets Are Essential for Preserving Vascular Barrier Function in the Absence of Injury	10:51
Speaker: Shuchi Gupta (United States)	
BIN2 Orchestrates Platelet Calcium Signaling in Thrombosis and Thrombo-inflammation	11:03
Speaker: Sarah Beck (Germany)	
Q&A	11:15

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 1

OC 05, Coagulation and Natural Anticoagulants Oral Communication Session

Chair: Alberto Tosetto (Italy)

The Fibronectin Type II Domain of Factor XII Prevents Inappropriate Zymogen Activation	11:45
Speaker: Chantal C. Clark (the Netherlands)	
A Novel Contact Pathway Inhibitor Improves Hemostasis and Maintains Circuit Patency in a Piglet Model of Pediatric ECMO	11:57
Speaker: Christopher Reed (United States)	
Neutrophil Extracellular Traps and Inflammasomes Form an Inflammatory Circuit Promoting Venous Thrombosis	12:09
Speaker: Joana Campos (United Kingdom)	
Exogenous Microparticles Bearing Tissue Factor Improve Outcome After Collagenase-Induced Intracranial Hemorrhage	12:21
Speaker: Fanny Potzheha (France)	
Complement Regulator Factor H is a Cofactor for Thrombin in both Pro- and Anticoagulant Roles	12:33
Speaker: Genevieve McCluskey (United Kingdom)	
Q&A	12:45

Scientific Programme

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 2

OC 06, Role of Hemostatic System in Cancer, Inflammation and Immunity Oral Communication Session

Chair: Pierre Mangin (France)

OvCa-Chip: A New Organ-on-a-Chip Experimental Model to Dissect Platelet & Vascular (dys)Function in Ovarian Cancer	11:45
Speaker: Abhishek Jain (United States)	
Preclinical in Vivo Characterization of a First-In-Class, Fully Humanized Antibody Targeting Alternatively Spliced Tissue Factor	11:57
Speaker: Clayton Lewis (United States)	
Clotting Promotes Glioblastoma Progression	
Activated Protein C Reverses the p21-Mediated Hyperglycemic Memory in Diabetic Nephropathy	12:09
Speaker: Ahmed Elwakiel (Germany)	
Platelets Expressing FcγRIIA/CD32A Determine the Severity of Immunological Transfusion-Related Acute Lung Injury in Mice	12:21
Speaker: Beatrice Hechler (France)	
Q&A	12:33

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 3

OC 07, Thrombotic Microangiopathies Oral Communication Session

Chair: Ilaria Mancini (Italy)

How to Open ADAMTS13: An Integrative Approach to Build ADAMTS13 in Closed Conformation	11:45
Speaker: Bogac Ercig (the Netherlands)	
ADAMTS13 Conformation Is Closed in Acquired Thrombotic Thrombocytopenic Purpura in the Absence of Anti-ADAMTS13 Autoantibodies	11:57
Speaker: Elieen Roose (Belgium)	
Severity of Acute Events in Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) with or without Regular Plasma Prophylaxis: Results from the International Hereditary TTP Registry	12:09
Speaker: Erika Tarasco (Switzerland)	
Longitudinal Assessment of ADAMTS13-activity Helps Predict Recurrence of Immune Thrombotic Thrombocytopenic Purpura (iTTP): Results from the German TTP-registry	12:21
Speaker: Charis von Auer-Wegener (Germany)	
The Relative Impact of Treatment Approaches on the Outcome of Catastrophic Antiphospholipid Syndrome (CAPS): Analysis of an Updated Database	12:33
Speaker: Philip A Haddad (United States)	

Scientific Programme

Q&A

12:45

Plenary Session
13:15 - 13:45

Virtual Meeting Room 1

PL 02, Plenary Session

Chair: Raimondo De Cristofaro (Italy)
Chair: Armando Tripodi (Italy)

VWF in Hemostasis: From Basic Science to Clinic
Speaker: Peter J. Lenting (France)

13:15

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Arterial Thromboembolism Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acute Coronary Syndromes

Clopidogrel Resistance and P2y12 Receptor Gene Polymorphisms in Patients with Non-ST Elevated Acute Coronary Syndrome

Speaker: Dina Shorikova (Ukraine)

Improved Antithrombotic Activity and Diminished Bleeding Side Effect of a PEGylated α IIb β 3 Antagonist, Disintegrin

Speaker: Tur-Fu Huang (Taiwan, Republic of China)

Correlation of D-Dimer Levels with Troponin I in Patients with Acute Myocardial Infarction

Speaker: Muhammad Ismail (Pakistan)

How Much Evidence Is Needed to Conclude against the Use of Oxygen Therapy in Acute Myocardial Infarction?

Speaker: Ambrish Singh (India)

White Clot is More Permeable and Stronger than the Red Clot

Speaker: Dongjune Kim (United States)

Thrombophilia and Myocardial Infarction with Non-Obstructive Coronary Arteries

Speaker: Tatyana Kondrateva (Russian Federation)

Contribution of Fibrin and von Willebrand Factor to Platelet Adhesion on Ruptured Atherosclerotic Plaque in Acute Myocardial Infarction

Speaker: Atsushi Yamashita (Japan)

A Case Report of a Patient with Hereditary Angioedema and Samter's Syndrome Treated with Anticoagulant of Direct Action Anti Xa (Rivaroxaban), Secondary to Angioplasty due to Ischemic Heart Disease

Speaker: Fernando Vidal Martinez (Mexico)

Scientific Programme

Differential Effects of Clopidogrel with or without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Placebo-Controlled Trial in Healthy Volunteers

Speaker: Ludwig Traby (Austria)

Hydrodynamic Activation of von Willebrand Factor under Flow Conditions May Contribute to Thrombotic Complications in Coronary Heart Disease

Speaker: Zufar Gabbasov (Russian Federation)

Antiphospholipid Antibodies in Acute Myocardial Infarction

Speaker: Yang Zhang (China)

BDNFVal66Met Polymorphism Affects Cardiac Remodeling and Modulates Macrophage Polarization After Myocardial Infarction

Speaker: Leonardo Sandrini (Italy)

Plasma Exosomes in Patients with ST-Elevation Acute Myocardial Infarction (STEMI) and in Patients with Stable Coronary Artery Disease (CAD)

Speaker: Marta Zarà (Italy)

Interventions Needed in Antithrombotic Therapy in a Real Life Hospitalized Population; Evaluation of Interventions Initiated by a Multidisciplinary Antithrombotic Team Regarding Antithrombotic Agent Combinations in In-Patient Care

Speaker: Marlotte van der Veer (the Netherlands)

Changes of Soluble Fibrin-Monomer Complex Concentration in Different Types of Coronary Artery Disease

Speaker: Yuliya Tyravska (Ukraine)

In-Vivo Biomarkers of Platelet Function in Women with Ischemic Heart Disease: What We Learned from the EVA Study

Speaker: Lucia Stefanini (Italy)

Clot Formation, Ultrastructure and Lysis in Patients with Acute Phase Myocardial Infarction

Speaker: Stephen R Baker (United States)

Myocardial Infarction as a First Symptom of Activated Protein C Resistance Associated to Hyperhomocysteinemia

Speaker: Melek Kechida (Tunisia)

Postoperative Dual Antiplatelet Therapy Is Influenced by Platelet Regeneration

Speaker: Till Hoffmann (Germany)

New Rat Model of Ferric Chloride-induced Acute Coronary Artery Thrombosis for Pharmaceutical Treatment of Myocardial Infarction

Speaker: Charles-Edouard Laurent (Canada)

Smoking Status as Risk Factor and Risk Factors in Young and Elderly Patients Suffered from Myocardial Infarction

Speaker: Nebojsa Antonijevic (Serbia)

Atherosclerosis

High-Dose Atorvastatin - Loaded Microbubbles-Mediated Sonoporation Therapy using B - Mode Ultrasound - Guided Focused Electrohydraulic Shock Waves Decreases Inflammation and Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Scientific Programme

Synthetic Antisense Oligodeoxynucleotides - Loaded Microbubbles - Mediated Transfection Therapy using B-Mode Ultrasound - Guided Focused Shock Waves Decreases Neointimal Hyperplasia Restenosis after Laser Angioplasty of Advanced Atherosclerotic Severe Stenosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of Phosphomimetic Endothelial Nitric Oxide Synthase - Loaded Microbubbles-Mediated Transfection Therapy using B-Mode Ultrasound-Guided Focused - Low Level Confocal Dual-Pulse Electrohydraulic Shock Waves on Early Stage Atherosclerosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Intravenous Lipid-Based Encapsulated Paclitaxel Nanoparticles Administration Enhances 5-Aminolevulinic Acid- Mediated B- Mode Ultrasound- Guided Focused- Electrohydraulic Shock Wave Sonodynamic Therapy of Intermediated Stage Atherosclerosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Immuno-Radio-Metric TSH in TRH Test of Optimal Substitutive Thyroid Hormones

Speaker: Pierre-Jean Guillausseau (France)

Association of MMP-12 and SDF1 with Symptomatic and Asymptomatic Atherosclerosis

Speaker: María Marcos Jubilar (Spain)

Antioxidant Defense Gene Polymorphism in the Nenets Population

Speaker: Nadezda Vorobyeva (Russian Federation)

Diabetes Mellitus and Risk of Intracranial Atherosclerosis: A Meta-Analysis Using Real-World Evidence

Speaker: Salman Hussain (India)

In vitro Occlusive Clot Growth and Retraction

Speaker: Britt Johanna Maria van Rooij (the Netherlands)

Selective Targeting of Shear Gradient Activated Von Willebrand Factor by the Novel Single-Chain Antibody Scfv-A1 Reduces Occlusive Thrombus Formation

Speaker: Akshita Rana (Australia)

Trash Feet: Is Anticoagulation Therapy Useful?

Speaker: Veerendra Chadachan (Singapore)

Impact of Gut Microbiota on Late Atherosclerosis and Atherothrombosis: A Study with Germ-Free Mice

Speaker: Giulia Pontarollo (Germany)

In vitro Investigation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on Endothelial Cells

Speaker: Helene Haguet (Belgium)

In vitro Evaluation of the Impact of BCR-ABL Tyrosine Kinase Inhibitors on Atherosclerosis Plaque Rupture

Speaker: Helene Haguet (Belgium)

Evaluation of the Selectivity of BCR-ABL Tyrosine Kinase Inhibitors (TKIs): A Systematic Review

Speaker: Helene Haguet (Belgium)

The Role of ERp44 in the Atherosclerosis

Speaker: Qiuya Lu (China)

Scientific Programme

Importance of Arginase-1 in Erythrocytes for Smooth Muscle Cell Calcification and Atherosclerosis

Speaker: Rajinikanth Gogiraju (Germany)

Absence of Protein Tyrosine Phosphatase-1B in Smooth Muscle Cells Promotes Perivascular Fibrosis: Role of Receptor Tyrosine Kinase Signaling

Speaker: Sogol Gachkar (Germany)

Relationship between Distal Venous Thrombosis and Asymptomatic Atherosclerotic Disease

Speaker: Luca Spiezia (Italy)

Un Targeted Lipidomic Analysis Reveals Lactosylceramide as Mediator of Monocyte Migration in Coronary Artery Disease Patients

Speaker: Susanna Fiorelli (Italy)

Effect of BTK Inhibition on Platelet-mediated Inflammation in an Obese Rhesus Macaque Model of Early Atherosclerosis

Speaker: Tia Kohs (United States)

Effect of Photobiomodulation Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Early Stage Atherosclerosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of Photodynamic Therapy on Arterial Biomechanical Parameters in a Rabbit Carotid Artery Model of Neointimal Hyperplasia

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Cardiovascular Risk Factors

The Level of SPECAM-1 and von Willebrand Factor during the Supraventricular Arrhythmia Episodes in Patients with Arterial Hypertension

Speaker: Eugene Shorikov (Ukraine)

The State of Carotids and the von Willebrand Factor Levels in Patients with Arterial Hypertension

Speaker: Eugene Shorikov (Ukraine)

Assessing the Impact of Switching to the Tobacco Heating System on Cardiovascular Disease: Translating Basic Science into Clinical Benefit

Speaker: Calin Pater (Switzerland)

Comparison and Association of Fibrinogen, von Willibrand Factor and Factor VIII Levels with Risk of Cardiovascular Disease in Cigarette Smokers Residing in Calabar Metropolis, Nigeria

Speaker: Dorathy Chioma Okpokam (Nigeria)

A Study on Pressure Overload-Induced Cardiac Hypertrophy Model in Mice by Applying Transverse Aortic Constriction and O-Ring Ascending Aortic Banding Technique: A Comparative Analysis

Speaker: Anas Rashid (Italy)

Factor V Leiden but Not Factor II 20210G>A Is a Risk Factor in a Large Cohort of Iranian Patients with Premature Coronary Artery Disease

Speaker: Ilaria Mancini (Italy)

Thrombin-Induced Platelet Fibrin Clot Strength Identified by Thromboelastography: A Potential Marker of Increased Thrombotic Risk in Older Adults with Coronary Artery Disease

Speaker: Rahul Chaudhary (United States)

Scientific Programme

Tissue Factor Cytoplasmic Tail Promotes Inflammatory Myeloid Cell Derived Superoxide Formation and TGF- β 1 Driven Cardiac Remodeling in Myocardial Infarction

Speaker: Venkata Garlapati (Germany)

Crosstalk between Platelet and Endothelial Dysfunction in Survivors of Allogeneic Hematopoietic Cell Transplantation Independently of Traditional Cardiovascular Risk Assessment

Speaker: Eleni Gavriilaki (Greece)

Study of Fluctuations in the Endothelin Concentration of the Crew Trans-Latitude Journey Transarctica-2019

Speaker: Nadezda Vorobyeva (Russian Federation)

Study of Thrombine Generation Assay Parameters of the Crew Trans-Latitude Journey Transartika-2019

Speaker: Nadezda Vorobyeva (Russian Federation)

Monitoring the Safety and Effectiveness of Antiplatelet Therapy

Speaker: Nadezda Vorobyeva (Russian Federation)

Aspirin Antiplatelet Effects Are Associated with Body Weight

Speaker: Lisa Dannenberg (Germany)

Overexpression of FXII as a Risk of Thrombosis in Patients with SAMTER Syndrome, Angioneurotic Edema, and its Association with Smoking Rate and Hematological Parameters

Speaker: Brenda Sarai Ascencio (Mexico)

Folate Exchange in Athletes of North-West Russia

Speaker: Nadezda Vorobyeva (Russian Federation)

Changes in the Hemostasis System in Athletes

Speaker: Nadezda Vorobyeva (Russian Federation)

The Antidepressant Drug Desipramine Prevents Arterial Thrombosis in a Mouse Model Carrying the Human BDNFVal66Met Polymorphism

Speaker: Silvia Stella Barbieri (Italy)

Gender-Associated Cardiometabolic Biomarkers in Young Adults

Speaker: Vasilii Chulkov (Russian Federation)

MiR-146a Mediates Neutrophil Extracellular Traps Formation in Acute Myocardial Infarction (AMI) in Young Patients

Speaker: Ascensión María de los Reyes-García Pastor (Spain)

Study of the Endothelial Dysfunction in Patients with Cancer: Preliminary Results

Speaker: Elisabetta Borella (Italy)

Platelet Glycoprotein IIIa Leu 33 Pro Polymorphism and Susceptibility to ST-segmented and Non-ST-segmented Myocardial Infarction

Speaker: Ellshazali Mohamed Ahmed (Sudan)

Cardiovascular Risk in Systemic Lupus Erythematosus

Speaker: Melek Kechida (Tunisia)

Apolipoprotein A-IV Is an Endogenous Inhibitor of Thrombosis: The Roles of Polymorphisms in the Risk of Cardiovascular Disease

Speaker: Daniel *MacKeigan (Canada)

Scientific Programme

Von Willebrand Factor in Stroke and Non-valvular Atrial Fibrillation Patients

Speaker: Martha Eva Viveros-Sandoval (Mexico)

PCSK9 Regulates Nox2-Mediated Platelet Activation via CD36 Receptor in Patients with Atrial Fibrillation

Speaker: Vittoria Cammisotto (Italy)

Systemic Aspirin Esterification in Subjects with Cardiovascular Disease: Impact of Body Size

Speaker: Benedetta Porro (Italy)

Endogenous PCSK9 Is Related to Circulating CD34^{bright}/CD146⁻ Cells in Patients with Type 2 Diabetes Mellitus

Speaker: Romina Tripaldi (Italy)

Clinical Implications of White Blood Cell Count and Platelet Indices in Individuals with Risk Factor of Coronary Artery Disease

Speaker: Supakanya Lasom (Thailand)

Proteases from Pathogenic and Non-pathogenic Bacteria Activate Prothrombin (ProT) in Human Plasma: Implications in Thrombotic Diseases

Speaker: Vincenzo De Filippis (Italy)

Evaluation of Biological Effects of Airborne / Urban Pollution Particles

Speaker: Cornelis Kluft (the Netherlands)

The Clinical Predictors of Coronary Artery Disease: A Population-based Study from Developing Country

Speaker: Muhamad Fajri Addai (Indonesia)

African American Women with Diabetes Undergoing Catheterization Represent Most Prothrombotic Subgroup: An Explanation for the Platinum Diversity Study Results?

Speaker: Paul Gurbel (United States)

Pulmonary Thromboembolism in General Practice

Speaker: Tamar Saralidze (Georgia)

Cerebrovascular Disorders

Thromboembolism in Thalassemia Patients: Is Aspirin Protective against Brain Ischemia over Three Years Follow Up in Beta Thalassemia Patients?

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Silent Brain Ischemia in Thalassemia Patients: Breaking the Silence

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Hereditary Thrombophilia in Arterial Ischemic Stroke: A Study from the South of Tunisia

Speaker: Fatma Megdich (Tunisia)

Histological Analysis of a Thrombectomy-Resistant Thrombus in Acute Ischemic Stroke

Speaker: Senna Staessens (Belgium)

Impact of Protease Nexin-1 in Cerebral Ischemia

Speaker: Marie-Christine Bouton (France)

Hemorrhagic and Ischemic Stroke in Patients after Allogeneic Stem Cell Transplantation

Speaker: Xuan Cai (China)

Scientific Programme

A Recurrent Ischaemic Stroke Case with Type 1 von Willebrand Disease

Speaker: Handan Haydaroğlu Şahin (Turkey)

Plasma Calprotectin as a Novel Independent Predictor of Mortality in Acute Ischemic Stroke

Speaker: Manuel Navarro-Oviedo (Spain)

Effect of Pulsatility on Thrombosis Modelling in Cerebral Aneurysms

Speaker: Struan Hume (South Africa)

Temporary Hypofibrinogenemia in Reversible Cerebral Vasoconstriction Syndrome (SRVC) Associated a Cannabis Overdose

Speaker: Sonia Herrero (Spain)

Secondary Brain Damage in Mouse Models of Focal and Global Ischaemia and Haemorrhagic Stroke: A Comparative Study

Speaker: Maithili Sashindranath (Australia)

Characterization and Antithrombotic Treatment of Patients with Acute Ischemic Stroke and No Atrial Fibrillation: A Real-world Study

Speaker: Lu Wang (United States)

Plasma Concentration of Apolipoprotein C-III is Associated with Ischemic Cerebrovascular Events in High-Risk Cardiovascular Patients Taking Anticoagulant Therapy with Warfarin

Speaker: Filippo Stefanoni (Italy)

PI3KC2 β Deficiency Stabilizes Adherens Junctions and Preserves Vascular Integrity in Stroke Models

Speaker: Marie-Pierre Gratacap (France)

Antiaggregation Evaluation of Aspirin and Clopidogrel in Endovascular Treatment of Intracranial Aneurysms with Flow Diverter Stents

Speaker: Antonio Moscardó (Spain)

Thrombin Generation in Patients with Non-traumatic Intracerebral Hemorrhage

Speaker: Linda Lóczy (Hungary)

Characteristics and Recurrence of Acute Ischemic Stroke in Children: An Examination Using Real World Data

Speaker: Jill Hardin (United States)

The Use of in Vitro Clot Lysis Assay for Predicting Outcomes in Non-traumatic Intracerebral Hemorrhage Stroke Patients

Speaker: Rita Orbán-Kálmándi (Hungary)

The Epinephrine-induced Platelet Aggregation Changes in Arterial Hypertension of Very High Risk

Speaker: Eugene Shorikov (Ukraine)

The Optimal Treatment of Atrial Fibrillation in Patients with Cancer

Speaker: Inna Tzoran (Israel)

Incidence of Recurrent Ischemic Stroke in Patients without Atrial Fibrillation: A Real-world Study

Speaker: James Weaver (United States)

Peripheral Artery Disease

Scientific Programme

Acute Leriche Syndrome in a 55-Year-Old Woman with Recurrent Central Pulmonary Embolism: A Case Report

Speaker: Viktoria Muster (Austria)

Elevated Levels of Activated Factor XII Are Associated with an Increased Risk of Atherothrombotic Events in Peripheral Artery Disease

Speaker: Bram Kremers (the Netherlands)

The Prevalence of Peripheral Artery Disease in Hospitalized Patients with Heart Failure

Speaker: Chiara Fantoni (Italy)

Poorly Compressible Lower Extremity Arteries Are Associated with Venous Thromboembolism

Speaker: Fadi Shamoun (United States)

Development of a Clinical Cohort of HIV-infected Patients with Peripheral Vascular Disease

Speaker: Elizabeth Mayne (South Africa)

Rationale and Design for the Study Apixaban versus Clopidogrel on a Background of Aspirin in Patients Undergoing InfraPopliteal Angioplasty for Critical Limb Ischemia - AGRIPPA Trial

Speaker: Rodrigo Biagioni (Brazil)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Coagulation and Natural Anticoagulants Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Animal Models in Thrombosis and Hemostasis

Small-Molecule Factor XIa Inhibitor, BMS-986177/JNJ-70033093, Prevents and Treats Arterial Thrombosis in Rabbits at Doses that Preserve Hemostasis

Speaker: Pancras Wong (United States)

Developing of a New Animal Artery Model of Atherothrombotic Stenosis using Perivascular Monopolar High-Frequency Electrical Current-Mediated Endothelial Injury Followed by a Cholesterol-Rich Diet Injury and Finally Perivascular Severe Cold Injury using Liquid Nitrogen

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Liquorice and Sumac Attenuate Brain Damage Caused by Ischemic Stroke in Rat

Speaker: Mohammad Babaeian (Iran, Islamic Republic of)

Anti-Aggregant Effect of Butanolic Extract of Rubia Tinctorum on Platelets in vitro and ex vivo

Speaker: Fatima Zahra Marhoume (Morocco)

Hemolysis Triggers Platelet-Dependent Pulmonary Arteriole Thrombosis

Speaker: Tomasz Brzoska (United States)

Increased Levels of von Willebrand Factor Associated with Acute Inflammation Contribute to Enhanced Venous Thrombosis

Speaker: Seon Jae Choi (Canada)

Scientific Programme

Non-Invasive Optical in vivo Imaging Reveals Tumor-Derived Prothrombin with a Functional Role in Hemostasis and Tumor Progression

Speaker: Lina Katharina Schott (Germany)

Heart Failure, Induced by Excess Neurohormonal Activation, Results in Significant but Non-Critical Telomere Shortening in Cardiomyocytes and Peripheral Blood Mononuclear Cells

Speaker: Hendrik Dörschmann (Germany)

The Initial Formation of a Transient Sub-Occlusive Mural Thrombus Appears to Protect Coagulation to Leave a Thin Platelet- and Fibrin-Rich Patch Covering the Site of Injury

Speaker: Alexandra Yakusheva (France)

High Salt Intake Increases Platelet Counts and Plasma Fibrinogen Levels but Has No Effect on Thrombus Formation or Resolution in a Murine Model of Venous Thrombosis

Speaker: Johannes Wild (Germany)

Platelet Analysis of Diet-Induced Obesity Rat Model: Elucidating Platelet Dysfunction in Obesity

Speaker: Maria N. Barrachina (Spain)

Fibrin Deposits on Peritoneal Carcinomatosis Serves as a Niche for Cancer Cell Implantation and Dissemination. A Scanning Electron Microscopy Analysis

Speaker: Iman Aldybiat (France)

Novel Mouse Model for Studying Hemostatic Function of Human Platelets

Speaker: David S. Paul (United States)

Cardiac Myosin Promotes Thrombin Generation and Coagulation in vitro and in vivo

Speaker: Meenal Shukla (United States)

Thrombin Generation Following Vipera berus Envenomation: A Canine Model

Speaker: Hannah Jayne Harjen (Norway)

Multiple Gene Knockdowns Simultaneously to Study Hemostasis in Zebrafish

Speaker: Pudur Jagadeeswaran (United States)

Sex Bias in Animal Models of Thrombosis Research

Speaker: Paul Thuan Tieu (Canada)

CRISPR/Cas9-Mediated Generation of a RUNX1 Knock-In Mice Model and Platelet Characterization

Speaker: Ana Marín-Quílez (Spain)

Maternal Deficiency of Endothelial Protein C Receptor Causes Severe Pregnancy Complications Prevented by Inactivation of Protease Activated Receptor 4, but not Clotting Factor VIII

Speaker: Michelle Castillo (United States)

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Increase Susceptibility to Venous Thrombosis

Speaker: Xinjie Lu (United Kingdom)

Antithrombotic Properties of Carvedilol Shown in Two Independent Intravital Real Time Models of Thrombosis

Speaker: Przemyslaw Czajkowski (Poland)

Scientific Programme

Reported Values and Methodologies for Detecting Plasma D-dimer in Rat Models: A Systematic Review and Meta-analysis

Speaker: Jason Chung (Canada)

Von Willebrand Factor (VWF) Deficiency Leads to Altered Angiogenesis in the Gastrointestinal Tract

Speaker: Mario von Depka (Germany)

Real-time in vivo Visualization of Infused FVIIa in Hemophilia A Mice Following Injury

Speaker: Juliana C Small (United States)

Novel Oral Anticoagulants Do Not Expand Haematoma Volume in a Intracerebral Hemorrhage Model in Rats

Speaker: Juliana Ferreira (Brazil)

Effects of Hibernation on the Platelet Proteome of 13-lined Ground Squirrels

Speaker: Joseph Aslan (United States)

Identification of Thrombosis Predictors in an ex vivo Shunt Model through Retrospective Analysis

Speaker: Hari Hara Sudhan Lakshmanan (United States)

Early Indicators of Thromboembolic Events Caused by Prolonged Tourniquet Application: A Rat Model

Speaker: Jason Chung (Canada)

Coagulation Factors and Inhibitors

Inhibitor against Congenital Coagulation Factor XIII Deficiency: A Case Report

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Activated recombinant Factor VII (rFVIIa) Inhibitor in Iran: Immunogenicity is a Major Challenge through Treated Bleeds Covered with rFVIIa

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Efficacy and Safety of Prothrombin Complex Concentrate in Obstetric Hemorrhage

Speaker: Alexandr Ronenson (Russian Federation)

Protein C Activity and Fibrinogen Levels in Nigerians Receiving Renal Replacement Therapy for Chronic Kidney Disease

Speaker: Omolade Awodu (Nigeria)

von Willebrand Factor Levels and Expression Pattern Are Altered in Response to Aging

Speaker: Parnian Alavi (Canada)

A Novel Rare C. - 39C>T Mutation in the PROS1 5'UTR Causes Protein S Deficiency by Creating a New Upstream Translation Initiation Codon and an Overlapping Open Reading frame

Speaker: David-Alexandre Trégouët (France)

G-Quadruplex Related Aptamers to Thrombin Exosite I with Additional Duplex Region. Relationships between their Structure, Stability and Anti-thrombin Activity

Speaker: Alexey Mazurov (Russian Federation)

Prophylaxis in Adult Population. Experience and Results in a 5-Year Follow-up Cohort

Speaker: Claudia Casas (Colombia)

Scientific Programme

Operational Feasibility of a Pharmacist-Guided Personalized Medicine Consult Service for Warfarin in Mandatory and Optional Testing Settings

Speaker: Ashwini Zolekar (United States)

Acquired Haemophilia Spanish Registry, First Five Years of Activity

Speaker: María Eva Mingot-Castellano (Spain)

Impact of DOACs on Hemostasis Diagnostic Tests. Practical Recommendations and Guidance for the Laboratory

Speaker: Romain Siriez (Belgium)

Drug Interactions in Edoxaban Treated Patients: A Pilot Study Revealing the Changes of the Metabolite to Parent Ratio and its Potential Clinical Importance

Speaker: Romain Siriez (Belgium)

Comparison of a Validated UHPLC-MS/MS Method and Chromogenic Anti-Xa Assays from Different Manufacturer for the Assessment of Edoxaban and its M4 Metabolite Levels in Plasma

Speaker: Romain Siriez (Belgium)

Anticoagulation with the Novel, Small-molecule Factor XIa (fXIa) Antagonist, EP-7041, Prevents Oxygenator Clotting but Conserves Hemostasis in a Canine Extracorporeal Circulation (ECMO) Model

Speaker: Michael Andrew Kurz (United States)

Rivaroxaban Reduces Arterial Thrombosis by Inhibition of FXa Driven Platelet Activation via Protease Activated Receptor-1

Speaker: Lisa Dannenberg (Germany)

Validation of a Non- Sensitive aPTT Reagent for the Presence of Anti-Phospholipid Abs (Lupus Anti-Coagulant)

Speaker: Sigal Nakav (Israel)

A Novel Prediction Platform to Enhance the Design of Therapeutic SERPINS

Speaker: Wariya Sanrattana (the Netherlands)

Natural Compounds as Anticoagulant Drug: A New Avenue for Improving Thrombosis Outcome

Speaker: Swati Sharma (India)

Factor Xa Stimulates PAR-Independent Pro-Inflammatory Responses in Primary Adult Rat Cardiac Fibroblasts

Speaker: Elisa D'Alessandro (the Netherlands)

Evaluation of the CEPHEN™ Reagent for the Determination of Activated Partial Thromboplastin Time in Current Practice

Speaker: Corinne Frere (France)

Natural Anticoagulant from Peony

Speaker: Margarita Lyapina (Russian Federation)

Identification of Novel Proteins Binding to Coagulation Factor XIII Free B-Subunit

Speaker: Bojun Li (Switzerland)

Higher Protection against Inhibitors with pdFVIII/VWF Complex Concentrate Compared to Complex Formed in the Circulation between Isolated FVIII and VWF of HA Patients: An ex vivo Study

Speaker: Maria Isabel Bravo (Spain)

Scientific Programme

Rare Coagulation Disorders in Children - Is it Like to Buy a Pig in a Poke or Nothing Special? Experience of Saint Petersburg, Russia

Speaker: Natalia Sokolova (Russian Federation)

Transplacental Delivery of Maternal Factor VIII for Induction of Immune Tolerance to Therapeutic Factor VIII

Speaker: Angelina Mimoun (France)

Endocytosis of Factor VIII by Human Dendritic Cells in the Presence of Anti-Factor VIII Antibodies from Patients with Hemophilia A

Speaker: Mélissa Bou Jaoudeh (France)

Antithrombotic Effects of a Novel Small Molecular Fxii Inhibitor BMS-986177/JNJ-70033093 in a Rabbit AV-Shunt Model of Thrombosis

Speaker: Xinkang Wang (United States)

Effects of Anticoagulants on Fibrin Clot Structure: A Comparison between Vitamin K Antagonists and FXa inhibitors

Speaker: Julia S. Gauer (United Kingdom)

Anticoagulant Effects of Parenteral Sulodexide as Measured by Activated Clotting Time. Relevance to Dosing in Various Indications

Speaker: Bharathi Daravath (United States)

Structures in the Presence and Absence of an Anti-Factor VIII C1 Domain Antibody Bound to a Bioengineered Factor VIII Construct Indicates Multiple C2 Domain Conformations

Speaker: P. Clint Spiegel (United States)

Pharmacopeial Potency Equated Sulodexide Produces Comparable Anticoagulation as Studied in Whole Blood

Speaker: Bharathi Daravath (United States)

Factor XII Deficiency - A Very Rare Coagulation Disorder: Case Report

Speaker: Deniza Stambolieva (Macedonia, the Former Yugoslav Republic of)

Suppression of Factor VIII-Specific Memory B Cells by Murine and Human BAR-Tregs

Speaker: David Scott (United States)

Preclinical Pharmacology of BAY 2433334, a Small Molecule Inhibitor of Coagulation Factor XIa

Speaker: Stefan Heitmeier (Germany)

Role of Kunitz Domain 3 of Tissue Factor Pathway Inhibitor in Zebrafish

Speaker: Revathi Raman (United States)

A Double Heterozygous Factor VII (FVII) Deficiency: Exon 9 Missense Mutation (Arg364Gln - FVII Padua) and a Novel Exon 3 Missense Mutation (Ala87Gly)

Speaker: Christian Aledia Gallardo (Singapore)

Congenital Factor X Deficiency with Isolated Prothrombin Time Prolongation

Speaker: Dilek Gurlek Gokcebay (Turkey)

Molecular Analysis in 12 factor XI Deficiency Patients from China: Identification of Three Novel Splicing Mutations

Speaker: Donglei Zhang (China)

Scientific Programme

Point-of-Care and Storage-Stable, Single-Use 8-Channel Microfluidic Chip for Rapid Testing of DOACs and DOAC Reversal Agents under Whole Blood Flow

Speaker: Jason Rossi (United States)

Transplacental Delivery of Fc-fused Factor VIII (rFVIII-Fc) in FVIII-Deficient Mice

Speaker: Sandrine Delignat (France)

Identification of Key Residues in Protein Z Dependent Protease Inhibitor (ZPI) for Efficient Protease Inhibition

Speaker: Chellam Gayathri Subash (India)

Protein S Deficiency, Inflammation and Sick Cell Anemia

Speaker: Awa Oumar Touré (Senegal)

First-in-Human Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of ONO-7684, an Oral Small Molecule Factor XIa Inhibitor in Healthy Subjects

Speaker: Dominic Beale (United Kingdom)

Library Screening and Combinatorial Approaches Identify an Alpha-1 Proteinase Inhibitor Variant with Enhanced Specificity for Factor XIa

Speaker: William Sheffield (Canada)

The Antiplasmin Activity of the Kunitz Protease Inhibitor Domain of Protease Nexin 2 Affects Thrombolysis and Thrombosis in Mouse Models

Speaker: William Sheffield (Canada)

Nontoxic Polyphosphate Inhibitor that Reduces Thrombosis without Increased Bleeding

Speaker: Stephanie A. Smith (United States)

A Comparison of Mass and Potency Equated Bovine and Porcine Heparins

Speaker: Sharan Krishnappan (United States)

Optimisation of Assays for Laboratory Monitoring of Eficizumab in Treated Patients

Speaker: Aine N McCormick (United Kingdom)

Comparison of Medication Adherence Between Different Oral Anticoagulants: A Propensity Weighted Nationwide Cohort Study

Speaker: Arnar B. Ingason (Iceland)

The FibWave, a New Sensitive and Relevant Tool for Analysing the fibrin Clot Formation: Comparison with the Calibrated Automated Thrombogram to Assess Direct Oral Anticoagulants

Speaker: Jonathan Evrard (Belgium)

Hypodysfibrinogenemia with a New Heterozygous Mutation in Fibrinogen in a Patient with Thrombotic Complications

Speaker: Soraya Hadjali - Saichi (Algeria)

Characterisation and Evaluation of a Candidate Bethesda Assay Reference Reagent Developed from Recombinant, Patient-Derived FVIII Inhibitors

Speaker: Carmen Coxon (United Kingdom)

Rare Bleeding Disorders in North India - Study from a Tertiary Care Centre

Speaker: Sabina Langer (India)

Discordance Between the Neutralization Profile of Apixaban, Betrixaban, Edoxaban and Rivaroxaban in the Clotting Assays and Anti-Xa Measurements

Speaker: Fakiha Siddiqui (United States)

Scientific Programme

Circulating T Helper 17 Cells (Th17) Increase at a Higher Rate than Tregs in Previously Untreated Patients with Severe Hemophilia A Who Develop Inhibitors During the First 50 Exposure Days to rFVIII

Speaker: Deborah Brown (United States)

New Peptide Inhibitors of Serine Proteases of the Blood Coagulation System

Speaker: Liliya Mukhametova (Russian Federation)

HIPS Qualification Testing (HQT): Qualification of Hemophilia Treatment Centers to Perform PBMC Re-Stimulation for the Hemophilia Inhibitor in Previously Untreated Patients (HIPS) Study

Speaker: Deborah Brown (United States)

Anticoagulant Effect of Novel Nanoparticles Functionalized with Synthetic Piperazinone Derivatives as FXa Inhibitors

Speaker: Flavia Zacconi (Chile)

Bisecting the Role of the C-terminal End of Antithrombin: Natural Variants due to a Frameshift at Different Secondary Structures May Exacerbate or Ameliorate a New Dominant-negative Effect

Speaker: Carlos Bravo-Perez (Spain)

Deep Vein Thrombosis and Coagulation Factor Deficiency: A Paradoxical Association

Speaker: Yosra Cherif (Tunisia)

Clinical Significance of T-cell Subsets for the Inhibitor Development in Pediatric Hemophilia A Patients

Speaker: Zhenping Chen (China)

Effect of Mg(II) Ion on the Interaction of Coagulation Factors with Phospholipid Membranes

Speaker: Yasuo Shikamoto (Japan)

Warfarin and Vitamin K Epoxide Reductase: A Mechanism for Inhibition Using Molecular Dynamics Simulation

Speaker: Sangwook Wu (Korea, Republic of)

Are the Plasma Levels Thresholds of DOAC Rationale and Appropriate for Clinical Decision-making? A Reappraisal Using Thrombin Generation Testing

Speaker: Jonathan Evrard (Belgium)

Combined Analysis of Dendritic Cell (DC) HLA-class-II (HLA-II) Peptidomic Profiling Data Derived from Different Therapeutic Factor VIII Proteins (tFVIs) in Independent Experiments/Laboratories

Speaker: Tom E Howard (United States)

Perioperative Management of Acquired Factor XI Deficiency: A Case Report and Review of Literature

Speaker: Corentin Achard (France)

Probing Interaction of TOS with ATIII Using MD Simulation and Biophysical Studies; Its Effect on Clot Formation and fXa Inhibition

Speaker: Irshad Ahmad (India)

A Novel Coagulation Factor VIII with Reduced Immunogenicity

Speaker: Steffen Kistner (Germany)

Scientific Programme

A Sensitive and Specific Assay to Measure TF Activity in Cell-derived Extracellular Vesicles Based on Thrombin Generation

Speaker: Bjarne Østerud (Norway)

Measurement of Polyphosphate in Biologic Samples

Speaker: Stephanie A. Smith (United States)

Anti-factor V Inhibitor after Liver Transplantation

Speaker: Alessandro Ciavarella (Italy)

Addition of Histone Deacetylase Inhibitors Increases Recombinant Factor V Expression in BHK Cells

Speaker: Teodolinda Petrillo (United States)

The Distribution of Hemophilia A-causing Genetic Variants by Race/Ethnicity and Association with Inhibitors among Enrollees in the Hemophilia Inhibitor Research Study (HIRS)

Speaker: Amanda B. Payne (United States)

The Anticoagulant Effect of Protamine - A Stabilizer of the Factor V Procofactor State

Speaker: Teodolinda Petrillo (United States)

To Determine the Effect on Gender and Age of Prothrombin Time (PT), Activated Partial Thromboplastin Time (aPTT) Levels and International Normalized Ratio (INR)

Speaker: Aysha Sultana (Pakistan)

Lysine Residues Impair the Efficacy of N-glycosylation: Pathological and Physiological Relevance in Antithrombin

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Whole Genome Sequencing Study of Coagulation Factor VIII and von Willebrand Factor Reveals New Genetic Associations

Speaker: Paul S de Vries (United States)

Baseline VWF Antigen Level Is Associated with the Outcome of Immune Tolerance Induction Using pdFVIII/VWF Concentrate in Hemophilia A with Inhibitor

Speaker: Zekun Li (China)

Assessment of Four Factor Prothrombin Complex Concentrate (4F-PCC) Usage in Emergency Department Patients: A Single Center Experience

Speaker: Hannah McRae (United States)

Sequence Mismatch Between Therapeutic (t) and Endogenous (e) Factor VIII Proteins (FVIII_t), and HLA-class-II (HLA_{II})-binding in the Development of Neutralizing Anti-tFVIII_t-Antibodies in Hemophilia A (HA): Evidence from the PATH Study

Speaker: Vincent P. Diego (United States)

Inactivation of Tissue Factor Pathway Inhibitor through Specific Citrullination by Peptide Arginine Deiminase 4

Speaker: Rory Koenen (the Netherlands)

Always Ask Relevant Questions to Patients Might Be They Tell You the Diagnosis

Speaker: Arshi Naz (Pakistan)

X-ray Crystallography and Hemostatic Activities of a Neutralizing Anti-TFPI Antibody, Marstacimab

Speaker: Debra Pittman (United States)

Contact Pathway

Scientific Programme

Allosteric Modulation of Exosite 1 Attenuates the Enhancing Effect of Polyphosphate on FXI Activation by Thrombin

Speaker: Ruiqi Yin (Canada)

Histidine-Rich Glycoprotein Attenuates the Prothrombotic Activity of Polyphosphate in a FXII-Dependent Manner

Speaker: Rida Malik (Canada)

First Evaluation of the Safety, Pharmacokinetics and Pharmacodynamics of BAY 2433334 a Small Molecule Targeting Coagulation Factor XIa in Healthy Young Male Participants

Speaker: Dirk Thomas (Germany)

Are Therapeutic Immunoglobulins Free from Factor XIa?

Speaker: Helen Wilmot (United Kingdom)

ONO-1600586, an Oral Direct Factor XIa Inhibitor, Suppresses Thrombus Formation in Rabbit Jugular Vein without Bleeding Tendency

Speaker: Nobuyuki Oguri (Japan)

Detecting Oral Kallikrein-Targeting Therapy through Triggered Contact Activation: A Phase I Study

Speaker: Chantal C. Clark (the Netherlands)

A Critical Role of Carboxyl-Terminal Alpha-Helix in the Secretion of Coagulation Factor XI

Speaker: Yuri Hayakawa (Japan)

Activation of Coagulation by 5.8S RNA

Speaker: Pudur Jagadeeswaran (United States)

Coagulation Assays Based on Surface-Mimicking Antibodies against Factor XII

Speaker: Marco Heestermans (Germany)

Factor XII and Kininogen Complex with gC1qR/C1QBP/P32 Is Governed by Zinc Ions

Speaker: Jonas Emsley (United Kingdom)

Importance of the Non-Catalytic Heavy Chains of the Homologs Factor XII and HGFA in Protease Function

Speaker: Aleksandr Shamanaev (United States)

Structure-Function Relationships in Factor XII Studied with Factor XII-HGFA Chimeras

Speaker: Aleksandr Shamanaev (United States)

Effects of Plasmin on Factor XII Structure and Activation

Speaker: Ivan Ivanov (United States)

Evolutionary History of the Kallikrein-Kinin System and Factor XI

Speaker: Michal Ponczek (Poland)

Neutralization of Osocimab-Induced Anticoagulation with Prothrombin Complex Concentrate, Activated Prothrombin Complex Concentrate and Recombinant Activated FVII in vitro

Speaker: Anja Buchmueller (Germany)

Identification of the Histidine-rich Glycoprotein Domain Responsible for Contact Pathway Inhibition

Speaker: Tammy Truong (Canada)

Scientific Programme

Design of Polyphosphate Inhibitors that Reduce Thrombosis without Increased Bleeding

Speaker: Chanel Carmen La (Canada)

Plasma Contact Activation through T Cell-Derived Polyphosphate

Speaker: Reiner K. Mailer (Germany)

Quantification of Free FXIa by an Innovative “Catch and Release” Assay

Speaker: Stan van der Beelen (the Netherlands)

The Misfolded Protein Glycated Albumin Activates the Contact System Leading to Plasma Kallikrein Activity But Not Intrinsic Coagulation

Speaker: Lewis Hardy (United Kingdom)

In-vivo Evidence for Contact Activation after Implantation of a Left Ventricular Assist Device in Patients with End-stage Heart Failure

Speaker: Omayra Liesdek (the Netherlands)

Relevance of Thrombin in the Activation of the Fluid Contact Phase in Patients with Hereditary Angioedema Carrying the F12 p.Thr309Lys Variant

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Corn Trypsin Inhibitor in the Preanalytical Phase of Contact Activation Assays

Speaker: Matthias M. Engelen (Belgium)

Critical Care and Perioperative

„Plasma Free” Perioperative Approach during Lung Transplantation Does Not Seem to Impair Secondary Hemostasis Measured by ROTEM

Speaker: Miroslav Durila (Czech Republic)

„Plasma Free” Perioperative Approach during Lung Transplantation Seems to Decrease FXIII Level which Is Not Clinically Significant

Speaker: Miroslav Durila (Czech Republic)

Hemostasis Critical Values in a Laboratory without Hospitalization from CABA, Argentina

Speaker: María Luisa Iglesias Varela (Argentina)

Indiscriminate Coagulation Testing for Bleeding Risk Assessment Prior to Orthopedic Surgery. Is it a Rational Approach?

Speaker: Maria Ali (Pakistan)

Hematologic Laboratory Parameters and Hemostatic Thresholds for the Safe Administration of Neuraxial Anesthesia in Adults with Pre-Existing Bleeding Disorders: A Scoping Review

Speaker: Wynn Peterson (Canada)

External Quality Assurance (EQA) for the Thromboelastometry Devices: UK NEQAS BC Programme Update

Speaker: Dianne Patricia Kitchen (United Kingdom)

Thrombohemorrhagic Events and Management of Haemostasis in Adult Patients under Berlin Heart Excor Devices

Speaker: Miguel Argüello (Spain)

The Association of Prothrombin Complex Concentrates with Transfusion Requirement and Postoperative Outcomes in Cardiac Surgery: A Post-Hoc Analysis of the FIBRES Randomized Controlled Trial

Speaker: Justyna Bartoszko (Canada)

Scientific Programme

Delay in Time to Hip Fracture Repair Surgery among Elderly Patients Treated with Anti Platelet Therapy

Speaker: Aaron Lubetsky (Israel)

Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal with 4F-PCC (KVAD Study)

Speaker: Jessica Rimsans (United States)

Low Preoperative Antithrombin Activity Is Associated with Increased Red Cell and Plasma Transfusion during Neonatal and Infant Cardiac Surgery

Speaker: Zhe Amy Fang (Canada)

ROTEM Parameters As Bleeding Predictors In Pediatric Cardiac Surgery With Cardiopulmonary Bypass

Speaker: Diem Truong-Pham (Viet Nam)

Implementation of the Management of Anticoagulation in the Periprocedural Period (MAPPP) App into an Electronic Health Record (EHR): A Prospective Cohort Study

Speaker: Dimitrios Giannis (United States)

Coagulation Research in Paediatric ECMO: Delayed Consent to Improve Enrolment

Speaker: Suelyn Van Den Helm (Australia)

The Comparison of Critical Care Instrument CoaguChek® Pro II with Coagulation Analyzers Sysmex CS-5100 and Cobas t 511

Speaker: Martin Pulcer (Czech Republic)

Coagulation Research in Paediatric ECMO: The Need for a Common Language

Speaker: Joppe Geert Frederik Drop (the Netherlands)

Presentation of Three Patients Treated with Dabigatran that Strongly Confirm the Importance of Quantitative Measurement of Dabigatran Concentration in Selected Clinical Situations: Case Reports

Speaker: Ivana Čelap (Croatia)

Clinical Outcome of Using Three-Factor Prothrombin Complex Concentrate in Patients with Major Bleeding Associated with Factor Xa Inhibitor

Speaker: Thipsumon Raksintham (Thailand)

Comparison of a New Point-of-Care Hemostasis Analyzer with Laboratory Parameters in Patients with Veno-venous Extracorporeal Membrane Oxygenation

Speaker: Corinne Frere (France)

Haemostatic Markers in Cardiopulmonary Bypass Surgery

Speaker: Amita Ranger (United Kingdom)

Use of Recombinant von Willebrand Factor Alone during Surgeries in Type 2 von Willebrand Patients: Case Reports

Speaker: Sara Boukhilal (France)

Pharmacodynamic Approach to Manage Patients on Direct Oral Anticoagulants Undergoing Elective Major Surgery and Operative Endoscopy

Speaker: Sophie Testa (Italy)

Scientific Programme

Prospective Study of Haemostatic Activation Markers and Correlation with Bleeding and Thrombotic Complications in Patients Receiving Veno-Venous Extra-Corporeal Membrane Oxygenation (VV-ECMO) - HAE Study

Speaker: Deepa Jayakody Arachchillage (United Kingdom)

PTT a Surrogate for Quantification of Factor VIII Inhibitor

Speaker: Kimberly Klein (United States)

A Multicenter Experience with Idarucizumab “In Real World” as Reversal Anticoagulation of Dabigatran

Speaker: Irene Amarilla Lanzas (Spain)

Whole Blood Coagulation Profiles at the Time of Emergency Unit Admission in Patients with Major Trauma

Speaker: Luca Spiezia (Italy)

Postoperative Heparin Monitoring by Anti-Xa Is More Accurate Than by aPTT After Pulmonary Endarterectomy - Role of Increased Systemic and Endothelial Production of Factor VIII

Speaker: Antti Nykanen (Canada)

Predictors of Residual Preprocedural DOAC Levels

Speaker: Joseph Shaw (Canada)

Microstructural Characterisation of in vivo Paediatric ECMO Circuit Binding and Blood Clot Structure

Speaker: Tengyi Cai (Australia)

Investigation of the Coagulation Potential of PAS-E Resuspended Platelets

Speaker: Anaïs Lotens (Belgium)

Use of Prothrombin Complex Concentrate for Reversal of Oral Anticoagulants in the Clinical Practice of a Portuguese Tertiary Hospital

Speaker: Diana Cibebe (Portugal)

Efficacy and Safety of Ciraparantag in Reversing Apixaban and Rivaroxaban as Measured by Whole Blood Clotting Time in Healthy Adults

Speaker: Jack Ansell (United States)

Assessment of the Difference Between EXTEM and FIBTEM Amplitudes (PLTEM) and Their Correlation with Platelet Count (PLT), and the Effect of Fibrinogen and Hematocrit (HTC) in Cardiovascular Surgery (CVS)

Speaker: Marina Sol Lopez (Argentina)

Outcomes of Patients with Anti-Xa versus APTTr Monitoring for Unfractionated Heparin Infusions during Extracorporeal Membrane Oxygenation

Speaker: Andrew Doyle (United Kingdom)

Profile of Effect of Sugammadex on Coagulation and Fibrinolysis

Speaker: Cornelis Kluft (the Netherlands)

Reversal of Heparin Anticoagulation by Andexanet Alfa (Andexanet) in Human Plasma and Whole Blood: Differential Effect of Andexanet on Antithrombin-Dependent Anticoagulants and Direct Thrombin Inhibitors (DTIs)

Speaker: Genmin Lu (United States)

Scientific Programme

Rapid Thaw Plasma Units Thaw Significantly Faster than Standard Plasma Units while Retaining Similar Coagulation Profile over 5 Days of Cold Storage

Speaker: Kathleen M. Madden (United States)

Investigation of Several Four Factor PCCs to Restore Thrombin Generation Following Anticoagulation with Rivaroxaban: Ex vivo Study

Speaker: Oliver Grottke (Germany)

Clinical Study of Children's Intracranial Hemorrhage in Single Hemophilia Center in China

Speaker: Xiaoqin Feng (China)

Bleeding and Thrombotic Complications in Patients Undergoing Major Cardiac Surgery on Single, Dual Antiplatelet Treatment Compared to Controls

Speaker: Christopher Little (United Kingdom)

Thrombocytopenia in adult ICU patients with sepsis

Speaker: Lene Russell (Denmark)

A Strategy of Continued Antiplatelet Agents, Vitamin K Antagonists, and Direct Oral Anticoagulants throughout the Perioperative Period of Diabetic Foot Surgery in Patients Receiving Chronic Antithrombotic Therapy

Speaker: Dmytro Dmytriiev (Ukraine)

VMX-C001 Is a Reversal Agent for FXa-inhibiting DOACs and Displays a Favorable Pharmacokinetic and Pharmacodynamic Profile

Speaker: Daniël Verhoef (the Netherlands)

Management of Intracranial Hemorrhage in Patients under Non-vitamin K Antagonist Oral Anticoagulants

Speaker: Lúcia Vieira (Portugal)

Routine Coagulation Assays for the Detection of Residual NOAC Levels in Patients Undergoing Elective Invasive Procedures

Speaker: Thomas Vanassche (Belgium)

Haemostatic Changes in Patients Undergoing Renal Transplantation

Speaker: Ruchika Kohli (United Kingdom)

Reversal of Dabigatran by Idarucizumab in Heart Transplantation Surgery: A Case Report

Speaker: Filipe Robles de Vasconcelos (Portugal)

Prevention of Thromboembolism Complications in Preoperative Patients

Speaker: Tamari Svanidze (Georgia)

FVIII/IX

Comparative Pharmacokinetics of Two Recombinant FVIII Concentrates in Chinese Pediatric Patients with Severe Hemophilia A: A Single-Center Study

Speaker: Kun Huang (China)

Monitoring and Pharmacodynamic Effect of Eftrenonacog-Alfa (Alprolix®) in Severe Hemophilia B Patients: A Real-Life Study

Speaker: Georges Jourdi (France)

Identification of a Novel "Laminin G" Domain Mutant of Protein S Defective in Binding and Inhibiting FIXa and Unaffected in APC/TFPI Cofactor Activities

Speaker: Rinku Majumder (United States)

Scientific Programme

Bleeds and Imaging Scores in Relation to Pharmacokinetics of Coagulation Factor VIII in Chinese Pediatric Patients with Severe Hemophilia A

Speaker: Huang Kun (China)

Emicizumab Treatment in Pediatric Patients with Hemophilia A without Inhibitors: A Single-Institution Study

Speaker: Mika Mori (Japan)

Comparative Analysis of the Coagulometric and Chromogenic Methods for the Determination of Factor VIII Activity in the Plasma of Patients Suspected with Blood Coagulation Disorders

Speaker: Ewelina Wojtasinska (Poland)

Inhibitor Risks Estimation Associated with F9 Genotype Types in Patients with Severe Haemophilia B: Argentine vs EAHAD Database

Speaker: Pamela Radic (Argentina)

A New Test Set up to Dose Factor VIII Ability to Bind Exogenous VWF

Speaker: Aurélie Juif (France)

Use of Thromboelastography to Monitor Emicizumab in a Patient with Severe Haemophilia A without Inhibitor

Speaker: Elvira Grandone (Italy)

FVIII Gene Mutation Analysis and Evaluation of Clinical Data: One Center Result

Speaker: Birol Baytan (Turkey)

Identification of Zebrafish Orthologue to Human Factor IX Gene and its Age Dependent Regulation

Speaker: Neha Iyer (United States)

Difference Molecular Profiles of Type 1 and 2 Inhibitor Developed in Mild/Moderate Hemophilia A

Speaker: Shoko Furukawa (Japan)

Treatment and Joint Health in Nordic Moderate Haemophilia Patients - the Mohem Study

Speaker: Ragnhild Måseide (Norway)

Screening of Hematuria in Children with Hemophilia: A Preliminary Report

Speaker: Dilek Gurlek Gokcebay (Turkey)

Evaluation of Structurally Altered Protein in Factor VIII Therapeutic Products Using Chromatography on Immobilized von Willebrand Factor

Speaker: Andrey Sarafanov (United States)

New Hyperactive Factor IX Variants Identified with a Novel Computational Analysis

Speaker: Ben Samelson-Jones (United States)

Potential Role for Regulatory B-cells in the Control of Immune Tolerance to Factor VIII Treatment in Haemophilia A: Evaluation of Involvement of Regulatory Cell Types and Markers in Immune Tolerance Induction (ITI) in Haemophilia A

Speaker: Sarah Schep (the Netherlands)

Protease Domain Determinants of the Distribution, Clearance and in vivo Activity of Human Factor IX(a) in Hemophilic Mice

Speaker: John Sheehan (United States)

Scientific Programme

aPTT Reaction Curves Provide Important Additional Information in Hemophilia Patients

Speaker: Josipa Pavic (Bosnia and Herzegovina)

Real-world Analysis of Hemophilia Patients in China: A Single Center's Experience

Speaker: Xuewen Song (China)

Evaluation of Coagulation FIX Binding to Collagen IV and the Impact on Thrombin Generation

Speaker: Gael Beverley Morrow (United Kingdom)

Evaluation of the Effect Emicizumab Neutralizing Antibodies on aPTT Clotting-based Tests Results in Patients Treated with Emicizumab

Speaker: Cristina Novembrino (Italy)

An Overview of Patients with Hemophilia A in China: Epidemiology, Disease Severity, and Treatment Strategies

Speaker: Xuewen Song (China)

Detection and Quantification of F8 Inv1 and Inv22 Inversions Using Digital Droplet PCR and Mile-post Assays

Speaker: Eric Manderstedt (Sweden)

Prevalence and Incidence of Non-neutralizing Antibodies in Congenital Hemophilia - A Systematic Review and Meta-analysis

Speaker: A. Abdi (the Netherlands)

Pleiotropic Effects of PCSK9-inhibition on Hemostasis: Anti-PCSK9 Reduce FVIII Levels by Enhancing LRP1 Expression

Speaker: Francesco Paciullo (Italy)

B Cell Cytokines in Italian Hemophilia A Patients with Inhibitors

Speaker: Bhavya Doshi (United States)

Analytical Variability (CV) of One Stage Factor VIII Assay: A Quality Control (QC) Experience. Argentinian Group of Biochemists in Hemophilia

Speaker: Mirta Arias (Argentina)

Real-life Inter-individual Variability of Pharmacokinetics - Reason for Individualization of Replacement Therapy in Haemophilia

Speaker: Adina Traila (Romania)

Development and Performance Characterization of an Automated Chromogenic Assay for Human Factor IX Activity

Speaker: Narayanan Ramamurthy (United States)

Hemostasis and Organ Dysfunction

Effect of Warfarin Addition in Diabetic Foot Ulcer Patients Receiving Cilostazol In Mohammad Hoesin Hospital, South Sumatera, Indonesia

Speaker: Erti Sundarita Maksudin (Indonesia)

Haemostatic Profile of Nigerian Children with Nephrotic Syndrome (NS)

Speaker: Theresa Nwagha (Nigeria)

Role of Serpine2 (PN-1) in Diabetic Nephropathy

Speaker: Véronique Arocas (France)

Scientific Programme

Liver Dysfunction Biomarkers Correlate with a Prothrombotic and Not with a Prohemorrhagic Hemostatic Profile in Cirrhotic Patients

Speaker: Maxime G. Zermatten (Switzerland)

Utility of Prophylactic Fresh Frozen Plasma Transfusion for Correction of Coagulopathy Prior to Image-Guided Drainage for Infected Collections

Speaker: Pradakshna Porchezian (India)

Mechanisms of Blood Clotting Activation by Amniotic Fluid

Speaker: Kirill Butov (Russian Federation)

Predictive Role of Natural Anticoagulants in Prognosis of Chronic Liver Disease in Pediatric Age Group

Speaker: Sana Ajmal (Pakistan)

Simvastatin Prevents Liver and Kidney Microthrombosis After Exposure to Lipopolysaccharide by Preserving the Antithrombotic Properties of the Endothelium

Speaker: Vincenzo La Mura (Italy)

ADAMTS-13/VWF as Biomarker for Portal Vein Thrombosis Development in Cirrhotic Patients: A Prospective Study

Speaker: Monica Sacco (Italy)

APML: 2 Cases of Discordant Coagulation Results and ROTEM Testing

Speaker: Ashlyn Chee (Australia)

Diagnosis and Treatment of Obstetrics Disseminated Intravascular Coagulation in Resource Limited Settings

Speaker: Helen C. Okoye (Nigeria)

State of the Hemostatic System in Diffuse Congenital Arteriovenous Malformations of the Extremities

Speaker: Larisa Chernukha (Ukraine)

Microparticles

Microparticle-Associated Thrombin Generation in Patients with Philadelphia-Negative Myeloproliferative Neoplasms

Speaker: Olesya Matvienko (Russian Federation)

Microparticles Contribute to Hypercoagulation, but Not to Coagulation in Healthy Controls

Speaker: Muriel Meiring (South Africa)

miRNAs 126 and 223 in Microparticles from Patients with Coronary Ischemic Disease

Speaker: Aurora De la Peña Diaz (Mexico)

Influence of Specific Therapy on Microparticle-Associated Thrombin Generation in Patients with Primary Myelofibrosis

Speaker: Olesya Matvienko (Russian Federation)

Adhesive Properties of Plasma-Circulating and Platelet-Derived Microvesicles

Speaker: Elena Artemenko (Russian Federation)

Granulocyte Microvesicles with a High Plasmin Generation Capacity Promote Clot Lysis and Improve Outcome in Septic Shock

Speaker: Sylvie Cointe (France)

Scientific Programme

Plasma Platelets Microparticles as a Biomarker of Thrombotic Event in Thrombotic Thrombocytopenic Purpura Patients

Speaker: Leila Tahmasbi (Iran, Islamic Republic of)

Effects of Chemotherapy on Extracellular Vesicles and Coagulation Activation in Advanced Colorectal Cancer Patients

Speaker: Ludwig Traby (Austria)

Plasma Levels of Platelet-derived Microvesicles Are Associated with Future Risk of Venous Thromboembolism

Speaker: Omri Snir (Norway)

Expression of Circulating Microparticles Procoagulant Activity in Cirrhotic Patients

Speaker: Belakremi Mejda (Tunisia)

Characterisation of Plasma Microvesicles in Type 2 Diabetes mellitus Patients with and without Microalbuminuria

Speaker: Aishwarya Vaidya (United Kingdom)

Procoagulant Microparticles Improve Hemostasis in Mice with Haemophilia A

Speaker: Yanan Zong (Sweden)

Protein C Pathway

The Diagnostic and Prognostic Role of Protein C and Padui Scale for Prediction of Lung Vessel Thrombosis in Patients with Community-Acquired Pneumonia

Speaker: Mariia Krykhtina (Ukraine)

The Effect of Protein C on Various Links of Hemostasis

Speaker: Aziza Makhmudova (Uzbekistan)

Activated Protein-C up Regulates Microparticles Release from Ovarian Cancer Cell Line

Speaker: Massoud Mirshahi (France)

A Single-Domain Antibody that Exerts an Anticoagulant Effect Dependent on Protein S

Speaker: Josepha-Clara Sedzro (France)

Role of Endothelial Protein C Receptor Gene Polymorphisms (4678G>C and 6936A>G) in Young Indian DVT Patients

Speaker: Amit Sharma (India)

Correlation between Protein C and CCL18 Levels in Multiple Sclerosis

Speaker: Nicole Ziliotto (Italy)

Inter-Laboratory Variability of the Standardized ETP-Based APC Resistance Assay

Speaker: Laure Morimont (Belgium)

Paradoxical Platelet Inhibitory Effect of Protein C Deficiency in Shear-dependent Thrombus and Fibrin Formation

Speaker: Sanne L.N. Brouns (the Netherlands)

Clinical Presentation and Management of Homozygous Protein C Deficiency: Cukurova Experience

Speaker: Nihal Boz (Turkey)

Regulation of Coagulation

Scientific Programme

Thr90Ser Mutation in Antithrombin Causes Recurrent Thrombosis in a Heterozygous Carrier

Speaker: Yeling Lu (China)

The Effects of Acids on Whole Blood Coagulation is Depended on the Type of Acid and Concentration as Assessed by Thromboelastography (TEG)

Speaker: Gordon Ogwenko (Kenya)

Neutrophil Extracellular Trap in Patients with Peritoneal Carcinomatosis of Several Origins

Speaker: Shahsoltan Mirshahi (France)

A Hereditary Bleeding Disorder Caused by a Novel Homozygous Mutation of Thrombomodulin Gene

Speaker: Makoto Osada (Japan)

Acute Deep Vein Thrombosis Is Associated with Increased Platelet Thrombin Generation and Increased Procoagulant Oxidised Phosphatidylethanolamine

Speaker: Samya G Obaji (United Kingdom)

Heparin Affects the Induction of Regulatory T Cells Independent of Anticoagulant Activity and Suppresses the Allogeneic Immune Responses

Speaker: Yuji Kashiwakura (Japan)

Red Blood Cells Support Factor X Activation via Intrinsic Tenase

Speaker: Ivan A Chabin (Russian Federation)

Inhibition of Protein Disulfide Isomerase (PDI) with PACMA-31 Amplifies LPS-Induced Expression of Tissue Factor (TF) in Monocytes

Speaker: Lennart Beckmann (Germany)

Correlation between ADAMTS13 and VAP1 Levels in Multiple Sclerosis with Cerebral Microbleeds

Speaker: Nicole Ziliotto (Italy)

Praxbind for Reversal of Dabigatran: Experience in a Tertiary Hospital

Speaker: Aaron Lubetsky (Israel)

Platelet Activation via GPVI Initiates FXII- and TF-independent Thrombin Generation

Speaker: Li Li (the Netherlands)

Exploring the Effectiveness of DNA and Glycosaminoglycans as Inhibitors of Histones

Speaker: Neha Sharma (Canada)

The Role of the Protein C Pathway in Hemostasis: The Importance of Physiological Context

Speaker: Tanya T. Marar (United States)

Inhibition of Factor Xa by Specific Reversible Inhibitors Is Selective for Factor Xa Generated by Factor IXa

Speaker: Cornelis Kluft (the Netherlands)

System Wide Investigation into Coagulation Profile of Premature Myocardial Infarction Subjects

Speaker: Joanne Dunster (United Kingdom)

A novel Interaction between Coagulation Factor XI and its Activated Form, FXIa, with the Complement Protein Properdin

Speaker: Samantha Louise Heal (United Kingdom)

Scientific Programme

Plasma Levels of DNase I Activity and Circulating-free DNA Are Associated to an Increased Risk of Venous Thromboembolism

Speaker: Julia Oto (Spain)

Study of a New Synthetic Thrombin Inhibitor IEM-2280

Speaker: Daria Grigorieva (Belarus)

Coagulation Factor Xa [(Recombinant) Andexxa®] for Reversal of Apixaban and Rivaroxaban in Patients Diagnosed with Intracranial Hemorrhage

Speaker: Mark Vestal (United States)

Tissue Factor Pathway

A Membrane-Adjacent Region in Tissue Factor Provides Substrate Selectivity

Speaker: Fabienne Birkle (United States)

Coagulation Factor IIIa (f3a) Knockdown in Zebrafish Leads to Defective Angiogenesis and Bleeding Phenotype

Speaker: Saravanan Subramaniam (United States)

Plasma Tissue Factor Pathway Inhibitor (TFPI) in Pediatric End Stage Liver Disease

Speaker: Amir H Navaei (United States)

Tissue Factor Pathway Inhibitor Is Increased in Plasma of Patients with a mild to Moderate Bleeding Tendency Independent of Known Genetic Variations in the factor V Encoding Gene

Speaker: Dino Mehic (Austria)

Simulation of TF-dependent Factor X Activation on Phospholipid Vesicles: The Role and Importance of Individual Reaction Stages

Speaker: Tatiana Kovalenko (Russian Federation)

Anticoagulant Activity in Unclassified Bleeding Disorders

Speaker: Danielle White (United Kingdom)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Diagnostics and OMICs Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Biomarkers of Thrombosis and Hemostasis

Gene-Gene Interactions of Folate Cyclein as a Potential Factor of the Risk of Thromboses in Patients with Breast Cancer

Speaker: Alexander Markovsky (Russian Federation)

The Diagnostic Significance of Platelet-Derived Microparticles Quantification by Flow Cytometry in Egyptian Patients with Ischemic Heart Disease

Speaker: Nermeen Farouq (Egypt)

High TAFI Level as a Predictor of VTE Recurrences during Long-Term Warfarin Therapy

Speaker: Natalya Vorobyeva (Russian Federation)

Scientific Programme

Soluble Glycoprotein VI is an Independent Predictor of Major Bleeding in Patients with Suspected Heparin-Induced Thrombocytopenia

Speaker: Allyson Pishko (United States)

Global Coagulation Assays in Patients with Chronic Kidney Disease

Speaker: Hui Yin Lim (Australia)

Evaluation of Global Coagulation Assays in Pregnancy

Speaker: Hui Yin Lim (Australia)

Laboratory Accuracy Assessment of a Novel INR Point-of-Care Test Compared with Laboratory Reference Methods Used Across Four Independent Clinical Sites

Speaker: Jayne Ellis (United Kingdom)

Platelet Procoagulant Membrane Dynamics in Cardiac Surgery with Cardiopulmonary Bypass: Outcomes of a Pilot Study

Speaker: Ejaife Ono Agbani (Canada)

Plasma Levels of von Willebrand Factor and Future Risk of Incident Venous Thromboembolism

Speaker: Magnus Sandvik Edvardsen (Norway)

Circulating MicroRNAs and Platelet Extracellular Vesicles as Novel Biomarkers in Acute Ischaemic Stroke

Speaker: Ceren Eyileten (Poland)

The Presence of Anti-Phosphatidylserine/Prothrombin Antibodies Enhance Differences in the Thrombin Generation Phenotype among Subjects with Lupus Anticoagulant Not Meeting Antiphospholipid Syndrome Criteria

Speaker: Diego Velasco-Rodríguez (Spain)

Canonical Signaling Pathways Dysfunctions in the Development of Major Cardiovascular Complications, Circulating Micrornas as Novel Biomarkers and their Link to Inflammation in Diabetic Patients

Speaker: Ceren Eyileten (Poland)

The Importance of Altered Symmetric Dimethylarginine Levels with Platelet Hyperreactivity in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

Speaker: Ceren Eyileten (Poland)

Standardization of a Flow Cytometry Platelet Sialylation Assay, and reference Values for Beta-Galactose Exposure in Healthy Subjects

Speaker: Alexandre Kauskot (France)

Upregulation of Inflammatory Biomarkers in Pulmonary Embolism as Studied by a Biochip-Array Profiling Approach

Speaker: Emily Bontekoe (United States)

Preanalytical Considerations for Evaluation of NETosis Biomarkers

Speaker: Chloé James (France)

Cell-free DNA Is Elevated in Chronic Myeloproliferative Neoplasms: Correlation with Thrombosis and Disease Progression

Speaker: Geraldine De Luca (Argentina)

Influence of Antiphospholipid Antibodies on Arterial Thrombosis in Myeloproliferative Neoplasia Patients: One Centre Experience

Speaker: Rūta Dambrauskienė (Lithuania)

Scientific Programme

Evaluation of Plasma Level of Soluble CLEC2, a Novel Platelet Activation Marker, in Patients with Sepsis Induced Coagulopathy -A Pilot Study

Speaker: Hiroyasu Ishikura (Japan)

Quantification of Neutrophil Extracellular Trap by Flow Cytometry: Technical Development

Speaker: Pierre-Elia Chaghouri (France)

Evaluation of the Accuracy of INR Values Measured by a POCT System in a German Clinic with Patients Taking Phenprocoumon as VKA Therapy

Speaker: Jayne Ellis (United Kingdom)

Comprehensive Platelet Phenotyping Supports the Role of Platelets in the Pathogenesis of Acute Venous Thromboembolism - Results from Clinical Observational Studies

Speaker: Marina Panova-Noeva (Germany)

Neutrophils Extracellular Traps (NETs) Contribute to Thrombin Generation (TG) Potential in Patients with Essential Thrombocythemia (ET)

Speaker: Sara Gamba (Italy)

Extensive Characterization of the Hemostatic Changes during Cytoreductive Surgery (CRS) with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients with Peritoneal Carcinomatosis

Speaker: Patricia Gomez Rosas (Italy)

The Role of Phosphatidylserine-Exposing Microparticles and Glycophorin-Exposing Microparticles in Hemostasis System in Children with Hemolytic Anemia

Speaker: Elena Seregina (Russian Federation)

Usefulness of D-dimers Levels Determination in the Prediction of Thromboembolic and Cardiovascular Events in Patients with Atrial Fibrillation during Anticoagulant Therapy

Speaker: Sarra Bounaas (Algeria)

Analysis of Biomarkers of Hemostatic Dysregulation and Inflammation in Lymphoma Patients

Speaker: Darko Antic (Serbia)

Clot Contraction Drives Structural Redistribution of Platelets, Fibrin and Red Blood Cells through Active Cell Sorting

Speaker: Valerie Tutwiler (United States)

Histidine-rich Glycoprotein Levels Contribute to Prolonged Clot Lysis Time in Acute Pulmonary Embolism

Speaker: Patrick Bladdek (Poland)

Platelet-Associated Tissue Factor Predicts 5-Years Mortality in Coronary Artery Disease Patients

Speaker: Marta Brambilla (Italy)

Dyslipidaemia Associated with Increase of Thrombin Generation in Renal Transplant Recipients

Speaker: Suellen Martins (Brazil)

Active Thrombin and its Value: New Approach to Diagnosis of Thrombosis?

Speaker: Jan Dyr (Czech Republic)

FM and D-di in Preeclampsia and in vitro Fertilization

Speaker: Tatiana Vavilova (Russian Federation)

Scientific Programme

Identification of a Circulating Lipid Profile Associated with Venous Thromboembolism

Speaker: Alvaro Fernandez-Pardo (Spain)

Circulating MicroRNA Levels Indicate Platelet Activation in Endotoxemia Despite Platelet P2Y₁₂ Inhibition

Speaker: Clemens Gutmann (United Kingdom)

Profiling of Inflammatory Biomarkers and Coagulation Factors in End-stage Renal Disease

Speaker: Emily Bontekoe (United States)

LBP as a Novel Plasma Protein Associated to Venous Thromboembolism

Speaker: Alvaro Fernandez-Pardo (Spain)

Development of a Microfluidic Pillar Device to Study Hemostasis in vitro

Speaker: Hari Hara Sudhan Lakshmanan (United States)

Familial Thrombophilia of Unknown Origin (TUO) Is Associated with Low Activated Protein C (APC) Response to in vivo Thrombin Formation in Stimulated Hemostasis Activity Pattern Evaluation (SHAPE)

Speaker: Heiko Rühl (Germany)

Cross-sectional Study of Thrombin Generation and Overall Hemostatic Potential in a Cohort Clinically Investigated for Thrombophilia

Speaker: Maria Farm (Sweden)

Molecular Pathogenesis of Bone Degenerative Disease and Associated Inflammatory and Thrombotic Processes

Speaker: Priya Joshi (United States)

Defining Acetylsalicylic Acid Responsiveness: Understanding the Relation between Thromboxane B₂ Inhibition and Aggregation Induced by Arachidonic Acid

Speaker: Paul Gurbel (United States)

The Prognostic Role of Red Cell Distribution Width in Venous Thromboembolism and Related Mortality

Speaker: Muhamad Fajri Adda'i (Indonesia)

Acquired Antithrombin III Deficiency Is a Risk Factor for Venous Thromboembolism after Severe Injury

Speaker: Jessica Cardenas (United States)

Evaluation of Thrombomodulin Levels in Women with Breast Cancer Undergoing Doxorubicin Treatment

Speaker: Michelle Teodoro Alves Vieira (Brazil)

RMean Platelet Volume to Lymphocyte Ratio and VTE Recurrence

Speaker: Ana Carina Pizzarossa (Uruguay)

Panel of Prothrombotic-inflammation Genetic Markers and Thrombin Generation Assay for Evaluation of Thromboprophylaxis and Thrombosis Risk in Thrombophilia Patients

Speaker: Ana-Rebeca Jaloma-Cruz (Mexico)

Blood Components and Management

Administration of Fibrinogen vs. Cryoprecipitate Stored out to 10 Days in Microfluidic Models of Coagulopathies in Hemorrhage

Speaker: Susan M. Shea (United States)

Scientific Programme

Improved Functional and Biochemical Characteristics of Buffy-Coat Platelet Concentrates Stored in Citrate-Free PAS-III Additive Solution for 7 Days

Speaker: Catherine Ravanat (France)

An Audit of Fresh Frozen Plasma Transfusions: Justified or Not?

Speaker: Ayesha Memon (Pakistan)

Thromboelastometry Identifies Coagulopathy Associated with Liver Failure and DIC Caused by Yellow Fever, Guiding Specific Hemostatic Therapy: A Case Report

Speaker: Tomaz Crochemore (Brazil)

Apoptosis Inhibition during Cold Storage of Apheresis Platelet Concentrates Improves Cell Vitality without Affecting the Functionality

Speaker: Irene Marini (Germany)

Study of the Stability of the Main Parameters of Hemostasis Over Six Hours

Speaker: Soraya Hadjali - Saichi (Algeria)

The Use of Platelet Transfusions during Extracorporeal Membrane Oxygenation in a Large Tertiary Centre

Speaker: Andrew Doyle (United Kingdom)

The Functional Profiles of Platelets Collected from Blood Diversion Pouches and Apheresis Concentrates Are Comparable to the Ones from Platelets Isolated through Standard Methods

Speaker: Pavel Davizon-Castillo (United States)

Deciphering the Protein Secretome of Leukocyte-platelet Rich Fibrin

Speaker: Lidia Hermida Nogueira (Spain)

Six Years of Experience with Plasma Fractionation Industries at a Private Super Speciality Hospital in South India: Renaissance in Usage of Excess Plasma in Blood Banks

Speaker: Bala Bhasker (India)

Overdosing of Protamine during Cardiopulmonary Bypass May Increase Use of Unnecessary Blood Product Administration when Monitoring with ROTEM

Speaker: Christopher Webb (United States)

Cellular Therapies

Enhancing Transfusable Platelets Using mRNA Therapy to Produce Exogenous Proteins

Speaker: Jerry Leung (Canada)

Gene Therapy Model by Modification of F9 Gene through CRISPR/Cas9 for Functional Factor IX Production in Mesenchymal Stem Cells: Preliminary Results

Speaker: Irving Jair Lara Navarro (Mexico)

Epigenetics, OMICs and Bioinformatics

Quantitative Mass-Spectrometry-Based Targeted Proteomics of Plasma from Colorectal Cancer Patients with Venous Thromboembolism

Speaker: Jeroen T Buijs (the Netherlands)

Interest of Improved Z-Score Bivariate Analysis: Application to a ECAT DDimer Survey

Speaker: Frederic Sobas (France)

Physicochemical Changes by Missense Mutations Influences in Hemophilia A Determination

Speaker: Mariana Meireles (Brazil)

Scientific Programme

Protein Expression Profiling Suggests Relevance of Non-Canonical Pathways in Isolated Pulmonary Embolism

Speaker: Vincent Ten Cate (Germany)

Development of an Accessible Open Source Code in Python for High-Resolution Melting Data Analysis from Patients Diagnosed with Hemophilia A in Bogotá, Colombia

Speaker: Juliana Lago (Colombia)

Exome-array Analysis of Plasma Hemostatic Factors D-dimer, tPA and PAI-1 Identifies Novel Genes

Speaker: Florian Thibord (France)

The CDC Hemophilia A Mutation Project (CHAMP) F8 Mutation List: 2020 Update

Speaker: Amanda B. Payne (United States)

Von Willebrand Disease Type 1 Is Associated with Number of Rare Nonsynonymous Variants in the VWF Gene

Speaker: Brooke Sadler (United States)

Laboratory Diagnostics

Severe Haemophilia A Plasma Artificially Spiked with Emicizumab and Recombinant Factor VIII Concentrates: Measurement by One-Stage and Chromogenic Factor VIII Assays

Speaker: Annette Bowyer (United Kingdom)

The use of an Automated Thrombin Generation Assay for the Measurement of Emicizumab and Recombinant Factor VIII in Spiked Plasma

Speaker: Annette Bowyer (United Kingdom)

Diagnosing and Categorizing Acquired Fibrinolysis Activity with Global Hemostatic Assays

Speaker: Ganesh Mohan (India)

Negative Effect of Pre Pre-Analytical Error Sources on the APTT Test

Speaker: Carmen Delianu (Romania)

Rotational Thromboelastometry - A Point of Care Tool to Assess Bleeding Risks in Hemophilia A and B

Speaker: Andaleb Kholmukhamedov (United States)

Effect of Dabigatran versus Enoxaparin on Blood Coagulation using the Viscoelastic Coagulation Test

Speaker: Vanessa M. Silva (Brazil)

Low-Angle Light Scattering for the Analysis of the Platelet Functions: Preanalytical Variables and Evaluation in Pediatric Patients

Speaker: Galina Svidelskaya (Russian Federation)

Lidocaine Effects on Coagulation Assessed by Whole Blood Rotational Thromboelastometry

Speaker: Ecaterina Scarlatescu (Romania)

The Sensitivity of Two New APTT Reagents to Factors VIII, IX and XI

Speaker: Annette Bowyer (United Kingdom)

Establishment of a Novel Mixing Test Using Activated Partial Thromboplastin Time (aPTT)-Based Clot Waveform Analysis

Speaker: Naruto Shimonishi (Japan)

Scientific Programme

Influence of Anticoagulants on the Biomechanical Phenotype of Platelets

Speaker: Raghavendra Palankar (Germany)

Evaluation of the Newly-developed Collagen Induced Platelet Aggregation Level (CPAL) System in Aggregometer on Automated Coagulation Analyzer

Speaker: Keisuke Kitano (Japan)

Heparin-Insensitive Chromogenic Measurement of Activated Factor XI

Speaker: Alfred Weber (Austria)

UK NEQAS for Blood Coagulation D-Dimer Point of Care Testing Programme: A Review of Data

Speaker: Dianne Patricia Kitchen (United Kingdom)

Laboratory Test Ordering Practices for Suspected Heparin-Induced Thrombocytopenia

Speaker: Paul Lindholm (United States)

Comparison of the Biophen® Heparin LRT with the HemosIL® Liquid Anti-Xa Assay for the Measurement of Apixaban, Edoxaban and Rivaroxaban

Speaker: Christian Bundschuh (Austria)

Estimation and Analysis of Measurement Uncertainty Acceptability: The Interest of Bayesian Inference

Speaker: Frederic Sobas (France)

Long-Term Internal Quality Control Management: The Interest of Bayesian Inference

Speaker: Frederic Sobas (France)

The Effect of RBCs on Different Platelet Count Enumeration Methods in Patients with Hemoglobinopathies

Speaker: Roshini Shekhar (India)

Inter-Centre and Inter-Observer Agreement of Determination of DOACs in Urine Samples of Patients by Means of DOAC Dipstick Test

Speaker: Job Harenberg (Germany)

Discrimination between Acquired Hemophilia A and Lupus Anticoagulant Using Rotational Thromboelastometry (ROTEM)

Speaker: Yushi Chikasawa (Japan)

Development of a Logistic Regression Model for Prediction of Conversion Risk from Mild Cognitive Impairment (MCI) to Alzheimer's Disease (AD)

Speaker: Gisele Santos Gonçalves (Brazil)

XIIa-Dependent Fibrinolysis in Patients with Ph-Negative Myeloproliferative Neoplasms (MPN)

Speaker: Natalya Silina (Russian Federation)

Multicentre Performance Evaluation of the Protein C Chromogenic Assay on the Cobas t 711 Analyser

Speaker: Moniek P.M. de Maat (the Netherlands)

Performance Evaluation of Anysis-200 Platelet Function Analyzer in Cardiology Patients

Speaker: Sehyun Shin (Korea, Republic of)

The Basic Evaluation of the Newly Developing Modified Diluted Prothrombin Time Reagent for Direct Oral Anticoagulants Measurements

Speaker: Osamu Kumano (Japan)

Scientific Programme

New Formula of “Ratio of Inhibited Thrombin Generation” Based on Modified Diluted Prothrombin Time Reagent Predicts Bleeding Risk of Patients with Low Coagulation Activity in Direct Oral Anticoagulants Therapy

Speaker: Osamu Kumano (Japan)

Extensive Experiments in (Un)Diagnosed Bleeding Patients with Prolonged Platelet Function Analyser Closure Times

Speaker: Floor Heubel-Moenen (the Netherlands)

Assessing the Quality of Interpretative Comments for Prolonged Activated Partial Thromboplastin Time and Mixing Tests

Speaker: Josep Miquel Bauça (Spain)

APTT Clot Waveform Analysis: A Tool in Prediction of Pre-Analytical Errors in Short APTT-Retrospective Analysis

Speaker: Rajesh Phatale (India)

Paediatric APTT, PT and Fibrinogen Reference Intervals Using STA® - CK Prest, STA® - NeoPTimal and STA® - Liquid Fib

Speaker: Natasha Letunica (Australia)

Impact of Combination of Factor VIII-Deficient Plasma and Activator in One-Stage Clotting Assay on Potency Testing of Factor VIII Products

Speaker: Atsuo Suzuki (Japan)

Establishing an External Quality Assessment Scheme (EQAS) for D-Dimer Assay in India: Results from a Pilot

Speaker: Sukesh Nair (India)

Multicentre Performance Evaluation and Reference Range Determination for a New Assay for the Quantitative Evaluation of Factor VIII in Citrated Plasma

Speaker: Anna Lowe (United Kingdom)

Correlation between the VerifyNow P2Y12 Assay and the Newly-Developed APAL System in Neuroendovascular Patients

Speaker: Tasuku Sakayori (Japan)

FIBTEM Parameters Correlate Well with the Fibrinogen Concentration Measured by the Clauss Assay in Patients and Healthy Subjects

Speaker: Judith Juliana de Vries (the Netherlands)

Performance of Thrombophilia Markers Assays Evaluated from Results of an External Quality Assessment Program

Speaker: Chantal Bon (France)

Comparison of New Scoring System of Platelet Aggregation on Automated Coagulation Analyzer CN-6000 with CS-5100

Speaker: Tasuku Sakayori (Japan)

Basic Evaluation of Novel Automated Coagulation Analyzer CN-6000

Speaker: Ryosuke Narisada (Japan)

Sample Stability for a Broad Panel of Coagulation Assays on the Cobas t 711 Analyser Using Plasma Stored under Different Conditions

Speaker: Michael Hoffmann (Germany)

Scientific Programme

Comparison of a Novel Viscoelastic Device with Standard Laboratory Tests for its Clinical Validation in Peri-Operative Cardiac Patients

Speaker: Bethany Brannan (United Kingdom)

The PFA Results Are Affected by Low Number of Platelets, Low Hematocrit and High Proportion of Immature Platelets

Speaker: Petr Kessler (Czech Republic)

Hemostatic and Inflammatory Markers in Patients with Alzheimer's Disease or Frontotemporal Dementia

Speaker: Cristina De Mello Loures (Brazil)

Effect of Antiepileptic Therapy on Platelet Aggregation

Speaker: Ivana Čelap (Croatia)

Analysis of Megathrombocytes as a New, Fast, and Low Cost Tool to Indicate Thrombosis and Predict Prognosis in Sickle Cell Disease

Speaker: Luciana Wermelinger Serrao (Brazil)

Does Normal Diluted Russell Viper Venom Time Test Result Can Exclude Concentrations of Direct Oral Anticoagulants below 30 ng/mL?

Speaker: Sandra Margetić (Croatia)

Method Comparison of Eight Coagulation Assays on the Cobas t 411 versus Cobas t 511/t 711 Analysers

Speaker: Jürgen Oberstraß (Germany)

Effect of Activated Charcoal in Removing Interference in Thrombophilia Assays: Resistance to Activated Protein C, Activity of Coagulation Factor VIII and Antithrombin Activity

Speaker: Sandra Margetić (Croatia)

Modified Anti-Xa Assay for Measuring Betrixaban (Bevyxxa®) Activity in Plasma on STA-R Max

Speaker: Matthieu Bourdin (France)

An Improved Algorithm for the Detection of Lipemia as Interfering Substances on a Fully Automated Coagulation Analyzer

Speaker: Silke Echternacht (Germany)

Fibrinogen Prothrombin Time Derived Method Is Not Useful in Anticoagulated Patients with Apixaban

Speaker: Cristina Duboscq (Argentina)

Platelet Aggregation Testing by Light Transmission Aggregometry with Drug Specific Agonists in Patients on Mono and Dual Antiplatelet Therapy

Speaker: Sandra Margetić (Croatia)

Multicentre Performance Evaluation and Reference Ranges for a New Assay for Quantitative Determination of von Willebrand Factor (vWF) Activity

Speaker: Steve Kitchen (United Kingdom)

Comparison of Two Quantitative Methods for Determination of Dabigatran Concentration: Diluted Thrombin Time Test and Innovance Dabigatran Test in Real Life Patients Treated with Dabigatran

Speaker: Sandra Šupraha-Goreta (Croatia)

Scientific Programme

Pre - Analytical Variables in Haemostasis: Results of the UK National External Quality Assessment Scheme for Blood Coagulation Haemolysis Supplementary Exercise

Speaker: Lilia Brown (United Kingdom)

Loop-Mediated Isothermal Amplification without DNA Extraction for Simultaneous Detection of Factor V Leiden and Prothrombin-G20210A Genetic Variants

Speaker: Giovanni, Luca Tiscia (Italy)

Comparative Evaluation of the Aggregation Studies in a Sysmex CS2500 Coagulometer with a Standard Turbidimetric Technique

Speaker: Ana Belen Moreno Castaño (Spain)

Multicentre Performance Evaluation and Reference Ranges for the Quantitative Determination of Factors II, V and VII by One-Stage Factor Assay on the Cobas t 711 Analyser

Speaker: Steve Kitchen (United Kingdom)

Low Molecular Weight Heparin Calibrated Anti-Xa Assays can Identify Patients with Low Apixaban or Rivaroxaban Drug Levels

Speaker: Siraj Mithoowani (Canada)

Bethesda Assay for the Detection and Titration of an Anti-VIII Inhibitor: Interest of the Chromogenic Assay

Speaker: Christophe Nougier (France)

Thrombin Generation Analysis in Patients with Venous Thromboembolism and Atrial Fibrillation on Anticoagulant Therapy: Comparison between Direct Oral Anticoagulants and Antivitamin K Antagonists

Speaker: Claudia Dellanoce (Italy)

Validation of a Warfarin Dose Prediction Model: A Single Center Retrospective Study

Speaker: Aaron Lubetsky (Israel)

Biosimilar Enoxaparin Sodium Inhixa® Compared with Clexane®: An in vitro Study

Speaker: Claudia Dellanoce (Italy)

Discrepant Interpretation of HIT Screening Results on the Same Sample - Data from a UK NEQAS for Blood Coagulation Exercise

Speaker: Ian Jennings (United Kingdom)

Antifactor Xa Levels vs. Activated Partial Thromboplastin Time for Monitoring Unfractionated Heparin

Speaker: Vanessa M. Silva (Brazil)

Effects of Rivaroxaban on Thrombophilia Screening Tests - Results from a UK NEQAS (Blood Coagulation) Exercise

Speaker: Ian Jennings (United Kingdom)

Analytical Performance Validation of the T-TAS 01 PL Assay

Speaker: Jeffrey Dahlen (United States)

Clinical Validation of the T-TAS 01 PL Assay in Patients with von Willebrand Disease and Glanzmann's Thrombasthenia

Speaker: Jeffrey Dahlen (United States)

Clinical Validation of the T-TAS 01 PL Assay in Patients Taking Antiplatelet Therapy

Speaker: Jeffrey Dahlen (United States)

Scientific Programme

Comparison of the T-TAS 01 PL Assay with PFA-100 for Assessment of Primary Hemostatic Function

Speaker: Jeffrey Dahlen (United States)

Evaluation of a New Benzylsulfonyl-D-Arg-Pro-4-Amidinobenzylamide (BAPA) Blood Collection Tube for Platelet Function Studies

Speaker: Jeffrey Dahlen (United States)

Correlation between Thrombin Generation and Prothrombin Fragment F1+2 Plasma Levels

Speaker: Marco Capecchi (Italy)

Global Thromboelastometry in Patients with Acute Bleedings on Direct Oral Anticoagulant (DOA) Treatment: The RO-DOA Bleed Study

Speaker: Maria Cristina Vedovati (Italy)

Laboratory Assessment of Efficacy and Safety of Direct Oral Anticoagulants in Real Clinical Practice

Speaker: Nadezda Vorobyeva (Russian Federation)

Effect of Vitamin K Antagonist Therapy on the Dynamics of Hypercoagulation Syndrome in Patients with Deep Vein Thrombosis

Speaker: Nadezda Vorobyeva (Russian Federation)

An International Study on the Interpretation of Test Results of the APTT Mixing Test

Speaker: Piet Meijer (the Netherlands)

Challenges in Anticoagulation Management at an Academic Medical Center, 20 Years of Clinical Observations

Speaker: Scott Kogan (United States)

Influence of Phospholipids on the Measurement of Extended Half-Life Factor VIII Activity in One-Stage Clotting Assay

Speaker: Yuta Fujimori (Japan)

Application of EP15A3 and EP15A2 Protocols to Verify the Performance of a Coagulometer in the Coagulation Laboratory of the National Institute of Respiratory Diseases in Mexico City

Speaker: Brenda Sarai Zuñiga Ascencio (Mexico)

Accuracy of Commercial Universal Calibrators for Measurement of Heparin and Low Molecular Weight Heparin

Speaker: John Hogwood (United Kingdom)

The Effect of trough Dabigatran Plasma Concentration on Thrombin Generation

Speaker: Marija Milic (Croatia)

Sigma Metrics Scores for Routine Haemostasis Assays in a Small Laboratory

Speaker: Halimatun Radziah Binti Othman (Malaysia)

Laboratory Analysis of Half-Life-Prolonged Coagulation Factors VIII Rurioctocog Alfa Pegol and IX, Nonacog Beta Pegol and of rVWF - Vonicog Alpha in Spiked Human Plasma Samples - First Results of a Multicentre Study by the Austrian Laboratory Societies ÖGLMKC and ÖQUASTA

Speaker: Alexander C. Haushofer (Austria)

Comparison of Visual versus Reader Results of the Point of Care Test of Direct Oral Anticoagulants from Urine Samples

Speaker: Job Harenberg (Germany)

Scientific Programme

Monitoring of Direct Oral Anticoagulants in Routine Practice

Speaker: Lidija Lokar (Slovenia)

Performance of Thrombin Generation Test (TGT) versus Conventional Coagulometric Methods in Snakebites: Preliminary Results

Speaker: Rita Carolina Figueiredo Duarte (Brazil)

The Basic Evaluation of Light Transmission Platelet Aggregation Method on an Automated Coagulation Analyzer CN-6000

Speaker: Mai Egashira (Japan)

Comparison of the One-Stage Clot-Based and Chromogenic Factor VIII Activity Measurement

Speaker: Radhiya Al Buraidi (Oman)

A Strategy for the Prenatal Diagnosis for Fetus with Hemophilia A without Genetic Defects

Speaker: Yihong Li (China)

The Effects of EDTA as an Anticoagulant and Delayed Processing on the Measurement of Plasma VWF Antigen

Speaker: Matthew Christopher Sims (United Kingdom)

Evaluation of EQA Material on Lumira Dx Point of Care Platform: UK NEQAS for Blood Coagulation Study

Speaker: Lilia Brown (United Kingdom)

The Novel Prothrombin Time (MRX PT DOAC) Assay - Can Be Used to Detect Interfering DOACs in Thrombophilia Investigation

Speaker: Liselotte Onelöv (Sweden)

Assessment of ExpertCor, a New Set of Frozen Plasmas for Assay Comparability Studies

Speaker: Audrey Carlo (France)

Clinical Performance of the Tina-Quant D-Dimer Gen 2 Assay on the Cobas t 711 Analyser for Evaluation of Patients with Suspected Deep Vein Thrombosis (DVT) and/or Pulmonary Embolism (PE)

Speaker: Thomas Bertsch (Germany)

Reference Values of 117 Healthy Donors on the ST Genesia with the STG-BleedScreen, STG-DrugScreen and STG-ThromboScreen Reagents

Speaker: Marisa Ninivaggi (the Netherlands)

The Severity of Hemophilia A Patients Varies among Different Types of Factor VIII Gene Mutation

Speaker: Yihong Li (China)

Measuring Thrombin Generation in the Presence of Haemoglobin on the ST Genesia

Speaker: Marisa Ninivaggi (the Netherlands)

Variable Findings in One-Stage Clotting Assays in a Patient with Waldenstrom's Macroglobulinaemia

Speaker: Sean Platton (United Kingdom)

Assessing the Effect of Freezing and Thawing of Samples for Anti-Factor Xa Testing for the Determination of Enoxaparin Activity

Speaker: Susan Louw (South Africa)

Scientific Programme

Apixaban Plasma Concentration Estimation by Anti Xa Activity Assay Calibrated with Heparin Calibrators with 2 Different Reagent/Systems

Speaker: Marta M Martinuzzo (Argentina)

A Performance Evaluation of Chemiluminescent-Enzyme Immunoassays on a Routine Coagulation Analyser

Speaker: Chris Gardiner (United Kingdom)

Assessment of the CN-6000; a Novel, High-Speed Coagulation Analyser, Utilising Coagulation, Chromogenic, Immuno-Turbidimetric and Light Transmission Aggregation Technologies

Speaker: Anita Woolley (United Kingdom)

Can Bone Marrow Cells Be Differentiated and Counted Using a Novel Hematology Analyzer?

Speaker: Zühre Kaya (Turkey)

Excluding Anticoagulants and Antiplatelet Drugs with Rotational Thromboelastometry

Speaker: Anne-Marije Hulshof (the Netherlands)

Rivaroxaban Plasma Concentration Values and Risk Factors for Adverse Events in Patients Experiencing Bleeding: Results from a Prospective Study

Speaker: Jüri Arjakse (Estonia)

Clinical Exomes for the Diagnosis of Inherited Bleeding, Thrombotic and Platelet Disorders: The Belgian Experience

Speaker: Christine Van Laer (Belgium)

An Evaluation of the Assay Performance of the Antifactor Xa Assay for Rivaroxaban

Speaker: Vishnu Prasad (Singapore)

ISTH SSC Plasma Standard Lot #5 - Results in a UK National External Quality Assessment Scheme for Blood Coagulation (NEQAS BC) Exercise

Speaker: Ian Jennings (United Kingdom)

Analytical Verification of Automated Latex-Enhanced Particle Immunoturbidimetric D-Dimer Assays on Different Analytical Platforms and Comparability of Test Results

Speaker: Ivana Lapić (Croatia)

Correlation between INR Pocket Test and Standard Coagulation Test

Speaker: Alicia.B Vilaseca (Argentina)

The SSC Working Party on Thrombin Generation: Inventory of Thrombin Generation Methods

Speaker: Marisa Ninivaggi (the Netherlands)

DOAC Intra-individual Variability in Patients with Non Valvular Atrial Fibrillation

Speaker: Sophie Testa (Italy)

Evaluation of INR and APTTs Using the Q Family of Analysers in Comparison to ACL TOP

Speaker: Anita Woolley (United Kingdom)

Genetic Analysis for Investigation of Heritable Bleeding and Thrombotic Disorders - Variable Interpretation of Data Identified by the UK National External Quality Assessment Scheme (UK NEQAS) Blood Coagulation Programme

Speaker: Ian Jennings (United Kingdom)

Variability in Dabigatran and Apixaban trough Concentrations

Speaker: Patrizia Della Valle (Italy)

Scientific Programme

A Universal Quality Control Plasma for Anti-Xa and Anti-IIa Drugs

Speaker: Loris Pozzi (Italy)

Hemostatic Profile: Is There Any Difference between Alzheimer's Disease and Frontotemporal Dementia?

Speaker: Cristina De Mello Loures (Brazil)

How Does Changing the Reagent/Instrument Affect the INR?

Speaker: Mohamed Amine Hmida (Tunisia)

An Evaluation of Treatment Monitoring in Patients with VWD Using a Chemiluminescent (VWF:GP1bR) Assay Compared to a Lyophilised Platelet Assay with Ristocetin (VWF:RCO)

Speaker: Anne Riddell (United Kingdom)

Evaluation of the Succeder SF-8200 Fully Automated Coagulation Analyzer

Speaker: Oguzhan Zengi (Turkey)

Evaluation of Hemostatic Markers in Patients with Sickle Cell Disease Using or Not Hydroxyurea

Speaker: Melina Pinheiro (Brazil)

The Effect of Haemolysis in Patient Samples on Coagulation Tests Performed on ACL TOP 550

Speaker: Kieron Hickey (United Kingdom)

Analysis of Platelet Functional Activity by Flow Cytometry: Reference Intervals and Cut-off Value for Evaluating the Efficiency of Antiplatelet Therapy

Speaker: Aleksei Ermakov (Russian Federation)

Evaluation of IgG4 ELISA for the Screening of Factor VIII Inhibitors in Hemophilia A

Speaker: Namrata Awasthi (India)

Doac-Remove™ Can Neutralize the Effect of Direct Oral Anticoagulants on Lupus Anticoagulant Assay: A Single-centre Experience

Speaker: Diego Velasco-Rodríguez (Spain)

Influence of DOAC Remove on Coagulation Assays During Thrombophilia Testing in Patients Treated with Rivaroxaban or Dabigatran

Speaker: Mirjana Kovac (Serbia)

Impact of Centrifugation on Thrombin Generation Analysis Evaluated in Healthy Subjects and Patients Treated with Direct Oral Anticoagulants

Speaker: Michaël Hardy (Belgium)

Performance Evaluation of Automated Thrombin Generation Measurement on Ceveron® t100 with Normalized TGA Parameters

Speaker: Lieselotte Wagner (Austria)

Quantification of Emicizumab in a Modified APTT and with Clot Growth Analysis

Speaker: Cornelis Kluft (the Netherlands)

Comparison of Different Stago Instruments for Fibrinogen Level Assessment with STA-liquid Fib

Speaker: Audrey Carlo (France)

Analytical Validation of a Novel Whole Blood Coagulometer for NOAC Testing

Speaker: Sasha Bakhru (United States)

Scientific Programme

Rivaroxaban 20 mg Once Daily Decreases Thrombin Generation in Patients with Venous Thromboembolism for up to 24 Hours

Speaker: Jan Kvasnicka (Czech Republic)

Evaluation of Thrombogenicity of Apheresis-collected Platelet Concentrates under Blood Flow Condition

Speaker: Tomoka Nagasato (Japan)

A Novel Point-of-Care Whole Blood Coagulation Assay to Screen for Hemostatic Defects

Speaker: Sanjay Ahuja (United States)

Artificial Intelligence to Identify Neutrophil Extracellular Traps in Peripherical Blood Smears

Speaker: Morayma Reyes Gil (United States)

Monitoring of Different FVIII Replacement Drugs Using the FVIII One-stage Clotting Assay on Cobas t 511/711 Analyzers

Speaker: Carolin Ketteler (Germany)

Distinguishing Patients Presenting Prolonged Activated Partial Thromboplastin Time with and without Bleeding Diathesis by Comparison of Immediate and post Incubation Mixing Test

Speaker: Yu Liu (China)

Multimer Analysis in von Willebrand Disease Diagnosis: the Experiency of Use

Speaker: Alexander Poletaev (Russian Federation)

Establishing Reference Range and Validating Precision Performance of the TES-6s System

Speaker: Min Young Lee (Korea, Republic of)

Who May Benefit from Direct Oral Anticoagulant Level Monitoring? A Systematic Literature Review

Speaker: Rebecca Vicente-Steijn (the Netherlands)

Performance of the DP-Filter to Remove DOACs from Plasma. An Analytical Validation Demonstrating its Efficiency and Innocuity

Speaker: Julien Favresse (Belgium)

Validation of a New Point-of-Care Platelet Counter

Speaker: Magdolna Nagy (the Netherlands)

DP-Filter, a Medical Device to Remove Edoxaban and Edoxaban-M4 from Plasma of Patients Taking Edoxaban

Speaker: Julien Favresse (Belgium)

The Effect of DOAC-Stop® on Several Oral and Parenteral Anticoagulants

Speaker: Nicoletta Riva (Malta)

Results of Anti-Xa Activities for Monitoring Therapeutic and Prophylactic Doses of Low Molecular Weight Heparin in Children

Speaker: Jasna Obuljen (Croatia)

Fibrinolysis Detection by TEG and ROTEM Viscoelastic Analysers: An in vitro Comparison

Speaker: Joao. D Dias (Switzerland)

Real-time Intra-site and Multi-site Correlations and Evaluation of Time Stability with the Same Frozen Plasmas Kits which Cover the Full Measuring Range for Routine Tests and Anticoagulant Monitoring Tests

Speaker: Claire Flaujac (France)

Scientific Programme

Evaluation of the Atellica® COAG 360 (Siemens Healthineers) at Caen-Normandy University Hospital (FRANCE)

Speaker: Yohann Repessé (France)

Identifying and Reducing the Cause of Haemolysis in Coagulation Blood Samples due to Sample Transport in a Pneumatic Tube System

Speaker: Steve Kitchen (United Kingdom)

Calibrated Automated Thrombogram II: A New Thrombin Generation Test

Speaker: Magdolna Nagy (the Netherlands)

A Novel Quantitative Chromogenic Fibrinogen Assay Adaptable to Centralized Laboratory Analyzers

Speaker: San Pun (Switzerland)

Possibilities of Thromboelastography in Patients with Severe Burns

Speaker: Marina Presnyakova (Russian Federation)

Feasibility of a Universal Calibrator for Direct FXa Inhibitor DOACs

Speaker: Nikolaus B. Binder (Austria)

Comparison of Thromboelastography with T2MR Data

Speaker: Michael Stolz (Germany)

Evaluation of a New Device to Remove Direct Oral Anticoagulants (DOACs) from Plasma Samples

Speaker: Pierre Olivier Sevenet (France)

Performance Evaluation of a New Fibrinogen Assay Reagent Using Recombinant batroxobin

Speaker: Rojin Park (Korea, Republic of)

Improving Comparability of Optical Aggregometry Results from Automated Coagulation Analyzer Systems Compared with a Manual Aggregometer

Speaker: Florian Prüller (Austria)

Altered FIBTEM/Fibrinogen Correlation in Liver Transplant Patients Relative to Cardiac Surgery Patients

Speaker: Eric Salazar (United States)

Effects of Anticoagulants and Common Interfering Substances on Four Commercially Available dRVVT Assays

Speaker: Ali Sadeghi-Khomami (Canada)

A Correlation of Thrombin Generation Assay and Clot Waveform Analysis in Patients on Warfarin

Speaker: May Anne Cheong (Singapore)

Diagnostic Performances Evaluation of LIAPHEN Free Protein S on CS-2500

Speaker: Claire Dunois (France)

Top 50 Cited Papers in Developmental Hemostasis: A Scoping Review

Speaker: Paul Thuan Tieu (Canada)

Health Outcomes after the Implementation of POCT Rotational Thromboelastometry in Patients Undergoing Cardiac Surgery

Speaker: Isabel Rodríguez Martín (Spain)

Scientific Programme

How Does the Availability of Thromboelastography Influence Clinical Reasoning in a Paediatric Intensive Care Unit? A Narrative View

Speaker: Amy Knott (United Kingdom)

Laboratory Validation of a Novel Hexagonal Phase Phospholipid Neutralization Assay for Lupus Anticoagulant Detection

Speaker: Colin Douglas (Canada)

Determination of Serotonin Concentration in Single Human Platelets by Single-entity Electrochemistry

Speaker: Jaewoo Song (Korea, Republic of)

Point-of-Care Method in Determining the Activated Partial Thromboplastin Time

Speaker: Marinez Farana Matos (Brazil)

Development of a Flow Cytometry-based Assay for the Detection of ITP Autoantibodies

Speaker: Miguel Neves (Canada)

New Ready-to-Use Liquid Multiplatform Global Screening Assays with Extended Stabilities to Facilitate Laboratory Practice

Speaker: Claire Dunois (France)

Updated CLOTSref: A Mobile Application for Standardized Reference Ranges in Developmental Hemostasis

Speaker: Paul Thuan Tieu (Canada)

Unique Ready to Use, Highly Stable Multiplatform Chromogenic Assays to Facilitate Laboratory Practice

Speaker: Marie Peyrafitte (France)

Establishment of Reference Intervals for Automated Light Transmission Aggregometry

Speaker: Desiree Coen Herak (Croatia)

HFLC and IPF, Can these Two Parameters Reliably Distinguish between Dengue and ITP?

Speaker: Jawad Hassan (Pakistan)

Institutional Review of Reflex Factor Coagulation Testing in Patients with an Unexplained Prolonged aPTT

Speaker: Eman M. Mansory (Canada)

Validation of the Atellica COAG 360 Coagulation Analyzer

Speaker: Emilija Krstova Krajnc (Slovenia)

Rapid Latex Enhanced Immunoassay (LIA) for Heparin Induced Thrombocytopenia and False Positivity

Speaker: Daniel Welder (United States)

Advancing the Understanding and Significance of Genetic Testing Results in Hemostasis/Thrombosis

Speaker: Kristy Lee (United States)

Factor V inhibitor in a patient with Strongyloides Stercoides and antibiotic therapy

Speaker: Mirta Arias (Argentina)

Clinically Significant Disagreement between Point-of-Care INR and Central Laboratory-assessed INR in Acute Stroke Patients

Speaker: Eric Salazar (United States)

Scientific Programme

Inherited Coagulopathies Study by Massive Sequencing (NGS) Experience of a Diagnostic Portuguese Center

Speaker: Patrícia Martinho (Portugal)

Identifying DOACs in Mixing Study Samples

Speaker: Eric Salazar (United States)

Validation of the ROTEM PLATELET® Module as an Impedance Platelet Aggregation Test Compared to the Gold Standard Test: Conventional Platelet Aggregation

Speaker: João Guerra (Brazil)

Two Cases in which Measuring Dabigatran Plasma Levels Is Indicated and Recommended

Speaker: Franco Piovella (Italy)

Quantra Reported Stiffness Values Have a Strong Linear Relationship with Clot Max Stiffness

Speaker: Francesco Viola (United States)

Interference of C - Reactive Protein Level in Activated Partial Thromboplastin Time

Speaker: Marinez Farana Matos (Brazil)

Clinical Utilization of Lupus Anticoagulant Testing in a Large Hospital System

Speaker: Anjanaa Vijayanarayanan (United States)

Prevalence and Pattern of Pseudo-thrombocytopenia in a Nigerian Tertiary Hospital

Speaker: Abiola Bolarinwa (Nigeria)

Comparison of Thromboelastometry by ROTEM® Delta and ROTEM® Sigma in Obese Patients

Speaker: Cristiana Bulato (Italy)

On the Measurement of Direct Anti-Xa-Inhibitors

Speaker: Thomas Siegemund (Germany)

Use of Liquid Low Molecular Weight Heparin Anti-Xa Assay for Detection of Apixaban

Speaker: Nicole De Simone (United States)

Impact of Anticoagulant and of Time Elapsed Since Blood Collection on Platelet Function Assessed by Multiple Electrode Impedance Aggregometry

Speaker: Michaël Hardy (Belgium)

APTT Mixing Studies in the Preoperative Setting

Speaker: Meritxell Nomdedeu (Spain)

Algorithm for Detection of Procoagulant Samples with Elevated Prothrombin and Reduced Antithrombin by their Ability to Deplete Fluorogenic Thrombin Substrate

Speaker: Mikhail Ovanesov (United States)

Batroxobin Based Method to Measure Fibrinogen to Overcome Interfering Effects of New Anticoagulant Agents Targeting Thrombin

Speaker: Jaewoo Song (Korea, Republic of)

Thrombus Formation Study of Upstream Activation and Downstream Adhesion of Platelets in a Highly Integrated Microfluidic System

Speaker: Sehyun Shin (Korea, Republic of)

Nanotechnology and Novel Biomolecules

Scientific Programme

In vitro Studies of the Blood Compatibility of Water-Soluble Pristine C60 Fullerenes

Speaker: Tetiana Halenova (Ukraine)

Effects of Squalene-Adenosine Nanoparticles on Platelet Aggregation, Thrombin Generation and Endothelial Cells

Speaker: Julie Laloy (Belgium)

Blood Compatibility of Injectable Liposomes Encapsulating Estrogen Estetrol to Prevent Cerebral Ischemia of Prematurity

Speaker: Julie Laloy (Belgium)

Thermostable Inhibitor of Contact Activation (TICA) Fully Blocks Contact Activation when Added to Blood Withdrawal Tubes

Speaker: Tom van de Berg (the Netherlands)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Fibrinolysis and Proteolysis Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Fibrinogen and Factor XIII

A Case Report of Spontaneous and Recurrent Arterial and Venous Thrombotic Events in a Child with FGA c.1372C>T Mutation

Speaker: He Yixuan (China)

Assessment of in vitro Effects of Direct Thrombin Inhibitors on Activation of Coagulation Factor XIII through Enzyme Kinetics in the Synthetic Substrate-Based Assay

Speaker: Yuta Fujimori (Japan)

Fibrinogen Concentrate Replacement Guided by Thromboelastometry Can Improve Clot Strength in Adult Dengue with Severe Thrombocytopenia

Speaker: Tomaz Crochemore (Brazil)

Factor XIIIa-Mediated Red Blood Cell Retention in the Contracting Clot Is Impaired in Hereditary Dysfibrinogenemia

Speaker: Rita Marchi (Venezuela)

Effects of Lysine-Containing Peptides Treatment on FXIII Activity and Fibrinogen Level of Metabolic Disorders

Speaker: Tatyana Shubina (Russian Federation)

High Individual Variation of Thrombin Generation by Genesia and Correlation of Fibrin-Associated ROTEM with Fibrinogen Activity in Patients with Congenital Fibrinogen Defects

Speaker: Timea Szanto (Finland)

The Glycan Structure Associated to Factor XIII Subunit B and its Functional Importance

Speaker: László Muszbek (Hungary)

Congenital Qualitative Fibrinogen Disorders: Case Series from Argentina; Multicentric Collaborative Study

Speaker: Claudio Martín Rosa (Argentina)

Scientific Programme

Fibrin Deposition in Mouse Transfusion-Related Acute Lung Injury Via Coagulation or Fibrinolysis Dysfunction

Speaker: Yunhong Yu (China)

Cellular Factor XIII Externalization in Platelets and Platelet Microparticles Induced by Receptor Mediated and Non-Receptor Mediated Platelet Activation

Speaker: Laura Somodi (Hungary)

Fibrinogen Supplementation in Patients with Acquired Hypofibrinogenaemia: Meta-Analysis and Systematic Review

Speaker: Niels Rahe-Meyer (Germany)

Transcriptome Profiling of Coagulation Factor XIII Genes: Implications for Pleiotropic Pathways and Inter-Subunit Regulation

Speaker: Muhammad Ahmer Jamil (Germany)

Comparison Natural History and Genotype of 31 Patients with Inherited Dysfibrinogenemia

Speaker: Tomas Simurda (Slovakia)

Factor XIII Cross-Links Fibrin(ogen) Independent of Fibrin Polymerization in Experimental Acute Liver Injury

Speaker: Lauren G. Poole (United States)

The Effects of (Patho)Physiological Fibrinogen γ' Levels on Static and Dynamic Clot Formation

Speaker: Fraser Macrae (United Kingdom)

Performance of a New Automated FXIII Activity Assay

Speaker: Martina Leitner (Austria)

Plasma Fibrin Clots of Acute Pulmonary Embolism Patients Present Reduced Amounts of Coagulation Factor XIII and α 2-antiplasmin Compared to Clots Generated after 3-Month Anticoagulation

Speaker: Michal Zabczyk (Poland)

Eight Successful Pregnancies in Patients with Congenital Fibrinogen Disorders - Single Centre Study

Speaker: Viera Pohlreichová (Czech Republic)

Factor XIII-A Is Present within Organelles Known to Mediate Unconventional Protein Secretion

Speaker: Richard Pease (United Kingdom)

A Genetic Modifier of Venous Thrombosis in Zebrafish Reveals a Functional Role for Fibrinogen A α E in Early Hemostasis

Speaker: Richard Fish (Switzerland)

Multi-ethnic Whole Genome Sequence Analysis of Plasma Fibrinogen in over 150,000 Samples

Speaker: Jennifer Huffman (United States)

The Fibrinogen α C Region Is a Major Contributor to the Mechanical Strength of Fibrin Fibers

Speaker: Martin Guthold (United States)

A New Genetic Alteration in Fibrinogen Gene with a Direful Phenotype: A Tie-in in a Newborn

Speaker: Tehmina Nafees (Pakistan)

Scientific Programme

Fibrinolytic Factors and Inhibitors

Fibrinolytic Response Plays a Central Role in Trauma Induced Coagulopathy

Speaker: Hau Kwaan (United States)

Carboxypeptidase U (CPU, TAFIa, CPB2) Generation in Acute Ischemic Stroke Patients Undergoing Thrombolysis and Endovascular Thrombectomy

Speaker: Joachim Mertens (Belgium)

Dipicolinic Acid Produced by Fermentation (*Bacillus subtilis natto*)

Speaker: Hiroyuki Sumi (Japan)

Nattokinase - Inhibition of Melanin Synthesis (Whitening Effect)

Speaker: Hiroyuki Sumi (Japan)

Transition Patterns in the Fibrinolytic Response are Superior to Admission ROTEM Values in Stratifying Risk for Late Clinical Outcomes after Major Trauma

Speaker: Andrea Rossetto (United Kingdom)

Modulation of Thrombin Generation or Thrombin Activity on Activated Platelets Surface Largely Affected TAFI-Dependent Regulation of Fibrinolysis

Speaker: Yuko Suzuki (Japan)

HISTORY, an International Retrospective and Prospective Registry of Patients with Plasminogen Deficiency

Speaker: Amy Shapiro (United States)

Polyphosphate Nanoparticles Are More Potent Stabilizers of Fibrin than Linear Polyphosphates and Histones Enhance their Effect

Speaker: Miklos Lovas (Hungary)

Hypercoagulability State in Iranian Patients with β -Thalassemia

Speaker: Samin Mohsenian (Iran, Islamic Republic of)

Downregulation of the Procarboxypeptidase U (proCPU, TAFI, proCPB2) System in ApoE^{-/-}Fbn1C1039G^{+/-} Mice Is a Non-Lipid Related Pleiotropic Effect of Statin Therapy

Speaker: Karen Claesen (Belgium)

To Evaluate the Effect of Hydroxyurea on Blood Coagulation and Endothelial Activation in Sickle Cell Disease

Speaker: Munira Borhany (Pakistan)

Online Apps Improve Haemostasis Assay Reproducibility and Facilitate Open Data and Code Sharing

Speaker: Colin Longstaff (United Kingdom)

Deep Mutational Scanning and High-Throughput Kinetics to Quantitatively Assess Plasminogen Activator Inhibitor-1 Variants

Speaker: Laura M. Haynes (United States)

Changes in Fibrinolytic Factors in a Simulated Extracorporeal Membrane Oxygenator Circuit

Speaker: Andrew Doyle (United Kingdom)

Down-regulation of Plasminogen Activator Inhibitor-1 (PAI-1) by in vivo Thrombin Generation and Subsequent Formation of Activated Protein C (APC) in Carriers of the Factor V Leiden (FVL) and Prothrombin 20210G>A Mutation (PTM)

Speaker: Heiko Rühl (Germany)

Scientific Programme

Total and C-terminally Truncated Alpha2-plasmin Inhibitor Levels in Venous Thrombosis

Speaker: Éva Katona (Hungary)

Different Incorporation of Alpha2-plasmin Inhibitor C-terminal Forms into the Fibrin Clot

Speaker: Barbara Baráth (Hungary)

Production of Nanobodies Targeting Plasminogen and Plasmin

Speaker: Eva Maria Klein (Germany)

Targeted Measurement of Plasmin Kinetics on the Activated Platelet Membrane

Speaker: Megan Simpson (United Kingdom)

The Influence of Prothrombin Complex Concentrates on Clot Stability

Speaker: Cecilia Diaz Garcia (United Kingdom)

Low Fibrinolytic Activity Following Ischemia Reperfusion Is Not a Single Etiology: Fibrinolysis Shutdown versus Hypofibrinolysis

Speaker: Hunter Moore (United States)

Thrombolytic Therapy

B- Mode Ultrasound-Guided Photomechanic-Shock Wave Combination Thrombolytic Therapy of Embolic Artery Accompanied by Simultaneously Streptokinase - Loaded Microbubbles Administration

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of B-Mode Ultrasound-Guided Pulsed - High Intensity Focused Ultrasound-Mediated Inertial Cavitation Thrombolytic Therapy Accompanied by Air-Contained Sonicated Dextrose Albumin Microbubbles Administration on Embolic Artery Occlusion

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Effect of Streptokinase-Loaded Microbubbles-Mediated B-Mode Ultrasound-Guided Sono-Photomechanic Combination Thrombolytic Therapy on Atherothrombotic Stenosis

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

The Effect of the Fibrino(geno)lytic Enzymes from Tissues of Antarctic Hydrobionts on Hemostasis

Speaker: Nataliia Raksha (Ukraine)

Microlyse: A VWF-Targeting Thrombolytic Agent for Thrombotic Thrombocytopenic Purpura

Speaker: Steven de Maat (the Netherlands)

The Mechanism of Antifibrinolytic Action of Anionic Polyamidoamine Dendrimers

Speaker: Roza Aisina (Russian Federation)

Covalent Prourokinase-dendrimer Complexes with Increased Plasma Stability and High Thrombolytic Activity in vitro

Speaker: Elizaveta Ivanova (Russian Federation)

Elevated Levels of Circulating Markers of Neutrophil Extracellular Traps (NETs) Are Associated with Unfavorable Outcomes in Acute Ischemic Stroke Patients Undergoing Intravenous Thrombolysis

Speaker: Rita Orbán-Kálmándi (Hungary)

Scientific Programme

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Hemophilia and Rare Bleeding Disorders Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acquired Hemorrhagic Coagulation Disorders

The VWF/ADAMTS13 Unbalance, but Not Global Coagulation or Fibrinolytic Status, Is Associated with Outcome and Bleeding in Patients with Acute Liver Failure

Speaker: Ellen Driever (the Netherlands)

Acquired Deficiency of Dependent Coagulation Factors of Vitamin K, at the Teaching Center: Experience In 10 Years

Speaker: Claudia Casas (Colombia)

A Rare Case of Acquired Haemophilia A with Platelet Dysfunction Associated with Non Hodgkin Indolent Lymphoma

Speaker: Raffaella Rossio (Italy)

In vitro Correction of Thrombin Generation by Recombinant Porcine Factor VIII (rpFVIII) in Plasma Containing Anti-Factor VIII Inhibitory Antibodies

Speaker: Shannon. L. Meeks (United States)

The FARES Study: A Multicenter, Randomized, Active-Control, Pragmatic, Phase 2 Pilot Study Comparing Prothrombin Complex Concentrate versus Frozen Plasma in Bleeding Adult Cardiac Surgical Patients

Speaker: Keyvan Karkouti (Canada)

Postpartum Acquired Hemophilia A Persists as a Diagnostic Challenge

Speaker: Irtis O F Junior (Brazil)

Analysis of Patients with Diagnosis of Adquired Haemophilia in a Third Level Hospital

Speaker: Ana Gómez Martínez (Spain)

Real-World Use of Recombinant B-Domain-Deleted, Porcine-Sequence Factor VIII in Patients with Acquired Hemophilia A: An Interim Analysis of the Post-Authorization Safety Study in the European Union (EU)

Speaker: Wolfgang Miesbach (Germany)

Acquired Hemophilia in Argentina: A Multicentric Study

Speaker: Fernando Chuliber (Argentina)

Autoimmune Acquired Factor XIII Deficiency: A Case Report

Speaker: Ana Marco (Spain)

Global Coagulation Analysis for Acquired Hemophilia A Patients with the Marked Elevation of Factor VIII Activity during Remission Phase

Speaker: Masahiro Takeyama (Japan)

Emicizumab for the Treatment of Acquired Hemophilia A

Speaker: Paul Knoebl (Austria)

Real Life Experience on 61 Acquired Haemophilia A (AHA) Patients from a Single Center

Speaker: Marika Porrazzo (Italy)

Diagnosis and Management of Acquired Von Willebrand Disease in Two Italian Centers

Speaker: Antonietta Ferretti (Italy)

Scientific Programme

Advanced Principles of Prevention and Treatment of Preeclampsia in Women with Antiphospholipid Syndrome (APS) and MTHFR C677T Mutation

Speaker: Marina Jangidze (Georgia)

Major Bleeding after a Gynecological Operation in Patient with Thrombocytosis and Anemia: Acquired von Willebrand Syndrome?

Speaker: Karmen Bilic (Croatia)

Coagulation and Inflammation Genes Are Differently Expressed during the Acquired Coagulation Disorder Induced by Snake Envenomation

Speaker: Ana Teresa Azevedo Sachetto (Brazil)

Experience with Recombinant Porcine FVIII in Patients with Acquired Factor VIII Deficiency Undergoing Major Surgery

Speaker: Miguel Escobar (United States)

Prophylactic Potential of Standard and Modified Emicizumab Prophylaxis in 2 Patients with Acquired Hemophilia: A Case Report

Speaker: Miguel Escobar (United States)

Rutin and Rutin Succinate Improve Murine Survival in an Experimental Model of Acute Hemostatic Disturbances

Speaker: Ana Teresa Azevedo Sachetto (Brazil)

A Novel Therapeutic Approach for Acute Thrombo-hemorrhagic Disorders Evoked by Snake Venom: Potential of Rutin and Rutin Succinate

Speaker: Ana Teresa Azevedo Sachetto (Brazil)

Successful Treatment of a Rare Acquired Thrombin Inhibitor in a Patient with Hemodialysis-dependent End-stage Renal Disease

Speaker: Chatphatai Moonla (Thailand)

Acquired Hemophilia A in Young Nulliparous Woman: A Case Report

Speaker: Eunkyong You (Korea, Republic of)

Real World Experience on Use of Susoctocog-alfa (rpFVIII) in the Treatment of a Population of Italian Elderly Patients with Acquired Haemophilia A

Speaker: Ezio Zanon (Italy)

Disseminated Intravascular Coagulation

The ISTH DIC Score Predicts Outcome in Non-Septic Patients Admitted to a Cardiovascular Intensive Care Unit

Speaker: Jürgen Grafeneder (Austria)

A New Classification of Sepsis-Associated Disseminated Intravascular Coagulation (DIC) Based on Comprehensive Evaluation of Coagulation and Fibrinolysis

Speaker: Tomoko Onishi (Japan)

Coagulopathy in Pediatric Patients with Hemophagocytic Lymphohistiocytosis

Speaker: Mark Shamoun (United States)

A Multicenter Prospective Validation Study on Disseminated Intravascular Coagulation in Trauma-Induced Coagulopathy

Speaker: Satoshi Gando (Japan)

Scientific Programme

Hypofibrinogenemia Is a High Risk for Infectious Type of Disseminated Intravascular Coagulation

Speaker: Hideo Wada (Japan)

Hemophilia - Basic

Exploring the Relationship between Condition Severity and Health-Related Quality of Life in Haemophilia A

Speaker: Charlotte Camp (United Kingdom)

The Role of Genetic and Environmental Factors in Development of Inhibitor in Hemophilia A

Speaker: Narges Beigom Mirbehbahanin (Iran, Islamic Republic of)

Effect of the First Factor VIII Infusions on Immunological Biomarkers in Children with Hemophilia A: Results from the HEMFIL Study

Speaker: Letícia Lemos Jardim (Brazil)

Small RNAs Influence the Pathophysiology of Hemophilic Synovitis and Arthropathy

Speaker: Giridhara R. Jayandharan (India)

Self-Adjustment of Prescribed Dosing Regimens and Physical Activity by Persons with Hemophilia (PwH): Findings from the HemACTIVE Patient Survey

Speaker: Diane Nugent (United States)

Seeking New Approaches: Aberrant Clots, Fibrin Degradation Products and their Effects on Clot Stability

Speaker: Catherine Rea (United Kingdom)

X Chromosome Inactivation: A Modifier of Factor VIII and IX Plasma Levels in Haemophilia Carriers

Speaker: Isabella Garagiola (Italy)

Impact of APTT Reagents on Factor VIII Assay in Plasma Spiked with a Pegylated Recombinant FVIII: A French Multicentre Study

Speaker: Claire Pouplard (France)

Exploring the Relationship between Common Complications of Haemophilia and Anxiety and Depression in People with Haemophilia A

Speaker: Charlotte Camp (United Kingdom)

Contributions of the Individual Components of an Activated Prothrombin Complex Concentrate to Thrombin Generation in the Presence of Emicizumab

Speaker: Maureane Hoffman (United States)

Next Generation Sequencing Antibody Repertoire Analysis of Inhibitory Immune Response in Hemophilia A

Speaker: William D Lees (United Kingdom)

Examining the Hemophilia Disability Paradox

Speaker: Diane Nugent (United States)

Concizumab Does Not Affect Activated Partial Thromboplastin Time, Prothrombin Time or Factor VIII/IX Activity Measured Using One-Stage Clotting or Chromogenic Substrate Assays

Speaker: Marianne Kjalke (Denmark)

Unexpected Phenotypic Characteristics Associated with Severe Haemophilia B in Two Paediatric Patients with Deletions Involving the Whole F9 and Contiguous Genes

Speaker: Pamela Radic (Argentina)

Scientific Programme

In vitro Effect of Concizumab on Protein C Activation and Antithrombin Activity

Speaker: Marianne Kjalke (Denmark)

Emicizumab Prophylactic Therapy in Patients with Hemophilia A Is Better Measured by Thrombin Generation Assay Than Thromboelastography

Speaker: Erika J. Martin (United States)

Fibrin Polymerization Ability Is Variable in Patients with Severe Haemophilia and Might Influence their Joint Condition

Speaker: Paula Acuña-Butta (Spain)

Diagnosis and Management of Acute Hemarthrosis and Haemophilic Arthropathy in Spain Using Unified Clinical and Ultrasound Criteria: Preliminary Results

Speaker: Ana Chimeno Hernandez (Spain)

Association of Adherence and Bleeding Frequency among Severe Hemophilia A Patients on Prophylactic Factor VIII

Speaker: Fadzlin Mohd Mokhtar (Malaysia)

Testing the Impact of Recombinant von Willebrand Factor and Recombinant Factor VIII on Osteoclastogenesis

Speaker: Axel Schlagenhauf (Austria)

Prediction of the Response to FVIII Treatment in Haemophilia A

Speaker: Marisa Ninivaggi (the Netherlands)

Detection of Residual Factor VIII Levels Reveals the Occurrence of Readthrough Over the Majority of F8 Nonsense Mutations

Speaker: Maria Francesca Testa (Italy)

Increased Plasmin Generation in People with Severe Haemophilia

Speaker: Aisling M. Rehill (Ireland)

Identification of Novel Genetic Risk Factors in the Conserved Haplotype Region Surrounding the LCT Locus on Chromosome 2q21

Speaker: Andrea Cairo (Italy)

Uptake of MyABDR in Australia

Speaker: Sumit Parikh (Australia)

Bone Remodeling Alterations in Haemophilia: A Cell Biology Approach

Speaker: Stefano Lancellotti (Italy)

Reduced Splenic T Cells Count in an Untreated Mouse Model of Severe Hemophilia A

Speaker: Chiara Borsotti (Italy)

Discrepancies between FVIII Assays in Routine Diagnosis and Treatment Monitoring of Haemophilia A

Speaker: Charlotte Fauconnier (Belgium)

Factor VIII Does Not Elicit Danger Signals to Innate Immune Cells in Vivo

Speaker: Matthew Christopher Cormier (Canada)

Two-year Update on the WFH World Bleeding Disorders Registry

Speaker: Emily Ayoub (Canada)

Scientific Programme

In vitro and in silico Analysis of F9 Gene Missense Mutations at Exons 2 and 3 Causative of Severe Hemophilia B

Speaker: Lennon Melendez Aranda (Mexico)

Animal Model Construction for Hemophilic Arthritis: Evaluation of Hemophilia Joint by Ultrasound Detection

Speaker: Cong Xu (China)

Feasibility of Using Hospital Episode Statistics in England to Assess the Resource Use and Outcomes in Haemophilia

Speaker: George Morgan (United Kingdom)

Evaluation of Intron 22 and Intron 1 Inversions of Factor VIII Gene in Haemophilia A Patients

Speaker: Irsa Khuwaja (Pakistan)

Methodological Validation of the Measurement of Ultra-low Levels of Factor VIII Activity by Chronometric APTT-based Assay

Speaker: Clémentine Wahl (France)

Platelet Activation in Patients with Severe Haemophilia A

Speaker: Joachim Potgieter (South Africa)

Inflammation in Hemophilia Is Marked by Up-regulation of LPS-binding Protein

Speaker: Lynn M. Knowles (Germany)

Differences in the Prediction of the Time above Target in Hemophilia A Patients Using a Chromogenic Assay and a One-stage Assay in Model-informed Precision Dosing

Speaker: David William Uster (Germany)

Decreased Platelet Surface Phosphatidylserine Predicts Increased Bleeding in Patients with Severe Factor VIII Deficiency

Speaker: Andrew L. Frelinger III (United States)

ELISA-based Quantification of intracellular FVIII Protein in IPS Derived Vascular Endothelial Cells from HA-patients with Nonsense Mutations

Speaker: Heike Singer (Germany)

The Relationship between Societal Costs Associated with Haemophilia and Disease Severity: A Regression Analysis Using CHES II Data

Speaker: Tom Burke (United Kingdom)

Modelling the Cost of Equivalent trough Level across Gene Therapy and Factor IX Replacement Therapy in Haemophilia B

Speaker: Tom Burke (United Kingdom)

Intracellular Visualization of FVIII Protein in Selected Knockouts in the Conventional and Alternative Secretion Pathways

Speaker: Salima Hazzouri (Germany)

Proteomic Profile of Blood Outgrowth Endothelial Cells (BOEC) from a Severe HA Patient with the Reintroduction of FVIII

Speaker: Gillian E. Walker (Italy)

The Synergistic Effect of Emicizumab and Factor VIIa on Thrombin Generation Is Dependent on Factor VIIa Activation of Factor IX

Speaker: Maureane Hoffman (United States)

Scientific Programme

APC: A New Suspect in the Hunt for a Mechanism of Bone Disease in Hemophilia

Speaker: Galen Goldscheitter (United States)

The Annual Global Survey Continues to Close the Gap in Data Collection of Bleeding Disorders

Speaker: Jeffrey Stonebraker (United States)

Non-Human Glycans Regulate FVIII Inhibitor Formation in Mice

Speaker: Connie Arthur (United States)

A Comparative Analysis of the Immune Response to Homologous Coagulation Factors V and VIII

Speaker: Monica L. Sauer (United States)

Differential Systemic Transcriptional Responses to Induced Joint Bleeding in Wild-type and Factor VIII-deficient Mice

Speaker: Esther Cooke (United States)

Molecular Analysis of Factor VIII Genes in Patients with Hemophilia A; Identification of Specific Mutation in Colombian Patients with Inhibitors

Speaker: Samuel Sarmiento Doncel (Colombia)

A Generic Recombinant Factor VIIa Is Comparable to the Branded Novoseven in In-vitro and Pharmacokinetic Studies in Primates

Speaker: Massimo Iacobelli (United States)

Hemophilia - Clinical

Long Term Joint Outcomes through Ultrasound for Hemophilia: First Interim Results from Prospective J-DaUPHIN Study

Speaker: Azusa Nagao (Japan)

Healthcare Resource Utilization and Cost Burden of Hemophilia B in the US

Speaker: Tyler W Buckner (United States)

Hemophilia A with Spontaneous Left Frontotemporal Epidural Hematoma (EDH) and Left Frontotemporoparietal Subdural Hematoma (SDH)

Speaker: Ellyana Perwitasari (Indonesia)

Use of Thromboelastography and Thrombin Generation Assay in a Patient Treated with Emicizumab

Speaker: Dominique Desprez (France)

Finding the Efficacy of Low Dose Prophylactic Regimen in Children Diagnosed with Severe Hemophilia

Speaker: Arooj Fatima (Pakistan)

Endothelial Specific Isoform of Type XVIII Collagen (COL-18N): A Marker of Vascular Integrity in Hemophilic Arthropathy

Speaker: Nayera Abdelhafez (Egypt)

Incidence, Presentation and Management of Pseudotumors in Hemophilics: A Systemic Review

Speaker: Romana Akbar (Pakistan)

Limited Port-A-Cath Need for Hemophilia Patients in the Past: Experience in a Single Center

Speaker: Kaan Kavakli (Turkey)

Scientific Programme

BAY 81-8973 prophylaxis in Patients with Hemophilia A: Interim Usage and Safety Results from the TAURUS Real-World Study

Speaker: Cristina Santoro (Italy)

Prophylaxis Outcome in Patients with Severe Hemophilia in Southern Iran: Near Five-Year Experience from a Single-Center Study

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Clinical Review of Patients with Haemophilia (PwH) in a Malaysian Tertiary Center

Speaker: Yang Liang Boo (Malaysia)

Real-World Cost of Emicizumab

Speaker: Amy L. Dunn (United States)

The Role of Ultrasonography versus MRI in the Diagnosis of Joint Problems in Hemophilic Children

Speaker: Osama El Safi (Egypt)

A Real-World Qualitative Analysis of the Burden of Hemophilia B and Patient Experiences with Prophylactic Nonacog Beta Pegol

Speaker: Chai Phua (Canada)

Efficacy and Safety of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients with Severe or Moderately Severe Hemophilia A: Results from a Phase 4 Study

Speaker: Yongqiang Zhao (China)

Real Life Use of Emicizumab in Pediatric Patients without Inhibitors

Speaker: Sabine Irene Heine (Germany)

Longitudinal Analysis of rFVIII Fc Use and Efficacy in the UK: A Report from the National Haemophilia Database

Speaker: Caroline Wall (United Kingdom)

Real-World Effectiveness Evaluation of the Recombinant Factor VIII Fc Fusion Protein in Adolescents and Children with Hemophilia A in Japan: "Fc Adolescent and Children Treatment" Study (FACTs) Part 1 Interim Analysis

Speaker: Mutsumi Shiraishi (Japan)

Incidence of Neutralizing Antibody (Inhibitor) in Previously Untreated Patients (PUPs) with Severe Hemophilia A

Speaker: Shashikant Apte (India)

Successful Multiple Surgeries in Adult Patients with Haemophilia A (HA) Treated With Turoctocog Alfa Pegol (N8-GP) in the Pathfinder 3 trial

Speaker: Kingsley Hampton (United Kingdom)

Resolution of Target Joints (TJs) in Children with Severe Haemophilia A (HA) Treated with Turoctocog Alfa Pegol (N8-GP) Prophylaxis: Results from the Pathfinder 5 Trial

Speaker: Sonata Saulyte Trakymienė (Lithuania)

FIXa-Triggered Thrombin Generation Assay for Monitoring Very Low Levels of FVIII Activity in Hemophilia A

Speaker: Mei Juan Huang (China)

Total Elbow Replacement: Financial Burden Impact

Speaker: Jorge H Ramirez-Varela (Colombia)

Scientific Programme

Major Surgery in Emicizumab Haven 1 Trial Patients: The New Zealand Experience

Speaker: Paul A. Ockelford (New Zealand)

Prophylaxis with Turoctocog Alfa Pegol (N8-GP) Maintains Improvements in Health-Related Quality of Life (HRQoL) and Treatment Satisfaction (TS) over ≥ 4.5 Years in Patients with Haemophilia A (HA)

Speaker: Nicola J Curry (United Kingdom)

Treatment of Hemophilic Arthropathy with Hyaluron

Speaker: Aziza Makhmudova (Uzbekistan)

A French Multicentre Prospective, Non-Interventional Study (B-SURE) Evaluating Real-World Usage and Effectiveness of Recombinant Factor IX Fc Fusion Protein (rFIXFc) in People with Haemophilia B: Baseline Data

Speaker: Caroline Martinez (France)

Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Previously Treated Hemophilia A Patients

Speaker: Feng Xue (China)

The Current State of Biochemical Marker Research in Hemophilic Arthropathy: A Review

Speaker: E.D.P. van Bergen (the Netherlands)

Promising Prospective Data on the Effect of Ankle Joint Distraction in Hemophilic Arthropathy

Speaker: E.D.P. van Bergen (the Netherlands)

Detectability and Clinical Significance of Calcium Exchange and 25 (OH) D in the Development of Osteoporosis in Patients with Hemophilia

Speaker: Naima Akhrarova (Uzbekistan)

A Randomized Controlled Trial: Pharmacokinetic-Guided Dosing of Factor VIII Concentrate Versus Standard Replacement Therapy in Perioperative Hemophilia A Patients (OPTI-CLOT Trial)

Speaker: Iris van Moort (the Netherlands)

Assessing the Bleeding Phenotype in Non-Severe hemophilia by use of the ISTH Bleeding Assessment Tool (BAT)

Speaker: Fabienne Roelfien Kloosterman (the Netherlands)

Comparison of FVIII Prophylaxis Treatment Regimen and Associated Clinical Outcomes between rVIII-SingleChain and Other rFVIII Products Commonly Used in Italian Hemophilia A Patients

Speaker: Cristina Santoro (Italy)

Prophylactic Factor VIII Consumption and Clinical Outcomes in Italian Hemophilia A Patients who Switched to Extended Dosing Intervals with Long-Acting rVIII-SingleChain: A Retrospective Patient Chart Review

Speaker: Maria Elisa Mancuso (Italy)

Joint Health Outcomes in Patients with Hemophilia A Receiving Antihemophilic Factor (Recombinant) in a Real-World Setting: Results of a 6-Year Interim Analysis of the AHEAD International Study

Speaker: Margareth Ozelo (Brazil)

Pharmacokinetic Profile of Southeastern Brazilian Hemophilia A Patients on Prophylaxis with Octocog Alfa

Speaker: Ricardo Camelo (Brazil)

Scientific Programme

Plasma Factor VIII Activity Measured by Coagulation One-Stage and Chromogenic Assays in Patients with Hemophilia A Treated with Emicizumab

Speaker: Teruhisa Fujii (Japan)

Thrombin Generation is a Better Predictor for Factor VIII Replacement Therapy Effect Than Factor VIII Activity Levels

Speaker: Lars L.F.G. Valke (the Netherlands)

A Canadian, Multi-Center, Retrospective, Non-Interventional Study of Clinical Outcomes from Early Use of N9-GP Compared with Previous Treatment in Patients with Hemophilia B in a Real-World Setting

Speaker: Man-Chiu Poon (Canada)

Baropodometric Barefoot Analysis for Musculoskeletal Health Assessment in Congenital Hemophilia

Speaker: Roberta Gualtierotti (Italy)

Favourable Outcomes in Two Young Patients with Severe Haemophilia B After Switching to rIX-FP

Speaker: Gianluca Sottilotto (Italy)

Evaluation of Factors Associated with Extended Half-Life Product Utilization for Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018

Speaker: Fiona Bethea (United States)

Hip Bleeds in Boys with Mild Haemophilia A: A Single Centre Experience

Speaker: Deepan Gosrani (United Kingdom)

Rationale and Study Design for a Prospective, Low-Interventional Study to Investigate whether Systematic Joint Examination Impacts Haemophilia Treatment Management Decisions in Patients with Haemophilia A in France: The A-MOVE Study

Speaker: Yohann Repessé (France)

Evaluation of Bleeding in Haemophilia Carriers by ISTH-BAT: A Single Center Experience

Speaker: Mimosa Mortarino (Italy)

Current Challenges in Diagnosis and Management of Hemophilia Afghanistan

Speaker: Sayed Hamid Mousavi (Afghanistan)

Inhibitors in Hemophilia: Treatment Challenges in Afghanistan

Speaker: Sayed Hamid Mousavi (Afghanistan)

Elbow Embolization for Recurrent Massive Hemarthrosis: A Case Series with Successful Outcome

Speaker: Simona Maria Siboni (Italy)

Emicizumab Concentration in Children: A Single Centre Real World Experience

Speaker: Deepan Gosrani (United Kingdom)

Efficacy and Safety of BAY 94-9027 Prophylaxis for ≥ 5 Years: Outcomes in 36 Patients from the PROTECT VIII Extension Study

Speaker: Maria Elisa Mancuso (Italy)

Joint Bleeding Outcomes in Patients with Hemophilia A Receiving Long-Term Prophylaxis with BAY 94-9027 in the PROTECT VIII Extension Study

Speaker: Mark Reding (United States)

Scientific Programme

Final Safety Outcomes Following ≥ 5 Years' Observation of BAY 94-9027 Treatment in Patients with Hemophilia A in the PROTECT VIII Extension

Speaker: Johannes Oldenburg (Germany)

Real-World Outcomes before and after Switching from Standard Half-Life Factor VIII to Rurioctocog Alfa Pegol in the United States

Speaker: Shawn X. Sun (United States)

Personalizing Prophylaxis with Rurioctocog Alfa Pegol in Previously Treated Patients with Severe Hemophilia A: Outcomes from the Phase 3b CONTINUATION and Phase 3 PROPEL Studies

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Efficacy and Target Joint Resolution with Pharmacokinetic-Guided Rurioctocog Alfa Pegol Prophylaxis Targeting Two Factor VIII trough Levels in Patients with Severe Hemophilia A: Post-Hoc Analysis of the Phase 3 PROPEL Trial

Speaker: Peter Collins (United Kingdom)

Safety and Efficacy of Albutrepenonacog Alfa in Haemophilia Patients: The Greek Experience

Speaker: Marina Economou (Greece)

Screening of Inhibitor Development among Haemophilia A Patients Being Treated with Recombinant Factor VIII Concentrates in South-East Nigeria

Speaker: Eyiuche Ezigbo (Nigeria)

Prediction Markers for Development of Persistent Inhibitors in Previously Untreated Patients with Severe Hemophilia A

Speaker: Sayna Miri (Italy)

The Experience of Orthopedic Surgeries in Ukrainian Hemophilia Patients with Inhibitor

Speaker: Yuliia Kashpurenko (Ukraine)

Real-World Experience with Emicizumab in Persons with Hemophilia A (HA) with or without Inhibitors

Speaker: Magdalena Lewandowska (United States)

Hemlibra Treatment in Pediatric Hemophilia A Patients - Real World Data of Safety and Uptake in the PedNet Cohorts

Speaker: Gili Kenet (Israel)

Efficacy and Safety of a 21-Day Individualized Dosing Interval in Patients with Hemophilia B Treated with rIX-FP

Speaker: Ingrid Pabinger (Austria)

Total Hip Arthroplasty In Avascular Necrosis of the Femoral Head in a Patient with Hemophilia A

Speaker: Joana Cabral (Portugal)

Prospective, Non-Interventional Study to Assess the Burden in Adolescents and Adults with Haemophilia A (HA) without Inhibitors and their Caregivers in Spain - Hemolife Study

Speaker: María Eva Mingot-Castellano (Spain)

Dynamic Changes in Peripheral Blood Transcriptome Profiles May Predict Inhibitor Formation in Previously Untreated Patients with Severe Hemophilia A

Speaker: Paul Batty (Canada)

Scientific Programme

Cardiovascular Risk Factor Profile among North-Eastern Brazilian Adults with Haemophilia

Speaker: Ricardo Camelo (Brazil)

Real World Efficacy of Emicizumab in Haemophilia A with Inhibitors: A Report from the UK National Haemophilia Database

Speaker: Caroline Wall (United Kingdom)

No Relapse in Patients with Previous Inhibitors Switched to rFVIII Fc in Ongoing Observational Phase 4 Studies

Speaker: Stefan Lethagen (Sweden)

Improved Prophylaxis Adherence After Switching to Emicizumab: Real-World Data from a Single Center

Speaker: Tyler W Buckner (United States)

Does Variation between Label and Actual Potency of Factor VIII Concentrate Vials Affect Results of Pharmacokinetic (PK)-Guided Dosing of Replacement Therapy in Hemophilia A?

Speaker: Mariechristine Henriëtte Jeanine Goedhart (the Netherlands)

Surgical Experience from the Phase III STASEY Trial of Emicizumab Prophylaxis in Persons with Hemophilia A (PwHA) with FVIII Inhibitors: Data from the Second Interim Analysis

Speaker: Giancarlo Castaman (Italy)

Primary Prophylaxis Assessment in Patients with Severe Haemophilia A without Inhibitors Based on Genetic Load and Thrombin Generation Test

Speaker: Ana Marco (Spain)

Phase 1 Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Ascending Doses of Subcutaneous Marzeptacog Alfa (Activated) in Adult Subjects with Hemophilia

Speaker: Linda Neuman (United States)

Pharmacokinetics and Coagulation Biomarkers in Persons with Hemophilia A (PwHA) and FVIII Inhibitors Receiving Emicizumab in the Phase IIIb STASEY Study

Speaker: Anna Kiialainen (Switzerland)

Associations between Physical Activity Levels and Bleeding Frequency in People with Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHES II Study

Speaker: Francis Nissen (Switzerland)

Coinfection by Hepatitis B, C and HIV in Patients with Haemophilia

Speaker: Thais S Esposito (Brazil)

Haemostatic Efficacy of rVIII-SingleChain in a Case of Surgical Prophylaxis for Hip Replacement

Speaker: Cristina Dainese (Italy)

UK EHL Registry: Patient Reported Outcomes Measured by Haemoprefer Patient Treatment Preference and Perception Tool

Speaker: Pratima Chowdary (United Kingdom)

Real-World Data of First-Time and Rescue Immune Tolerance Induction with Recombinant Factor VIII Fc Fusion Protein in Patients with Hemophilia A with Inhibitors in Japan: "Fc Adolescent and Children Treatment" Study (FACTs) Part 2 Interim Analysis

Speaker: Mutsumi Shiraishi (Japan)

Scientific Programme

Population Pharmacokinetic (PK) Analysis of BIVV001 (Rfviii-fc-VWF-XTEN), a New Class of Factor VIII (FVIII) Replacement

Speaker: Suresh Katragadda (United States)

Long-Term Safety and Efficacy of Emicizumab for up to >5 Years in a Phase 1/2 Study in Patients with Severe Hemophilia A

Speaker: Midori Shima (Japan)

Females with Haemophilia in Nordic Countries Have a Higher Risk of Developing Pain, Anxiety and Depression Based on Treatment Patterns as Compared to Matched Controls: Data from a Registry Study over a Period of 11 Years

Speaker: Bent Winding (Sweden)

First Interim Analysis of a 24-Month, Prospective, Non-Interventional, Multicentre Study in Germany Evaluating the Real-World Usage and Effectiveness of rFVIII-Fc and rFIX-Fc in Patients with Haemophilia A or B (PREVENT)

Speaker: Christoph Bidlingmaier (Germany)

A Single Center Data on Extended Half-Life Recombinant Factor VIII (FVIII:Fc) in Patients with Hemophilia A

Speaker: Simon Braham (Italy)

Abdominal Catastrophe in Hemophilic Patients: Towards Wise Decision Making

Speaker: Mohamed Abdelkader Morad (Egypt)

Treatment-Based Risk Assessment of Developing Pain, Anxiety, and Depression as Compared to Matched Controls in People with Haemophilia. A Nordic Registry Study Over a Period of 11 Years

Speaker: Bent Winding (Sweden)

Final Results of PUPs B-LONG Study: Evaluating Safety and Efficacy of rFIX-Fc in Previously Untreated Patients with Haemophilia B

Speaker: Beatrice Nolan (Ireland)

A Randomized, Multicenter, Open-label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Prophylactic Emicizumab Versus No Prophylaxis in Persons with Hemophilia A in the Asia-Pacific region (HAVEN 5)

Speaker: Renchi Yang (China)

Second Interim Analysis Results from the STASEY Trial: A Single-Arm, Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Safety and Tolerability of Emicizumab Prophylaxis in People with Hemophilia A (PwHA) with FVIII Inhibitors

Speaker: Victor Jimenez-Yuste (Spain)

Safety and Efficacy of FVIII Replacement with Turoctocog Alfa in the UK

Speaker: Ben Palmer (United Kingdom)

Implication of Weight Excess in Hemophilic Arthropathy. The Results of a Colombian Reference Center

Speaker: Jose Lopez-Lopez (Colombia)

Adverse Event Reporting in Haemophilia A Patients with and without Inhibitors Treated with Emicizumab: A Report from the Co-morbidity Working Party of the UK Haemophilia Centres Doctors' Organisation (UKHCDO)

Speaker: Caroline Wall (United Kingdom)

One-Stage versus Chromogenic Factor IX Activity in Haemophilia B

Speaker: Maria Bruzelius (Sweden)

Scientific Programme

Use of Emicizumab Prophylaxis in Adult and Pediatric Hemophilia A Patients with and without Inhibitors: Single Center Experience

Speaker: Natalie Montanez (United States)

Evaluation of Factors Associated with Prophylaxis Treatment Regimen among Men with Hemophilia B Participating in the Community Counts Registry from 2014-2018

Speaker: Fiona Bethea (United States)

Comorbidities in Patients with Severe Haemophilia: Birth Cohort Analysis of Taiwan Society of Thrombosis and Hemostasis Database

Speaker: Jiaan-Der Wang (Taiwan, Republic of China)

The Feasibility of Teaching Handheld Ultrasound (HHUS) for Home Use to Identify Bleeding in Hemophilia

Speaker: Bruno Steiner (United States)

Comparison of Bleeding Pattern and Inhibitor Development among Hemophilia Patients: Prophylactic versus On-Demand Treatment

Speaker: Gilbert Wilfred (Malaysia)

The Impact of Switching Previously Treated Patients (PTPs) to Recombinant Factor VIII Fc Fusion Protein (rFVIII-Fc) in Reducing the Annualized Bleeding Rate (ABR): A Single Center Experience

Speaker: Olga Benítez (Spain)

"Best of Both Worlds": Combination Treatment of Desmopressin and FVIII Concentrates in Hemophilia Patients Optimizes Therapy and Reduces Costs

Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Monitoring of Hemlibra Prophylaxis in Children - Real World Data

Speaker: Ilia Tamarin (Israel)

The Clinical Picture in Romanian Patients with Severe Forms of Hemophilia A: What Role did the Intron 22 Inversion and Age Play?

Speaker: Mihnea-Alexandru Gaman (Romania)

Impact of a New Drug in the Real Child's Life

Speaker: Gabriela Sliba (Argentina)

Emicizumab and Surgery in Severe Haemophilia A with Inhibitor: Our First Experience

Speaker: Veena Selvaratnam (Malaysia)

Real-World Experience of rVIII-SingleChain Treatment in a French Single Center

Speaker: Abel Alain Hassoun (France)

Impact of Switching to Prophylaxis with Recombinant Factor IX Fc Fusion Protein Concentrate on Patient Reported Outcomes in People with Haemophilia B Using the PROBE Questionnaire

Speaker: Mairead O'Donovan (Ireland)

The CHiC Study: The Canadian Hemophilia Carriers Study - Preliminary Results

Speaker: Kalandra de Repentigny (Canada)

Perioperative Management with Recombinant Factor IX Fc Fusion (rFIX-Fc): Irish and UK Experience

Speaker: Mairead O'Donovan (Ireland)

Scientific Programme

Successful Parotid Tumor Surgery in Hemophilia a Patient after Immune Tolerance Induction (ITI) with High-Purity Human FVIII/ von Willebrand Factor (vWF)

Speaker: Merlyna Savitri (Indonesia)

The 2-Years Successful Experience of Immune Tolerance Induction (ITI) with High-Purity Human FVIII/ von Willebrand Factor (vWF) in Hemophilia A Patients

Speaker: Merlyna Savitri (Indonesia)

Surrogate FVIII Activity in Patient and Constructed Plasma Samples Containing Emicizumab: A National External Quality Assurance Scheme for Blood Coagulation (UK NEQAS BC) Exercise

Speaker: Anna Lowe (United Kingdom)

FVIII Assay and APTT Results on Obizur in-vitro Spiked Plasma Samples: Analysis from the First UK National External Quality Assurance Scheme for Blood Coagulation (UK NEQAS BC) Obizur Exercise

Speaker: Anna Lowe (United Kingdom)

The Role of Clinical Psychologist in Mothers of Children with Hemophilia

Speaker: Aya Nakao (Japan)

Physical Activity, Sport and Haemophilia: An Observational Study on Risk Assessment

Speaker: Antonio Coppola (Italy)

Low-Dose Prophylaxis versus On-Demand Treatment in Pakistan with Severe Hemophilia A: Updated

Speaker: Munira Borhany (Pakistan)

How to Treat Hemophilia A and B Patients Prophylactically on Standard and Extended Half-Life Factor Concentrates under Pharmacokinetic (PK) Guidance? First Experiences of a Prospective Cohort Study (OPTI-CLOT TARGET)

Speaker: Mariechristine Henriëtte Jeanine Goedhart (the Netherlands)

Data Mining: An Innovative Approach to Optimise Post-Hoc Analyses of Large Trial Data Sets into Clinically Relevant Results

Speaker: Pratima Chowdary (United Kingdom)

First Episode of Macroscopic Hematuria in Hemophilia: Causes and Treatment

Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Clinical Validation of Population Pharmacokinetic Model for Plasma-Derived Factor VIII/VWF Comparing 3 Years Follow-up

Speaker: Juan Eduardo Megías-Vericat (Spain)

Third Time 's the Charm? Tachyphylaxis of Desmopressin Response in Non-Severe Hemophilia A Patients and Comparison to Earlier Response: The DAVID Study

Speaker: Lorenzo Gaetano Renata Romano (the Netherlands)

Incidence of Factor VIII and IX Inhibitors in Hemophilia A and B in China

Speaker: Xueqing Dou (China)

Long-Term Immunogenicity, Efficacy and Safety of Simoctocog Alfa in Patients with Severe Haemophilia A who Had Completed the NuProtect PUP Study

Speaker: Ri Liesner (United Kingdom)

Scientific Programme

The Haemophilia A Patients whose FVIII: C by Chromogenic Substrate Assay were Higher than by One-Stage Substrate Assay Showed Risk of Development of Haemophilic Arthropathy Silently

Speaker: Nobuaki Suzuki (Japan)

Immune Tolerance Induction (ITI) with a Single Factor VIII/von Willebrand Factor Concentrate in Haemophilia A Patients with Inhibitors - Update from the ObsITI Study

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Dissecting the Paradox of “Severe” Hemophilia A (Clotting Factor VIII < 1%) with a Mild Clinical Phenotype in the Era of Prophylaxis

Speaker: Ohad S. Bentur (United States)

Differences in Pharmacokinetic Evaluated by Clotting and Chromogenic Factor VIII Assays in Twelve Persons with Severe Hemophilia A on Prophylaxis with Recombinant Factor VIII Fc Fusion Protein (rFVIII-Fc)

Speaker: Eugenia Cruz (Portugal)

Haemophilia B Patients Switched to Recombinant Factor IX-Albumin Fusion Protein (rIX-FP): Ultrasound and Clinical Joint Assessment

Speaker: Gianna Franca Rivolta (Italy)

Non-Severe Hemophilia Is Not Benign? - Insights from the PROBE Study

Speaker: Chatree Chai-Adisaksopha (Canada)

Prospective Comparative Analysis of Joint Structure and Function in Chinese Children with Severe Hemophilia A under Different Doses Factor VIII

Speaker: Lei Meng (China)

Pain Status in Patients with Hemophilia: Evaluation of Routine Pain Assessment in an Unselected Cohort of Patients with Hemophilia A and B

Speaker: Katharina Holstein (Germany)

The Impact of Physical Activity on the Pharmacokinetics of Factor VIII / IX in a Cohort of Pediatric Patients with Hemophilia A / B in Pharmacological Prophylaxis

Speaker: Carmela Pastore (Italy)

Validation of an Algorithm to Identify Hemophilia A Patients in Administrative Database

Speaker: Arafat Ul Alam (Canada)

Association Between Aging and Health Status in Persons Living with Hemophilia and Controls Without a Bleeding Disorder - Insights from the PROBE Study

Speaker: Federico Germini (Canada)

Inhibitor Development in Hemophilia A - Refining the Risk Assessment

Speaker: Ana Duraes (Portugal)

Subclinical deep venous thrombosis identified in 7,5% of people with hemophilia undergoing major orthopedic surgery in the absence of pharmacological thromboprophylaxis

Speaker: Cedric Hermans (Belgium)

Joint Damage in Non-severe Hemophilia A - Preliminary Results from an Explorative Study

Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Haemophilia Breakthrough in Developing Countries. Is it Possible?

Speaker: A. Patricia Nally (Argentina)

Scientific Programme

Measuring the Impact of Hemophilia on Families

Speaker: Victoria Price (Canada)

ATHN 7: A Natural History Cohort Study of the Safety, Effectiveness, and Practice of Treatment for People with Hemophilia-Demographics and Preliminary Results

Speaker: Tyler W Buckner (United States)

Management of Hemostatic Balance in Elective Joint Replacement Surgery in Patients with Haemophilia

Speaker: Oana Viola Badulescu (Romania)

Treatment Patterns and Bleeding Outcomes in Persons with Severe Hemophilia A and B in a Real-World Setting

Speaker: Leonard Perschy (Austria)

Comorbidities of Hemophilia & Factor XIII Deficiency Patients

Speaker: Majid Naderi (Iran, Islamic Republic of)

The Clinical Phenotype of Patients with Non-severe Hemophilia A and B

Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Efficacy of Platelet-rich Plasma in the Treatment of Hemophilic Arthropathy

Speaker: Peyman Eshghi (Iran, Islamic Republic of)

Quality of Life in Children with Congenital Bleeding Disorders: A Scoping Review of Current Research State and Knowledge Gaps

Speaker: Elise J. Huisman (the Netherlands)

Immune Tolerance Induction (ITI) with a Plasma-derived Factor VIII for Patients with Hemophilia A and Inhibitors: A Retrospective Study

Speaker: Novinyo Amega (United States)

Use of Desmopressin in the Treatment of Bleeding in Non-severe Haemophilia A

Speaker: Fabienne Roelfien Kloosterman (the Netherlands)

The Parameters of Modified Clot Waveform Analysis Using the Plasmas of Hemophilia A Patients Treated with Emicizumab

Speaker: Naoya Yamasaki (Japan)

Distribution of Hemophilia A and B within the INSIGHT Consortium

Speaker: Anne-Fleur Zwagemaker (the Netherlands)

Prophylaxis with Emicizumab in Children and Adults with Hemophilia A and Inhibitors: Real-World Data of 17 Patients from 4 Portuguese Hemophilia Treatment Centers

Speaker: Cristina Catarino (Portugal)

Thrombin Generation Assay to Tailored Treatment in Hemophilia a Patients

Speaker: María De Lourdes Herrera (Argentina)

Reference Ranges of HJHS Scores in Healthy Adult Males without Hemophilia

Speaker: Jean St-Louis (Canada)

Value of Super Microvascular Imaging and Contrast-enhanced Ultrasound in Evaluating the Neovascularization of Synovial Hypertrophy in Hemophilia Joints

Speaker: Yingjia Li (China)

Scientific Programme

A Multicenter Open-label Single Arm Trial to Evaluate Safety and Efficacy and Pharmacokinetics of Recombinant Human Coagulation Factor VIII (SCT800) in Previously Treated Patients with Severe Hemophilia A under Prophylaxis Therapy

Speaker: Wei Liu (China)

Pharmacokinetic and Clinical Improvements after PK-guided Switch from Standard Half-life to Extended Half-life Factor VIII Products

Speaker: Juan Eduardo Megías-Vericat (Spain)

Molecular Mechanisms Underlying Haemophilia A and B Expression in 7 Females

Speaker: Qiulan Ding (China)

Prophylactic Treatment with Low or Medium Dose Factor VIII for Children with Severe Hemophilia A in China: Evaluation of Joint Progression by Conventional Ultrasound and Hemophilia Joint Health Score

Speaker: Cong Xu (China)

Impact of Prophylactic Treatment Incorporation in Hemophilia A and B Hospitalization Rates of the State of São Paulo Patients - Brazil - from 2008 to 2018

Speaker: Ana Guersoni (Brazil)

Is intracranial haemorrhage in haemophilia patients still a present risk in the third millennium? The final results of the EMO.REC Registry: a 10-year Italian study on intracranial haemorrhage in haemophilia patients

Speaker: Ezio Zanon (Italy)

3D Gait Analysis, Hemophilia Joint Health Score, Leg Muscle Laterality, and Biomarkers of Joint Damage: A Cross-sectional Comparative Assessment of Hemophilic Arthropathy

Speaker: Peter Putz (Austria)

Pilot Study on Low-Dose Immune Tolerance Induction (ITI) Therapy in Severe Hemophilia A Children with High-Titer Inhibitors

Speaker: Mohsen Elalfy (Egypt)

Immune Tolerance Induction with Octanate® in Patients with Haemophilia A and Inhibitors: An Ongoing Case Series from a Malaysian Centre

Speaker: Zulaiha Muda (Malaysia)

MOdern Treatment of Inhibitor-PositiVe PATiEnts with Haemophilia A - MOTIVATE

Speaker: Carmen Escuriola-Ettingshausen (Germany)

The Health Status of Older Patients with Hemophilia in the Netherlands

Speaker: Shermarke Hassan (the Netherlands)

Immune Tolerance Induction with Simoctocog Alfa in Patients with Haemophilia A: An Ongoing Multicentre Case Series from the UK

Speaker: Georgina W. Hall (United Kingdom)

Correlations of Von Willebrand Factor Levels, Factor VIII (FVIII) Pharmacokinetics and Prophylaxis Dose in Severe Haemophilia A Patients Switching to rFVIII-Fc Studied by Individual and Population Tool-assisted PK Assessments

Speaker: Gabriele Quintavalle (Italy)

Lack of Inhibitor Development after Switching to Rurioctocog Alfa Pegol in the American Thrombosis and Hemostasis Network (ATHN) 2: Factor Switching Study

Speaker: Janna Journeycake (United States)

Scientific Programme

Treatment of Hemophilia A with rVIII-SingleChain in Italy: Physician and Patient Survey

Speaker: Cristina Santoro (Italy)

Real-world Evidence on the Use of rIX-FP in Patients with Hemophilia B: Interim Results from Three Multinational Prospective, Non-interventional, Post-market Surveillance Studies

Speaker: Giancarlo Castaman (Italy)

A Simplified Health Education Program Improves Knowledge and Practices of Home Treatment in Hemophilia A Adolescents in a Developing Country

Speaker: Tamer Hassan (Egypt)

Vitamin D Status and Risk of Osteoporosis in Hemophilia Patients

Speaker: Marwa Zakaria (Egypt)

ASCVD Risk Score among Haemophilia Patients: Time to Formally Evaluate Cardiovascular Risk in People with Haemophilia

Speaker: Ricardo Camelo (Brazil)

Association between Platelet Glycoprotein Common SNVs and Bleeding Severity in Haemophilia Patients

Speaker: Loredana Bury (Italy)

Satisfaction and Preference of Hemophilia A Patients and Parents for the Treatments in Korea; Results from a Multicentered, Cross-sectional, Observational Study

Speaker: Kiyoun Yoo (Korea, Republic of)

Case report: Inhibitor Improvement with Low Dose Immune Tolerance Induction (ITI) with rFVIII-Fc and Emicizumab after Failed First Line Therapy with High Dose ITI

Speaker: Ivonne Wieland (Germany)

Impact of Extended Half-life Product versus Conventional Factor Product in Children with Hemophilia A - Findings from a Tertiary Care Centre

Speaker: Mahasen Saleh (Saudi Arabia)

Successful Use of Immunotherapy in the Management of Cancer in Patients with Hemophilia B

Speaker: David Hedrick (United States)

rFVIII-Fc at Lower Doses Can Achieve Clinically Meaningful Reduction of Annualized Bleed Rates in Children with Severe Haemophilia A

Speaker: Aby Abraham (India)

A Snapshot of a Prospective, Non-interventional Study to Evaluate Routine Practice Prophylactic Treatment Schedules - NIS-Previq

Speaker: Susan Halimeh (Germany)

Bleeding Outcomes, Factor Utilization and Cost Comparisons after Switching to an Extended Half-life Product for Prophylaxis in Haemophilia A in Austria

Speaker: Cihan Ay (Austria)

Rapid Desensitization and Subsequent Immune Tolerance Induction in a Patient with Hypersensitivity and Inhibitor to Factor VIII

Speaker: William Mitchell (United States)

Population Pharmacokinetic Simulation Analysis for Extended Dosing Regimens of Recombinant Coagulation Factor IX Albumin Fusion Protein (rIX-FP) in Adult and Pediatric Patients with Hemophilia B

Speaker: William McKeand (United States)

Scientific Programme

Evaluation of Inhibitor Risk Prediction Tools Based on Genetic Risk Factors in Persons with Hemophilia A

Speaker: Amanda B. Payne (United States)

Lower Incidence of Cardiovascular Disease in Patients with Haemophilia

Speaker: Paul van der Valk (the Netherlands)

Utilizing Continuous Factor Infusion Replacement in a Hemophilia B Patient Undergoing Cardiac Surgery

Speaker: Sarah Sewaralthahab (United States)

rFIXFc at Lower Doses Can Achieve Very Significant Reduction of Annualized Bleed Rates in Children with Severe Haemophilia B

Speaker: Aby Abraham (India)

Hemostatic Management of Severe Hemophilia A (SHA) Patient with Dilated Myocardiopathy through Extracorporeal Membrane Oxygenation (ECMO), Ventricular Assist Device (VAD) and Heart Transplant (HT)

Speaker: Maria Florencia Tisi Bana (Argentina)

No Peak of New-onset Inhibitors in the Aging Hemophilia Population: An International, Retrospective, Observational, Cohort Study of New Inhibitors in People with Hemophilia Aged 40 Years and Older (the NIAP Study)

Speaker: Jan Astermark (Sweden)

Real World Experience with Rurioctocog Alfa Pegol in Vall d'Hebron University Hospital

Speaker: Gustavo Robayo Buitrago (Spain)

Switch to Extended Half-life Recombinant Single Chain Factor VIII in Haemophilia A Patients. Experience in One Centre

Speaker: Reyes Jimenez-Barcenas (Spain)

Feasibility of Implementation of Point-of-Care Musculoskeletal Ultrasound in Joint Status Assessment in Children with Hemophilia

Speaker: Osman Khan (United States)

A Descriptive Study of Physical Activity and Fitness Level Profiles of Nigerians with Haemophilia

Speaker: Helen C. Okoye (Nigeria)

Factor VIII trough Levels in Patients with Hemophilia A on Secondary Prophylaxis in Relation to Clinical and Radiological Outcomes

Speaker: Azza Tantawy (Egypt)

Successful Inhibitor Eradication for Hemophilia A Children with Poor-risk High-titer Inhibitor Using Low-dose Immune Tolerance Induction Strategy

Speaker: Zekun Li (China)

Total Knee Arthroplasty in Patients with Hemophilia A and B: Impact on Quality of Life

Speaker: Alessandra Nunes Loureiro Prezotti (Brazil)

Inhibitor Formation and Immune Tolerance Induction with Fc-fusion-Protein Recombinant Factor IX in Severe Hemophilia B

Speaker: Ali Amid (Canada)

Clinical Improvement of Haemophilic Arthropathy in a Female Pediatric Patient with Severe Hemophilia A Following Treatment with Emicizumab

Speaker: Frederico Xavier (United States)

Scientific Programme

Emicizumab Prophylaxis in a Racially Diverse Pediatric Population with Hemophilia A with and without Inhibitors

Speaker: Jessica Garcia (United States)

Mode of Delivery in Haemophilia: Vaginal Delivery and Cesarean Section Carry Similar Risk for Inhibitor Development in Severe Haemophilia A

Speaker: Julie Tarrant (Canada)

Inhibitor Epidemiology among People Living with Haemophilia A in South West Nigeria

Speaker: Abiola Bolarinwa (Nigeria)

Is Radiosynovectomy a Tool in Advanced Hemophilic Arthropathy?

Speaker: Guilherme Ocampos (Brazil)

Surgery in People with Hemophilia and Inhibitors: 10 Years of Experience in a Portuguese Comprehensive Care Centre

Speaker: Cláudia Vaz (Portugal)

Immune Tolerance Induction in Children with Hemophilia A, in Times of Emicizumab: A Real Life Experience

Speaker: Jesúa Ardila (Colombia)

Hemophilia Gene Therapy

Long-Term Vector Genome Outcomes and Immunogenicity of AAV FVIII Gene Transfer in the Hemophilia A Dog Model

Speaker: Paul Batty (Canada)

Frequency, Location and Nature of AAV Vector Insertions After Long-Term Follow up of FVIII Transgene Delivery in a Hemophilia A Dog Model

Speaker: Paul Batty (Canada)

In the Future, Will ADSCs Become the Target Cells for Hemophilia A Gene Therapy?

Speaker: Zhen Yu Yan (China)

Increase in the Treatment Efficacy of Genome Editing for Hemophilia B by Codon-Optimization of SaCas9 in Mice

Speaker: Tsukasa Ohmori (Japan)

Multi-Centre Field Study of One-Stage and Chromogenic Factor IX Assays in Samples Containing the Factor IX Padua Variant

Speaker: Jonathan Foley (United Kingdom)

Consistent Structural Kinetics of Valoctocogene Roxaparvovec DNA in Human Blood Samples

Speaker: Chris Russell (United States)

Adenovirus Mediates Expression of Human Coagulation Factor IX Gene in Adipose-Derived Mesenchymal Stem Cells

Speaker: Zhen Yu Yan (China)

Clinical Immunogenicity of Valoctocogene Roxaparvovec in GENER8-1, a Phase 3 Study of AAV5-Mediated Gene Therapy Encoding Human FVIII for the Treatment of Hemophilia A

Speaker: Brian Long (United States)

Mechanistic Evaluation of Factor IX-Padua Activity in Chromogenic FIX and Thrombin Generation Assays

Speaker: Erald Shehu (United Kingdom)

Scientific Programme

Surgical Experience with Fidanacogene Elaparvovec

Speaker: Lindsey A George (United States)

A Novel Human Factor VIII Variant Exhibits Increased Factor VIII Expression after AAV Gene Therapy in a Unique Hemophilia A Dog Model that is Tolerant to Human Factor VIII

Speaker: Giang Nguyen (United States)

The World Federation of Hemophilia Gene Therapy Registry

Speaker: Mayss Naccache (Canada)

Expectations and Concerns of Patients with Haemophilia towards Gene Therapy - Results of Patients and Expert Focus Groups

Speaker: Sylvia von Mackensen (Germany)

Ultrasound Mediated Gene Delivery Targets Liver Sinusoidal Endothelial Cells to Achieve Endothelial-specific Factor VIII Expression

Speaker: Megan Manson (United States)

Prevalence and Affinity/Avidity Assessment of Pre-Existing Neutralizing Antibodies (NABs) against Adeno-Associated Virus (AAV) Vector Serotypes 2, 5 and 8 Analyzed in the Serum of 300 Healthy Donors

Speaker: Anna Majowicz (the Netherlands)

Investigating the Stability of Lentiviral Vector Targeted Liver Cells during Post-Natal Growth for in Vivo Gene Therapy of Hemophilia

Speaker: Michela Milani (Italy)

Activity Measurement of Factor IX Padua against the 4th International Standard for FIX, Plasma

Speaker: Elaine Gray (United Kingdom)

Surgical Management of a Hemophilia B Gene Transfer Clinical Trial Participant: A Case Report Following Etranacogene Dezaparvovec (AMT-061) Gene Therapy

Speaker: Adam Giermasz (United States)

Exploring RNA Editing System as Innovative Correction Strategy for Hemophilia A

Speaker: Silvia Pignani (Italy)

Combined Gene and Cell Therapy for the Treatment of Hemophilia A within an Implantable Therapeutic Device

Speaker: Cristina Olgasi (Italy)

Platelet-targeted Hyperactive Factor IX (FIX) Gene Therapy for Hemophilia B Mice with Pre-existing Anti-FIX Immunity

Speaker: Qizhen Shi (United States)

Influence of N-linked Glycosylation in the A and C Domains on the Immunogenicity of Factor VIII

Speaker: Amber Vander Kooi (United States)

Assessment of Vector Integration of AAV5-hFIX in Mice and Non-human Primates Indicates No Association with Tumorigenic Risk

Speaker: Lisa Spronck (the Netherlands)

Management of Bleeding and Trauma

Scientific Programme

Activated Prothrombin Complex Concentrates for the Management of Direct Oral Anticoagulant-Associated Bleeding Events and Pre-Operative Administration for Urgent Surgery: Hemostatic and Thrombotic Outcomes

Speaker: Joseph Shaw (Canada)

Reversal of Direct Oral Anticoagulants with Three-Factor Prothrombin Complex Concentrate: Real World Experience from a Tertiary Centre in Hong Kong

Speaker: Shun Yin Kong (Hong Kong)

Effect of Oral Anticoagulant Use on Surgical Delay and Outcomes in Hip Fracture Patients: A Systematic Review and Meta-Analysis

Speaker: Yan Xu (Canada)

Low-Factor Consumption and Cost Effectiveness for Surgeries in Hemophilia B Patients with N9-GP

Speaker: Shuichi Okamoto (Japan)

Effect of rFVIIa on Thromboelastogram Parameters in Haemophilia A Patients with Inhibitor

Speaker: Valeriia Krasivska (Ukraine)

Continuous Infusion with Kovaltry (Octocog Alfa) during Cardiac Surgery for Tetralogy of Fallot in an Hemophilic Child

Speaker: Anna Amoruso (Italy)

Comparison of Coagulation Parameters Associated with Fibrinogen Concentrate and Cryoprecipitate for Treatment of Bleeding in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei: Results from the FORMA-05 Study

Speaker: Cristina Solomon (Switzerland)

Andexanet and Prothrombin Complex Concentrate Give Comparable Haemostatic Efficacy for Major Bleeding in Patients on Factor Xa Inhibitors

Speaker: Tessa C.C. Jaspers (the Netherlands)

Treatment Options in Severe Hemophilia A Patients from Romania: What Role did the Intron 22 Inversion and Age Play?

Speaker: Mihnea-Alexandru Gaman (Romania)

Idarucizumab to Neutralize Dabigatran in a University Hospital: The Relevance of Renal Function

Speaker: Annalisa Fattorini (Italy)

Methodological and Reporting Quality in Case Series of Four-Factor Prothrombin Complex Concentrate in the Management of Oral Factor Xa Inhibitor-Associated Bleeding

Speaker: Olivia S. Costa (United States)

The Obstetric Experience of Carriers of Haemophilia

Speaker: Ozlem Turan (United Kingdom)

The Need for Red Cell Support during Surgery in a Tertiary Care Hospital Is Associated to Pretransfusion Levels of FXIII and the Platelet Count

Speaker: Wolfgang Korte (Switzerland)

Endovascular Abdominal Aortic Aneurysm Repair in a Mild Haemophilia A Patient: A Case Report

Speaker: Elsa Lopez Ansoar (Spain)

Scientific Programme

Direct Oral Anticoagulants Bleeding Events in Patients with Atrial Fibrillation Vs Venous Thromboembolism Admitted to an Emergency Department: Real-Life Study

Speaker: Farès Moustafa (France)

The Age Dependent Effects of Female Sex on Platelet Behavior after Injury

Speaker: Zachary Matthay (United States)

Improved Sensitivity of Global Hemostasis Assays Using Different Combinations of Phospholipid Reagent and Tissue Factor

Speaker: Puja Soni (India)

Extended Half-life FIX and Disruptive Therapies in Carriers with FVIII and FIX Deficiencies: Preliminary Experience

Speaker: Cedric Hermans (Belgium)

Desmopressin Response and Clinical Outcome in Bleeding Disorders: A 30 Year Retrospective Analysis

Speaker: Maria Rita Peralta (United Kingdom)

Glycocalyx Shedding as a Potential Driver of Trauma-induced Coagulopathy in Severe Trauma Patients: Insights from the TRAUCC Trial

Speaker: Maximilien Desvages (France)

Biomarkers of Fibrinolysis Predict the Need for Massive Transfusion in Trauma

Speaker: Anton Ilich (United States)

The Effect of Bypassing Agents in Combination with Emicizumab-treatment

Speaker: Nina Haagenrud Schultz (Norway)

Intravenous Synthetic Platelet Nanotechnology for the Treatment of Bleeding Complications

Speaker: Anirban Sen Gupta (United States)

The 2020 World Federation of Hemophilia Guidelines for the Management of Hemophilia

Speaker: Alok Srivastava (India)

Novel Biotherapeutics in Hemophilia

Emicizumab in the Management of Hemophilia A: Real World Experience in East Malaysia

Speaker: Andy Sing Ong Tang (Malaysia)

Perioperative Management of Patients with Hemophilia Receiving Fitusiran, an Investigational RNAi Therapeutic Targeting Antithrombin for the Treatment of Hemophilia

Speaker: K. John Pasi (United Kingdom)

Correction of Human Hemophilia B Gene in iPSCs by Base-Editing Approach Based on Engineered Cas9 with Broad PAM Flexibility

Speaker: Takafumi Hiramoto (Japan)

A Next Generation Recombinant Factor VIII for Subcutaneous Hemophilia A Prophylaxis

Speaker: Peter Herbener (Germany)

New Factor VIII Function-Mimetic Bispecific Antibodies Engineered from Emicizumab for Further Improving the Treatment of Hemophilia A

Speaker: Yuri Teranishi (Singapore)

Thrombin Generation Potential of Modified FIX: Dalcinonacog Alfa

Speaker: Stella Williams (United Kingdom)

Scientific Programme

A Novel FVIIIa-Mimetic Bispecific Antibody, Mim8, Enhances FIXa Proteolytic Activity While Allowing for Efficient, Lipid-Dependent Assembly with FX

Comparison of Bypassing Agents in Patients on Emicizumab Using Global Hemostasis Assays

Speaker: Hande Kizilocak (United States)

Determining the Approximate Factor VIII Level Equivalency of Patients with Severe Hemophilia A on Emicizumab Using Global Hemostasis Assays

Speaker: Hande Kizilocak (United States)

Assay of Emicizumab Using the Modified One-Stage Clotting Assay

Speaker: Helen Wilmot (United Kingdom)

Optimization of Measurement of Emicizumab, FVIII and Anti-FVIII Activity in Patients Treated with Emicizumab

Speaker: Laura Heireman (Belgium)

Determining the Optimal Method for FVIII:C and Anti-FVIII Quantification in a Patient Treated with Adynovi® who Developed Anti-FVIII during Treatment

Speaker: Laura Heireman (Belgium)

SIG-001 for Hemophilia A: Preclinical Safety and Efficacy Studies Conducted in Mice and Non-Human Primates

Speaker: Guillaume Carmona (United States)

Surgical Experience with Emicizumab: A Single Centre Experience with Central Venous Access Device Removal

Speaker: Saket Badle (United Kingdom)

Characterization of Factor IX-FIAV: A Factor IX Variant that Displays Cofactor-Independent Activity

Speaker: Viola J.F. Strijbis (the Netherlands)

Rescue of the Endogenous FVIII Expression in Hemophilia A Mice Using CRISPR/Cas9 Gene Editing

Speaker: Chun-Yu Chen (United States)

Design of a Novel Factor IX Albumin Fusion Protein with Enhanced Coagulant Activity and Pharmacokinetic Profile

Speaker: Silvia Lombardi (Italy)

Optimizing Outcomes in Hemophilia A Prophylaxis Using Recombinant Factor VIII Fc Fusion Protein (rFVIII-Fc): Results from Three Portuguese Haemophilia Centers

Speaker: Sara Morais (Portugal)

Characterization of Neutralizing Anti-emicizumab Antibody Developed in a Hemophilia A Patient

Speaker: Flora Peyvandi (Italy)

Raising Factor VIII's Half-life to the Next Level

Speaker: Steffen Kistner (Germany)

Emicizumab, beyond Annualized Bleeding Rates: Real World Joint Health and Physical Activity Data

Speaker: Beth Boulden Warren (United States)

Scientific Programme

Marzeptacog Alfa (Activated) Population PK: Simulations for Dose Selection in Phase 3 Trials

Speaker: Tom Knudsen (United States)

Emicizumab beyond Annualized Bleeding Rate: Do Laboratory Assays Help Predict Emicizumab Effects?

Speaker: Genevieve Moyer (United States)

Emicizumab beyond Annualized Bleeding Rate: How Does Emicizumab Affect Bone Biomarkers?

Speaker: Marilyn J. Manco-Johnson (United States)

A Simple Algorithm to Identify Emicizumab Interference in Samples Received in the Clinical Coagulation Laboratory

Speaker: Brian Poirier (United States)

Rare Bleeding Disorders

Rare Bleeding Disorders in Southern Iran: Revisited and Updated Data

Speaker: Mohammadreza Bordbar (Iran, Islamic Republic of)

Isolated Factor VII Deficiency

Speaker: Amireche Amira (Algeria)

Results from a Phase 4, Real-World Study Confirm the Safety and Effectiveness of rFXIII-A2 for the Treatment of Congenital FXIII A-Subunit Deficiency

Speaker: Lone Hvitfeldt Poulsen (Denmark)

Economic Burden Associated with Vaso-Occlusive Crisis Management in Patients with Sickle Cell Disease

Speaker: Abiola Oladapo (United States)

Clinical Characteristics of Patients with Rare Bleeding Disorders: Real-Life Data from the Netherlands (RBiN Study)

Speaker: Joline L. Saes (the Netherlands)

Usefulness of Tissue Factor-Independent Coagulation Parameters for Monitoring FXI-Concentrate Replacement in Patients with FXI-Deficiency

Speaker: Debora Bertaggia Calderara (Switzerland)

Fibrin Clot Properties in Patients with Qualitative Fibrinogen Disorders: Data from the PRO-RBDD Cohort

Speaker: Alessandro Casini (Switzerland)

Inherited Rare Bleeding Disorders in Non-Consanguinity

Speaker: Ampaiwan Chuansumrit (Thailand)

Evaluation of the Potential Utility of the Total Thrombus-Formation Analysis System (T-TAS) in Comparison to the Platelet Function Analyzer (PFA) in Subjects with Primary Hemostatic Defects

Speaker: Mathieu Fiore (France)

Efficacy and Safety of Fibrinogen Concentrate for On-Demand Treatment of Acute Bleeding and Surgical Prophylaxis in Pediatric Patients with Congenital Fibrinogen Deficiency: Results from the FORMA-04 Study

Speaker: Bruce Schwartz (United States)

Scientific Programme

Achenbach Syndrome in a 19 Year-Old Girl: A Clinical Case

Speaker: Nathalia N S Magalhaes (Brazil)

Long-Term Anticoagulant Treatment in Patients with Factor VII Deficiency: A Single Centre's Experience

Speaker: Baldomero Moriano (Spain)

Blocking Tissue Factor Pathway Inhibitor (TFPI) Function Has a Therapeutic Benefit in Murine Models of Factor Deficiencies

Speaker: Lacramioara Ivanciu (United States)

Collagen Turnover and Plasma Ascorbic Acid Levels in Patients Suspected of Inherited Bleeding Disorders Harboring Variants in Collagen-related Genes

Speaker: Marcus Fager Ferrari (Sweden)

Uncharacterised bleeding Disorders Are Associated with Reduced Platelet and Microparticle Thrombin Generation and Decreased Procoagulant Oxidised Phosphatidylcholine

Speaker: Samya G Obaji (United Kingdom)

Single Centre Experience of Rare Bleeding Disorders

Speaker: Monica Martinez (Argentina)

FXI Gene Mutations in Northern Region of Turkey

Speaker: Canan Albayrak (Turkey)

A Bypass Surgery with Congenital Factor 5 and Factor 8 Deficiency

Speaker: Vahap Okan (Turkey)

Molecular Diagnosis of Quantitative and Qualitative Fibrinogen Deficiencies: A Portuguese Centre Experience

Speaker: Catarina Silva Pinto (Portugal)

The F7 p.Val22Ile Missense Mutation Affects Splicing and Can Be Counteracted by a Compensatory U1snRNA

Speaker: Paolo Ferraresi (Italy)

Modulation of Alternative Splicing of the F5 Gene Using Morpholino Antisense Oligonucleotides

Speaker: Alice Todaro (the Netherlands)

Congenital Combined Bleeding Disorders, a Study on a Large Number of Iranian Patients

Speaker: Shadi Tabibian (Iran, Islamic Republic of)

Combined Factor Deficiencies Rare among the Rare Bleeding Disorders among Pediatric Population, Seven Years Experience in a Tertiary Care Center of Lahore, Pakistan

Speaker: Tooba Fateen (Pakistan)

Inhibitor Development in a Patient with Severe Congenital Factor V Deficiency

Speaker: Natasha Pardy (Canada)

Perioperative Management of Patients with Rare Bleeding Disorders in a Hemophilia Comprehensive Care Centre

Speaker: Carlos Francisco Hernandez Mata (Spain)

Use of the ISTH Bleeding Assessment Tool in Diagnosis of Bleeding Disorders in West Algeria

Speaker: Driss Benlaldj (Algeria)

Scientific Programme

Characterization and Management of Patients with Mild or Moderate Hereditary Factor X Deficiency: A Retrospective Chart Review

Speaker: Suchitra Acharya (United States)

A Digestive Hemorrhage Like No Other

Speaker: Yosra Cherif (Tunisia)

Inherited Factor VII Deficiency in Women: Low Rate of Bleeding in Non-severe Disease

Speaker: Fernando Chuliber (Argentina)

Congenital Afibrinogenemia. Report of a Case in the Children´s Hospital of Mexico Federico Gomez

Speaker: José Francisco Mariano González (Mexico)

Afibrinogenemia: Identification of a New Mutation in FGB

Speaker: Elena Chinni (Italy)

Menorrhagia in Egyptian Adolescents with Inherited Bleeding Disorders: A Single Centre Study

Speaker: Magy Abdelwahab (Egypt)

Important Sex Differences in Patients with Autosomal Inherited Bleeding Disorders

Speaker: Ferdows Atiq (the Netherlands)

Fibrinolytic Alterations in a Thrombomodulin-associated Coagulopathy Are Diminished by Coinheritance of a TAFI Mutation

Speaker: Claire S Whyte (United Kingdom)

Missense Mutations and Predicted Effects on Splicing in Factor XI Deficiency

Speaker: Federica Riccardi (Italy)

Genotype and Phenotype Characterization in RBDs: A Spanish Pilot Study

Speaker: Beatriz Rey Búa (Spain)

An Italian Survey on the Real-world Use of rFXIII (Catridecacog) in Patients with Factor XIII Deficiency

Speaker: Samantha Pasca (Italy)

Severe Factor V Deficiency Caused by Two Novel Pathological F5 Variants - First Insights into their Effect on Factor V Function

Speaker: Justine Brodard (Switzerland)

Comparative Analysis of Three Custom Gene Panels Based on Next Generation Sequencing for Diagnostic of Inherited Coagulation Bleeding Disorders

Speaker: Nina Borràs (Spain)

Unclassified Bleeding Disorder (UBD)-Bleeding Phenotype and Management

Speaker: Susan Halimeh (Germany)

Whole Exome Sequencing Approach to Address the Genetic Heterogeneity of Inherited Platelet Disorders

Speaker: Laura Martin-Fernandez (Spain)

Safety of Antithrombotic Therapy in Subjects with Hereditary Hemorrhagic Telangiectasia

Speaker: Fabiana Agostini (Italy)

Scientific Programme

Inherited Factor VII Deficiency Associated with Thrombo-hemorrhagic Phenotype: A Case Report

Speaker: Alena Stryckova (Slovakia)

Evaluation of the Skeletal Lesions in the Lebanese Patients with Afibrinogenemia

Speaker: Claudia Djambas Khayat (Lebanon)

Thrombotic Events in the Patients with Haemorrhagic Disorders of Haemostasis

Speaker: Lucia Stanciakova (Slovakia)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Nurses Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Nurses and Allied Health

Warfarin - A Real Threat in Evaluation of Acute Poisoning in the Emergency Department (ED) of a Tertiary Care Hospital - A Base Line Study to Make a Strategy for Better Patient Outcome

Speaker: Feroza Perveen (Pakistan)

Implementation of Prefilled Doses- A Novel Approach to Decrease Medication Time to Administration and Errors In Critically Ill Pediatric Patients of Emergency Department (ED)

Speaker: Feroza Perveen (Pakistan)

Socio-Demographic Data and some Haematological Parameters of Nigerian Children Living on the Street: A Comparative Study

Speaker: Patience Akpan (Nigeria)

Knowledge and Attitude towards Safe use of Direct Oral Anticoagulants (DOACs) among Doctors, Nurses and Pharmacist in a Developing Country, Karachi, Pakistan

Speaker: Sumaira Khan (Pakistan)

A Nurse Led Service Providing Safe and Effective Peri-Operative Anticoagulation

Speaker: Paul Priest (United Kingdom)

Effect of Foot Bath on the Plasma Concentration of Plasminogen Activator Inhibitor-1 Produced by Endothelial Cells in Healthy Subjects

Speaker: Tatsuya Hayashi (Japan)

Elderly Patients with Atrial Fibrillation Have Higher Risk of Geriatric Syndromes: Results of the Nursing Study

Speaker: Irina Tsareva (Russian Federation)

Monitoring of Adverse Event of INR>6 Using IHI Global Trigger Tool in Cardiology Hospital, Pakistan

Speaker: Sumaira Khan (Pakistan)

Recommendation on the Treatment of Venous Thromboembolism in Cancer Patients at a Brazilian Public Oncological Institution: Educational Plan

Speaker: Cynthia Rothschild (Brazil)

Scientific Programme

The Role of the Nurse in the Therapeutic Education of Hemophiliac Patients in Preparation for Physiotherapy

Speaker: Mhamed Djaafri (Algeria)

Effectiveness of a Self-management Program in the Treatment Control of Oral Anticoagulants Antivitamin K

Speaker: Mireia Constans (Spain)

Successful Development and Implementation of Pharmacist-led VTE Stewardship. An Australian Tertiary Hospital Perspective

Speaker: Julianne Chong (Australia)

Psychosocial Burden of Hemophilia in a Canadian Cohort

Speaker: Julia Hews-Girard (Canada)

A Multi Centre Non-randomised Clinical Trial to Establish the Efficacy of Peer Reviewed Physiotherapy Treatment Protocols among PWH in India

Speaker: Pamela Narayan (India)

Patient Compliance with Aspirin and Rivaroxaban Post Elective Joint Replacement Surgery: A Quality Assurance Initiative

Speaker: Laurie Sardo (Canada)

Canadian Guidelines Regarding Safe Blood-draw Volumes for Research in Pediatric Participants

Speaker: Korinne Hamilton (Canada)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Pediatrics Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Bleeding in Neonates and Children

Single Center Analysis of the Phenotype of Children Immune Thrombocytopenia with Mutation Related to Common Variable Immunodeficiency

Speaker: Jingyao Ma (China)

High-throughput Sequencing in the Diagnosis of Inherited Immune-Thrombocytopenia from among Children with Apparent Chronic/Refractory ITP

Speaker: Jingyao Ma (China)

Chronic Refractory Immune Thrombocytopenia is Associated with a High Frequency of Potentially Damaging Variants in Immune Genes

Speaker: Shasha Zhao (China)

Retrospective Analysis of Characteristics and Outcomes of 340 Pediatric ITP Patients in One Center

Speaker: Rongwei Li (China)

Variability in Diagnosis and Management of Immune Thrombocytopenia in Children: Real Life According to Spanish Pediatricians and Hematologists

Speaker: Rubén Berrueto (Spain)

Scientific Programme

Secondary Immune Thrombocytopenia in Children: Characteristics and Outcome of a Large Cohort from Two Spanish Centers

Speaker: Rubén Berrueco Moreno (Spain)

Impact of a Standardized, Moderate-Intensity Aerobic Exercise Regimen on Hemostasis in Adolescent Hemophilia A Carriers: A Pilot Investigation

Speaker: Riten Kumar (United States)

Moderate Intensity Aerobic Exercise and Intranasal Desmopressin Additively Increase Factor VIII and von Willebrand Factor (VWF) Levels in Adolescent Males with Mild Hemophilia A - Principal Findings from a Randomized Trial

Speaker: Riten Kumar (United States)

Haemostatic Disorders and their Correlation with Hepatic Fibrosis Markers in Case of Hepatic Cirrhosis in Children

Speaker: Ekaterina Konovalova (Russian Federation)

The Relationship between Platelet Phenotype and Function with Clinical Outcomes in 57 Paediatric Veno-Arterial ECMO Patients

Speaker: Suelyn Van Den Helm (Australia)

Isolated Thrombocytopenia in Children Is Not Always an Immune-Associated Disorder

Speaker: Alkistis Adramerina (Greece)

Thrombin Generation Measurement Using ST-Genesia System in a Cohort of Healthy Children Including Neonates: Normal Values and Variability

Speaker: Philippe Nguyen (France)

U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPS Matter Study) Interim Analysis of the 2010-2019 Birth Cohort

Speaker: Shannon Carpenter (United States)

Inflammation Associated Cell-Free microRNA Levels in Cerebrospinal Fluid of Premature Infants Upon Intraventricular Hemorrhage

Speaker: Zsolt Fejes (Hungary)

Challenges in Diagnosing and Treating Polycythemia Vera with Acquired von Willebrand Disease in a Pediatric Patient

Speaker: Juhi Jain (United States)

Predictive Factors for Disseminated Intravascular Coagulation in Childhood Acute Lymphoblastic Leukemia

Speaker: Natsaruth Songthawee (Thailand)

Validity and Reliability of Self-Administered Thai Pediatric Bleeding Questionnaire (TPBQ) Application to Predict Risk of Bleeding in Pediatric Bleeding Disorders

Speaker: Darintr Sosothikul (Thailand)

Comparison between Bleeding Time and PFA-200 to Evaluate Platelet Function Disorder in Children

Speaker: Darintr Sosothikul (Thailand)

Hemostasis in Parenteral Nutrition Associated Cholestasis in Preterm Infants: An Observational Study

Speaker: Erica Scalabrino (Italy)

Scientific Programme

Assessment of Vitamin K Level in Newborn Presenting with Bleeding in Population of Rural Sindh, Pakistan

Speaker: Nazia Hafeez (Pakistan)

Application of the First Russian Biosimilar of Recombinant Clotting Factor VII in an Infant with Antenatal Cryptogenic Hepatitis and Bleeding Developed After Laparoscopic Liver Biopsy

Speaker: Karina Papayan (Russian Federation)

Features of Epistaxis Predictive of a Mucocutaneous Bleeding Disorder (MBD) in Children

Speaker: Margaret Rand (Canada)

Quantitation of Bivalirudin Effect Using Microliter Scale Sample Microfluidic Assay in a Pediatric ECMO Population

Speaker: Galit Frydman (United States)

Assessing Anticipatory Guidance Needs in Adolescents with Bleeding Disorders

Speaker: Daisy Cortes (United States)

Impact of Intravenous Iron Therapy in Post-menarchal Adolescents Hospitalized with Acute Heavy Menstrual Bleeding

Speaker: Hyojeong Han (United States)

Use of 'Virtual Clinics' Telehealth Model in Pediatric Patients with Hemophilia and Inherited Bleeding Disorders: Experience from a Tertiary Care Center

Speaker: Mahasen Saleh (Saudi Arabia)

Prevalence and Management Approach to the Newborn with Classical and Late Vitamin K Deficiency Bleeding (VKDB) in LMIC

Speaker: Gul Ambreen (Pakistan)

Pediatric Heart Transplantation and Mechanical Circulatory Assistance: A Challenge for Hemostasis

Speaker: Caroline Gomes (Brazil)

Use of Prolong Parenteral Lipid Emulsions in NICU and Hematologic Disorders

Speaker: Gul Ambreen (Pakistan)

Thrombosis in Neonates and Children

Asymptomatic Catheter Related Thrombosis in Neonates: The Role of Thrombophilia Testing

Speaker: Bader Allahyani (Canada)

Pediatric Hospital-Acquired Venous Thromboembolism: Mayo Eugenio Litta Children's Hospital Experience

Speaker: Melissa Azul (United States)

Self-Management of Oral Anticoagulation with Vitamin K Antagonist Programs Progressively Improves Time in Therapeutic Range in Pediatric Population

Speaker: Rubén Berruero (Spain)

Pharmacokinetic Modelling and Simulation Support the Age and Body-Weight-Adjusted Dosing of Dabigatran Etexilate in Paediatric Patients with Venous Thromboembolism

Speaker: Daniel Roeshammar (Sweden)

Scientific Programme

Pharmacokinetic-Pharmacodynamic Relationship between Dabigatran Plasma Concentrations and Coagulation Laboratory Parameters in Paediatric Patients with Venous Thromboembolism

Speaker: Lesley Mitchell (Canada)

Improve the Quality of Life in Children with Thrombosis and Need for Oral Anticoagulation: The "Coagulin Project"

Speaker: Rafael Martos Martínez (Spain)

Heparin Induced Thrombocytopenia in a 9 Years Old Child: A Case Report

Speaker: Katerina Zdrahalova (Czech Republic)

The Role of Hereditary Elevated Lipoprotein (a) as a Thrombophilic Risk Factor in Two Siblings with Cerebral Vein Thrombosis

Speaker: Sarah Schober (Germany)

Right Atrial Thrombosis in Children: Patient Characteristics, Outcomes, and Interrater Reliability of Echocardiographic Characterization

Speaker: Benjamin T. Barnes (United States)

Management and Outcomes of Newborns at Risk for Inherited Antithrombin Deficiency at the Karolinska University Hospital, Stockholm, Sweden

Speaker: Susanna Ranta (Sweden)

Polygenic Risk Score-Analysis of Thromboembolism in Patients with Acute Lymphoblastic Leukemia

Speaker: Kirsten Brunsvig Jarvis (Norway)

Ischemic Strokes in Children

Speaker: Karina Papayan (Russian Federation)

Impact of a Perioperative Venous Thromboembolism Prophylaxis Screening Tool for Pediatric Orthopedic Surgical Patients

Speaker: Ketan Kulkarni (Canada)

Prevalence, Characteristics and Risk Factors of Peripherally Inserted Central Catheter-Related Venous Thromboembolism in a Pediatric Intensive Care Unit: A Cross-Sectional Retrospective Study

Speaker: Samantha Terhaar (United States)

Homocystinuria in the Etiology of Sinus Vein Thrombosis Presented with Focal Seizure: A Case Report

Speaker: Elif Güler Kazancı (Turkey)

Pediatric Thrombosis: A Retrospective Analysis of the Incidence, Characteristics and Risk Factors in a Spanish Center

Speaker: Irene Sánchez Bazán (Spain)

Coagulation Activation Via Extrinsic Pathway Is the Major Cause of Hypercoagulation in Newborns during First Days of Life

Speaker: Ekaterina Koltsova (Russian Federation)

Impact of Inherited Thrombophilia on Risk of a First Perinatal Arterial Stroke and Further Course or Recurrence Rates: A Systematic Review and Meta-Analysis of Observational Studies

Speaker: Tido Bajorat (Germany)

Scientific Programme

The Frequencies of Thrombophilic DNA Polymorphisms in Children with Hemolytic Uremic Syndrome from the North-Western Region of Russia

Speaker: Eugene Pankov (Russian Federation)

The Throm-PED Registry: The Cornerstone of the International Pediatric Thrombosis Network

Speaker: C.Heleen van Ommen (the Netherlands)

Thrombosis and Anticoagulant Therapy among Pediatric Patients with Active Cancer: Real Life Data

Speaker: Momen Zeineddin (Jordan)

Thrombosis and Laboratory Monitoring in Children with Acute Lymphoblastic Leukemia

Speaker: Elena Seregina (Russian Federation)

Bivalirudin as the Primary Anticoagulant for Pediatric Patients with a Berlin EXCOR Ventricular Assist Device (VAD)

Speaker: Michael Silvey (United States)

Expanding the Spectrum of Heterozygous Antithrombin Deficiency Type II HBS? Unusual Presentation of Thromboembolic Events in Two Children

Speaker: Karin Beutel (Germany)

Venous Thromboembolism (VTE) in Children with Community-acquired Staphylococcus Aureus Bacteremia (CA-SAB) in Children: Risk Factors and Prevalence Study from a Single Pediatric Tertiary Care Center in Argentina

Speaker: Carolina Cervio (Argentina)

Pulmonary Embolism in Pediatric Age: Retrospective Analysis of 10 Year Period in a Tertiary Hospital

Speaker: Diana Cibeles (Portugal)

Arterial Ischemic Stroke in Greek Infants, Children and Adolescents: a Single-Centre Experience

Speaker: Athina Dettoraki (Greece)

Pulmonary Embolism in Pediatric Patients: A Ten-year Experience from a Tertiary Center in Brazil

Speaker: Liana Lira (Brazil)

Hospital Acquired Thrombosis in Pediatric Population

Speaker: Bushra Moiz (Pakistan)

Heparin Resistance in Pediatric Patient with Homozygous Antithrombin Deficiency, Treated with Dabigatran: A Case Report

Speaker: Evalina Doncheva (Bulgaria)

Qualitative and Quantitative Characterization of Plasma Exosomes from Neonates and Adults

Speaker: Julia Peñas Martínez (Spain)

A Rare Case of Phlephlebitis; An Unusual Underlying Reason for Portal Venous Thrombosis

Speaker: Selin Aytac (Turkey)

The Prevalence of Lupus Anticoagulant in Children and Adolescents Referred to the Reference Coagulation Laboratory of Iranian Blood Transfusion Organization

Speaker: Mino Ahmadinejad (Iran, Islamic Republic of)

Scientific Programme

Clinical and Radiological Outcome in a Single Center Cohort of Pediatric Patients with Focal Cerebral Arteriopathy (FCA). Safety of Antithrombotic Prophylaxis and Therapy

Speaker: Andrea Beccaria (Italy)

A Child with Ischemia of the Glans Penis after Circumcision

Speaker: Ludi Dhyani Rahmartani (Indonesia)

Global Hemostasis, Procoagulation and Anticoagulation Proteins Derangements in Children and Adolescents with Hemoglobin H and Beta-Thalassemia/Hemoglobin E Diseases

Speaker: Rungrote Natesirinilkul (Thailand)

Risk Factors for the Development of Hospital-acquired Pediatric Thromboembolism - Dealing with Potentially Causal and Confounding Risk Factors Using Direct Acyclic Graph (DAG) Analysis

Speaker: Leonardo R. Campos (Brazil)

Risk Factors for Symptomatic Venous Thromboembolism in Children and Adolescents with Lymphomas

Speaker: Dmitrii Evstratov (Russian Federation)

Moyamoya Disease - A European Clinical Case Report

Speaker: Lúcia Vieira (Portugal)

Effectiveness and Safety of Primary Thromboprophylaxis in Pediatric Renal Transplant: a Systematic Review of the Literature and Meta-Analysis

Speaker: Ahmad Al-Huniti (Canada)

A Rise in Plasma Coagulability During the First 3 Months Following Provoked Venous Thromboembolism is Associated with the Development of Post-Thrombotic Syndrome in Children and Young Adults: Analysis of the Kids-DOTT Multicenter Trial-Derived Biobank

Speaker: Marisol Betensky (United States)

Antithrombin Activity Level below 60% in Children Has Implications for Heparin (LMWH) Dosing

Speaker: Irene Regan (Ireland)

Impact of Blood Group on the Incidence of Thrombosis in Neonates

Speaker: Kulsajan Bhatia (Canada)

Bivalirudin Administration in Pediatric Ventricular Assist Devices and in Pediatric ECMO

Speaker: Chiara Giorni (Italy)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Platelet Disorders and von Willebrand Disease Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Acquired Thrombocytopenias

Can we Predict the Clinical Course of Children with ITP by MPV? A Preliminary Study

Speaker: Yoonkyung Lee (Korea, Republic of)

Scientific Programme

Megakaryocytic Hyperplasia in Bone Marrow Biopsy as a Novel Predictor of Response in Patients with Immune Thrombocytopenia

Speaker: Jacopo Agnelli Giacchello (Italy)

Phase I/II, Open-Label, Ongoing Study of PRN1008 (Rilzabrutinib), an Oral Bruton Tyrosine Kinase Inhibitor, in Patients with Heavily Pretreated Immune Thrombocytopenia (ITP)

Speaker: David J. Kuter (United States)

Characteristics of Patients with Cyclic Thrombocytopenia: An Observational Cohort Study

Speaker: Oskar Steinbrecher (Austria)

Pathogenic Mechanisms Contributing to Thrombocytopenia in Patients with Systemic Lupus Erythematosus

Speaker: Maria Constanza Baroni Pietto (Argentina)

Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating Let-7b in Immune thrombocytopenia

Speaker: Yang He (China)

Role of Bone Marrow-Derived Mesenchymal Stem Cell Defects in CD8+ CD28- Suppressor T-Lymphocyte Induction in Patients with Immune Thrombocytopenia and Associated Mechanisms

Speaker: Huiyuan Li (China)

Platelet Surface GPIIb/IIIa, Platelet Surface Activated GPIIb-IIIa and Platelet Surface P-Selectin in Venous-Arterial Extracorporeal Membrane Oxygenation Patients

Speaker: Yifeng Wu (United States)

Predictive Factors of Chronicity in Adult Idiopathic Thrombocytopenic Purpura

Speaker: Nadia Sari Hassoun (Algeria)

Antithyroid Treatment Improves Thrombocytopenia in a Young Patient with Graves' Disease: A Case Report

Speaker: Viviana Valeria Palmieri (Italy)

Apoptotic Markers May Help in Predicting the Disease Course of Pediatric Immune Thrombocytopenic Patients

Speaker: Sarina Levy Mendelovich (Israel)

Glucocorticoid Receptor Modulates the Mitochondria Function of Myeloid-Derived Suppressor Cells in Immune Thrombocytopenia

Speaker: Shuwen Wang (China)

Desmopressin for Procedures or Radiological Interventions (DRIVE): Participant Characteristics in a Placebo-Controlled Double-Blind, Randomised Feasibility Trial of Desmopressin in Thrombocytopenic Critically Ill Patients Prior to Procedures

Speaker: Michael Desborough (United Kingdom)

Atorvastatin Restores the Imbalance of CD4+ T cells in Immune Thrombocytopenia via Ras/MEK/ERK and mTOR/PI3K/AKT Pathways

Speaker: Pengcheng Xu (China)

Use of Eltrombopag in Children with Chronic Immune Thrombocytopenia (ITP): A Real Life Retrospective Multicenter Experience of the Italian Association of Pediatric Hematology and Oncology (AIEOP)

Speaker: Giuseppe Lassandro (Italy)

Scientific Programme

Relationship between Platelet Function and Glycome Composition in Immune Thrombocytopenia

Speaker: Nora Butta (Spain)

Can we Predict the Outcome of Splenectomy for Primary Immune Thrombocytopenia? Conclusion Based on Systematic Review and Meta-Analysis

Speaker: Mirjana Mitrovic (Serbia)

Achieving Clinically Relevant Platelet Count Response Thresholds with Avatrombopag (AVA) in Immune Thrombocytopenia (ITP)

Speaker: Michael Vredenburg (United States)

Efficacy and Safety of Romiplostim in Children with Chronic and Persistent Immune Thrombocytopenic Purpura

Speaker: Mohammadreza Bordbar (Iran, Islamic Republic of)

Outcome of Splenectomy in Adult Refractory Immune Thrombocytopenic Purpura - A Descriptive Analysis

Speaker: Gilbert Wilfred (Malaysia)

Romiplostim Treatment in Patients with Refractory Immune Thrombocytopenia Purpura: Experience in a Single Center

Speaker: Bianca Díaz Roldán (Spain)

Treatment of Immune Thrombocytopenia with Eltrombopag in Children: Single Center Experience

Speaker: Aylin Ayhan (Turkey)

Clinical and Laboratory Factors Affecting Chronicity in Children Diagnosed with Immune Thrombocytopenia

Speaker: Yilmaz Ay (Turkey)

Eltrombopag Suppresses Excessive Inflammation in Hepatitis B-Related Immunologic Thrombocytopenia through Inhibition of Toll-Like Receptor 4 Signaling Pathway

Speaker: Cheng Zhang (China)

Sustained Remission after Withdrawal of Thrombopoietin Receptor-Agonists in Immune Thrombocytopenia

Speaker: Jun Yamanouchi (Japan)

Risk Stratification for Intracranial Hemorrhage in Adults with Immune Thrombocytopenia: A Retrospective Multicenter Study

Speaker: Peng Zhao (China)

Factors Influencing Bleeding Severity in Adult Patients with Primary Immune Thrombocytopenia

Speaker: Johanna Gebhart (Austria)

CD4+ T Cell Expression of IL-10 Compared to IL-17 is Lower in Patients with Immune Thrombocytopenia (ITP) Who Do Not Respond Clinically to High Dose Corticosteroid

Speaker: Charlotte Bradbury (United Kingdom)

Clinical Practise of SMOG System for Assessing Severity of Hemorrhagic Manifestations of Immune Thrombocytopenia (ITP) in Children

Speaker: Daria Sigunova (Russian Federation)

Scientific Programme

Platelet Count Variation in a Cohort of Patients with Chronic HCV-Related Liver Disease Treated with Direct-Acting Antivirals

Speaker: Gianmarco Podda (Italy)

Response to Avatrombopag (AVA) in Chronic Immune Thrombocytopenia: Alternative Efficacy Measures

Speaker: Michael Vredenburg (United States)

Pharmacokinetic/Pharmacodynamic (PK/PD) Modeling Providing Guidance for Selecting Avatrombopag (AVA) Dose when Switching from Eltrombopag in Chronic Immune Thrombocytopenia (ITP)

Speaker: Michael Vredenburg (United States)

The Prevalence, Risk Factors, and Bleeding Tendency of Thrombocytopenia in Patients with Hepatitis C Virus and Hepatitis B Virus Infection

Speaker: Cih-En Huang (Taiwan, Republic of China)

Pooled Safety Analysis of Avatrombopag (AVA) from Clinical Trials

Speaker: Michael Vredenburg (United States)

Stability of Crushed Avatrombopag Tablets Demonstrated in Multiple Food Vehicles

Speaker: Michael Vredenburg (United States)

The Significance of Platelet Factor 4 (Pf4 Antibody) in Diabetic and Non-Diabetic Population during Heparin Therapy In Pakistan

Speaker: Razia Asif Abbasi (Pakistan)

Eltrombopag Therapy in Pediatric Acute and Chronic Immune Thrombocytopenia

Speaker: Emine Zengin (Turkey)

Immune Thrombocytopenia Treatment with Fostamatinib, a Spleen Tyrosine Kinase Inhibitor: Reducing the Risk of Thrombosis

Speaker: Nichola Cooper (United Kingdom)

Long Term Complications after Splenectomy in Chronic pITP Patients: A Retrospective Case Control Study

Speaker: Marilena Marcosano (Italy)

Fostamatinib as Second-Line Therapy for ITP and in Earlier Stage ITP Patients

Speaker: Waleed Ghanima (Norway)

Glibenclamide-Induced Thrombocytopenia: A Case Report

Speaker: Yosra Cherif (Tunisia)

Randomized Study for the Treatment of Primary Immune Thrombocytopenic Purpura (pITP) in Newly Diagnosed Untreated Adult Patients. Comparison of Standard Dose Prednisone versus High-dose Dexamethasone. Preliminary Results. GIMEMA Protocol ITP0207

Speaker: Maria Gabriella Mazzucconi (Italy)

Outcomes of Patients with Worsening Acquired Thrombotic Thrombocytopenic Purpura (TTP) Despite Daily Therapeutic Plasma Exchange (TPE) in the Phase 3 HERCULES Trial

Speaker: Marie Scully (United Kingdom)

Response Rate and Response Duration after Discontinuation of Treatment with Thrombopoietin Receptor Agonists (TPO-RAS) in Patients Affected by Primary Immune Thrombocytopenia (pITP): Retrospective Study. Preliminary Results. GIMEMA Protocol ITP0714

Speaker: Maria Gabriella Mazzucconi (Italy)

Scientific Programme

Comparison of Various Diagnostic Methods in Assessing Platelet Count in Patients with Immunotrombocytopenia

Speaker: Michal Witkowski (Poland)

A Long Term Survival Chronic DIC with ITP Treated with Low Dose Steroid

Speaker: Yoshinobu Seki (Japan)

Artificial Neural Network for Prediction of Hemorrhagic Severity in Patients with Immune Thrombocytopenia Purpura

Speaker: Tiago Dias Martins (Brazil)

Possible Impact of Polymorphism of GSTM1 and GSTT1 Genes on Bleeding Tendency in Immune Thrombocytopenia

Speaker: Samina Naz Mukry (Pakistan)

A Subpopulation of ITP Patients Resembling Glanzmann Thrombasthenia Phenotype Revealed by Flow Cytometry Analysis of Platelet Intracellular Signalling

Speaker: Alexey Martyanov (Russian Federation)

First Report of Rituximab Dependent Anti-platelet Antibodies as Cause of Acute Thrombocytopenia

Speaker: Yvonne Kong (Australia)

Pattern of Central Nervous System Involvement an Emerging Allied Complications of Dengue Hemorrhagic Fever. A literature Review

Speaker: Tanzeel Imran (Pakistan)

Characteristics and Outcome of Patients with Thrombocytopenia Secondary to Acute Cytomegalovirus Infection: Case Series and Literature Review

Speaker: Tamir Shragai (Israel)

Evaluation of Thrombocytopenia and Fetomaternal Outcome in Pregnancy at a Tertiary Care Hospital

Speaker: Kiran Aamir (Pakistan)

Investigations of the Impact of Sialidase-mediated Changes on the Life Span of Human Platelets Using a Humanized in vivo Mouse Model

Speaker: Lisann Pelzl (Germany)

Antimicrobial Prophylaxis in Patients with Immune Thrombocytopenia Treated with Rituximab: A Retrospective Multicenter Analysis

Speaker: Mariasanta Napolitano (Italy)

Corticosteroid Reduction or Discontinuation after Initiation of Avatrombopag Treatment in Patients with Chronic Immune Thrombocytopenia (ITP)

Speaker: Michael Vredenburg (United States)

Monoclonal Antibody Immobilization of Megakaryocyte Antigens (MAIMA) Assay: A Novel Tool for Detecting Human Platelet Antigens

Speaker: Josip Lucic (Germany)

Prevalence and Clinical Significance of Abnormal T-cell Large Granular Lymphocytes in Patients with Immune Thrombocytopenia

Speaker: Caroline Gabe (Canada)

Management of Steroid Refractory Acute Immune Thrombocytopenia Purpura - A Single Center Experience from India

Speaker: Nitin Gupta (India)

Scientific Programme

Antiplatelet Therapy

Platelet Function Assay PFA-200 for Monitoring of Antiplatelet Drug Effect

Speaker: Tatjana Makarovska Bojadjeva (Macedonia, the Former Yugoslav Republic of)

Long-term Variation of Platelet Reactivity in High-Risk Patients on Antiplatelet Therapy after Percutaneous Coronary Intervention

Speaker: Renske Olie (the Netherlands)

Synthesis of Antiplatelet Ortho-Carbonyl Hydroquinones: A Spiro Derivative is Selective against Collagen-Stimulated Platelets

Speaker: Diego Mendez (Chile)

The Effect of Aspirin in Tumor Growth of Obese Mice Involving Inhibition of Metabolism

Speaker: Jiaan-Der Wang (Taiwan, Republic of China)

Desmopressin for Reversal of Antiplatelet Drugs in Stroke due to Haemorrhage (DASH): Interim Report on Recruitment from a Phase II Double Blind Randomised Controlled Trial

Speaker: Michael Desborough (United Kingdom)

Lysine-Containing Peptides as Promising Antiplatelet Drugs

Speaker: Marina Grigorjeva (Russian Federation)

Efficacy of Antiplatelet Therapy in Patients with Acute Ischemic Stroke Treated with Acetylsalicylic Acid

Speaker: Lenka Bultasova (Czech Republic)

Detection of Clopidogrel Resistance: Comparison of Light Transmission Aggregometry and INNOVANCE® PFA P2Y Cartridge and Correlation with CYP2C19 Variants

Speaker: Laura Heireman (Belgium)

Potent platelet inhibition results in improved long-term clinical outcome independent from clinical variables

Speaker: Gloria Gager (Austria)

Comparison of Platelet Function Testing in Patients Undergoing Neuroradiological Flow Diversion Stents

Speaker: Mansour Gergi (United States)

Ticagrelor Mechanism of Action on Gram-Positive Bacteria

Speaker: Lucia Musumeci (Belgium)

Evaluation of Dual Antiplatelet Therapy Combining Aspirin and Clopidogrel for Intracranial Stenting Procedures: A Retrospective Single Center Study

Speaker: Luciana Goncalves (Portugal)

The Effect of Plasma Fibrinogen Level on Predictive Value of VerifyNow P2Y12 Assay Results in Patients Undergoing Percutaneous Coronary Interventions

Speaker: Anatoly Dobrovolsky (Russian Federation)

Discontinuation of Chronic Low Dose Acetylsalicylic Acid Therapy Upon Intensive Care Medicine Department Admission Appears to Increase Mortality

Speaker: Filipa Martins Pereira (Portugal)

Evaluation of Platelet Reactivity in Pediatric Patient on Dual Antiplatelet Therapy after Stent Implantation of Ductus Arteriosus: A Case Report

Speaker: Dobrinka Dineva (Bulgaria)

Scientific Programme

Circulating Myeloid-related Protein (MRP)-8/14 May Contribute to Suboptimal Response to Low Dose Aspirin in Patients with Type 2 Diabetes mellitus

Speaker: Paola Giustina Maria Simeone (Italy)

Correlation of VASP Phosphorylation Assay with Light Transmission Aggregometry for Patients Treated with Clopidogrel or Ticagrelor

Speaker: Maxime Moulard (France)

Intra-individual Residual Platelet Reactivity upon Antiplatelet Therapy in the Perioperative Period Significantly Differs over Time - What Is the Ideal Moment to Monitor Efficacy of Antiplatelet Therapy in Vascular Patients?

Speaker: Suzanne Korporaal (the Netherlands)

Assessment of the Hemostatic System by Total Thrombus-formation Analysis System (T-TAS) in Patients with Chronic Coronary Syndromes

Speaker: Olga Sirotkina (Russian Federation)

HIT

Evaluation of Fondaparinux (Arixtra®) at a Large Academic Medical Center

Speaker: Cassandra Marsh (United States)

Prospective Comparison of Two Specific IgG Immunoassays (HemosIL® AcuStar HIT IgG and HAT 45-G®) for the Biological Diagnosis of Heparin-Induced Thrombocytopenia: A Bayesian Approach

Speaker: Eve Anne Guery (France)

Characterization of Murine Monoclonal Anti-PF4/Polyanion Antibodies, as Potential Useful Tools for Studies on Typical and Autoimmune HIT

Speaker: Caroline Vayne (France)

Autoimmune Heparin-Induced Thrombocytopenia Successfully Treated using Direct Oral Anticoagulant and Intra-Venous Immunoglobulin

Speaker: Valérie Proulle (France)

Interaction of Unfractionated Heparin and Sulodexide with Functional Anti-Heparin Platelet Factor 4 Antibodies as Investigated in Platelet Aggregation Assays

Speaker: Ambar Farooqui (United States)

Insights into Autoimmune Heparin-Induced Thrombocytopenia

Speaker: Nora Krause (Germany)

Comparison of Clinical Adverse Events during Empiric Therapy for Patients with Suspected HIT

Speaker: Kaitlyn Dykes (United States)

Therapeutic Plasma Exchange in the Pre-Operative Management of Acute HIT

Speaker: Candice Cavalié (France)

Heparin-Induced Thrombocytopenia in Intensive Care Patients with Extracorporeal Circulation

Speaker: Karina Althaus (Germany)

The Utility of a Platelet Count-Based Electronic Medical Record Alert to Facilitate Diagnosis of Heparin-Induced Thrombocytopenia

Speaker: Jori May (United States)

Scientific Programme

Detection of Pathogenic Anti-platelet Factor 4 Antibodies by Impedance Spectroscopy

Speaker: Nida Zaman Khan (Germany)

Evaluation of 4T Probability Scores, Heparin PF4 Antibody, and Serotonin Release Values in End Stage Renal Disease Patients in the Assessment of Heparin Induced Thrombocytopenia

Speaker: Julie Kelly (United States)

Inhibition of 12-LOX with VLX-1005 Has Clinical Utility for Prevention and Intervention of HIT

Speaker: Michael Holinstat (United States)

Underlying Causes Greatly Influence the Development of HIT Antibodies and Clinical Outcomes in Patients with Heparin-induced Thrombocytopenia

Speaker: Shigeki Miyata (Japan)

Platelet Flow Cytometry in the Diagnosis of Heparin-induced Thrombocytopenia

Speaker: Polina Lavrova (Russian Federation)

First Performance Data of a New Latex Enhanced Immunoassay to Detect HIT Antibodies in Plasma Samples *

Speaker: Matthias Ehm (Germany)

Addition of Exogenous Platelet Factor 4 in the Heparin Induced Platelet Activation (HIPA) Assay for the Detection of Pathogenic Heparin-induced Thrombocytopenia Antibodies

Speaker: Dorothée Faille (France)

Effect of Synthetic Inhibitors on HIT Antigenic Complex - Therapeutic Approach Alternative to Anticoagulation

Speaker: Lubica Rauova (United States)

Anaphylactic Shock to Apixaban in a Patient Treated for Heparin-induced Thrombocytopenia (HIT)

Speaker: Mariana Afonso (Portugal)

A Challenging Case of Delayed-onset Refractory Heparin-induced Thrombocytopenia Complicated with Arterial Thrombosis

Speaker: Saartje Van de Vondel (Belgium)

HIT Antibody-induced Aggregation of Breast Cancer Cells

Speaker: Thi Nguyen (Germany)

Inherited Thrombocytopenias

A Novel Missense Mutations of the WASp Gene Cause a Familial X-linked Thrombocytopenia

Speaker: Huiqing Liu (China)

Diagnostic Approach to Inherited Thrombocytopenias in a Low-Income Setting

Speaker: Ana C. Glembotsky (Argentina)

Highly Disturbed Platelet Ultrastructure in Two Families with Novel IKZF5 Variants and Inherited Thrombocytopenia

Speaker: Eva Leinoe (Denmark)

Diagnosis of Inherited Platelet Disorders on a Blood Smear: The One-Year Experience of a Reference Laboratory

Speaker: Carlo Zaninetti (Italy)

Scientific Programme

Clinical, Morphological and Functional Platelet Tests in Inherited Thrombocytopenia

Speaker: Filipe Gonçalves (Portugal)

Genotypic Analysis at Transition from Idiopathic Thrombocytopenic Purpura to Inherited Thrombocytopenia

Speaker: Canan Albayrak (Turkey)

Clinical Use of Carica Papaya Leaf Extract in Thrombocytopenia in Bernard-Soulier Syndrome

Speaker: Osama El Safi (Egypt)

MYH9-Related Inherited Thrombocytopenia: 14 Newly Diagnosed Chinese Pedigree

Speaker: Xueqing Dou (China)

Refractory Thrombocytopenia with TUBB1 Variants: Clinical Features and Responses to Eltrombopag Treatment

Speaker: Miao Jiang (China)

Phenotype and Characteristics of a Cohort of Macrothrombocytopenic Patients Related to the AlphaIIb beta3 Variants

Speaker: Anne Vincenot (France)

Flow Cytometry of Platelets: A Way for Distinguishing Patients with MYH9-related Disease from Patients with Other Inherited Thrombocytopenias and Immune Thrombocytopenia

Speaker: Daria Fedorova (Russian Federation)

Determination of the Genotype of von Willebrand Disease Type 3

Speaker: Dana Provaznikova (Czech Republic)

Variants of GFI1B: Phenotype/Genotype of a Series of 9 New Cases

Speaker: Anne Vincenot (France)

New Clues to GNE Gene Role in the Pathogenesis of Inherited Thrombocytopenias

Speaker: Ilaria Persico (Italy)

Platelets Function and Cytoskeletal Organization in a Patient with a Novel Variant in ACTB Causing Macrothrombocytopenia

Speaker: Claudia Maria Radu (Italy)

Bernard - Soulier Syndrome (BSS): From Identification of the Variants to their Functional Studies

Speaker: Giorgia Fontana (Italy)

Inherited Thrombocytopenia Associated with Haematological Malignancies

Speaker: Michela Faleschini (Italy)

First Autosomal Recessive Variant in TUBB1 Impairs Proplatelet Formation and Results in Inherited Macrothrombocytopenia

Speaker: Veronica Palma-Barqueros (Spain)

Identification and Functional Study of a New Germline Variant in Mecom Gene

Speaker: Nicole Papa (Italy)

Ex vivo Observation of Platelet-granulocytes Interactions in Pediatric Patients with Congenital Platelet Defects

Speaker: Daria Morozova (Russian Federation)

Platelet Antagonists and Novel Therapeutics

Scientific Programme

High-Dose Dexamethasone Effectively Replaces Traditional Full-Dose Prednisone as the First-Line Treatment of Children Immune Thrombocytopenia: A Prospective Randomized Single-Center Study

Speaker: Lingling Fu (China)

Tyrosine Kinase Inhibitors (TKIs) Targeting Syk and BTK Signaling Differentially Affect PI3K Organization and Inhibit Platelet Function

Speaker: Tony Zheng (United States)

Identification of the Sequence Specificity in C-Src SH3 Required for Binding to Integrin B3 as a Novel Anti-Thrombotic Target without Compromising Primary Hemostasis

Speaker: Xiaodong Xi (China)

Inhibition of Platelet Adhesion, Thrombus Formation and Fibrin Formation by a Potent α IIb β 3 Integrin Inhibitor

Speaker: D.L. van den Kerkhof (the Netherlands)

Selatogrel, a Potent P2Y₁₂ Receptor Antagonist, Dissolves Pre-Formed Platelet-thrombi in vivo

Speaker: Markus A. Riederer (Switzerland)

Method of Anticoagulation Influences Potency of Reversible P2Y₁₂ Receptor Antagonists

Speaker: Martine Baumann (Switzerland)

Idelalisib Selectively Inhibits GPVI-mediated Platelet Activation and Shows Anti-atherothrombotic Activity

Speaker: Maria Nuñez Barrachina (Spain)

Role of Multidrug Resistance Protein 4 on Both Platelet Nitric Oxide Resistance and ADP Induced Platelet Aggregation

Speaker: Maria Luisa Guarino (Italy)

Antithrombotic Therapy by Charged Nanoparticles

Speaker: David N. Ku (United States)

Platelet Function Disorders, Acquired

Complex Changes in Plasma Associated with Platelet Dysfunction in Trauma Patients

Speaker: Alexander St. John (United States)

Platelet Dysfunction and Coagulation Activation in Intracerebral Hemorrhage

Speaker: Hau Kwaan (United States)

Platelet Purinergic Signaling Regulates Pulmonary Thrombosis in Sickle Cell Disease

Speaker: Tomasz Brzoska (United States)

«Aspirin-Like» Platelet Defect Induced by Gabapentin: A Case-Report

Speaker: Tatiana Baglo (France)

Uremia Induced Pre-Activation Results in Platelet Function Impairment in Chronic Kidney Disease

Speaker: Constance Baaten (Germany)

Bleeding Symptoms Associated with Platelet Function Abnormalities on Ibrutinib Therapy

Speaker: Anastasia Ignatova (Russian Federation)

Scientific Programme

Severe Platelet Dysfunction in Patient with Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia (Ph+ALL) after Tyrosine Kinase Inhibitor (TKI) Therapy

Speaker: Maria Rita Cozzi (Italy)

Dual Antiplatelet Therapy in One Patient with a Immune GPVI Deficiency

Speaker: Martine Jandrot-Perrus (France)

Quality of Life Today in Patients with Chronic Immune Thrombocytopenic Purpura

Speaker: Claudia Cristina Tarniceriu (Romania)

Dysregulation of Platelet Serotonin and Platelet 14-3-3-Related Biomarkers in Sudden Infant Death Syndrome

Speaker: Andrew L. Frelinger III (United States)

Assessment of Platelet Function after Shear Stress Simulation Using an ex vivo Model for Extracorporeal Circulation

Speaker: Oleg Hidiatov (Germany)

First Evidence: Rivaroxaban, Apixaban and Edoxaban Reduce Thrombin-Dependent Platelet Aggregation

Speaker: Juraj Sokol (Slovakia)

First Evidence: Edoxaban Affects TRAP-dependent Platelet Aggregation

Speaker: Lubica Vadelova (Slovakia)

Platelet Function Disorders, Hereditary

Successful Perioperative Hemostasis for Glioblastoma Surgery in a Patient with Glanzmann Thrombasthenia

Speaker: Dario Schiavo (Italy)

A Whole Blood Flow Cytometric Method for Diagnosis of Platelet Function Disorders

Speaker: Rutvi Gautam Dave (India)

Platelet Activation Markers and Impaired Procoagulant Response in Pediatric Patients with Inherited Platelet Function Disorders

Speaker: Dmitrii Polokhov (Russian Federation)

Hemarthrosis and Chronic Synovitis in Glanzmann Thrombasthenia

Speaker: Raghad Tarawah (Saudi Arabia)

Defective Endocytosis of Albumin, Fibrinogen and IgG in Platelets with RUNX1 Haplodeficiency

Speaker: A Koneti Rao (United States)

Usefulness of ISTH-BAT in Clinical Assessment of Inherited Platelet Disorders: Experience of the Spanish National Project

Speaker: José María Bastida (Spain)

Periodic rFVIIa Prophylaxis due to Recurrent Haemarthroses into the Right Ankle Joint in a Patient with Glanzmann's Thrombasthenia

Speaker: Pawel Laguna (Poland)

The contribution of flow cytometry in the diagnosis of inherited thrombocytopathies

Speaker: Hacene Brouk (Algeria)

Scientific Programme

Glanzmann Thrombasthenia in Pakistani Patients: Biochemical Analyses & Identification of Novel Pathogenic Variants in the Fibrinogen Receptor $\alpha\text{IIb}\beta_3$

Speaker: Muhammad Younus Jamal Siddiqi (Pakistan)

Inherited Platelet Disorders: Identification of Novel Disease Causing Variants Using Next Generation Sequencing

Speaker: Doris Boeckelmann (Germany)

Clinical and Molecular Characterization of Chinese Patients with Wiskott-Aldrich Syndrome

Speaker: Xian Zhang (China)

Genetic Characterization of Inherited Platelet Disorders in a Single Portuguese Center for Coagulopathies

Speaker: Sara Morais (Portugal)

Utility of the ISTH Bleeding Assessment Tool and the Pediatric Bleeding Questionnaire in predicting platelet function defects in pediatric patients with excessive bleeding

Speaker: Daria Fedorova (Russian Federation)

Correlation GLATIT Scores and the Number of Bleeding Episodes in the Assessment of the Prognosis of Inherited Platelet Disorder

Speaker: Reda Messaoudi (Algeria)

Utility of the ISTH Bleeding Assessment Tool (BATs) in Diagnosis of Glanzmann Thrombasthenia Patients - Experience from Pakistan

Speaker: Nazish Saqlain (Pakistan)

Efficacy of Novoseven in the Treatment of Bleeding Episodes During Glanzmann's Thrombasthenia

Speaker: Reda Messaoudi (Algeria)

Use of a Whole Exome "Slice" for Evaluation of Inherited Platelet Disorders

Speaker: Kevin Todd Jr. (United States)

Defective RAB31-mediated Endosomal Trafficking in RUNX1 Haplodeficiency

Speaker: A Koneti Rao (United States)

Clinico-pathological Spectrum of GlanzmannThrombasthenia

Speaker: Dinesh Chandra (India)

Global Tests of Primary Hemostasis for the Diagnosis of Mild/Moderate Bleeding Disorders (MMBD): Rehabilitating the Skin Bleeding Time

Speaker: Andrea Baccolo (Italy)

Strategies for Analysis of Novel Molecular Variants in the RUNX1 Gene as a Cause of Familial Platelet Disorder with Predisposition to Acute Myeloid Leukemia (FPD/AML)

Speaker: Veronica Palma-Barqueros (Spain)

Identification of a Novel Molecular Variant in the PTGS1 Gene that Causes a Loss of a Glycan in the Catalytic Domain, Defects in Platelet Thromboxane A2 Synthesis, and Bleeding

Speaker: Veronica Palma-Barqueros (Spain)

Variants in the LLR5 Domain Confer to GPIIb Increased Affinity for VWF: A Novel Case of Platelet-type von Willebrand Disease

Speaker: Loredana Bury (Italy)

Scientific Programme

Molecular Insights into Glanzmann's Thrombasthenia through Family Forums for Gene Sequencing and Discovery

Speaker: Diane Nugent (United States)

Glanzmann Thrombasthenia-like Syndrome: Report of 2 Cases

Speaker: Khalida Mendi (Algeria)

LAD III, Platelet Pathology Related to GT: A Case Report

Speaker: Khalida Mendi (Algeria)

Platelet Reactivity, Independent of Platelet Count, Is Associated with Bleeding Severity in Patients with Gaucher Disease

Speaker: Shoshana Revel-Vilk (Israel)

Current Data About Arterial Thrombotic Events in Cerebrovascular Circulation Caused by Sticky Platelet Syndrome in the National Registry of Thrombophilic States in Slovak Republic

Speaker: Monika Brunclikova (Slovakia)

Targeted High-throughput Sequencing for Genetic Classification of Patients with Inherited Platelet Disorders

Speaker: Harald Schulze (Germany)

Association of Genetic Variability in Selected Genes in Patients with Deep Vein Thrombosis and Platelet Hyperaggregability

Speaker: Lenka Lisá (Slovakia)

Gynaecological Outcomes in Women with Inherited Platelet Function Disorders: Preliminary Data from the ISTH REDCap Registry

Speaker: Deborah Obeng-Tuudah (United Kingdom)

von Willebrand Factor Biology

The Method of Purification of von Willebrand Factor

Speaker: Nataliya Shurko (Ukraine)

Golgi SNARE STX5 Regulates Golgi Morphology and WPB Biogenesis

Speaker: Ellie Karampini (the Netherlands)

Inertial Forces Generated by a Vortex System Promote Cleavage of von Willebrand Factor

Speaker: Katrina Ashworth (United States)

Diagnosis of von Willebrand Disease in Algeria Laboratory and Clinical phenotype: Single Center Experience

Speaker: Driss Benlaldj (Algeria)

Structural Analysis of the VWF molecule with Compound in Cis Heterozygous p.R924Q and p.A2178S Mutations Causing a Type 2B-Like von Willebrand Disease

Speaker: Raimondo De Cristofaro (Italy)

The Scavenger Receptor Scara5 Mediates Clearance of the von Willebrand Factor Propeptide

Speaker: Orla Rawley (Canada)

Monitoring Recombinant and Plasma-Derived VWF Concentrates: An in vitro Study

Speaker: Melanie Daniel (France)

Scientific Programme

Excessive Angiogenesis in von Willebrand Factor Knockout Mice is Accompanied by Increased Perivascular Coverage of Neovessels

Speaker: Maureane Hoffman (United States)

Explanations for Rise of Levels of Factor VIII and von Willebrand Factor Antigen with Age

Speaker: Eugenia Biguzzi (Italy)

Comparison of an Automated von Willebrand Factor Activity Assay by HemosIL Werfen® with Ristocetin Cofactor Assay by Aggregometry in Thrombocytic Patients with Myeloproliferative Neoplasms or Secondary Thrombocytosis

Speaker: Chloé James (France)

The Super Glue of Ultra-Large Multimers - Characterisation of Recombinant and Platelet Derived von Willebrand Factor

Speaker: Thorsten Kragh (Germany)

Investigating Pathomolecular Mechanisms of Type 2A VWD Variants Located in D1 and A Domains of the VWF

Speaker: Hamideh Yadegari (Germany)

Reduced Cleavage of Circulating Ultra-large von Willebrand Factor by ADAMTS13 Exacerbates Microvascular Disease Following Traumatic Injury

Speaker: William Plautz (United States)

Lyophilized Human Platelets Show Hemostatic Function Independent of von Willebrand Factor

Speaker: Braden Ishler (United States)

Type 2B Mutations Differentially Alter Conformational Dynamics of VWF A1 Domain

Speaker: Emily R. Legan (United States)

Extracellular Role of the Von Willebrand Factor Propeptide (VWFpp) in Symptomatic Low VWF (SLVWF) in Flowing Blood

Speaker: Eric F. Grabowski (United States)

VWF and von Willebrand Factor Disorders - Clinical Conditions

Clinical Presentation of Von Willebrand Disease in a Developing Country-A Cross Sectional Study

Speaker: Arooj Fatima (Pakistan)

Population Pharmacokinetics and Pharmacodynamics of Recombinant von Willebrand Factor

Speaker: Martin Wolfsegger (Austria)

Symptomatic Venous Aneurysm of the Internal Jugular Vein Presenting with Small Thrombotic Inclusions in von Willebrand Disease Type I

Speaker: Katharina Guetl (Austria)

The Utility of ISTH-BAT in Iranian Patients with von Willebrand Disease

Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

Investigating the Relationship between VWF Multimeric Pattern and VWF: RCo Activity through Population PK Modeling in Patients with Severe VWD Treated with Recombinant VWF

Speaker: Alexander Bauer (Austria)

Scientific Programme

Recombinant Human von Willebrand Factor (rVWF) Differs in Structure and Function from Plasma Derived Concentrates

Speaker: Peter L Turecek (Austria)

von Willebrand Disease Combined with Other Coagulation Defects: Experience at a Single Reference Coagulation Laboratory in Iran

Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

Harnessing Social Media to Improve Awareness of Bleeding Disorders

Speaker: Fatimah Alaya (Ireland)

Characterization of Type 2B VWD in the US Zimmerman Program

Speaker: Pamela Christopherson (United States)

Response to Treatment for Gastro-Intestinal Bleeding in von Willebrand Disease

Speaker: Eugenia Biguzzi (Italy)

Real-life Management of Digestive Endoscopies: Is There a Bleeding Risk for Patients with von Willebrand Disease?

Speaker: Valerie Horvais (France)

A Retrospective Study to Evaluate the Efficacy and Safety of a Plasma-Derived, von Willebrand Factor-Containing FVIII Concentrate, in Patients with Von Willebrand Disease (VWD) in Spain: Interim Analysis Results

Speaker: Roser Mir (Spain)

von Willebrand Factor Propeptide: Useful Diagnostic Add-On to Differentiate von Willebrand Disease Based upon Increased von Willebrand Factor Clearance

Speaker: Oliver Tiebel (Germany)

WISH-QoL Study: Assessment of Health-Related Quality of Life and Health-Economic Aspects in Patients with von Willebrand Disease in France: Results from the 2nd Interim Analysis on the 355 Enrolled Patients

Speaker: Annie Borel Derlon (France)

The Role of the von Willebrand Factor Propeptide (VWFpp) in the Evaluation of Desmopressin Response in a Patient with Acquired von Willebrand Syndrome (AVWS)

Speaker: Paola Colpani (Italy)

Retrospective Chart Review of Gastrointestinal Bleeding in Patients with von Willebrand Disease: Study Design and Initial Demographic Results

Speaker: Peter Kouides (United States)

Treatment with Emicizumab Leads to Clinical Improvement in a Type 3 von Willebrand Disease Patient with Inhibitor Suffering from a Left Ankle Arthropathy

Speaker: Marianne Sigaud (France)

Clinically Relevant Differences between Two New Generation VWF: GPIbR Assays in a Patient with Acquired von Willebrand Syndrome - Case Report

Speaker: Katarzyna Mayger (United Kingdom)

Recombinant von Willebrand Factor (rVWF) in Patients with von Willebrand Disease (VWD) Undergoing Elective or Emergency Surgery in Real World Setting - The Dijon University Hospital Experience from March 2019 to January 2020

Speaker: Fabienne Genre Volot (France)

Scientific Programme

Inhibition of ADAMTS13 Rescues Acquired von Willebrand Syndrome in a Preclinical Mechanical Circulatory Support Animal Model

Speaker: Shannen Deconinck (Belgium)

Quality of Peri-Procedural Care in Patients with von Willebrand Disease

Speaker: Craig Seaman (United States)

Clinical and Phenotypic Evaluation of Patients with Low von Willebrand Factor

Speaker: Omid Seidi Zadeh (Iran, Islamic Republic of)

The Compound Heterozygosity with Two in Cis Mutations p.R924Q and p.A2178S in the D'D3 and D4 Domain Causes a Type 2B-Like von Willebrand Disease

Speaker: Stefano Lancellotti (Italy)

Increased von Willebrand Factor Levels in Polycythemia Vera and Phenotypic Differences with Essential Thrombocythemia

Speaker: Monica Sacco (Italy)

Prevalence and Diagnostic Rate of von Willebrand Disease in an Argentine Medical Care Program

Speaker: Fernando Chuliber (Argentina)

Evaluation of Carriers of Type 3 von Willebrand Disease with PFA200

Speaker: Tulasi Geevar (India)

Prophylaxis with Recombinant von Willebrand Factor in a Case of Concomitant von Willebrand's Disease and CREST Syndrome

Speaker: Claudia Binder (Germany)

Pelvic Haematoma in Women with Bleeding Disorders: A Single Center Experience

Speaker: Veena Selvaratnam (Malaysia)

The Impacts of Genetic Polymorphisms on the Von Willebrand Factor Level in Type 1 Von Willebrand Disease

Speaker: Yeu-Chin Chen (Taiwan, Republic of China)

Adolescent Menorrhagia and Von Willebrand Disease

Speaker: Yamina Ouahelent (Algeria)

Response to Desmopressin Acetate in Von Willebrand Disease Type 2

Speaker: Guilherme Almeida Maia (Brazil)

Gastrointestinal Bleeding from Angiodysplasia in Constitutional von Willebrand Disease: Improved Diagnosis Yield and Risk Stratification when Using Video Capsule on Top of Conventional Endoscopy

Speaker: Antoine Rauch (France)

Successful Surgical Interventions In Children with von Willebrand Disease Type 3

Speaker: Karina Papayan (Russian Federation)

Establishing Reference Intervals for von Willebrand Factor Multimers

Speaker: Marika Pikta (Estonia)

Inhibitor Development in Patients with Type 3 von Willebrand Disease, a Comprehensive Study on a Large Number of Iranian Patients

Speaker: Shadi Tabibian (Iran, Islamic Republic of)

Scientific Programme

The Homozygous Variant p.Gln1311* in Exon 28 of VWF Is Causing Type 3 von Willebrand Disease and Is at High Risk of Allo-Immunisation

Speaker: Fanny Lassalle (France)

High Variability of Laboratory Phenotype in Genetically Proven von Willebrand Disease Type 2B

Speaker: Ralf Knöfler (Germany)

Increasing Levels of von Willebrand Factor (VWF) and Factor VIII (FVIII:C) with Age in Patients Affected by von Willebrand Disease (VWD)

Speaker: Eugenia Biguzzi (Italy)

Desmopressin in Patients with Type 2B von Willebrand Disease: Differential Impact on VWF and Platelet Function

Speaker: Annabelle Dupont (France)

Comparison of von Willebrand Factor (VWF) Multimeric Profile Obtained by a Commercial Electrophoretic Test (Hydrigel 5 von Willebrand Multimers) and Classical Home-made with a Discontinuous 1% Agarose Gel Electrophoresis

Speaker: Marina Sol Lopez (Argentina)

Gynaecological Problems, Management and Outcomes in Women with Moderate and Severe von Willebrand Disease (VWD)

Speaker: Ozlem Turan (United Kingdom)

Degradation of High Molecular Weight von Willebrand Factor Multimers during Extracorporeal Membrane Oxygenation-Treatment

Speaker: Min-Sun Kim (Korea, Republic of)

Acquired von-Willebrand-Disease (aVWD) in ECMO Patients: a 3-Year Cohort Study

Speaker: Tido Bajorat (Germany)

Prothrombotic Gain-of-Function Variants of von Willebrand Factor

Speaker: Maria A. Brehm (Germany)

Type 2N von Willebrand Disease (VWD2N): Is it Always a Recessive Trait?

Speaker: Adriana Ines Woods (Argentina)

Severe Thrombocytopenia after DDAVP Test (DDAVPt) in a Girl with a p.Cys1272Gly Variant of the VWF Gen

Speaker: Juan Pablo Frontroth (Argentina)

Measurement of VWF:FVIII Binding (VWF:FVIII:B) in a Cohort of Patients with Suspected Type 2N VWD and Correlation with Genetic Analysis of the VWF Gene

Speaker: Mairead Doyle (Ireland)

Uncommon Types of von Willebrand Disease

Speaker: Petr Birke (Czech Republic)

Diagnostic Performances Evaluation of LIAPHEN vWF: Ag on CS-2500

Speaker: Claire Dunois (France)

Diagnosis and Management of von Willebrand Disease in a Portuguese Reference Center of Congenital Coagulopathies

Speaker: Teresa Fidalgo (Portugal)

Real World Experience of Major Surgery and Delivery in Von Willebrand Disease

Speaker: Brian Craven (United Kingdom)

Scientific Programme

Von Willebrand's Disease: A Diagnostic Evaluation Using Current Guidelines

Speaker: Emily Bar (United Kingdom)

Laboratory Monitoring of Perioperative von Willebrand Factor Replacement

Speaker: Cynthia Rothschild (Brazil)

The VWF Variant D1472H Affects VWF Binding to Ristocetin in vitro in the Platelet Agglutination Assay but Not with Latex Particles (HemosIL® Acustar VWF:GplbR): The Usefulness to Change Practices to Avoid VWD Genotyping

Speaker: Fanny Lassalle (France)

Gum Bleeding in Low Von Willebrand Factor- What's the Score?

Speaker: Alison Dougall (Ireland)

On-Demand Poster Session

14:00 - 15:00

Virtual Meeting Room 6

Platelets and Megakaryocytes Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Megakaryocytes and Thrombopoiesis

Megakaryocytes Possess a Functional Necroptosis Pathway

Speaker: Diane Moujalled (Australia)

Combined $\alpha 4a$ - and $\beta 1$ -Tubulin Deficiencies Profoundly Affect Platelet Biogenesis and Haemostasis

Speaker: Quentin Kimmerlin (France)

Systmetic Study of Biological Properties and Functions of Bone Marrow Mesenchymal Stem Cells from Patients with Essential Thrombocythemia and Explore the Effects of Interferon α -2b on Them

Speaker: Ting Sun (China)

A Novel Image-Based Chemical-Genetics Screen Identifies Inducers of Platelet Release from Immortalized Megakaryocytic Cell Lines, Enabling Clinical-Scale Production of Functional Platelets

Speaker: Arunoday Bhan (United States)

Mesenchymal Stromal Cells Display Metabolic Alterations in JAK2-Mutant Myeloproliferative Neoplasms

Speaker: Ting Sun (China)

Dysfunctional RBM8A/Y14 Does Not Impair Megakaryopoiesis but Terminal Thrombopoiesis in Thrombocytopenia Absent Radii (TAR) Syndrome

Speaker: Georgi Manukjan (Germany)

Essential Thrombocythemia (ET): A Study of Clinical Features and Treatment Outcome in Pediatric Patients at King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Speaker: Muhammad Ameen (Saudi Arabia)

Scientific Programme

Autoantibody Mediated Changes in Megakaryocytes Glycan Pattern: Potential Impact on Thrombopoiesis in Immune Thrombocytopenia

Speaker: Irene Marini (Germany)

Megakaryocyte Mitochondrial Dynamics and Oxidative Metabolism Are Essential to Initiate Platelet Biogenesis

Speaker: Dominique Baruch (France)

The Ablation of Collagen VI Leads to the Release of Platelets with Altered Functions

Speaker: Vittorio Abbonante (Italy)

Generation of Megakaryocytes from Human Bone Marrow Aspirates as a Simple Diagnostic and Research Tool: Assay Development and Validation

Speaker: Kirill Butov (Russian Federation)

A Close Relationship between Adipocytes and Megakaryocytes

Speaker: Sonia Severin (France)

Thrombopoiesis in Bone Marrow Culture in Norm and in Some Pathological States

Speaker: Tamar Saralidze (Georgia)

Short-term Application of Caffeic Acid Specifically Promotes Expansion of Hematopoietic Stem Cells

Speaker: Ruting Wang (China)

TREM-like Transcript-1 Is a Positive Regulator of Platelet Production and Thrombosis

Speaker: Alexandra Mazharian (France)

Accelerated Death of Wiskott-Aldrich Syndrome Megakaryocytes

Speaker: Sergei Obydennyi (Russian Federation)

Impact of Irradiation on the Bone Marrow Matrix and Megakaryopoiesis

Speaker: Kristina Faber (Germany)

Hyperactive SRC Kinase Results in Inherited Thrombocytopenia: Transcriptomics and Proteomics to Delineate the Defect in Megakaryopoiesis

Speaker: Lore De Kock (Belgium)

Role of Platelet Production/Destruction Imbalance on the Interindividual Variability in Aspirin Response in Diabetic and Non-diabetic Patients

Speaker: Rossella Liani (Italy)

Rap1a/b Isoforms Differentially Regulate Megakaryocyte Biology

Speaker: Dorsaf Ghalloussi (United States)

Ikaros/AhR Interaction Favors Expansion of Megakaryocytic Precursors with a High Potential to Produce Proplatelets

Speaker: Valentin Do Sacramento (France)

Platelet Function and Interactions

Association of Platelet Derived - Microparticles and Endothelia Dysfunction in NVAf Patients Undertaking PCI

Speaker: Bing Ding (China)

Thrombotic Disease Caused by Hypothermia-Induced Activation of the Splenic Platelet Pool in a Mouse Model

Speaker: Kie Horioka (Sweden)

Scientific Programme

Kupffer Cells Clear Aged Platelets through Macrophage Galactose Lectin

Speaker: Carsten Deppermann (Germany)

Cold over Room Temperature Storage of Apheresis Platelets Better Preserves Hemostatic Function out to 21 Days

Speaker: Susan M. Shea (United States)

Video Rate, High Contrast Morphological Imaging of Blood Thrombus using Label - Free Coherent Optical Scattering and Interferometry (COSI) Microscopy

Speaker: Yujie Zheng (Australia)

Exercise Training Enhances Mitochondrial Bioenergetics of Platelets in Patients with Peripheral Arterial Disease

Speaker: Jong-Shyan Wang (Taiwan, Republic of China)

Evaluation of Platelet Count and Platelet Indices of Male Cannabis Sativa (Marijuana) Consumers in Calabar South, Cross River State, Nigeria

Speaker: Dorathy Chioma Okpokam (Nigeria)

Epinephrine Enhances Platelet Aggregation at the Expense of Procoagulant Activity

Speaker: Alessandro Aliotta (Switzerland)

MiR-204-5p Regulates Platelet Adhesion to Fibrinogen

Speaker: Alix Garcia (Switzerland)

Platelet Aggregation is Suppressed in the Quinonoid Dihydropteridine Reductase Knockout Mice

Speaker: Yui Suganuma (Japan)

Platelets form Fibrillar Adhesions: Implications for Force-Regulated Thrombus Remodeling

Speaker: Sebastian Lickert (Switzerland)

An Elevated Platelet Count Increases the Rate of Prothrombin Activation, but Not the Total Amount of Thrombin Formed

Speaker: Qiuting Yan (the Netherlands)

Effect of Three Types of Mixed Anesthesia (MMB) for Platelet Function

Speaker: Taiki Kano (Japan)

Antibodies Protect Platelets against Streptococcus Pneumoniae Toxin Pneumolysin

Speaker: Stefan Handtke (Germany)

Modified Plasma Recalcification Assay for Evaluation of Platelet Procoagulant Activity

Speaker: Alexey Mazurov (Russian Federation)

Importance of Platelet Contractility at Different Stages of Thrombus Formation

Speaker: Martin Kenny (Ireland)

The Effect of IL-6-Primed Platelets on ADAMTS13-Mediated Clearance of Platelet-Bearing ULVWF and its Mechanism

Speaker: Hyun-Jeong Kim (Korea, Republic of)

Reduced GPVI Signalling in Genetic and Disease Models of Thrombocytopenia

Speaker: Stephanie R. Hyslop (Australia)

Microparticles Released from Stored Platelet Increase Coagulation Ability

Speaker: Ippei Noboruo (Japan)

Scientific Programme

Characterization of the Hypercoagulable State and NETosis in Systemic Lupus Erythematosus

Speaker: Elena Monzón Manzano (Spain)

The Active Recruitment of Red Blood Cells to Activated Platelets via CD36 and FasR Is Crucial for Arterial Thrombus Formation

Speaker: Kim Krott (Germany)

Interaction between Platelets and Streptococcus pneumoniae

Speaker: Axel Florian Aschenbrenner (Germany)

Streptococcus pneumoniae Toxin Pneumolysin Renders Platelets Non-Functional

Speaker: Sven Hammerschmidt (Germany)

Septins Contribute to Platelet Shape and Functionality

Speaker: Oleg Kim (United States)

LV-AO Angle Is Associated with Platelet Reactivity in Patients with Aortic Stenosis

Speaker: Lisa Dannenberg (Germany)

Collagen-Induced Thrombocyte Aggregation in Essential Arterial Hypertension with Subclinical Organ Damage

Speaker: Dina Shorikova (Ukraine)

The Effects of E.coli Lipopolysaccharides on Platelet Function Are Limited to Re-Sensitization

Speaker: Alexey Martyanov (Russian Federation)

Emerging Roles of CLEC-2 during Development of Monocrotaline-Induced Liver Injury in Mice

Speaker: Shimon Otake (Japan)

Assessment of Thrombus Formation under Flow-Conditions in Essential Thrombocythemia/ Polycythemia Vera

Speaker: Yuichi Ikeda (Japan)

Healthy Pediatric Platelets are Moderately Hyporeactive But Hyper-Coagulant within a Wide Age Range

Speaker: Evgeniya Ponomarenko (Russian Federation)

Bcl-XI Deamidation State Tells Platelets Age

Speaker: Chloé James (France)

Platelet Functions Defects in Calreticulin and JAK2V617F MPN Patients

Speaker: Mathieu Fiore (France)

Characterizing Platelet Granules of von Willebrand Disease Patients Using Super-Resolution Structured Illumination Microscopy

Speaker: Maurice Swinkels (the Netherlands)

Effects of GPVI on Clot Structure: Reduction in Procoagulant Platelets in GPVI-Deficient Clots

Speaker: Julia S. Gauer (United Kingdom)

Targeting the Chemokine Receptor CXCR7 Favours an Anti-thrombotic Platelet Lipidome and Regulates Thromboinflammatory Functions

Speaker: Madhumita Chatterjee (Germany)

Scientific Programme

Platelets and Aortic Valve Calcification: Insights from a Rabbit Model and from Patients with Severe Aortic Stenosis

Speaker: Nathalie Donis (Belgium)

Dietary Intake of Zinc Modulates Platelet Intracellular Levels and Haemostatic Parameters

Speaker: Ummay Sumya (United Kingdom)

Platelet Ageing Is Associated with Cytoskeletal Degradation and a Reduction in Cytoskeletal Dynamics

Speaker: Harriet E. Allan (United Kingdom)

Direct Temporal Labelling of Platelets in vivo Allows Monitoring and Examination of Newly Formed and Aged Platelets to Reveal Changes in Receptor Expression Levels and Loss of Functional Ability

Speaker: Paul Armstrong (United Kingdom)

Omega-3 Fatty Acids Significantly Improve the Antiplatelet Profile of Triflusal

Speaker: Aikaterini N. Tsouka (Greece)

Platelet-Derived Extracellular Vesicles Actively Process Proteins and Present Antigen via MHC Class I

Speaker: Genevieve Marcoux (Canada)

A Novel Reporter Mouse Line Enables in vivo Imaging of Intracellular Calcium Fluxes in Platelets

Speaker: Vanessa Klaus (Germany)

Hyperglycemia Primes Procoagulant Platelet Formation and Exacerbates Ischemic Stroke Independent of Platelet Glucose Uptake

Speaker: Frederik Denorme (Belgium)

C-type Lectin-like Proteins D and E, but Not Botrocetin, Cause Thrombocytopenia during Bothrops jararaca Snakebite Envenomation

Speaker: Marcelo L. Santoro (Brazil)

Variability in Platelet Function among Patients with von Willebrand Disease Type 2B (VWD2B): Focus on Patients Historically Diagnosed with Montreal Platelet Syndrome (Historic-MPS)

Speaker: Margaret Rand (Canada)

Mepacrine Uptake & Release Assay in Thrombocytopenic Patients

Speaker: Macarena Asensio (Argentina)

Liver Diseases Contribute to Functional Platelet Aggregation Defects

Speaker: Cassandra Bacher (United States)

Large and Small Platelets Differently Contribute to Whole-Blood Thrombus Formation

Speaker: Stefan Handtke (Germany)

A Novel Methodology to Study $\alpha IIb\beta 3$ Interactions with Polymerizing Cross-linked Fibrin

Speaker: Claudia Buitrago (United States)

The Role of Coagulation-generated Components on GPVI-mediated Platelet Activation

Speaker: Ilaria De Simone (the Netherlands)

Evaluation of a New Agonist (ADP-HS®) for Platelet Function Testing with Light Transmittance Aggregometry: A Bi-Center Study

Speaker: Alain Stepanian (France)

Scientific Programme

Glycans on the Surface of Platelet Microparticles Mediate Binding by Hepatocytes

Speaker: Dianne E. van der Wal (Australia)

The Role of Platelets in the Adhesion of Normal Freshly Isolated Lymphocytes to Fibrin

Speaker: Alexey Solpov (Russian Federation)

Platelet Activation and Aggregation Induced by NS1 Dengue Protein

Speaker: Nallely Itandehui Garcia-Larragoiti (Mexico)

Platelet PN-1 Regulates Clot Structure and Retraction

Speaker: Stephane Loyau (France)

Tyrosine Kinase Inhibitor Sunitinib Delays Platelet-induced Coagulation: Additive Effects of Aspirin

Speaker: Marijke J E Kuijpers (the Netherlands)

Implication of Platelet Adhesiveness in the Risk of Venous Thromboembolic Disease

Speaker: Maribel Diaz-Ricart (Spain)

Assessing Platelet Function in Large Cohorts, a Means to Donor Stratification

Speaker: Joanne Dunster (United Kingdom)

PCSK9 in Human Platelets: Characterization and Mechanism of Platelet Activation

Speaker: Marta Brambilla (Italy)

The Effects of Platelet Agonists and Priming on Platelet Populations

Speaker: Alicia Veninga (the Netherlands)

Platelet Interactions with von Willebrand Factor under Dynamic Shear Stress

Speaker: Tatiana Salikhova (Russian Federation)

Novel Role for Intracellular Lipases in Platelets

Speaker: Madeleine Goeritzer (Austria)

Platelet Procoagulant Potential Is Reduced in Platelet Concentrates ex vivo But Appears to Be Restored in vivo Following Transfusion

Speaker: Ibrahim Tohidi-Esfahani (Australia)

Mean Platelet Volume, and Not Platelet Aggregation, Is Associated with Diabetes: Population Studies from 3,000 to 463,000 Individuals

Speaker: Melissa Victoria Chan (United States)

Physiological extracellular calcium levels impairs platelet aggregation as a result of iPLA2 inhibition due to lack of calcium stores' depletion

Speaker: Aleksandra Filkova (Russian Federation)

Characterization of Thrombus Heterogeneity and Dynamics of Formation on Collagen Spots in a Parallel-plate Flow Chamber

Speaker: Alexander Ryabykh (Russian Federation)

An Activation-dependent Pathway Modulated by Dicer1 Neosynthesis and Down-regulating Platelet Reactivity Is Impaired in Diabetes

Speaker: Elisa Piselli (Italy)

Acquired GPVI Deficiency Is a Biomarker for Early Diagnosis and Prognostic Assessment of Patients with Sepsis

Speaker: Lukas Johannes Weiss (Germany)

Scientific Programme

Towards the Correlation of Age with Size in Human Platelets under Steady State

Speaker: Martina Wolff (Germany)

The Iron Uptake Receptor Transferrin Receptor 1 (TfR1) Is Required for Proper Platelet and Megakaryocyte Function in Mice

Speaker: Timo Vögtle (Germany)

Profiling of COX-dependent Eicosanoids Produced by Blood Cells and the Vasculature

Speaker: Marilena Crescente (United Kingdom)

Bile Acids Maintain Platelet Homeostasis via p38 and Akt Pathway

Speaker: Zhipeng Cheng (China)

The Platelet Indices in Patients with Obesity in Najran Area, Saudi Arabia

Speaker: Osama M Alshehri (Saudi Arabia)

Migraine in Patent Foramen Ovale Patients: Role of Platelet Activation

Speaker: Paola Canzano (Italy)

The Effect of Ceramic Materials on Platelet Aggregation

Speaker: Irina P. Antropova (Russian Federation)

The Effect of γ -Irradiation at a Dose of 1 Gy on Calcium Metabolism in Rat Platelets

Speaker: Volha Bichan (Belarus)

Platelet Alpha-granule Secretion in Total Hip Replacement

Speaker: Irina P. Antropova (Russian Federation)

Platelet Force-Producing Subpopulations Predicted by a Stochastic Model

Speaker: David Bark (United States)

Maternal Platelet Function Altered by Cigarette Smoking in Early Pregnancy

Speaker: Steven Cullen (Ireland)

SHARPIN Restrains α IIb β 3 Activation in Platelets in Three Dimensions

Speaker: Ana Kasirer-Friede (United States)

Platelet Proteomics and Genomics

In-Depth Platelet Releasate Proteome Profiling: A Novel Source of Biomarkers for Early-Onset Preeclampsia

Speaker: Paulina B. Szklanna (Ireland)

Finding the “Switch” in Platelet Activation - Prediction of Key Mediators Involved in the Reversal of Platelet Activation Using a Network Biology Approach

Speaker: Titus Paul Lemmens (the Netherlands)

Phosphoproteomic Fingerprint of Platelets in Obesity: Insights into Platelet Reactivity

Speaker: Maria Nuñez Barrachina (Spain)

DOAC Pharmacogenomics: Personalized Therapeutics to Avoid Bleeding and Thrombotic Complications

Speaker: Caleb Schekel (United States)

Quantitative Phosphoproteomic Profiling and Causal Analysis Reveal Signaling Relations in GPVI/ITAM-Mediated Platelet Activation Programs

Speaker: Joseph Aslan (United States)

Scientific Programme

Lipidome Profile in Platelets from Obese Patients: New Assistances of Platelet Dysfunction in Obesity

Speaker: Maria Nuñez Barrachina (Spain)

Towards Complete Assignment of the Full Platelet Proteome and Transcriptome

Speaker: Jingnan Huang (the Netherlands)

Platelet Proteomics to Understand the Pathophysiology of Immune Thrombocytopenia: Studies in Mouse Models

Speaker: Patricia Martínez-Botía (Spain)

High Efficiency Transfection and Preservation of Platelets with Tumor Suppressing Short RNA

Speaker: Amber Lee (United States)

Platelet Receptors

P2Y₁₂ Receptor Gene Polymorphisms and Platelet Aggregation at Patients with Arterial Hypertension in Bukovinian Region

Speaker: Dina Shorikova (Ukraine)

Platelets as Immune Cells: Lateral Mobility Dynamics of FcγRIIA on Human Platelets is Directly Linked to Integrity of Platelet Cytoskeleton

Speaker: Raghavendra Palankar (Germany)

An Artificial Lipid Membrane Platform as an Approach to Study CLEC-2 Receptor Clustering

Speaker: Marcin Andrzej Sowa (United Kingdom)

First novel Pathogenic Variant in ITGA2B in a Ecuatorian Patient with Glanzmann Thrombasthenia

Speaker: Nuria Bermejo (Spain)

A Humanised CLEC-2 Mouse Model to Study Anti-Human CLEC-2 Biologics in vivo

Speaker: Helena Brown (Germany)

Heme Activates Platelets and Exacerbates Rhabdomyolysis-Induced Acute Kidney Injury via CLEC-2 and GPVI/FcRγ

Speaker: Saori Oishi (Japan)

Targeting of a Conserved Epitope in Mouse and Human GPVI Differently Affects Receptor Function and in vivo Depletion

Speaker: Stefano Navarro (Germany)

Tetraspanin CD9 Regulates GPIIb-IIIa-Mediated Platelet Function: Identification of Unique Protein Interactomes

Speaker: Jayaprakash Kotha (United States)

Differential Regulation of the Platelet GPIb-IX Complex by Anti-GPIbβ Antibodies

Speaker: Renhao Li (United States)

Non-redundant Roles of Platelet Glycoprotein VI and IIb/IIIa via Syk Kinase in Fibrin-dependent Thrombus Shielding under Flow

Speaker: Gina Perrella (the Netherlands)

Role of Receptor for Advanced Glycation End-products (RAGE) in Human Platelets

Speaker: Daniela Recabarren-Leiva (Chile)

Scientific Programme

Prediction of Dynamic Structural Changes in the Complex of Platelet Glycoprotein (GP) Iba Bound with von Willebrand Factor in the Absence and Presence of Coagulation Factor XI using Molecular Dynamics Simulations

Speaker: Masamitsu Nakayama (Japan)

Physiological Significance of Lysophosphatidylinositol/G Protein-coupled Receptor 55 System in the Regulation of Platelet Function

Speaker: Adam Gadd (United Kingdom)

The Recombinant Disintegrins Jarastatin and Jararacin and their Inhibitory Activity on Platelet and Endothelial Adhesion

Speaker: Russolina Zingali (Brazil)

Platelet Signaling

Role of HIF-2 α in Promoting Thrombogenicity through PAI-1 Synthesis & EV-Release during Adaptive Signalling in Human Platelets

Speaker: Ram Lala Mallick (Nepal)

Reelin Modulates Glycoprotein VI and Integrin Outside-in Signaling of Platelets

Speaker: Irena Krueger (Germany)

Plasma Fibrinogen Interaction with Prion Peptide Mitigates Prion-Mediated Neuronal Cell Toxicity And Human Platelet Activation

Speaker: Deepa Gautam (India)

NAADP/SERCA3-Dependent Ca²⁺ Stores Pathway Specifically Controls Early Autocrine ADP Secretion Potentiating Platelet Activation

Speaker: Miao Feng (France)

The Inhibitory Mechanism of Adiporon during Platelet Activation

Speaker: Xianghui Zhou (China)

Fibrillar Amyloid Peptides Promote Platelet Aggregation through the Coordinated Action of ITAM- and ROS-Dependent Pathways

Speaker: Ilaria Canobbio (Italy)

Phosphorylation and Activation of Pannexin-1 upon Platelet Activation and Thrombus Formation

Speaker: Lisa Maria Metz (Germany)

Feedback Inhibition of Human Platelet Syk by PKC-caused Syk S297 Phosphorylation

Speaker: Stephanie Makhoul (Germany)

Dysfunctional CLEC-2- and GPVI-mediated Signaling in Syk Y342F Knock-in Mouse Platelets

Speaker: John Kostyak (United States)

Acetyl-CoA Carboxylase Inhibition Alters Tubulin Acetylation and Aggregation in Thrombin-stimulated Platelets

Speaker: Marie Octave (Belgium)

NADPH Oxidase 1 and Protein Disulphide Isomerase Synergize to Modulate Platelet Function

Speaker: Renato Gaspar (United Kingdom)

Role of RXR β in Platelet Function and Arterial Thrombosis

Speaker: Tobias Petzold (Germany)

Scientific Programme

Acetylation of α -Tubulin by Aspirin and Histone Deacetylase 6 in Human Platelets

Speaker: Antonio Moscardo (Spain)

Interplay between the Tyrosine Kinases Chk, Csk and Phosphatase CD148 Is Critical for Regulating Platelets in Mice

Speaker: Zoltan Nagy (United Kingdom)

Influence of Bile Acids on Hemostasis and Arterial Thrombosis

Speaker: Friedrich Reusswig (Germany)

Loss of the Exocyst Complex Component, EXOC3, Accelerates Arterial Thrombosis

Speaker: Tony Walsh (United Kingdom)

Omega-6 DPA and its 12-LOX Oxylipins Regulate Platelet Reactivity in a Non-genomic PPAR α -dependent Manner

Speaker: Michael Holinstat (United States)

Important Role for SHARPIN in Supporting Platelet Linear Ubiquitination and Thrombus Formation

Speaker: Ingeborg Hers (United Kingdom)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Role of Hemostatic System in Cancer, Inflammation and Immunity Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Coagulation Proteins Beyond Hemostasis

Cross-Talk of Activated Protein C(aPC) with Integrin and its Effect on T-Cell Signaling

Speaker: Dheerendra Gupta (Germany)

Chronically Elevated Interleukin-6 Levels in Mice Lead to a Disturbance in the Coagulation System

Speaker: Tanja Knopp (Germany)

Human Plasma Kallikrein (PKa) Potentiates ADP-Induced Platelet Activation

Speaker: Maria Luiza Vilela Oliva (Brazil)

The Fc and C1/C2 Domains of Recombinant Factor VIII Fc Fusion Protein Engage Monocytes in an Fc γ RII-Dependent Manner to Reduce Their Differentiation Potential into Osteoclasts

Speaker: Susu Duan (United States)

Coagulation Factor XII Signaling Triggers Inflammasome-associated Renal Damage in Diabetic Nephropathy

Speaker: Ahmed Elwakiel (Germany)

A Validated Model for the Diagnosis of Periprosthetic Joint Infection with Coagulation-related Markers: TGT and NETs

Speaker: Julia Oto (Spain)

Scientific Programme

Coagulation Markers, Neutrophil Extracellular Traps and Thrombin Generation Test, in the Detection and Risk Stratification of Prostate Cancer

Speaker: Julia Oto (Spain)

Plasma Concentration of Activated Factor VII-antithrombin, But Not Tissue Factor Pathway Inhibitor and Factor VII Levels, Predicts Mortality in Subjects with Liver and Colon Cancer Undergoing Curative Surgical Intervention

Speaker: Domenica De Santis (Italy)

Hemostatic and Thrombotic Profiles in Pre and Post Remission Induction Phase of Acute Leukemia

Speaker: Arshi Naz (Pakistan)

Complement and Hemostatic System

The Role of Antithrombin in Complement Activation: Pilot Data from Patients with Inherited Antithrombin Deficiency

Speaker: Katarzyna Mayger (United Kingdom)

Complement Mannan-Binding-Lectin Is Associated with Activated Platelets during Clot Formation in a Microfluidic Bleeding Model

Speaker: Murielle Golomingi (Switzerland)

Anti-complement Effect of Heparin in Stimulated Whole Blood

Speaker: John Hogwood (United Kingdom)

Activated Factor XI Promotes Complement Activation by Neutralizing Complement Factor H

Speaker: Owen McCarty (United States)

Infection and Hemostatic Factors

Lung Vessels Thrombosis Induced by Severe CAP: 3D Model of Thrombus

Speaker: Mariia Krykhtina (Ukraine)

Relationship between HAART treatment and Markers of Coagulation among People Living with HIV/AIDS (PLWHA) in Gombe, Nigeria

Speaker: Sani Adamu (Nigeria)

Coagulation Profile in Patients with Pneumonia Assessed by Thrombin Generation Procedures

Speaker: Erica Scalambrino (Italy)

M1 Protein from Group A Streptococcus Regulates Fibrin Clot Formation, Structure and Fibrinolytic Potential

Speaker: Sophie Cherrington (United Kingdom)

Coagulation Factor XII Binds to the Opportunistic Pathogen, Candida albicans and Promotes Biofilm Formation

Speaker: Maria Louise Williams (United Kingdom)

Platelets and Cancer

Successful Improvement Sexual Dysfunction After Pelvic Irradiation by Platelet Growth Factor

Speaker: Saeed Mohammadi (Iran, Islamic Republic of)

Platelet Function in Primary Myelofibrosis

Speaker: Olga Smirnova (Russian Federation)

Scientific Programme

ML355 Inhibits Platelets via GC Activation and Blocks Caspase-Dependent Apoptosis in Platelets

Speaker: Valentina Shpakova (Russian Federation)

Modulation of ABT-737 Induced Platelet Apoptosis by Curcumin

Speaker: Valentina Shpakova (Russian Federation)

Anti-Platelet Drug Ticagrelor Has a Direct Anticancer Activity

Speaker: Omar Elaskalani (Australia)

Platelet Function and Coagulation Abnormalities in Polycythemia Vera Patients: Effects of Low-Dose Aspirin

Speaker: Rossella Cacciola (Italy)

Comparison of Platelet Parameters in the Patients with JAK2 V617F Mutated Essential Thrombocythosis and Reactive Thrombocytosis

Speaker: Yifeng Wu (United States)

Tumor Platelet Transcriptome Changes in Hyperthrombotic Mice

Speaker: Carina Santos (Germany)

Generation of 12-HETE in Platelet-Cancer Cell Crosstalk

Speaker: Melania Dovizio (Italy)

Platelet-derived Microparticles Regulate Migration, But Do Not Influence Proliferation of Breast Cancer Cells

Speaker: Mauro Vismara (Italy)

A Potential Role for the FcγRIIIa in Vinorelbine Induced Thrombocytopenia and Neutropenia

Speaker: Marian Brennan (Ireland)

Chemotherapy - Induced Thrombocytopenia in Pediatric Acute Lymphoblastic Leukemia: A Single-institution Report

Speaker: Mane Gizhlaryan (Armenia)

The Assessment of Platelet Membrane Alteration in Patients with Chronic Myeloproliferative Neoplasms

Speaker: Viola Maria Popov (Romania)

Platelets and Infection

High-throughput Mechano-Phenotyping of Single Platelet Activation Induced by Bacterial Proteins

Speaker: Raghavendra Palankar (Germany)

Risk Factors, Outcomes, and Score Models of Serious Pulmonary Infection in Non-Splenectomized Immune Thrombocytopenia Adults

Speaker: Yejun Wu (China)

Platelet Activation in Community-acquired Pneumonia Remains Increased Until 30 Days Later

Speaker: Antonio Moscardo (Spain)

Lyophilized Human Platelets Exhibit Adhesive Interactions with Staphylococcus aureus

Speaker: Amber Lee (United States)

Effects of the Bacterial Toxin Cytotoxic Necrotising Factor 1 on Platelet Function

Speaker: Francisco Rivero (United Kingdom)

Scientific Programme

From the Antiplatelet Drug Ticagrelor to New Antibiotics

Speaker: Nicolas Jacques (Belgium)

Platelets and Inflammation

Effect of cART on Platelet:Lymphocyte Ratio in HIV Patients Initiating Treatment

Speaker: Hannah Omunakwe (Nigeria)

Acute Exacerbations of COPD Induce a Prothrombotic State through Platelet-Monocyte Complexes, Endothelial Activation and Increased Thrombin Generation

Speaker: Lisa N. van der Vorm (the Netherlands)

Role of Formyl Peptide Receptor 2 (FPR2/ALX) and its Anti-Inflammatory Ligand, Lipoxin A4 Analogue (BML-111) in the Modulation of Platelet Function

Speaker: Shatha AlOmar (United Kingdom)

Prognostic Value of Platelet-Derived Parameters in Septic Patients: A Prospective Study

Speaker: Ghada Alharbi (Bahrain)

Platelet and Extracellular Vesicle Mediated Inflammasome Activation Impairs Embryonic Survival by Reducing Placental Thrombomodulin Expression

Speaker: Shrey Kohli (Germany)

Is Platelet Hyper-Reactivity a Modifiable Risk Factor in Inflammatory Arthritis?

Speaker: Dermot Kenny (Ireland)

Role of Platelets in Processes of Myocardial Healing After Myocardial Ischemia and Reperfusion in Mice

Speaker: Meike Klier (Germany)

Toll-Like Receptor 2 Ligands Promote and Enhance Platelet Activation

Speaker: Ivan Parra-Izquierdo (United States)

Platelets Express a Stable and Functional Proteasome System and All Components of the Antigen Processing and Presentation Pathway (APP) Machinery

Speaker: Lisa Colberg (Germany)

Sirolimus Is Effective in Autoimmune Lymphoproliferative Syndrome (ALPS)/ALPS-Like Syndrome: Results of a Single Centre Experience

Speaker: Hao Gu (China)

Cold Storage of Apheresis Platelets Promotes IL-8 Release in Platelet: Leukocyte Co-cultures

Speaker: Kimberly A. Thomas (United States)

Platelets Are Active Players as Inflammatory Cells in Nonalcoholic Fatty Liver Disease

Speaker: Erica De Candia (Italy)

Sarcoidosis and Autoimmune Thrombocytopenic Purpura: Random Association or Hematologic Manifestation of Sarcoidosis?

Speaker: Yosra Cherif (Tunisia)

Immature Platelet Fraction and Platelet Indices in Acute Coronary Syndrome

Speaker: Yetti Hernaningsih (Indonesia)

Platelet $\beta 1$ and $\beta 3$ Integrins Cooperate to Stop Cutaneous and Cerebral Bleeding under Inflammatory Conditions in Mice

Speaker: Emily Janus-Bell (France)

Scientific Programme

Platelets in Resolution of Liver Inflammation and Tissue Regeneration

Speaker: Sylwia Anna Stefańczyk (Germany)

Effect of Human Myeloperoxidase on Ca²⁺-response, Membrane Conductivity and Phosphatidylserine Exposure on Platelet Surface

Speaker: Ekaterina Shamova (Belarus)

Influence of HOCl-modified Myeloperoxidase on Platelet and Neutrophil Activity

Speaker: Irina Gorudko (Belarus)

Specific Inhibition of MRP4 Affects Several Signaling Pathways and Thrombus Formation in Human Platelets

Speaker: Bernhard H. Rauch (Germany)

Critical Role of Platelets during Pulmonary Fibrosis

Speaker: Raphaël Martos (France)

Critical Role for Platelet Ral GTPases in the Regulation of Venous Thrombosis

Speaker: Yong Li (United Kingdom)

Fat Emulsion for Parental Nutrition as Well as Lipid Emulsion of the Drug Propofol Strongly Enhance Platelet Activation Induced by Human Albumin, Misfolded by Structural Modification with the Granulocyte Defence Weapon HOCl

Speaker: Beate E. Kehrel (Germany)

Platelet Depletion Limits the Severity But Does Not Prevent the Occurrence of Experimental Transfusion-related Acute Lung Injury

Speaker: Fabrice Cognasse (France)

P-selectin (CD62P) Deficiency Is Associated with Increased Coxsackievirus B3 Myocarditis But Not Influenza A Virus Infection in Mice

Speaker: Silvio Antoniak (United States)

Defining the Effects of Storage Lesion on Platelet Autophagic Activity

Speaker: Sebastien Fauteux-Daniel (France)

Platelets Induce Rapid Subset and Phenotypic Switching in Monocytes in Whole Blood

Speaker: Paul Armstrong (United Kingdom)

Evaluation of Analyser Flag 'Abnormal Platelet Distribution' in Routine Complete Blood Count (CBC)

Speaker: Fatmawati Kamal (Malaysia)

Proteases and Cancer

Hypochlorous Acid Modification to Antithrombin Results in Generation of Neo-epitopes, and a Shift towards Prothrombotic and Proangiogenic State in Cancer Patients

Speaker: Parvez Ahmad (India)

Hepsin Is Involved in the Tumorigenicity and in the Hypercoagulability of Colon and Gastric Cancer Cells

Speaker: Mari Carmen Rodenas (Spain)

Novel Urokinase-derived Peptides Inhibiting the Pro-tumoral Activity of Cancer-associated Fibroblasts

Speaker: Maria Patrizia Stoppelli (Italy)

Scientific Programme

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Thrombotic Microangiopathies Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

ADAMTS13 and TTP

Oligosymptomatic Thrombosis in a Young Girl with Upshaw-Schulman Syndrome (USS) Not Receiving Prophylactic Plasma Infusion

Speaker: Saori Tanabe (Japan)

Differential Diagnosis of Thrombotic Thrombocytopenic Purpura at Acute Phase by the Ratio of VWF Activity to VWF Antigen Based on Automatic Immunologic Assays

Speaker: Ning Tang (China)

Prognostic Value of A Disintegrin and Metalloprotease with Thrombospondin Motif 13 in Patients with Severe Sepsis and Septic Shock

Speaker: Syed Shahid Habib (Pakistan)

Rituximab Prolongs the Time to Relapse in Patients with Immune Thrombotic Thrombocytopenic Purpura: Analysis of Off-Label Use in Japan

Speaker: Masayuki Kubo (Japan)

Exploration of Coagulation Disorders, von Willebrand Factor and ADAMTS13 in a Cohort of 45 Patients with Hemophagocytic Lymphohistiocytosis

Speaker: Bérangère Joly (France)

Automated Chemiluminescent ADAMTS13 Activity Immunoassay for Thrombotic Thrombocytopenic Purpura Diagnosis and Follow-up

Speaker: Nicolas Beranger (France)

Caplacizumab in a Case of Acquired Thrombotic Thrombocytopenic Purpura (TTP) Poor Responsive to Plasma Exchange and Immunosuppressive Therapy

Speaker: Alfredo Molteni (Italy)

Current Possibilities of ADAMTS 13 Diagnostics - Advantages and Limitations

Speaker: Ludek Slavik (Czech Republic)

Relapsing or Refractory Thrombotic Microangiopathies: The Key Role of ADAMTS13 Activity and Complement Testing

Speaker: Eleni Gavrilaki (Greece)

Clinical Analysis of 83 Patients with Thrombotic Thrombocytopenic Purpura

Speaker: Wang Xiyan (China)

PLASMIC Score Predicts Outcome of Transplanted Patients with Severe Thrombotic Thrombocytopenic Purpura

Speaker: Yael Cohen (Israel)

Pregnancy and Non-Pregnancy Related Acquired Thrombotic Thrombocytopenic Purpura in Women of Reproductive Age: Clinical Course and Outcomes

Speaker: Amihai Rottenstreich (Israel)

Retrospective Study of 30 TTP Patients from 2017 to 2019 in a Single Center of Suzhou, China

Speaker: Jie Yin (China)

Scientific Programme

Development and Validation of a Prediction Model (AHC) for Early Identification of Refractory Thrombotic Thrombocytopenic Purpura Using Nationally Representative Data

Speaker: Qiu-Sha Huang (China)

Follow-up Evaluation of Patients with Hereditary Thrombotic Thrombocytopenic Purpura (hTTP) from the International Hereditary TTP Registry: Incidence of Acute Disease Episodes with or without Regular Prophylactic Plasma Infusions

Speaker: Erika Tarasco (Switzerland)

Multicentric Multicountry Evaluation of the Fully Automated Adamts13 Activity Assay

Speaker: Cristina Pascual (Spain)

Genetic Study of von Willebrand Factor Variants in Congenital Thrombotic Thrombocytopenic Purpura Patients

Speaker: Chiara Lupo (United Kingdom)

Patients with Acute Thrombotic Thrombocytopenic Purpura (TTP) Should Be Managed in a Critical Care Setting - A UK Single TTP Referral Centre Experience

Speaker: Rebecca Shaw (United Kingdom)

Performance Evaluation of a New Fully Automated Fluorogenic ADAMTS13 Activity Assay

Speaker: Marcos Llusà (Austria)

Efficacy of Preemptive Subcutaneous Rituximab in Immune-Mediated Thrombotic Thrombocytopenic Purpura: A Study of 12 Cases

Speaker: Maxime Delrue (France)

Risk Factors Associated with Severe Neurological Symptoms in Thrombotic Thrombocytopenic Purpura (TTP)

Speaker: José Thiago Souza Castro (Brazil)

Influence of Personality and Life Conditions on Depression, Anxiety and Cognitive Performance in 104 Patients Having Survived Acute Autoimmune Thrombotic Thrombocytopenic Purpura (iTTP)

Speaker: Tanja Falter (Germany)

The Effect of Liver Transplantation on ADAMTS13 Activity and Antigen Levels

Speaker: Tanja Falter (Germany)

Is Therapeutic Plasma Exchange (TPE) Still Necessary for the Treatment of Thrombotic Thrombocytopenic Purpura (TTP)?

Speaker: Paul Knoebl (Austria)

Acquired Thrombotic Thrombocytopenic Purpura: Key Findings of Patients from Southern Italy

Speaker: Giovanni, Luca Tiscia (Italy)

Lombardy Network for the Study and Treatment of Patients Undergoing Apheresis

Speaker: Ilaria Mancini (Italy)

Correlation between Phenotype-genotype versus in-silico Prediction of Novel and Known Disease-causing Variants in Upshaw-Schulman Syndrome Patients in a Single Institution of Argentina

Speaker: Juvenal Paiva (Argentina)

Association of Plasmic Score with Neurological Symptoms in Patients with Thrombotic Thrombocytopenic Purpura (TTP)

Speaker: José Thiago Souza Castro (Brazil)

Scientific Programme

The Changing Face of Thrombotic Thrombocytopenic Purpura (TTP) in South Africa in the Human Immunodeficiency Virus (HIV) Era

Speaker: Susan Louw (South Africa)

Inhibitory Anti ADAMTS13 Antibodies with a New Rapid Fully Automated Clia Assay

Speaker: Barbara Montaruli (Italy)

Evaluation of a Rapid, Automated Chemiluminescent ADAMTS-13 Activity Assay for the ACL AcuStar

Speaker: Rebekah Ellen Fretwell (United Kingdom)

Clinical and Economic Impacts of a New Rapid ADAMTS-13 Assay for the Diagnosis of Suspected Thrombotic Thrombocytopenic Purpura

Speaker: Chiara Novelli (Italy)

Genetic Variants in ADAMTS13 in Patients with Acquired TTP (aTTP)

Speaker: Juvenal Paiva (Argentina)

Impact of Ultralarge von Willebrand Factor (VWF) Multimers and Platelets in Cultured Endothelial Cells in Acute Immune-mediated Thrombotic Thrombocytopenic Purpura

Speaker: Chiara Vendramin (United Kingdom)

Treatment of Acquired Thrombotic Thrombocytopenic Purpura in Rituximab Era: A Single Center Experience from India

Speaker: Nitin Gupta (India)

Varied Presentations of TTP

Speaker: Anil Aribandi (India)

Antiphospholipid Syndrome

Obstetric Antiphospholipid Syndrome: ADAMTS-13 Tested at Pregnancy Diagnosis Is Associated with the Occurrence of Early-Onset Pre-Eclampsia Despite Treatment

Speaker: Jean-Christophe Gris (France)

Role of Anti Phosphatidylserine/Prothrombin Antibodies on Thrombin Generation and Protein C Resistance in Carriers of Antiphospholipid Antibodies

Speaker: Elena Pontara (Italy)

Tetra Positive Thrombotic Antiphospholipid Syndrome: Major Contribution of Anti Phosphatidyl-Serine/Prothrombin Antibodies to Lupus Anticoagulant Activity

Speaker: Mariagrazia Cattini (Italy)

Effect of Immune-Purified $\alpha\beta 2$ -Glycoprotein I ($\alpha\beta 2$ GPI) and Anti Phosphatidylserine/Prothrombin (aPS/PT) Antibodies on Thrombin Generation

Speaker: Elisa Bison (Italy)

Lupus Anticoagulant and Antiphospholipid Antibodies: A Real-World Study

Speaker: Eva Kempers (the Netherlands)

Increased Baseline Platelet Activation and Decreased Platelet Reactivity in Patients with the Antiphospholipid Syndrome

Speaker: Lena Hell (Austria)

Observational Study of Outcomes in Patients with Antiphospholipid Syndrome Anticoagulated with Rivaroxaban

Speaker: Thura Win Htut (United Kingdom)

Scientific Programme

Laboratory versus Point-of-Care INR Measurement in Patients with Lupus Anticoagulant - A Retrospective Cohort Analysis

Speaker: Aaron Lubetsky (Israel)

The Prothrombin/MHC II Complexes on Cell-Surface of Monocytes Is the Antigenic Targets in Antiphospholipid Syndrome

Speaker: Yuichiro Fujieda (Japan)

Assessment and Comparison of Acquired Activated Protein C Resistance with Two Thrombin Generation Methods, CAT and ST-Genesia, in APS and SLE Patients

Speaker: Maria Efthymiou (United Kingdom)

Hydroxychloroquine Effect on the Immune System, Coagulation and Lipid Profile in Patients with Thrombotic Primary Antiphospholipid Syndrome

Speaker: Fernanda Orsi (Brazil)

IVF Outcomes in Women with Antiphospholipid Antibodies Circulation

Speaker: Jamilya Khizroeva (Russian Federation)

Monocyte Activation and Acquired Protein S Deficiency Promote Disseminated Intravascular Coagulation in a Patient with Antiphospholipid Antibodies

Speaker: Lennart Beckmann (Germany)

Lupus Anticoagulant-Hypothrombinemia Syndrome (LAHS): A Case Report

Speaker: Karan Mayani (Spain)

Cohort of Patients with Triple Antiphospholipid Antibodies: Differences between Asymptomatic and Symptomatic Individuals

Speaker: Patricia Casais (Argentina)

Does the von Willebrand Factor: ADAMTS-13 Axis Differ between Antiphospholipid Syndrome and Systemic Lupus Erythematosus?

Speaker: My Nhi Dang (United Kingdom)

Antiphospholipid Antibodies "Multi-Positivity" in Women with Thromboembolism

Speaker: Victoria Bitsadze (Russian Federation)

Thrombotic Outcomes in Pregnant Women with Antiphospholipid Antibodies in a Tertiary Referral Centre

Speaker: Amihai Rottenstreich (Israel)

MicroRNAs as Potential Biomarkers in Thrombotic Primary Antiphospholipid Syndrome

Speaker: Camila Oliveira Vaz (Brazil)

Identification of microRNAs Potentially Involved in Primary Antiphospholipid Syndrome Related Thrombosis

Speaker: Camila Oliveira Vaz (Brazil)

Secondary Thromboprophylaxis in Antiphospholipid Syndrome Patients with Arterial Thrombosis: A Systematic Review and Meta-analysis

Speaker: Tanawat Attachaipanich (Thailand)

What to Expect about Antiphospholipid Positivity in Otherwise Healthy Patients: Is There a Real Risk of Thrombosis?

Speaker: Lidia Costa (Portugal)

Scientific Programme

Treating Antiphospholipid Syndrome Patients with Vitamin K Inhibitors in Real Life; Long Term Outcomes from a Single Centre Retrospective Study of 101 Patients

Speaker: Charalampos Kartsios (United Kingdom)

Anti-β2-Glycoprotein I and Anti-Prothrombin Antibodies Cause Lupus Anticoagulant by Interfering with Factor Xa-Mediated Factor V Activation

Speaker: Tessa Noordermeer (the Netherlands)

Patients with Antiphospholipid Syndrome Display a Marked Resistance to the Profibrinolytic Activity of Anticoagulants

Speaker: Mario Colucci (Italy)

Penile Mondor's Disease Associated with Anticardiolipid Antibodies: A Very Rare Case of Antiphospholipid Syndrome

Speaker: Emmanouil Papadakis (Greece)

Neutrophil Activity in Patients with Antiphospholipid Syndrome-Related Thrombosis

Speaker: Fernanda Orsi (Brazil)

Catastrophic Antiphospholipid Syndrome, Kikuchi-Fujimoto Disease and Adult-Onset Still Disease: An Unusual Association

Speaker: Silvia Daniela Amanda Peres (Argentina)

Vitamin K Antagonist (VKA) Monitoring Using Point of Care Testing (POCT) in Patients with Antiphospholipid Syndrome (APS)

Speaker: Michael Masucci (United Kingdom)

Complement Regulatory Abnormalities are Frequent in Patients with Catastrophic APS and Refractory Patients Respond Rapidly to Eculizumab Treatment

Speaker: Ilene Weitz (United States)

Direct Oral Anticoagulants versus Vitamin K Antagonists in Antiphospholipid Syndrome: A Meta-analysis

Speaker: Adriana Iriarte Fuster (Spain)

Triple Positive Antiphospholipid Antibodies: A 10-year Retrospective Review of 37 Patients with Triple Positive Antiphospholipid Antibodies and their Thrombotic Outcomes and Mortality in a Single Centre in Singapore

Speaker: Bingwen Eugene Fan (Singapore)

Prevalence of "Cofactor Effect" on Lupus Anticoagulant Mixing Studies: Patients and Laboratory Characteristics

Speaker: Marta M Martinuzzo (Argentina)

FXI Levels as Independent Risk Factor for Antiphospholipid Syndrome: Development of a New Predictive Score, APS-FXI

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

β2-Glycoprotein I (β2GPI) Is a Fibrinogen Binding Protein

Speaker: Vincenzo De Filippis (Italy)

Mixing Studies in Lupus Anticoagulant Tests: A Useful Tool at the Time of Analysis

Speaker: Sergio Felipe Pinzon Mariño (Spain)

CLIA Immunoassay: Better Identification of High Thrombotic Risk Triple Positive Antiphospholipid Patients

Speaker: Barbara Montaruli (Italy)

Scientific Programme

Contribution of Beta2 Glycoprotein1 IgA (B2GP1 IgA) Antibodies Research in Diagnosis of Seronegative Antiphospholipid Syndrome in Cerebral Thrombosis: A Case Series of 21 Patients

Speaker: Imene Hocine (Algeria)

Thrombosis and Antiphospholipid Antibodies

Speaker: Ivanka Nikoloska (Macedonia, the Former Yugoslav Republic of)

Lupus Anticoagulant Testing in Patients with Prolonged INR, Mixing Test Results

Speaker: Teresa Villalba (Spain)

Recurrence of Thrombotic Events in Antiphospholipid Syndrome Patients Receiving Prolonged Vitamin K Antagonists Therapy

Speaker: Marcos Sousa (Portugal)

Weakly Positive Lupus Anticoagulants Are also Associated with High Event Rate

Speaker: Frances Compton (United States)

HUS

Differential Expression of CD46 in Leukocytes by Flow Cytometry: Methodological Aspects

Speaker: Sabrina Rotondo (Argentina)

Personalized Dosing of Eculizumab Using C5 Functional Activity and Eculizumab Level in Complement-mediated Thrombotic Microangiopathy: A Safe and Cost-saving Approach

Speaker: Meera Sridharan (United States)

Non HUS/TTP Microangiopathies

Fulminant Pulmonary Tumor Thrombotic Microangiopathy (PTTM) in a Young Man: Clinical and Immunoistochemical Characterization of a Rare Complication of Gastric Signet Ring Cell Carcinoma

Speaker: Raffaella Rossio (Italy)

Complement Pathway and Endothelial Dysfunction in Severe Preeclampsia

Speaker: Marta Palomo (Spain)

Factor VIII/Protein C and Not ADAMTS13/VWF:Ag Ratio Is a Prognostic Risk Factor for Patients with Cirrhosis and Low MELD Score

Speaker: Niccolò Bitto (Italy)

An Unusual Case of Cerebral Cavernous Malformation Complicated with Consumptive Coagulopathy and Heightened Fibrinolysis

Speaker: Ming Ching Shen (Taiwan, Republic of China)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Vascular Biology Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Blood Cells and Vessel Wall

Scientific Programme

The Red Laser- Mediated Photobiomodulation Therapy, Accompanied by Aspirin Administration, Improve Endothelial Dysfunction after Balloon Angioplasty in the Rabbit Model of Carotid Artery Injury

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Neointimal Hyperplasia Regression using Lipid- Based Encapsulated Methotrexate Nanoparticles- Mediated Catheter- Based Low- Level Blue Laser Photodynamic Therapy

Speaker: Hossein Mehrad (Iran, Islamic Republic of)

Neutrophils and Neutrophil Extracellular Traps (NETs) Can Promote Clotting and Impact Clot Structure in a Distinctive Manner

Speaker: Yu Shi (United Kingdom)

Morphological and Functional Alterations of Platelets from Transgenic APP23 Mice at Early Alzheimer Disease State

Speaker: Lili Donner (Germany)

CTL-2 is a VWF Receptor Involved in Neutrophil Activation

Speaker: Gaia Zirka (France)

Tripeptides Affected Hemostas in Various Pathologies

Speaker: Maria Golubeva (Russian Federation)

Expression Profiles of the Internal Jugular and Saphenous Veins: Focus on Hemostasis Genes

Speaker: Nicole Ziliotto (Italy)

The Induction Strategies Administered in the Treatment of Multiple Myeloma Exhibit a Deleterious Effect on the Endothelium

Speaker: Julia Martinez-Sanchez (Spain)

Colonization with the Minimal Microbial Consortium Altered Schaedler Flora Hampers the Formation of Neutrophil Extracellular Traps in Acute Mesenteric Ischemia-Reperfusion Injury

Speaker: Franziska Bayer (Germany)

Role of Thrombopoietin in Rescuing Vascular Niche of ITP Patients

Speaker: Jieyu Ye (China)

The Antioxidant and Antiinflammatory Effect of Synbiotic Beverage from Soybean Water Kerfir on Aortic Tissue of Hyperlipidemic Rats Model

Speaker: Mochamad Afifudin (Indonesia)

Vessel-On-A-Chip Model Revealing Rapid Offset and Onset Mechanisms of Collagen- and Thrombin-Induced Platelet Activation

Speaker: Isabella Provenzale (the Netherlands)

Redox Regulation of Neutrophil Mac-1 Function by Protein Disulphide Isomerase

Speaker: Alexander Dupuy (Australia)

Mechanisms and Functional Consequences of Platelet-derived Extracellular Vesicle and Chemokine Internalisation by Endothelial Cells

Speaker: Alexandra. C.A Heinzmann (the Netherlands)

Aortic Ring Angiogenesis Proceeds Normally Despite Minimal Tissue Factor Expression

Speaker: Maureane Hoffman (United States)

Scientific Programme

Development of a Novel Mouse Model of Abdominal Aortic Aneurysm with Intraluminal Thrombus

Speaker: Katia Yahiaoui (France)

Optimization of Disease- and Patient-specific in vitro Assays for Endothelial Dysfunction Investigation by Using Endothelial Colony-forming Cells

Speaker: Francesca Calcaterra (Italy)

Generation and Isolation of Extracellular Vesicles from Endothelial and Smooth Muscle Cells Grown out of Human Blood

Speaker: Plinio Ferreira (United Kingdom)

The Effects of Hypoxia on Activation of Endothelial Cells

Speaker: Casper Ullsten-Wahlund (Norway)

Differential Expression of Inflammatory Mediators in Venous Tissue and Serum Suggest Natural Killer (NK) Cell-mediated Responses in Chronic Venous Insufficiency

Speaker: Ulka Sachdev (United States)

Endothelial Cell Signaling

Elevated Plasminogen Activator Inhibitor Type-1 and Soluble Thrombomodulin of Type 2 Diabetes Mellitus Subjects with Increasing Loss of Glycemic Control in Calabar, Southern Nigeria

Speaker: Margaret S. Edem (Nigeria)

Snake Venom Cysteine-Rich Secretory Proteins (SVCRISS) from North American Vipers: Mechanism of Action on Blood and Lymphatic Endothelial Cells

Speaker: Montamas Suntravat (United States)

Trimethylamine N-oxide (TMAO) Disrupts Haemostasis Balance in Human Vascular Endothelial Cells

Speaker: Saravanan Subramaniam (United States)

The survival of endothelial cells in the conditions of nutrient deficiency

Speaker: Tetiana Nikolaienko (Ukraine)

TRPV4 Channel Activation Induces the Transition of Venous and Arterial Endothelial Cells Toward a Pro-Inflammatory Phenotype

Speaker: Kathia Beddek (France)

MADD Regulates von Willebrand Factor Trafficking in Endothelial Cells via Activation of Weibel-Palade Body-Associated Rab GTPases

Speaker: Marije Kat (the Netherlands)

Novel Anti-Inflammatory Network: The Phosphatase Domain of Soluble Epoxide Hydrolase Mediates the regulation of β_2 Adrenergic Receptor-IL-6 Signaling and Vascular Endothelial Activation

Speaker: Eriko Suzuki (Japan)

Epigenetic Regulation of Endothelial Dysfunction in Venous Thromboembolism

Speaker: Marion Pilard (France)

Endothelial Protein C Receptor Signaling via Protease-activated Receptor 1 Promotes Neovascularization after Ischemia in Mice

Speaker: Magdalena Bochenek (Germany)

Scientific Programme

The R398w Gata-2 Variant Negatively Regulates E-Nos Activity: Possible Role in GATA2 Deficiency-associated Thrombosis

Speaker: Giulio Purgatorio (Italy)

Astrocytes Are Central Contributors in Restoration of the Blood Brain Barrier via Transcriptional Upregulation of Key Gap Junction Proteins between Endothelial Cells

Speaker: Preston Stafford (United States)

Inflammation and Sepsis

The Anti-Inflammatory Effects Of 3'-Hydroxygenkwanin from Aquilaria sinensis in Human Neutrophils

Speaker: Hsiang-Ruei Liao (Taiwan, Republic of China)

The Tissue Factor Surface Expression of Monocyte Subsets during Sepsis

Speaker: Kathryn Mary Musgrave (United Kingdom)

The Tissue Factor Expression of Monocyte Subsets and the Activation of Coagulation during Human Endotoxaemia

Speaker: Kathryn Mary Musgrave (United Kingdom)

Prevalence of Disseminated Microvascular Thrombosis, Unresolved Infection, and Lymphoid Depletion in Autopsies of Pediatric Sepsis-Induced Disseminated Intravascular Coagulation (DIC)

Speaker: Trung Nguyen (United States)

Ca²⁺ Release from Stores Controlled by Sarco/Endoplasmic Reticulum Ca²⁺-ATPase 3 (SERCA3) Is Involved in Endothelial Permeability and Inflammatory Response

Speaker: Kathia Beddek (France)

Pro-Inflammatory Cytokines, Tissue Factor Gene Polymorphism (A603G, C1322T, C1812T, G1442C) and Tissue Factor Expression in Patient with Erysipelas

Speaker: Artur Emelyanov (Russian Federation)

Design and Characterization of Novel Activated Protein C (APC) Variants for the Proteolysis of Cytotoxic Extracellular Histone H3

Speaker: Joram Huckriede (the Netherlands)

Inhibitory Effect of Heparin and Modified Heparin on Neutrophil Migration

Speaker: John Hogwood (United Kingdom)

Significance of Macrophage Migration Inhibitory Factor and Toll-Like Receptor 4 as Predictive Factors of Sepsis in Shock Patients

Speaker: Sung-Hyuk Choi (Korea, Republic of)

Significance of Macrophage Migration Inhibitory Factor for Sepsis in Hemorrhagic Shock Patients

Speaker: Sung-Hyuk Choi (Korea, Republic of)

Defibrotide Prevents Sepsis Induced Endothelial Cell Activation

Speaker: Marta Palomo (Spain)

The Role of α 1AMP-Activated Protein Kinase (α 1AMPK) in Haemostatic Dysfunctions Induced by Sepsis

Speaker: Julien De Poortere (Belgium)

Systemic Inflammation in Sepsis Patients Is Demonstrated by Levels of IL-8, IL-13, and TAFI

Speaker: Emily Bontekoe (United States)

Scientific Programme

Immunization with Recombinant Atherogenic Antigen (AHC) Does Not Enhance Susceptibility to Sepsis

Speaker: Xinjie Lu (United Kingdom)

Cell-free DNA and Citrullinated Histone H3 Plasma Levels Improve the Prediction of Mortality in Septic Patients

Speaker: Mauro Hernán Moiana (Argentina)

Fibrinolytic Activity in Patients with Granulomatosis with Polyangiitis (GPA)

Speaker: Teresa Iwaniec (Poland)

Megakaryocytes Are Reprogrammed by Lipopolysaccharide Exposure during Bacterial Sepsis

Speaker: Krystin Krauel (Germany)

Neutrophilic Extracellular Traps (NETs) Are a Subset of Smudge Cells Identifiable by Peripheral Smear Autoanalyzers

Speaker: Morayma Reyes Gil (United States)

Promising Therapeutic Effects of a Novel RNA Aptamer, Apta-1, in a Severe Systemic Inflammation Model on Non-human Primates

Speaker: Luiza Jedlina (Sweden)

Cytokine Network Architecture at the Endothelial Interface

Speaker: A.J. Hoogendijk (the Netherlands)

Biomarkers of Platelet Activation and their Prognostic Value in Patients in Sepsis Associated Coagulopathy

Speaker: Debra Hoppensteadt (United States)

Human Vascular Endothelial Cell Derived Exosomes Contribute to the Excessive Inflammatory Response Observed in Sepsis through a Dysregulated MicroRNA Expression Profile

Speaker: Glenn Fitzpatrick (Ireland)

Candida albicans Expresses an Integrin-like Protein that Is Involved in Yeast Adhesion to Endothelial Cells

Speaker: Danielle Nader (Ireland)

Diabetes Mellitus Increases Thrombin and Activated Protein C Effects on Mast Cell and Macrophages

Speaker: Liubov Gorbacheva (Russian Federation)

Altered Coagulation Parameters and D-Dimer Measurements in Sepsis Are Useful in Scoring the Risk Stratification

Speaker: Divya Joshi (United States)

Innate and Adaptive Immunity

Activation of ERK Signaling Pathway by Plasma IgG in Venous Thromboembolism Patients without Antiphospholipid Antibodies

Speaker: Sylvie Bouvier (France)

Determinants of Neutrophil Extracellular Trap Formation in the General Population: Based on the Rotterdam Study Cohort

Speaker: Samantha Joyce Donkel (the Netherlands)

Scientific Programme

Ageing Affects Neutrophils - Changes in Activation, DNA Release and Neutrophil Extracellular Formation of Neutrophil Subpopulations with Human Age

Speaker: Lisa-Marie Mauracher (Austria)

The Gut Microbiota Restricts NETosis in Acute Mesenteric Ischemia-Reperfusion Injury

Speaker: Christoph Reinhardt (Germany)

Specialized Regulatory T Cells Control Venous Blood Clot Resolution

Speaker: Fatemeh Shahneh (Germany)

Neutrophil Extracellular Traps (Nets) Increase the Pro-Tumoral Properties of the Human Breast Cancer Cell Line, MCF7

Speaker: Robson Monteiro (Brazil)

In Vitro Disruption of Endothelial Barrier Integrity by Heme and by Serum from Patients with Sickle Cell Disease

Speaker: Erich Vinicius de Paula (Brazil)

mir-146a Deficiency Promotes Neutrophil Aging and Increases their Sensitivity to Form Neutrophil Extracellular Traps (NETs) in a Murine Model

Speaker: Maria Piedad Fernandez Perez (Spain)

Stabilin-2 Promoter Modulates Immune Response in the Liver of Lentiviral Vector Injected Mice

Speaker: Ester Borroni (Italy)

Antisense Oligonucleotide Targeting of Thrombopoietin Represents A Novel Platelet Depletion Method to Assess the Role of Platelets During Inflammation Resolution

Speaker: Tessa Barrett (United States)

Non-coding RNAs

Low Levels of Circulating Extracellular Vesicle-Encapsulated HULC Are Associated with Left Ventricular Hypertrophy in Japanese

Speaker: Satoshi Fujii (Japan)

MiR-146a Regulates Platelet Function and Thrombosis

Speaker: Ana Belén Arroyo (Spain)

Microrna-365a-3p, a Novel Modulator of Tissue Factor Protein Expression and Function

Speaker: Jiayin Tian (Australia)

Platelet miRNoma and Variability in the Responsiveness to Low-dose Aspirin in Patients with Type 2 Diabetes mellitus

Speaker: Sonia Ciotti (Italy)

High Efficiency Unassisted Transfection of Platelets with Naked Double-stranded miRNAs Modulates Signal-activated Translation and Platelet Function

Speaker: Sophie Lazar (United States)

Protease Activated Receptors

PAR1-Derived and PAR3-Derived Peptides and their Variants Synergistically Inhibit Human Macrophage NLRP3-Dependent Inflammasome Activity

Speaker: Laura Healy (United States)

Thrombomodulin Makes the Difference - Novel Role of Protease-Activated Receptor 4 as Low-Dose Thrombin Receptor

Speaker: Dorothea Monika Heuberger (Switzerland)

Scientific Programme

The Protective Effects of PAR1-agonists - Thrombin, Activated Protein C and Peptide 9 in the Model of the Neuroinflammation in vitro

Speaker: Irina Babkina (Russian Federation)

Stem Cells and Vascular Cell Growth

Pituitary Hormones Follicle-Stimulating Hormone (FSH), Luteinizing Hormone (LH) and Prolactin (PRL) Modulate Endothelial Colony Forming Cells Angiogenic and Thrombotic Properties

Speaker: Gregoire Detrich (France)

Thrombopoietin Rescues Megakaryopoiesis, Reduces Hemorrhage via Protecting Bone Marrow Endothelial Function of Chemotherapy-Treated Hematological Malignancies Patients

Speaker: Jieyu Ye (China)

Investigation of a Significant Factor to Improve an Establishment of Endothelial Colony Forming Cell

Speaker: Shuichi Okamoto (Japan)

Transplantation of Fetal Liver Cells into Newborn Hemophilic Mice for Hemophilia A Cell Therapy

Speaker: Simone Merlin (Italy)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Venous Thromboembolism Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Artificial Valves

Standard Versus Higher Intensity Anticoagulation for Patients with Mechanical Aortic Valve Replacement and Additional Risk Factors for Thromboembolism: A Multi-center Registry Analysis

Speaker: Sarah Hanigan (United States)

Atrial Fibrillation

Clinical Case: Reversal of Dabigatran Levels in Patients with Renal Insufficiency that Have Required the use of Idarucizumab

Speaker: Albert Tugues Peiró (Spain)

Reduced Bleeding After an Intervention to Limit Excess Aspirin Use Among Patients on Chronic Warfarin

Speaker: Jordan K. Schaefer (United States)

Relationship between TTR and Daily Vitamin K Intake in Patients Taking Warfarin: The Difference among VKORC1 Genotype

Speaker: Takehiko Nagao (Japan)

Persistence to Direct Oral Anticoagulants among Non-Valvular Atrial Fibrillation Patients in the Netherlands: A Nationwide Cohort Study

Speaker: Qingui Chen (the Netherlands)

Scientific Programme

Non-Valvular Atrial Fibrillation Patients Anticoagulated with Rivaroxaban Compared with Warfarin Exhibit Attenuated Plasma Platelet Activation Markers and Pro-Inflammatory Extracellular Vesicle Proteomic Signatures

Speaker: Luisa Weiss (Ireland)

Non-Persistence to Direct Oral Anticoagulants and Risk of Thromboembolic Stroke among Patients with Non-Valvular Atrial Fibrillation: A Dutch Nationwide Cohort Study

Speaker: Myrthe M.A. Toorop (the Netherlands)

Long-term Mortality and Functional Status in Older Adults with Atrial Fibrillation After Stroke

Speaker: Anna Parks (United States)

Characterization of VKA Control in Patients with Thrombotic and Major Hemorrhagic Events in Anticoagulation Hematology Units: Results from the EVENTHO Study

Speaker: Olga Gavín (Spain)

Ratio of Inhibited Thrombin Generation Based on Dilute Prothrombin Time May Predict the Major Bleeding or Thrombotic Tendency in NVAf Patients Treated with Anti-Xa DOAC

Speaker: Kazumasa Ohmura (Japan)

Differences in Treatment and Outcomes in Recently Diagnosed Atrial Fibrillation between the Netherlands and Belgium: Results from the GARFIELD-AF Registry

Speaker: Jaap Seelig (the Netherlands)

Factor V Leiden Is Associated with Atrial Fibrillation, but Not Ischemic Stroke in Atrial Fibrillation. The Tromsø Study

Speaker: Erin Mathiesen Hald (Norway)

Predictors of Left Atrial Thrombus before Catheter Ablation or Cardioversion in Patients with Non-Valvular Atrial Fibrillation

Speaker: Ivan Zaigraev (Russian Federation)

Effect of Patient and Surgery Characteristics on Clinical Outcomes in the Perioperative Anticoagulation Use for Surgery Evaluation (PAUSE) Study

Speaker: Kira MacDougall (United States)

Anticoagulation in Non-Valvular Atrial Fibrillation: Old or New Friends?

Speaker: Mihnea-Alexandru Gaman (Romania)

Management of DOACs in Elective Surgery Procedures: A Measurement Based Approach

Speaker: Loredana Tomassini (Italy)

Assessment and Predictors of Inappropriate Dose of Direct Oral Anticoagulants

Speaker: Mosaad Almegren (Saudi Arabia)

Vitamin K Antagonists Dosing According to Pharmacogenetics

Speaker: Elena Ristovska (Macedonia, the Former Yugoslav Republic of)

Rates, Management and Outcome of Bleeding Complications during Edoxaban Therapy in Daily Care - Results from the Dresden NOAC Registry

Speaker: Jan Beyer-Westendorf (Germany)

Association of Clinical Risk Factors and Biomarkers with Thromboembolism, Major Bleeding, and All-Cause Death in Patients with Atrial Fibrillation in a Tertiary Care Setting

Speaker: Daniel Kraemmer (Austria)

Scientific Programme

The Role of Hemodialysis in Patients with Re-Elevation of Dabigatran Levels After Idarucizumab Treatment: A Case Series

Speaker: Ana Boban (Croatia)

Differential Effect of Direct Oral Anticoagulants (DOACs) on Thrombin Generation and Clot Lysis in Patients with Non Valvular Atrial Fibrillation (AF) and Venous Thromboembolism (VTE)

Speaker: Mario Colucci (Italy)

Plasma from Patients under Direct Oral Anticoagulants (DOACs) Displays a Strong Resistance to Heparin Compared to Patients under Vitamin K Antagonists (VKA)

Speaker: Mario Colucci (Italy)

Clinical Outcomes for Patients of High Body Weight on Apixaban or Rivaroxaban

Speaker: Gurpreet Bahra (United Kingdom)

Fatal Intracerebral Hemorrhage in a Patient on Warfarin: A Case Report

Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Relationship of Health Literacy and Adherence to Treatment with Oral Anticoagulants in Patients with Atrial Fibrillation in Brazil

Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Emergency Room Access of Patients on DOACs: A Six Years Single Center Experience

Speaker: Luciano Crippa (Italy)

Anticoagulation Resumption After Intracerebral Hemorrhage in Two Cohorts of Patients Treated with Vitamin K Antagonists and Direct Oral Anticoagulants

Speaker: Daniela Poli (Italy)

More Precise Dosing of Acenocoumarol for Better Control in Patients Aged above 80 Years, a Randomized Controlled Pilot Study

Speaker: Margriet Piersma-Wichers (the Netherlands)

Time in Therapeutic Range During Therapy with Vitamin K Antagonists Is Lower in Women than in Men and Is Not Explained by Differences in Age

Speaker: Ilaria Avarello (Italy)

Towards Individualizing Apixaban Therapy in Elderly Patients Through Thrombin Generation

Speaker: Alejandra Scazzioti (Argentina)

Anticoagulant Management Strategies in Cancer Patients with Atrial Fibrillation in Daily Clinical Practice

Speaker: Gordon Chu (the Netherlands)

Heparin Resistance and a Probable Dabigatran Non Response in a Case of AFib and Left Auricular Atrium Clot

Speaker: Ana Coimbra (Portugal)

Single Centre Daily Practice Evaluation of Bleeding and Thromboembolic Complications in Cancer Patients with Atrial Fibrillation

Speaker: Gordon Chu (the Netherlands)

Stroke, Major Bleeding, and Net-clinical Benefit of Anticoagulation in Patients with Atrial Fibrillation on Hemodialysis

Speaker: Oliver Koenigsbruegge (Austria)

Scientific Programme

Study of Real Clinical Practice to Evaluate the Efficacy and Safety of Edoxaban in Prevention of Stroke in Patients with Non-valvular Atrial Fibrillation. Differences between Results by Age and Creatinine Clearance Greater than 95 ml/min

Speaker: Almudena Garcia Ruiz (Spain)

Beyond the Registry: A Nuanced Evaluation of Real World Anticoagulation for Nonvalvular Atrial Fibrillation Patients at a Tertiary Care Center

Speaker: Cali Lunowa (United States)

Association of Body Mass Index (BMI) with Bleeding Events in Patients Taking Oral Anticoagulation for Atrial Fibrillation (AF) or Venous Thromboembolism (VTE)

Speaker: Thane Feldeisen (United States)

The Association between Neighborhood Socioeconomic Status, Geographical Area and Non-persistence to Using DOACs

Speaker: Nienke van Rein (Denmark)

Inappropriate Dosing of Direct Oral Anticoagulants in Older Patients with Non-Valvular Atrial Fibrillation: Impact on Plasma Drug Levels

Speaker: Anne-Laure Sennesael (Belgium)

The Impact of Soluble Thrombomodulin and Circulating miRNAs on Catheter Ablation in Patients with Atrial Fibrillation

Speaker: Fuminori Namino (Japan)

Concomitant Use of Direct Oral Anticoagulants and Antiepileptic Drugs: A Prospective Cohort Study in Patients with Atrial Fibrillation

Speaker: Michela Giustozzi (Italy)

An observational Study of INR Control and Bleeding Events, According to European Society of Cardiology (ESC) Guidelines, in Non-valvular Atrial Fibrillation (NVAf) Stratified by Male and Female Sex

Speaker: Daniel Harris (United Kingdom)

Intracardiac Levels of Soluble P Selectin Is Associated with Ischemic Stroke Risk in Patients with Atrial Fibrillation

Speaker: Ferenc Sarkady (Hungary)

Atrial Fibrillation Treated with Warfarin at an Academic Medical Center: The Potential Impact of Direct Oral Anticoagulants on Future Management

Speaker: Peter Collins (United States)

Trends in Direct Oral Anticoagulant Use in Renal Failure

Speaker: Scott Kaatz (United States)

Preliminary Results from EGINA Registry: A New Model in the Management of Anticoagulation with DOACs in Southern Italy

Speaker: Nicola Ciavarella (Italy)

Using Baseline Characteristics to Differentiate Atrial Fibrillation Prevalence and Incidence in Pulmonary Embolism

Speaker: Dimpi Patel (United States)

Predictive Value of CBC Indices in Determining Risk of Atrial Fibrillation After Pulmonary Embolism

Speaker: Dimpi Patel (United States)

Scientific Programme

Profile of Patients Using Oral Anticoagulants in Primary Care: 'Anticoagula Divinópolis' Project

Speaker: João Antonio Oliveira (Brazil)

Cancer Associated Thrombosis

Efficacy of Primary Thromboprophylaxis Agents (PTA) in Multiple Myeloma (MM) Treated with Immunomodulators (IMiD): A Network Meta-Analysis

Speaker: Philip A Haddad (United States)

L-Asparaginase Induced Hyperlipidemia, Pseudohyponatremia and Cerebral Venous Thrombosis during Acute Lymphoblastic Leukemia Remission Induction Therapy

Speaker: Murat Soker (Turkey)

Amelioration of the Pathologic Changes in the Hepatocyte-Specific BRAFV600E Mutated Mice by Administration of Aspirin

Speaker: Hiroki Tanaka (Japan)

Use of Direct Oral Anticoagulants (DOACs) as Primary or Secondary Prophylaxis of Venous Thromboembolism in Patients with Multiple Myeloma on Immunomodulatory Drugs

Speaker: Carlos Aguilar (Spain)

JAK2 Mutation: A Predictor of Thrombotic Events in Myeloproliferative Neoplasia?

Speaker: Sindhura Lakshmi Koulmane Laxminarayana (India)

Development of Predictive Score for Venous Thromboembolism in Hematologic Malignancies

Speaker: Agnerys López Sacerio (Cuba)

Risks and Benefits of Antithrombotic Therapy in Polycythemia Vera: A Systematic Review

Speaker: Marissa Laureano (Canada)

Clinical Outcome of Anticoagulation for Acute Venous Thromboembolism Associated with Different Types of Cancer

Speaker: Waldemar Wysokinski (United States)

Survival after Cancer-related Venous Thrombosis: The Scandinavian Thrombosis and Cancer Study (STAC)

Speaker: Rayna Janine Sushmita Anijs (the Netherlands)

Risk of venous Thromboembolism among Subgroups of Cancer Patients Undergoing Chemotherapy: Post-Hoc Analysis of the AVERT Trial

Speaker: Ameeta Lubina Nayak (Canada)

Thrombosis in Hematologic Malignancies: A Five Year Single-Center Experience in Mexico

Speaker: María Teresa García-Lee (Mexico)

Risk Factors of Venous Thromboembolism in Patients Undergoing Systemic Cancer Therapy: A Systematic Review and Meta-Analysis

Speaker: Sandra Lee (Canada)

Elevated Von Willebrand Factor Antigen and Activity Levels Are Risk Factors for Predicting Thrombosis in Cancer

Speaker: Bin Yan (China)

Incidence and Risk Factors for Venous Thromboembolism (VTE) among Lymphoma Patients in a Southeast Asian Population

Speaker: Vanessa Cui Lian Chong (Singapore)

Scientific Programme

Increased Coagulation Potential in Patients with Polycythemia Vera and Essential Thrombocythemia with Thrombotic History

Speaker: Natalya Korsakova (Russian Federation)

Non-Randomized Patient Outcomes. ADAM-VTE Registry Analysis

Speaker: Ewa Wysokinska (United States)

Are Patients with an Active Cancer and those with a History of Cancer Carrying the Same Risks of Recurrent VTE and Bleeding while on Anticoagulants?

Speaker: Corinne Frere (France)

Effectiveness and Safety of Enoxaparin in Patients with Active Cancer and Venous Thromboembolism (VTE): A Systematic Literature Review

Speaker: Jenny Shan (France)

Long-Term Use of Tinzaparin for the Treatment of Cancer-Associated Thrombosis: A Subgroup Analysis of the Prospective Observational TROPIQUE Study

Speaker: Dominique Farge (France)

Intracranial Hemorrhage with Direct Oral Anticoagulants in Patients with Brain Metastases

Speaker: Avi Leader (the Netherlands)

Use of a Cancer Screening Tool as Part of a Conservative Approach to Screening for Occult Malignancy after Unprovoked DVT: The King's College Hospital Experience

Speaker: Catrin Cox (United Kingdom)

Increased Potential of Neutrophil Activation and Neutrophil Extracellular Trap Formation in Patients with Lung Cancer

Speaker: Lisa-Marie Mauracher (Austria)

No Impact of Previous Venous Thromboembolism on the Survival of Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation for Refractory Lymphoma

Speaker: Joanna Rupa-Matysek (Poland)

Risk Factors, Mortality and Costs of Cancer-Associated Thrombosis in Hospitalised Patients

Speaker: Wei Ying Jen (Singapore)

Assessment of the Ottawa Score in the Prediction of Recurrent Venous Thromboembolism in Patients Treated for Lymphoma

Speaker: Joanna Rupa-Matysek (Poland)

Massive Life-Threatening Intravascular Tumor Thrombus (ITT) as the Initial Manifestation of Renal Cell Carcinoma Complicated with Heparin-Induced Thrombocytopenia: A Case Study

Speaker: Elia Seguí (Spain)

Bleeding Risk Assessment Model for Older Multiple Myeloma Patients on Immunomodulatory Drugs (IMiDs)

Speaker: Ang Li (United States)

Empowering Cancer Patients for Non-Pharmacological Primary Prevention and Early Recognition of Cancer-Associated Thrombosis (CAT): The EMPATIC-CP Survey

Speaker: Marta Merino (Spain)

Venous Thromboembolism (VTE) Events with Cancer as a Risk Factor in a Teaching Hospital: 2015-2019

Speaker: Huw Rowsell (United Kingdom)

Scientific Programme

Risk of Arterial Thromboembolism in Cancer Patients: A Population-Based Cohort Study

Speaker: Frits I. Mulder (the Netherlands)

Haemostatic State in Hodgkin Lymphoma Patients

Speaker: Alexander Poletaev (Russian Federation)

Failure of the Ottawa Score to Predict the Risk of Recurrent Venous Thromboembolism in Patients with Cancer-Associated Thrombosis. A Pooled Analysis of two Prospective Cohort Studies

Speaker: Philippe Girard (France)

Biomarkers of Venous Thromboembolism Recurrence After Discontinuation of Anticoagulation for Cancer-Associated Thrombosis (HISPALIS- Study)

Speaker: Julia Oto (Spain)

Use of Anti-Factor Xa Levels in Cancer Patients Taking Direct Oral Anticoagulants

Speaker: Anna Weatherill (United Kingdom)

The Downregulation of Mucin1 Initiates Aberrant Calcium Signalling Pathways of Cancer Cells which Are Partly Responsible for the Procoagulant Phenotype

Speaker: Yunliang Chen (United Kingdom)

Current Status on Non-hematological Cancer Associated Thrombosis at Tertiary Care Hospital in India

Speaker: Mukul Aggarwal (India)

A Newly Developed Kit for High-Sensitivity Measurement of TF-Dependent Procoagulant Activity on Microvesicles Purified by High-Speed Centrifugation

Speaker: Tarik Bouriche (France)

Thromboprophylaxis with Rivaroxaban in Patients with Malignancy and Central Venous Lines (TRIM-line): a Multi-centre Open-label Pilot Randomized Controlled Trial

Speaker: Rick Ikesaka (Canada)

Elevated Plasma Factor VIII Levels Are Associated with Hypercoagulability and Shorter Survival in Patients with Non-Hodgkin Lymphoma

Speaker: Chatphatai Moonla (Thailand)

Plasma Levels of Procoagulant and Anticoagulant Factors in Patients with Acute Cancer-associated Thrombosis

Speaker: Elena Campello (Italy)

Apixaban Levels In Cancer-Associated Thrombosis In Low-Weight Individuals

Speaker: Veronica Bravo-Villa (Mexico)

Venous Thromboembolism in Patients with Cancer in Palliative Care

Speaker: Gabriela Cesarman-Maus (Mexico)

Catheter-Associated Upper Extremities Deep Vein Thrombosis in Cancer Patients: Does Anticoagulation Time Matter?

Speaker: Annalisa Dalla Salda (Italy)

Deep Venous Thrombosis and Intraductal Papillary and Mucinous Tumor of the Pancreas: about 3 Cases

Speaker: Yosra Cherif (Tunisia)

Aspects of Cancer-Related Venous Thrombosis in a cohort of 207 Tunisian Patients

Speaker: Marwen Mama (Tunisia)

Scientific Programme

Clinical Outcome of Splanchnic and Usual Site Venous Thrombosis in Patients with Solid Cancer

Speaker: Emanuele Valeriani (Italy)

Decreased Thrombin Generation Potential in Lymphoma Patients Is Associated with Increased D-dimer, CRP, vWF and TNF- α . Interrelationship between Thrombogenesis and Inflammation

Speaker: Fakiha Siddiqui (United States)

Differential Augmentation of Thrombin Generation by Andexanet Alfa in Lymphoma Patients

Speaker: Fakiha Siddiqui (United States)

Pulmonary Embolism as a Presenting Manifestation of Cerebral Glial Tumor

Speaker: Maroua Mrouki (Tunisia)

Uncovering Clinical Gaps in Treatment of Cancer-Associated Thrombosis: A Clinical Practice Assessment

Speaker: Jelena Spyropoulos (United States)

Influence of Tumor Site on Clinical Outcomes in Cancer Patients with Venous Thromboembolism. Insights from the Prospective PREDICARE Cohort Study

Speaker: Philippe Girard (France)

Anticoagulation Therapy as Prevention of Cancer Relapse

Speaker: Alexander Vorobev (Russian Federation)

Dynamics of ADAMTS13 and vWF Activity Change in Ovarian Cancer Patients

Speaker: Alexander Vorobev (Russian Federation)

Impact of Obesity in Pulmonary Embolism among Patients with Solid Malignancies

Speaker: Karol Quelal (United States)

Fondaparinux versus Enoxaparin in the Treatment of Venous Thromboembolism in Cancer Patients: Retrospective Cohort Study - "ONCOTEV"

Speaker: Barbara Abbate (Italy)

Histopathological Features of Cancer-Associated Venous Thromboembolism in Human

Speaker: Toshihiro Gi (Japan)

Anticoagulation Therapy Management in Oncological Patients: Experience in a Center

Speaker: Ana Pimentel Feliciano (Spain)

The Activated Coagulation Factor X (FXa) Directly Stimulates Colorectal Cancer Cell Migration and Proliferation - Characterizing the Underlying Molecular Mechanisms

Speaker: Ulrike Meyer (Germany)

Direct Oral Anticoagulants in Patients with Hematological Malignancies

Speaker: Alessandra Serrao (Italy)

Incidence, Risk Factors and Clinical Outcome of Venous and Arterial Thromboembolic Events in Patients Treated with Immune-checkpoint Inhibitors: A Single-center Cohort Study

Speaker: Florian Moik (Austria)

Cerebral Sinus Venous Thrombosis in Children with Leukemia: Single-institution Report

Speaker: Irina Melnichenko (Armenia)

Patients Experience of Living with Cancer Associated Thrombosis in Singapore (PELICAN)

Speaker: Simon Noble (United Kingdom)

Scientific Programme

Cooperation about the Treatment of the Venous Thromboembolism in Cancer Institute Hospitals and Neighboring Cooperation Acute Hospitals

Speaker: Chikao Yasuda (Japan)

Effectiveness and Safety of Direct Oral Anticoagulants in Patients with Ph-negative Myeloproliferative Neoplasms and Venous Thromboembolism

Speaker: Silvia Betti (Italy)

Differential Expression of Neutrophil Activation Markers in Venous Thromboembolism Patients with and without Association to Cancer

Speaker: Julia Oto (Spain)

Antimetastatic Profile of Bovine Intestinal Heparin and its Low Anticoagulant Activity Derivative

Speaker: Mariana Sá Pereira (Brazil)

Developing an ex vivo Method to Study Thrombosis in Cancer Patients: Cancer-associated Thrombosis-on-a-Chip

Speaker: Araci M R Rondon (the Netherlands)

ThroLy and Khorana Scores Comparison in a Group of Lymphoma Patients

Speaker: Pilar Llamas (Spain)

Effectiveness and Safety of Rivaroxaban in Patients with Cancer-associated Venous Thromboembolism

Speaker: Olivia S. Costa (United States)

Cancer Patients Has Lower Plasmin Generation by Simultaneous Thrombin and Plasmin Assay Evaluation

Speaker: Gabriele da Silva Souza Gois (Brazil)

Venous Thromboembolic Risk in Ambulatory Cancer Patients: Awareness Needed!

Speaker: Sara Lopes (Portugal)

No Agreement among Risk Prediction Scores for Venous Thromboembolism in Cancer Patients: A Prospective Cohort Study

Speaker: Millene Evelyn Alves de Almeida (Brazil)

Clinical Presentation and Outcomes of Cancer-associated Distal Deep Vein Thrombosis: Data from the RIETE Registry

Speaker: Jean-Philippe Galanaud (Canada)

Cancer Site and Distant Metastasis at Diagnosis Predict the Risk of VTE in Cancer

Speaker: Sigrid K. Braekkan (Norway)

Risk of Venous Thromboembolism in the Clinical Course of Osteosarcoma

Speaker: Milou A. M. Stals (the Netherlands)

Cancer Associated Thrombosis: Are DOACs a Treatment Option? Systematic Review and Meta-analysis of Randomised Controlled Trials

Speaker: Raza Alikhan (United Kingdom)

Genetic Risk Factors of Thrombosis

Thrombophilia Gene Screening in Pediatrics Solid Tumors with Thrombosis

Speaker: Osama El Safy (Egypt)

Scientific Programme

Does blood Group Predicts Thrombosis Risk? A Pilot Study Assessing Thrombin Generation

Speaker: María Marcos Jubilar (Spain)

Genetic Study for Idiopathic Venous Thromboembolism in Japanese Using Short-Read and Long Read Sequencers: A Pilot Study of Japanese Group of Idiopathic Thromboembolism

Speaker: Akihiro Tsuji (Japan)

The Sex-Related Risk of Venous Thromboembolism Attributed to Recognized Prothrombotic Genotypes

Speaker: Carl Arne Løchen Arnesen (Norway)

Role of ADAMTS13, VWF and FVIII in Deep Vein Thrombosis

Speaker: Maria Teresa Pagliari (Italy)

Clinical and Laboratory Characteristics of Patients with Hereditary Thrombophilias in the North-Western Region of Russia

Speaker: Olga Soldatenkova (Russian Federation)

Characterisation of a Novel F5 Gene Mutation (Ala2114Asp, Factor V Besançon) Associated with Factor V Deficiency and Recurrent Venous Thrombosis

Speaker: Elisabetta Castoldi (the Netherlands)

Assessment of Fibrinolysis Markers in Patients with Lower Limb Deep Venous Thrombosis: A Prospective Case-control Study

Speaker: Saniya Sharma (India)

Afibrinogenemia and Leiden FV Within the Same Family

Speaker: Soraya Hadjali - Saichi (Algeria)

"Gene-gene Interaction" between FXIII-A VAL34LEU and PAI-1 - 675 4G/5G Polymorphisms Can Modify the Risk of Pulmonary Embolism in Young VTE Patients

Speaker: Anna Chechulova (Russian Federation)

Homozygous State of Leiden Mutation in Factor V Associated with Other Genetic and Biochemical Risk Factors and Late Onset of Thrombotic Episodes in Five Clinical Cases

Speaker: Marija Vukovic (Bosnia and Herzegovina)

"Gene-gene Interaction" between PAI-1 - 675 4G/5G and TNF-A -308 G/A Polymorphisms Can Modulate the Risk of Pulmonary Embolism in Young Patients with Venous Thromboembolism

Speaker: Sergei Kapustin (Russian Federation)

Carrier Frequencies of Antithrombin-, Protein C-, or Protein S-deficient Variants Estimated Using a Public Database and Expression Experiments

Speaker: Koichi Kokame (Japan)

De Novo Variants in Antithrombin Deficiency: Incidence and Heterogeneous Mechanisms

Speaker: Maria Eugenia de la Morena-Barrio (Spain)

Structural Basis of the Pro-coagulant Phenotype of Prothrombin Variant Arg553Trp (p.Arg596Trp - Padua 2)

Speaker: Vincenzo De Filippis (Italy)

Pulmonary Embolism and Thrombophilia Gene Mutations: Georgian Population Study

Speaker: Tea Mukhuradze (Georgia)

Decreased Expression of Annexin A2 Is Associated with Reduced Cell Surface Fibrinolysis and Venous Thromboembolism

Speaker: Katherine Hajjar (United States)

Scientific Programme

Effects of Body Mass Index on the Human Plasma Proteome - Potential Drivers of Obesity-related Cardiovascular Disease?

Speaker: Lucy Goudswaard (United Kingdom)

Post-thrombotic Syndrome

Exploring Alternative Approaches of Using the Villalta Scale to Capture the Post-Thrombotic Syndrome: A Sub-analysis of the ATTRACT Trial

Speaker: Susan R Kahn (Canada)

Leukocyte Gene Expression in Post-Thrombotic Syndrome

Speaker: Aaron Frans Jacob Iding (the Netherlands)

Measuring Functional Limitations after Venous Thromboembolism: Optimization of the Post-VTE Functional Status (PVFS) Scale

Speaker: Frederikus A. Klok (the Netherlands)

VTE and its complications: A Real World View Daryl Pollock, RN, MN CNS Thrombosis/Haemostasis

Speaker: Daryl Pollock (New Zealand)

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome (The TILE Pilot Study): Rationale and Study Protocol

Speaker: Jean-Philippe Galanaud (Canada)

The Impact of Successful Ultrasound-Accelerated Catheter-Directed Thrombolysis on the Prevention of Post-Thrombotic Syndrome: A Post-Hoc Analysis of the CAVA-Trial

Speaker: Pascale Notten (the Netherlands)

Hokusai Post-DVT Study: A Follow-up Study on Long-term Outcomes of Deep Vein Thrombosis in Patients Treated with Edoxaban vs Warfarin

Speaker: Ingrid Bistervels (the Netherlands)

Recanalization of Venous Thrombosis by Robotic Assisted High Frequency Pulsed Cavitational Ultrasound Therapy: 2 Weeks Follow-up in a Swine Model

Speaker: Lina Khider (France)

Study of Plasma miRNAs and Microparticle miRNAs in Severe Forms of Pulmonary Hypertension

Speaker: Julia Oto (Spain)

Post-Thrombotic Syndrome in Patients with Venous Thromboembolism Treated with Dabigatran or Warfarin - a Long-Term Cross-Sectional Follow-up of RE-COVER Study Patients

Speaker: Hilde Skuterud Wik (Norway)

Effectiveness and Safety of Pulmonary Rehabilitation to Reduce Functional Impairment Based on the Post-PE Syndrome

Speaker: Duliëtte Boon (the Netherlands)

Endovascular Management with Iliofemoral Stenting in a Patient with Chronic Venous Occlusive Disease and Antiphospholipid Antibodies

Speaker: Franco Piovella (Italy)

Results of a Dedicated Diagnostic Work-up of Patients with Post-PE Syndrome

Speaker: Duliëtte Boon (the Netherlands)

Scientific Programme

Assessment of Radiological Signs of Chronic Thromboembolic Pulmonary Hypertension on CTPAs Performed for Acute Pulmonary Embolism Leads to Earlier Diagnosis of CTEPH

Speaker: Duliëtte Boon (the Netherlands)

Prevention of Post-thrombotic Syndrome with Elastic Compressive Stockings

Speaker: Rumjana Apostolovska (Macedonia, the Former Yugoslav Republic of)

Patency and Clinical Outcomes of Venous Recanalization in the Treatment of Postthrombotic Syndrome

Speaker: Lina Khider (France)

Quality of Life (QOL) Assessment Using VEINES/QOL Score for Deep Vein Thrombosis (DVT) Patients in Uruguay

Speaker: Maria Victoria Matosas (Uruguay)

Quality of Life Outcomes after Iliac Vein Stenting for Chronic Deep Venous Obstruction: A Tertiary Centre Experience Using the VEINES-QoL/Sym

Speaker: Rachael Morris (United Kingdom)

Thrombophilia

Are We Choosing Wisely? Heritable Thrombophilia (HT) Testing in a District General Hospital in the UK

Speaker: Leila Khalil (United Kingdom)

Evaluation of Platelet Indices in Patients with Splanchnic Vein Thrombosis

Speaker: Narender Kumar (India)

What Kind of Thrombophilia in Reunion Island?

Speaker: Sabine Mustun (Reunion)

High Prevalence of the Hereditary Anticoagulant Deficiency in Chronic Thromboembolic Pulmonary Hypertension (CTEPH)

Speaker: TianYu Lian (China)

Use of Direct Oral Anticoagulants in Congenital Thrombophilias

Speaker: Natalie Montanez (United States)

Positive Thrombophilia Study in the Context of Starting Hormonal Treatment in the Gender Dysphory: Experience in a Single Center

Speaker: Bianca Díaz Roldán (Spain)

Increased Levels of Procoagulant Factors and the Risk of Venous Thromboembolism

Speaker: Luca Spiezia (Italy)

Primary Aortic Thrombus with Multiple Visceral Embolisation: A Presenting Manifestation of Chronic Myelomonocytic Leukemia

Speaker: Veerendra Chadachan (Singapore)

Thrombophilia Testing in Patients with Arterial Thrombosis in Routine Clinical Practice

Speaker: Gala Aglaia Méndez Navarro (Spain)

A New Global Assay for Detection of Protein C Pathway-Associated Thrombophilia Using Thrombomodulin-Mediated Clot Waveform Analysis

Speaker: Naoki Hashimoto (Japan)

Thrombophilia Testing in Algerian Pediatric Patients

Speaker: Imene Hocine (Algeria)

Scientific Programme

The Prothrombin Belgrade Mutation Causing Antithrombin Resistance Does Not Affect Fibrin Clot Formation

Speaker: Sofija Dunjic (Serbia)

Is May-Thurner Syndrome a Forgotten Cause of Deep Vein Thrombosis?

Speaker: Sara Lopes (Portugal)

Relevance of Thrombophilia Screening in Adult Renal Transplant Recipients

Speaker: Dhouha Bahri (Tunisia)

Homozygous Antithrombin Budapest 3 Deficiency Causes Inferior Vena Cava System Agenesis

Speaker: Carlos Bravo-Perez (Spain)

Inherited Deficiency of Antithrombin, Protein C or Protein S Is Associated with an Increased Risk of Cancer at a Younger Age

Speaker: Daniela Tormene (Italy)

Mandor's Disease: A Manifestation of Rare Conditions

Speaker: Yosra Cherif (Tunisia)

Deep Vein Thrombosis Associated with Protein S Deficiency

Speaker: Pradana Romadhon (Indonesia)

Relation between the von Willebrand Factor and ADAMTS13 with Venous Thrombosis Risk. Results from the Retrove Project

Speaker: Dolors Llobet (Spain)

Characterisation of Antithrombin p.Thr147Ala, the First Common Founder Variant from African Origin Responsible for Inherited Antithrombin Deficiency

Speaker: Belén de la Morena-Barrio (Spain)

Thrombophilia and Thrombotic Complications in Armenia

Speaker: Heghine Khachatryan (Armenia)

Venous Thrombosis-dominant Congenital Dysfibrinogenemia Presenting with Cerebral Venous Sinus Thrombosis

Speaker: Hana Iris Lim (United States)

The Presence of Paraproteinaemia in Patients with Antiphospholipid Syndrome - A Single Centre Case Series

Speaker: Andrew Doyle (United Kingdom)

Risk of Recurrence after a First-lifetime Venous Thrombosis: Impact of Inherited Thrombophilia

Speaker: Maroua Belhadj (Tunisia)

Thrombophilic Abnormalities Screening in Elderly Women Patients with Venous Thrombosis

Speaker: Loredana Liliana Hurjui (Romania)

Hypoplasminogenemia - A Forgotten Diagnosis: A Case Series of Genotype and Phenotype Correlation

Speaker: Rosa Sonja Alesci (Germany)

Efficacy and Safety Profile of Direct Oral Anticoagulants in Consecutive Patients with Severe Hereditary Thrombophilia: A Single-centre Cohort Study

Speaker: Elena Campello (Italy)

Scientific Programme

Thrombophilic Mutations in Macedonian Women with Adverse Pregnancy Outcome

Speaker: Elena Petkovikj (Macedonia, the Former Yugoslav Republic of)

Upregulation of Factor XI in End Stage Renal Disease Is Associated with Increased Thrombin Generation and D-dimer

Speaker: Debra Hoppensteadt (United States)

Visceral Vein Thrombosis

Epidemiology and Clinicopathology of Latent versus Active JAK2-Myeloproliferative Neoplasms (MPN) in Splanchnic Venous Thrombosis

Speaker: Philip A Haddad (United States)

Association of Portal Vein Thrombosis and Clinical Outcomes in Cirrhotic Patients: A Nested Case-Control Study

Speaker: Pipu Tavornshevin (Thailand)

Case report: Renal Vein Thrombosis Associated with Oral Contraceptive Use and Posterior Nutcracker Syndrome

Speaker: Abdulaziz AlHumaidi (Saudi Arabia)

Anticoagulant Therapy for Splanchnic Vein Thrombosis: A Systematic Review and Meta-Analysis

Speaker: Emanuele Valeriani (Italy)

A Retrospective Cohort Study on Splanchnic Vein Thrombosis

Speaker: Eri Kawata (Iida) (Canada)

Portal Vein Thrombosis Revealing Paroxysmal Nocturnal Hemoglobinuria

Speaker: Melek Kechida (Tunisia)

Essential Thrombocythemia Complicated with Portal Vein Thrombosis and Liver Cirrhosis - A Case Report

Speaker: Nina Petkova (Bulgaria)

Budd Chiari Syndrome: Beyond 5 Years of Follow up

Speaker: Daniela Mezzarobba (Argentina)

VTE Diagnosis

Dynamic Upper Limb Ultrasound in Idiopathic Upper Extremity Deep Vein Thrombosis

Speaker: Hiu Lam Agnes Yuen (Australia)

D-Dimer is Useful in the Assessment of Suspected Recurrent Venous Thromboembolism in Patients on Rivaroxaban or Apixaban

Speaker: Hiu Lam Agnes Yuen (Australia)

Serial Ultrasounds in Deep Vein Thrombosis Diagnosis, a Single Centre Retrospective Review

Speaker: Ronald Yan (Canada)

Ten Years of Venous Thromboembolism Events in a Large Teaching Hospital: Changing Patterns of Disease

Speaker: Huw Rowsell (United Kingdom)

Elevated von Willebrand Factor Antigen Levels and Ristocetin Cofactor Activity are Risk Factors in Predicting Deep Vein Thrombosis

Speaker: Yiming Zhao (China)

Scientific Programme

Is There a Predictive Value of High Mean Platelet Volume in Early Diagnosis of Venous Thromboembolism in the Emergency Department?

Speaker: Andrei Braester (Israel)

Optimizing Magnetic Resonance Direct Thrombus Imaging for Differentiating Acute from Chronic Splanchnic Vein Thrombosis

Speaker: Lisette F. van Dam (the Netherlands)

Diagnosing Deep Vein Thrombosis in Patients with Suspected Symptoms and a Concurrent Malignancy: An Individual Participant Data Meta-Analysis

Speaker: Toshihiko Takada (the Netherlands)

Comparative Study between Thromboelastography and Conventional Coagulation Tests in Deep Vein Thrombosis

Speaker: Bin Yan (China)

A Systematic Review and Meta-Analysis on Diagnostic Delay in Pulmonary Embolism

Speaker: Geert-Jan Geersing (the Netherlands)

An Assessment of the Cost-Effectiveness of Whole-Leg Ultrasound Scans Compared to Proximal Leg Vein Ultrasound Scans in the Diagnosis of Acute Deep Vein Thrombosis

Speaker: Gianluca Bertone (United Kingdom)

Predictive Accuracy of Computed Tomography Pulmonary Perfusion Imaging for Adverse Outcome in Patients with Acute Pulmonary Embolism

Speaker: Lisette F. van Dam (the Netherlands)

The Use of ADJUST (age-adjusted) D-Dimer Cut-off in the Assessment of Individuals Over 50 Years Old with Suspected Deep Vein Thromboses Can Decrease the Need for Compression Ultrasonography: Initial Results of a Prospective Primary Care Study

Speaker: Andy Hughes (United Kingdom)

A Practical Comparison of a PE Diagnostic Approach: Is All Wells in the World?

Speaker: Lindsey Gerstein (Canada)

Outcome of the Symptomatic Subsegmental Isolated Pulmonary Embolism: The SSPE Padua Study

Speaker: Davide Ceccato (Italy)

Prospective Study of a Screening Protocol for Venous Thromboembolic Complications in Patients Operated on for Pelvic Ring Fractures

Speaker: Stéphanie Bonhomme (France)

D-Dimer Plasma Levels and the Anatomical Extension of Acute Symptomatic Deep Vein Thrombosis of the Lower Limbs

Speaker: Benilde Cosmi (Italy)

Identification of Somatic Mutations Associated with Clonal Hematopoiesis in Unprovoked Venous Thromboembolism

Speaker: Ana Marín-Quílez (Spain)

Venous Thromboembolism (VTE) Events in Elective and Emergency Orthopaedic Surgery in a Large Teaching Hospital 2011 to 2019

Speaker: Huw Rowsell (United Kingdom)

Safety of Using the Wells Rule and D-Dimer Test for Excluding Acute Recurrent Ipsilateral Deep Vein Thrombosis

Speaker: Lisette F. van Dam (the Netherlands)

Scientific Programme

Immuno-Magnetic Separation (IMS) Allows Efficient and Selective Extraction of Microvesicles Bearing Tissue Factor Activity from Various Liquid Biopsies

Speaker: Corentin Franco (France)

A Combination of Age Adjusted Cut-Off and Preanalytical Conditions Monitoring for Increased DDIM Assay Specificity

Speaker: Ludek Slavik (Czech Republic)

Cost-Effectiveness of Magnetic Resonance Direct Thrombus Imaging for Diagnosing Recurrent Ipsilateral Deep Vein Thrombosis

Speaker: Lisette F. van Dam (the Netherlands)

A Simplified Management Strategy for Suspected Pulmonary Embolism: External Validation of the YEARS Diagnostic Algorithm

Speaker: Helia Robert-Ebadi (Switzerland)

Radiological Parameters on Computed Tomography Pulmonary Angiography Correlate Poorly with Early Mortality from Acute Pulmonary Embolism

Speaker: Ian Wu (Singapore)

D-dimer Diagnostics: An International Assessment of the Quality of Laboratory Testing

Speaker: Carolyne Elbaz (Canada)

Vein Thrombosis after an Osteopathy Session

Speaker: Valentina Kieffer (France)

Impact of Beta-Blockers on the Clinical Diagnosis of Patients with Pulmonary Embolism

Speaker: Farès Moustafa (France)

Determining Predictive Factors of Venous Thromboembolism Using Design of Experiments

Speaker: Gabriel Yoshiaki Ottaiano (Brazil)

High Thrombus Burden and its Correlation with In-hospital Mortality or Right Ventricular Dysfunction in Patients with Acute Pulmonary Embolism and Low-risk Simplified-PESI Score

Speaker: Nicolas Torres (Argentina)

Detection of MicroRNA-126 as a Plasma Biomarker for Diagnosis of DVT

Speaker: Xia Bai (China)

The Significance of Haemostatic System's Changes in the Assessing of Unfavorable Prognosis in Patients with Burn Injury

Speaker: Elena Klychnikova (Russian Federation)

The Prognostic Role of Neutrophil to Lymphocyte Ratio (NLR) in Venous Thromboembolism and Related Mortality

Speaker: Muhamad Fajri Adda'i (Indonesia)

Acquired Type II (IIb) Protein S Deficiency, Case Report

Speaker: Tereza Fenclova (Czech Republic)

Venous Involvement in Behcet Disease: Clinical Spectrum and Predictive Factors

Speaker: Melek Kechida (Tunisia)

Incidental Pulmonary Embolism in an Internal Medicine Department

Speaker: Ines Naceur (Tunisia)

Scientific Programme

Developing Fluidic Models that Replicate Cephalic Arch Geometry and Flow Conditions of Dialysis Patients to Understand and Predict Access Thrombosis

Speaker: Andres Moya Rodriguez (United States)

Analysis of Hemodynamic and Hemocoagulation Changes in Mortality Structure in Polytrauma Patients

Speaker: Nadezhda Baranova (Ukraine)

A Non-invasive Diagnostic Work-up Is Safe and Efficient to Exclude Pulmonary Embolism in Low Risk Pregnant Women with Suspected Pulmonary Embolism: A Systematic Review and Meta-analysis

Speaker: Milou A. M. Stals (the Netherlands)

Right Ventricular to Left Ventricular Diameter Ratio Assessment with Non-ECG Gated Computed Tomography Scans and its Correlation with Right Ventricular Dysfunction in Acute Pulmonary Embolism

Speaker: Jorge Bilbao (Argentina)

Particularities of Venous Thromboembolism in Systemic Vasculitides

Speaker: Tayssir Ben Achour (Tunisia)

Deep Venous Thrombosis with Atypical Location: About 22 Cases

Speaker: Yosra Cherif (Tunisia)

Photoshop-GSM versus Customized-GSM Software to Analysis of Echogenicity of Residual Venous Obstruction

Speaker: Arlindo Lemos (Brazil)

VTE Epidemiology

Risk Factors and Hemostatic Aspects of Aseptic Cerebral Venous Sinus Thrombosis

Speaker: Kostiantyn Stepanchenko (Ukraine)

Epidemiologic Study of Patients with Thrombotic Events Referred to Tertiary Hospital in Southern Iran

Speaker: Mehran Karimi (Iran, Islamic Republic of)

Management Strategies and Clinical Outcomes in Patients with Inferior Vena Cava Thrombosis: Data from the GARFIELD-VTE Registry

Speaker: Omri Cohen (Italy)

The Influence of Anemia on Clinical Outcomes in Venous Thromboembolism: Results from GARFIELD-VTE

Speaker: Shinya Goto (Japan)

Pregnancy-Associated Venous Thromboembolism: Insights from GARFIELD-VTE

Speaker: Pantep Angchaisuksiri (Thailand)

Influence of Body Mass Index on Outcomes in Patients with Venous Thromboembolism: Insights from GARFIELD-VTE

Speaker: Jeffrey I. Weitz (Canada)

Risk Factors of Thrombotic Complications in Thai Thalassemia Patients

Speaker: Nonthakorn Hantrakun (Thailand)

The Association of BMI and Waist Circumference Improves the Prediction of VTE Risk as Compared to BMI Alone

Speaker: Lucia Maria Caiano (Italy)

Scientific Programme

Multidisciplinary Approach of Deep Venous Thrombosis (DVT) in Vall d'Hebron University Hospital: Two Years' Experience

Speaker: Milagros Aurora Suito Alcántara (Spain)

A Retrospective Study of Incidence of Venous Thromboembolism (VTE) and Prevalence of Risk Factors Associated with VTE in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Center Experience

Speaker: Bharath Ram S (India)

Risk Factors and Patterns of Lower Limb Deep Venous Thrombosis in Gombe, North-Eastern Nigeria

Speaker: Saleh Yuguda (Nigeria)

Clinical Spectrum and Prothrombotic Risk Factors of Cerebral Venous Sinus Thrombosis in Children

Speaker: Özcan Bör (Turkey)

Saddle Pulmonary Embolism: Demographics, Clinical Presentation, and Outcomes

Speaker: Kevin Wong (United States)

Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism

Speaker: Helle Jorgensen (Norway)

A Single-Centre Case Series of Venous Thromboembolic Disease

Speaker: José Portillo Sánchez (Spain)

Impact of Socioeconomic Status on the Risk of Receiving a Permanent Work-Related Disability Pension After Incident Venous Thromboembolism

Speaker: Helle Jorgensen (Norway)

High Levels of Uric Acid Are Associated with Increased Risk of Recurrent Venous Thromboembolism

Speaker: Lara De Lucchi (Italy)

Impact of Clostridium Difficile Infections on In-Hospital Outcomes of Venous Thromboembolism (DVT or PE) Hospitalizations

Speaker: Khushali Jhaveri (United States)

Plasma Levels of Complement Factor D and Future Risk of Incident Venous Thromboembolism

Speaker: Tobias Frischmuth (Norway)

Correlation between Intrinsic D-Dimer Levels and D-Dimer Measured at First Venous Thromboembolism (VTE)

Speaker: Fridtjof B. Rinde (Norway)

Impact of Competing Risk of Death on the Cumulative Incidence of Venous Thromboembolism in a Nationwide Danish Cohort of Men and Women

Speaker: Carl Arne Løchen Arnesen (Norway)

Recovery from Acute Kidney Injury in Patients with Pulmonary Embolism: A Monocenter Study

Speaker: Laurent Bertoletti (France)

Tissue Factor Pathway Inhibitor, Activated Protein C Resistance and Risk of Venous Thrombosis Associated with Menopausal Hormone Therapy

Speaker: Deeksha Khialani (the Netherlands)

Scientific Programme

Incidence of Chronic Thromboembolic Pulmonary Hypertension: Results from a Longitudinal Prospective Cohort (Osiris Study)

Speaker: Remedios Otero-Candelera (Spain)

The Characteristics of Patients with Isolated Superficial Vein Thrombosis of the Legs, their Follow-up and Outcomes

Speaker: Jana Hirmerova (Czech Republic)

Retinal Vein Thrombosis and the Association with Inherited Thrombophilia, Cardiovascular Risk Factors and the Risk of Occult Cancer. a Prospective Study

Speaker: Daniela Tormene (Italy)

Association of Surgical and Medical Hospitalizations with Venous Thromboembolism (VTE) in a Primary Care Population

Speaker: Ximena Jordan Bruno (United States)

Prevalence of Bilateral DVT in Ghanaian Patients

Speaker: Dela Fiawoo (Ghana)

A Decade of Experience in Peripherally Inserted Central Catheter (PICC) Related Thrombosis in Hematological Malignancies of a Single Spanish Center

Speaker: Marta Fonseca (Spain)

Seasonality in Hospitalizations for Pulmonary Embolism between 2006 - 2016

Speaker: Andrea Torres (United States)

Relevance of Immobility as Deep Vein Thrombosis Risk Factor for Medically Ill Patients

Speaker: Michelangelo Sartori (Italy)

Risk of Venous Thrombosis in the Elderly: Lifestyle and its Joint Effect with Factor V Leiden and Prothrombin 20210A

Speaker: Huijie Wang (the Netherlands)

Characterising the Burden of Hospital-acquired Venous Thromboembolism Arising during Admission and Following Discharge in an Irish Hospital Group Serving a Population of over One Million Individuals

Speaker: Karl Ewins (Ireland)

The Season Role in the Occurrence of Thromboembolic Disease

Speaker: Wafa Skouri (Tunisia)

Catheter-associated Thrombosis at the Hematology Center: Analysis of 2212 Medical Records from a Developing Country

Speaker: Liana Hambarzumyan (Armenia)

Prevalence of Pulmonary Embolism in Patients Accessing the Emergency Department, Reported by Country of Study: A Systematic Review and Meta-analysis

Speaker: Federico Germini (Canada)

The Impact of Body Mass Index (BMI) Dynamics on the Risk of Venous Thromboembolism Recurrence (VTE)

Speaker: Leslie Padrnos (United States)

The Review of the Data from the National Registry of Thrombophilic States in the Slovak Republic

Speaker: Lucia Stanciakova (Slovakia)

Scientific Programme

Apo(a) Polymorphisms rs3798220 and rs10455872 in a Brazilian Population of Deep Venous Thrombosis Patients

Speaker: Isabella Macedo Toni (Brazil)

Epidemiology and Risk Factors for Thrombosis in Pregnancy and Puerperium. Experience in One Reference Center in Mexico

Speaker: Eunice Rojas-Zaldivar (Mexico)

VTE Prophylaxis

Factors Associated with Major Bleeding Risk in Medical and Surgical Patients: Findings from a Multi-Center, Cross-Sectional Study (DissoLVE-2)

Speaker: Zhu Zhang (China)

Post-Discharge Hospital-Associated Venous Thromboembolism

Speaker: Hiu Lam Agnes Yuen (Australia)

Risk Factors and Frequency of Recurrent Long-Term Venous Thromboembolism After Superficial Vein Thrombosis of The Lower Limbs

Speaker: Konstantinos M. Nikolakopoulos (Greece)

Clinical Indications and Efficacy of Low Molecular Weight Heparin (LMWH) in Pregnancy

Speaker: Romana Akbar (Pakistan)

VTE Prophylaxis Performance in a Tertiary and Secondary Level Hospital in Ireland

Speaker: Alice Talbot (Ireland)

Prevention of Thrombogenesis in the Development of Metabolic Syndrome

Speaker: Ludmila Lyapina (Russian Federation)

Is Low Molecular Weight Heparin-Calibrated Chromogenic Anti-Xa Assay Suitable for Assessing Anticoagulant Effect of Apixaban in Adolescents?

Speaker: Ivana Čelap (Croatia)

Thromboprophylaxis to International Conferences and Number of Thromboses (PINOT) study

Speaker: Hannah Stevens (Australia)

A Prospective Observational Multicentre Study to Assess the Incidence of and Risk Factors for (T) Thrombosis (I) in Patients with (L) Lower (L) Limb (I) Injuries (R) Requiring (I) Immobilisation in Ireland (TILLIRI)

Speaker: Denis O'Keeffe (Ireland)

The Application of the Lymphoma International Prognostic Index (IPI) to Predict Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma (DLBL)

Speaker: Hikmat Abdel-Razeq (Jordan)

Can an Effective anticoagulation Clinic Reduce Bleeding Risks?

Speaker: Ahmed Al-Hassani (United Kingdom)

Weight-Adjusted versus Fixed Dose Heparin Thromboprophylaxis in Hospitalized Obese Patients: A Systematic Review and Meta-Analysis

Speaker: Davide Ceccato (Italy)

Efficacy and Safety of Pre-Operative Insertion of Inferior Vena Cava Filter in Patients Undergoing Bariatric Surgery: A Systematic Review

Speaker: Rick Ikesaka (Canada)

Scientific Programme

Incidence and Risk Factors of Venous Thromboembolism in Patients Undergoing Bariatric Surgery

Speaker: Valentina Baez (United States)

The Added Benefit of Mechanical Compression to Prevent VTE after Hip or Knee Arthroplasty: Post-Hoc Analysis of the EPCATII Study

Speaker: Christopher J.M. Green (Canada)

Weight-Adjusted Tinzaparin for Venous Thromboembolism Prophylaxis in Bariatric Surgery Patients Weighing 160kg or More

Speaker: Allen Li (Canada)

The Application of the Original and a Modified Version of the ThroLy Risk Assessment Model (RAM) to Predict Venous Thromboembolic Events (VTE) in Patients with Diffuse Large B-Cell Lymphoma (DLBL)

Speaker: Hikmat Abdel-Razeq (Jordan)

Antithrombotic Offices of the Arkhangelsk Region Russia

Speaker: Nadezda Vorobyeva (Russian Federation)

Lysophosphatidic Acid Promotes Thrombus Stability by Inducing Rapid Formation of Neutrophil Extracellular Traps via a Peptidylarginine Deiminase 4-Dependent Pathway: A New Mechanism of Thrombosis

Speaker: Rui Peng (China)

Prevalence and Predictors of Thromboembolic Events in Patients with Gastric Cancer

Speaker: Razan Mansour (Jordan)

Real Life Experience of an Antithrombotic Stewardship Program for Thrombosis Prophylaxis during Hospitalisation in a Large Teaching Hospital

Speaker: Mehmet Taskopru (the Netherlands)

Venous Thromboembolism in Patients with Renal Transplantation

Speaker: Daniela Poli (Italy)

Is the Caprini Score a Reliable Tool to Predict the Risk of Venous Thrombosis in Orthopedic Patients?

Speaker: Roberto Zambelli (Brazil)

Visualization of Thrombin Formation on Activated Platelets and Fibrin Formation in Venous Flow Condition

Speaker: Naoko Sugita (Japan)

Prevalence and Predictors of Venous Thromboembolic Events (VTE) in Patients Undergoing Salvage Chemotherapy and Autologous Stem Cell Transplantation for Relapsed Lymphomas

Speaker: Mohammad Ma'koseh (Jordan)

Dilemma in Initiating Thromboprophylaxis in Critically Ill Patients

Speaker: Pearla Lasut (Indonesia)

Predictors of Venous Thromboembolic Events (VTE) in Patients with Testicular Cancer

Speaker: Rashid Abdel-razeq (Jordan)

Efficacy and Safety of Apixaban for the Primary Prevention of VTE among Patients with Gastrointestinal Cancers: A Post-hoc Analysis of the AVERT Trial

Speaker: Danyal Ladha (Canada)

Scientific Programme

An Audit Examining Information Provided to Patients Regarding Venous Thromboembolism (VTE) at Discharge

Speaker: Kishan Karia (United Kingdom)

Preventing Maternal Death and Morbidity from Venous Thromboembolism (VTE): Results from a VTE Risk Score Trial during Hospitalization

Speaker: Venina Barros (Brazil)

The Incidence of Venous Thromboembolism along with Adherence to Guideline in Major Orthopedic Surgery

Speaker: Hun-Gyu Hwang (Korea, Republic of)

Effectiveness of Implementing a Prophylaxis Protocol for Thromboembolic Events in Patients Admitted to a Tertiary Hospital

Speaker: Monica Amorim de Oliveira (Brazil)

Prevention of Catheter Complications in Patients with Cystic Fibrosis: Enoxaparin vs. a Direct Oral Anticoagulant

Speaker: Paul Dobesh (United States)

Effectiveness of Thromboprophylaxis in the Prevention of Peripherally Inserted Central Catheter (PICC) Associated Venous Thromboembolism in Pediatric Patients: A Case-control Study

Speaker: Matthew Speckert (Canada)

Point-of-Care Monitoring of Unfractionated Heparin Treatment in the Intensive Care Unit: Preliminary Results of a Comparative Study with Laboratory-based APTT and Anti-Xa Activity

Speaker: Benjamin Lardinois (Belgium)

Thromboprophylaxis Audit in a Public Hospital - The Impact of Protocol Implementation

Speaker: Pedro Henrique Fernandes do Carmo Las Casas (Brazil)

VTE Treatment

Two Weeks of Low Molecular Weight Heparin for Isolated Symptomatic Distal Vein Thrombosis (TWISTER Study): Final Analysis of 242 Patients

Speaker: Eileen Merriman (New Zealand)

Fixed Dose Rivaroxaban Can Be Prescribed in Extremes of Bodyweight, Results of a Population Pharmacokinetic Analysis

Speaker: Victoria Speed (United Kingdom)

Management and Outcomes of Idiopathic Axillosubclavian Vein Thrombosis: Impact of the Treating Specialty

Speaker: Hiu Lam Agnes Yuen (Australia)

Rivaroxaban for Extended Thromboprophylaxis in Acutely Ill Medical Patients 75 Years of Age or Older

Speaker: Walter Ageno (Italy)

Variability of Management of Peripheral Catheter-Related Upper Extremity Superficial Vein Thrombosis

Speaker: Hiu Lam Agnes Yuen (Australia)

Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the Mariner Trial

Speaker: Alex Spyropoulos (United States)

Scientific Programme

Reasons and Associated Outcomes in Delayed Anticoagulation in Venous Thromboembolism

Speaker: Nichole E Brunton (United States)

Effect of Antiplatelet Therapy on Clinical Outcome of Patients Treated with Anticoagulation for Acute Venous Thromboembolism

Speaker: Ana I Casanegra (United States)

Preliminary Investigation of Venous Thromboembolism Risk Assessment and Prophylaxis for Medical In-patients: A Multicenter Study in Nigeria

Speaker: Angela Ogechukwu Ugwu (Nigeria)

Direct Oral anti-Xa Inhibitors for Treatment of Venous Thromboembolism after Gastrectomy: Report on 3 Cases

Speaker: Lisbeth Eischer (Austria)

Apixaban versus Heparin/Warfarin Treatment in Pulmonary Embolism: Results from the UK Apixaban Length-of-Stay Pulmonary Embolism - Hospital Admissions Study (ALPHA-PE)

Speaker: Steven Lister (United Kingdom)

Demographics and Clinical Outcomes of Patients Younger than 40 Years Treated for Acute Venous Thromboembolism

Speaker: Danielle T Vlazny (United States)

Pre-Treatment with Heparinoids Does Not Impact Clinical Outcome of Apixaban and Rivaroxaban in Patients Treated for Venous Thromboembolism

Speaker: Danielle T Vlazny (United States)

Demographics and Clinical Outcomes of Older Adults Treated for Acute Venous Thromboembolism

Speaker: Rahul Chaudhary (United States)

Management of Intermediate-High Risk Pulmonary Embolism Utilizing a PE Response Team

Speaker: Yuri Matusov (United States)

Inferior Vena Cava Filter (IVCF) Utilization: Quality Assurance at a Quaternary Care Medical Center

Speaker: June Choe (United States)

Management and Outcomes Following Subsegmental Pulmonary Embolism: Single Centre Experience at King's College Hospital

Speaker: Rita Pardal (United Kingdom)

Edoxaban for the Long-Term Therapy of Venous Thromboembolism in Real-Life RIETE Registry

Speaker: Giuseppe Camporese (Italy)

Management of Acute Venous Thromboembolism in Patients Taking Antiplatelet Therapy: A Bi-Center Analysis

Speaker: Marie Giraud (France)

Edoxaban Treatment of Venous Thromboembolism in Routine Clinical Practice in the Non-Interventional Global ETNA-VTE Program: A Sub-Analysis by Age Groups

Speaker: Giancarlo Agnelli (Italy)

The Use of Fondaparinux for Recurrent Thrombotic Events

Speaker: Zara Sayar (United Kingdom)

Scientific Programme

Role of Residual Pulmonary Vascular Obstruction on the Risk of Long-Term Recurrence of Venous Thromboembolism After Pulmonary Embolism: A Cohort Study

Speaker: Marco Paolo Donadini (Italy)

Effectiveness and Safety of Apixaban for Treatment of Venous Thromboembolism in a Large Daily Practice Cohort

Speaker: Stephan V. Hendriks (the Netherlands)

Home Treatment Compared to Initial Hospitalization in Patients with Acute Pulmonary Embolism in the Netherlands: A Cost Analysis

Speaker: Stephan V. Hendriks (the Netherlands)

Direct Oral Anticoagulants and Vitamin K Antagonists for Treatment of Cerebral Vein Thrombosis

Speaker: Marco Capecci (Italy)

Risk of Bleeding of Concomitant Antiplatelet and Anticoagulation Therapy in Patient Treated for a Venous Thromboembolic Event

Speaker: Antoine Fayol (France)

Long-Term Management of Anticoagulants in Patients with Cancer-Associated Thrombosis (CAT) Beyond 6 Months: A 432-Patient Retrospective Non-Interventional Study

Speaker: Ludovic Plaisance (France)

Sodium Valproate-induced Drug Interactions with DOAC Anticoagulant Activity: A Case Report

Speaker: Ivanka Paskaleva (Bulgaria)

Hypermenorrhea and Menometrorrhagia during Rivaroxaban Therapy

Speaker: Olga Dzhennina (Russian Federation)

Rivaroxaban versus Warfarin for Treatment and Prevention of Recurrent Venous Thromboembolism in Obese Patients

Speaker: Olivia S. Costa (United States)

Venous Thromboembolism Profile and Management Differences between Sexes in a RIETE's Hospital in Brazil

Speaker: Ana Rocha (Brazil)

The Impact of an Educational Intervention in Patients with Atrial Fibrillation Treated with Warfarin

Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

90-Day Follow up in Patients with Suspected Deep Vein Thromboses (DVT) who Have Had a DVT Excluded: Should this Be Routine Clinical Practice?

Speaker: Andy Hughes (United Kingdom)

Hokusai Post-PE Study: A Follow-up Study on Long-Term Outcomes of Pulmonary Embolism in Patients Treated with Edoxaban vs Warfarin

Speaker: Roisin Bavalia (the Netherlands)

Development of Cyclic Peptide Inhibitors of Coagulation Factor XIa for Safer Anticoagulation

Speaker: Vanessa Carle (Switzerland)

Risk Factors of Hemorrhagic Complications on the Anticoagulant Therapy

Speaker: Nadezda Vorobyeva (Russian Federation)

Scientific Programme

EmpoderACO: Elaboration and Validation of a Protocol for Behavioral Change in Patients on Warfarin

Speaker: Maria Auxiliadora Parreiras Martins (Brazil)

Evaluation of Thrombin and Fibrin Generation in Venous Thromboembolism (VTE) Patients Receiving Anticoagulation

Speaker: Julie Wang (Australia)

Variability in Exposure to Non-Vitamin K Antagonist Oral Anticoagulants (NOACs) in Hospitalised Patients

Speaker: Emmanouela Kampouraki (United Kingdom)

Heparin Induced Thrombocytopenia in an Obese Pregnant Woman with Venous Thrombosis

Speaker: Matija Kozak (Slovenia)

ETNA-VTE Europe: The Effect of Body Mass Index on 12-Month Outcomes in VTE Patients with Edoxaban

Speaker: Marc Schindewolf (Switzerland)

Predicting Recurrence and Bleeding in Patients with Venous Thromboembolism: A Systematic Review and Critical Appraisal of Prediction Models

Speaker: Maria Adriana de Winter (the Netherlands)

ETNA VTE Europe: A Contemporary Snapshot of VTE Patients Treated with Edoxaban in Clinical Practice across Eight European Countries

Speaker: Alexander Cohen (United Kingdom)

Upper Extremities Deep Vein Thrombosis and DOAC Treatment: a Prospective Cohort Study

Speaker: Maria Cristina Vedovati (Italy)

Saddle Pulmonary Embolism in the Era of Incidental Events: Incidence, Clinical Findings and Outcomes in a Single Center Cohort

Speaker: Mario Aramberri (Spain)

Early Physiotherapy Intervention Reduces the Long Term Effects of Venous Thromboembolism and Promotes an Improved Quality of Life: Results from a Pilot Study

Speaker: Regitse Lewis (United Kingdom)

Retrospective Study of Patients with Upper Extremity Clots Presenting to Emergency Departments in Tertiary Care Hospitals in a Major Canadian City in the Last Five Years

Speaker: Tania Pannu (Canada)

How Often Measurements of Direct Oral Anticoagulant Levels Have Consequences in Anticoagulation Management

Speaker: Roisin Bavalia (the Netherlands)

Survey on the Prescription and Biological Monitoring of Direct Oral Anticoagulants in Algeria

Speaker: Sarra Bounaas (Algeria)

Outcomes of the First Australian Pulmonary Embolism Response Team (PERT) Model of Care for Intermediate to High Risk Pulmonary Embolism

Speaker: Jennifer Curnow (Australia)

Anticoagulant Therapy for Splanchnic Vein Thrombosis in Patients with Liver Cirrhosis: A Systematic Review and Meta-Analysis

Speaker: Emanuele Valeriani (Italy)

Scientific Programme

Analysis of Outcomes Following Inferior Vena Cava (IVC) Filter Placement in a Single Center Population

Speaker: Claudio Enciso (Argentina)

Single Centre Experience of DOAC Use in Patients with Antiphospholipid Syndrome (APS) with Venous Thromboembolism

Speaker: Karen A Breen (United Kingdom)

Anticoagulation in Cirrhosis: Thrombin Generation Assay vs Anti FXa Activity

Speaker: Silvina Pons (Argentina)

Investigation of the Optimal Dose of aPCC in Reversing the Effect of Factor Xa Inhibitors Rivaroxaban and Apixaban- an in vitro Study

Speaker: Nina Haagenrud Schultz (Norway)

Time in Therapeutic Range in Venous Thromboembolic Diseases in a North African Geriatric Population

Speaker: Maroua Mrouki (Tunisia)

Clinical Characteristics and Outcomes of Non-cancer, Non-CVC Associated upper Extremity DVT

Speaker: Omri Cohen (Italy)

Venous Recanalization after a Thromboembolic Event in a North African Population

Speaker: Maroua Mrouki (Tunisia)

Antithrombin III Levels Immediately Following Acute Venous Thromboembolism

Speaker: Christopher Kabrhel (United States)

Concentration Levels of Direct Oral Anticoagulants and Clinical Relevance in a Tertiary Hospital

Speaker: Filipa Martins Pereira (Portugal)

Antithrombotic Stewardship: A Novel Approach to Appropriate Anticoagulant Prescription

Speaker: Maral Koolian (Canada)

Management Strategy of Venous Thrombosis in a Dialysis Patient with History of Heparin Induced Thrombocytopenia

Speaker: Putu Amrita (Indonesia)

A Case Report of Deep Vein Thrombosis after Kidney Transplantation

Speaker: Ira Puspitawati (Indonesia)

Extended Treatment in Unprovoked Venous Thromboembolism: What Is Important to Patients?

Speaker: Anouk van de Brug (the Netherlands)

The Increasing Bleeding Risk from Drug-drug Interactions in Patients with Direct Oral Anticoagulants

Speaker: Ji Yun Lee (Korea, Republic of)

Improvements in Short- and Long-term Outcomes in Patients with Pulmonary Embolism after Outpatient Pulmonary Rehabilitation

Speaker: Stephan Nopp (Austria)

Efficacy of Reversible Factor Xa Inhibitors is Related to the Level of Factor VIII: Best Practice is Adjustment of the Dose for Factor VIII Level?

Speaker: Cornelis Kluft (the Netherlands)

Scientific Programme

Drug-Drug Interactions between Direct Oral Anticoagulants and Hepatitis C Direct-Acting Antiviral Agents: A Systematic Review

Speaker: Marta Bellesini (Italy)

Anticoagulation Control with the Point-of-Care INR: A Retrospective Pre-/Post-analysis

Speaker: Nicoletta Riva (Malta)

Association Between Index VTE Event and 12-Months Outcomes for Patients in Routine Clinical Practice Enrolled in the ETNA-VTE-Europe Registry

Speaker: Michiel Coppens (the Netherlands)

Oral Anticoagulation Therapy for Venous Thromboembolism in Norway: Patient Characteristics, Treatment Trends and Patterns

Speaker: Waleed Ghanima (Norway)

Major Bleeding Complications from Direct Oral Anticoagulants in Thai Adult Patients

Speaker: Pitiphong Kijrattanakul (Thailand)

Long-term Anticoagulant Treatment of Splanchnic Venous Thrombosis in High Risk Patients: Direct Oral Anticoagulants vs Vitamin K Antagonists

Speaker: Alessandra Serrao (Italy)

Direct Oral Anticoagulants in Comparison with Vitamin K Antagonists and Antiplatelet Agents on Timing and Outcomes in Hip Fracture Surgery Patients Older than 75: The ORTHO-GER-DOAC Study

Speaker: Benilde Cosmi (Italy)

The Effect of rs4148738 Polymorphism of ABCB1 on the Plasma Concentrations of Direct Oral Anticoagulants and Bleeding and Thromboembolic Complications

Speaker: Benilde Cosmi (Italy)

Direct Oral Anticoagulants in Patients with Severe Familial Thrombophilia

Speaker: Daniela Tormene (Italy)

Cerebral Vein Thrombosis Treatment with Direct Oral Anticoagulants: A Case Series

Speaker: Sofia Barbar (Italy)

An Evaluation of the Basis for Anti-Xa Testing in Patients on Low Molecular Weight Heparin and its Impact on Subsequent Management

Speaker: Shu Hui Yeang (Singapore)

May Thurner Syndrome, Experience on Argentinean Hospital

Speaker: Daniela Mezzarobba (Argentina)

Systematic Review of the Risk of Bleeding in Patients with Chronic Kidney Disease Treated with Tinzaparin

Speaker: Esteve Colomé (Spain)

The Psychosocial Impact of Venous Thromboembolism: An Exploratory Systematic Review and Narrative Synthesis

Speaker: Gabrielle Saul (United Kingdom)

Correlation of Reperfusion Therapy and In-hospital Mortality in Patients with Intermediate Risk Acute Pulmonary Embolism and Right Ventricular Dysfunction

Speaker: Jose Bonorino (Argentina)

Scientific Programme

Risk of Intracranial Bleeding in Patients with Primary Brain Cancer Receiving Therapeutic Anticoagulation for Venous Thromboembolism: A Meta-analysis

Speaker: Marzia Giordano (Italy)

Correlation between Anti-Xa Activity and Plasmatic Levels of Apixaban

Speaker: Diego Velasco (Spain)

The Effect of Postoperative Analgesia on the Hemostatic System in Gerontological Patients with Multiple Trauma

Speaker: Yuliya Volkova (Ukraine)

VTE Treatment in Routine Clinical Practice: A Pre-specified Combined Evaluation of XALIA and XALIA-LEA with Additional Analyses of Special Patient Populations

Speaker: Sylvia Haas (Germany)

ETNA-VTE Global: Evaluation of Bleeding Risk Based on VTE-BLEED Score on 12-month Outcomes in a Population Treated with Edoxaban

Speaker: Alexander Cohen (United Kingdom)

DOACs in Real Clinical Practice

Speaker: Maria Hulikova (Slovakia)

Predicting Factors for Pulmonary Embolism Response Team (PERT) Activation in a General Pulmonary Embolism Population

Speaker: Christian Schmidt Mortensen (Denmark)

A Single Centre Experience on the Use of Direct Oral Anticoagulants in People with Human Immunodeficiency Virus (HIV)

Speaker: Sheena Patel (United Kingdom)

The Use of Thrombolytic Therapy in a Multidisciplinary Pulmonary Embolism Response Team

Speaker: Anders Kramer (United States)

Impact Analysis of Prognostic Stratification for Pulmonary Embolism (iAPP): A Randomized Controlled Trial

Speaker: Alessandra Grittini (Italy)

Direct Oral Anticoagulants vs. Warfarin for the Treatment of Venous Thromboembolism in Patients with Thrombophilia. A Single Center Experience

Speaker: Maha Elsebaie (United States)

Appropriateness of Direct Oral Anticoagulant Prescriptions in Emergency Department Outpatients with Acute Deep Vein Thrombosis

Speaker: Justin Tabah (Canada)

E-selectin Inhibitor Is Superior to LMWH for Treatment of Experimental Venous Thrombosis

Speaker: Daniel Myers, Jr (United States)

Heparinox, a Generic Version of Low Molecular Weight Heparin Enoxaparin, Is Bioequivalent to the Branded Version

Speaker: Dalia Qneibi (United States)

Implementation of a Text-message Intervention to Warfarin Users in a Brazilian Primary Care Setting

Speaker: Maira Viana Rego Souza e Silva (Brazil)

Scientific Programme

Optimal Duration and Dose Intensity of the Anticoagulation Therapy with Doacs in Venous Thromboembolism: Retrospective, Cohort Study “Real Choice”

Speaker: Angelo Ghirarduzzi (Italy)

National Survey about Management of Venous Thromboembolism (VTE) Associated with Pregnancy / Puerperium or Oral Contraceptives in Uruguay

Speaker: Valentina Mérola (Uruguay)

Biological and Pharmacological Profiling of Pentosan Polysulfate (PPS) in Comparison to Heparin and its Relative Neutralization by Protamine Sulfate

Speaker: Vishnu Venkitasubramony (United States)

Direct Oral Anticoagulants and Antiepileptic Drugs: Is There Room for Concurrent Treatment?

Speaker: Sofia Barbar (Italy)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Women's Health Abstracts

The full abstract text will be available on June 29, 2020 at 09:00 AM U.S. Eastern Time. The ePoster will be available on the ISTH 2020 Virtual Congress Platform starting July 12, 2020.

Estrogens and Progestinics

Oral Contraceptives and Venous Thromboembolism: Focus on Testing that May Enable Prediction and Assessment of the Risk

Speaker: Jonathan Douxflis (Belgium)

Hematologic Alterations in Patients Undergoing Controlled Ovarian Stimulation for in vitro Fertilization: A Prospective Observational Study

Speaker: Maria T. DeSancho (United States)

Development and External Validation of a Risk Assessment Model for First Venous Thromboembolism in Women Starting Combined Oral Contraceptives

Speaker: Deeksha Khialani (the Netherlands)

Trends in Combined Oral Contraceptive Use in the Netherlands: 2002-2016

Speaker: Deeksha Khialani (the Netherlands)

Knowledge vs Actual Thrombotic Risks Associated with Hormonal Contraception in Young Women

Speaker: Yan Deng (Canada)

Low Dose Warfarin (LDW) for the Prevention of Hypercoagulation of Blood and Venous Thromboembolism (VTE) in Women Receiving Hormone Replacement Therapy (HRT)

Speaker: Vladimir Sukhanov (Russian Federation)

Use of Oral Contraceptives (OCs) and Thrombin Generation: Cross-sectional Analysis of the Longitudinal Study of Adult Health (ELSA-Brazil)

Speaker: Thaís Batista (Brazil)

Levonorgestrel Releasing Intrauterine System (LNG-IUS) in a Patient with Deep Endometriosis, Adenomyosis and Behcet's Disease: Case Report

Speaker: Rayana Valéria Cruz (Brazil)

Scientific Programme

Lack of Association between the Use of Female Hormones and Platelet Volume Indexes: Evidence from the Longitudinal Study of Adult Health (ELSA-Brasil)

Speaker: Thaís Resende (Brazil)

Pregnancy and Pregnancy Complications

Management of a Pregnancy in a Woman with Hypodysfibrinogenemia: An Experiment in Strasbourg

Speaker: Dominique Desprez (France)

Study of the State of the Hemostatic System in Women with Various Pregnancy Complications

Speaker: Irina Gribkova (Russian Federation)

Analysis of Population Values in Pregnant Women

Speaker: María Luisa Iglesias Varela (Argentina)

Comparative Study of the Clinical Application of Two Bleeding Grading Systems for Pregnant Women with Immune Thrombocytopenia (ITP)

Speaker: Mei Juan Huang (China)

Maternal Thrombocytopenia in Women Initiating Antenatal Care: A Hospital-Based Study

Speaker: Hannah Omuakwe (Nigeria)

Pregnancy Complications among Filipino Women

Speaker: Cherry Ann Durante (Philippines)

Haematologic and Haemorheologic Parameters of Pre-Eclamptic Patients in a Nigerian Tertiary Hospital

Speaker: Patience Akpan (Nigeria)

Systematic Review of Viscoelastic Testing (TEG/ROTEM) in Obstetrics and Recommendations for Future Studies

Speaker: Ariunzaya Amgalan (United States)

Reassessment of Venous Thromboembolism Risk and Prophylaxis in Post-Delivery Period of Healthy Women

Speaker: Andrei Braester (Israel)

Safety of Withholding Antithrombotic Treatment in Pregnancies after Antiphospholipid Antibodies Disappearance in Women with Obstetric Antiphospholipid Syndrome, a Cohort Study

Speaker: Maria Manuela Clavijo (Argentina)

Microvesicles, Fibrinolytic and Coagulation Biomarkers in Blood from Pregnant Women

Speaker: Sylvie Bouvier (France)

D-Dimer Variability in the Postpartum Period

Speaker: Tanja Malinova (Macedonia, the Former Yugoslav Republic of)

Anticoagulation for Women with Mechanical Heart Valves during Pregnancy: A Survey

Speaker: Isabelle Malhame (Canada)

Multidisciplinary Care of Pregnancies with VWD Improves Rates of Primary Postpartum Hemorrhage

Speaker: Sajida Kazi (Canada)

Scientific Programme

Systemic Evaluation of Neuroserpin, Interleukin-17 and Hemostatic Factors in Association with Clinical Parameters in Preeclamptic Women: A Principal Component Analysis Approach

Speaker: Luiza Oliveira Perucci (Brazil)

Efficacy and Safety of Low-Molecular-Weight Heparin for the Prevention of Pregnancy-Related Recurrent Venous Thromboembolism and Obstetrical Complications

Speaker: Maria Abbattista (Italy)

Investigation of Risk Factors of Deep Vein Thrombosis during Pregnancy Using a CFD Model

Speaker: Qudus Jimoh-Taiwo (South Africa)

Low Molecular Weight Heparins in the Prevention of Placenta-Mediated Complications in Carriers of the Prothrombin G20210A Mutation

Speaker: Mariya Nikolaeva (Russian Federation)

Approach to Venous Thromboembolism Risk in Women with Physical Disability in Pregnancy - Multidisciplinary Survey

Speaker: Sajida Kazi (Canada)

Thromboprophylaxis during Pregnancy - 10-year Review of Women Seen in the Haematology Clinic at King's College Hospital (KCH)

Speaker: Jignesh Patel (United Kingdom)

The Role of Antithrombotic Therapy in the Prevention of Adverse Pregnancy Outcomes

Speaker: Alexander Makatsariya (Russian Federation)

Efficiency of Inhibition of Thrombin Generation and Stimulation of Fibrinolysis in vitro Fertilization Programs

Speaker: Mariya Nikolaeva (Russian Federation)

Peculiarities of the Hemostasis System in Pregnant Women with Severe Preeclampsia

Speaker: Bakhodir Kurbanov (Uzbekistan)

Histone H4 Plasma Levels in Women with Pregnancy Complications

Speaker: Luca Spiezia (Italy)

Lack of Disease Modification of HbF on Pregnant Women with Sickle Cell Disease

Speaker: Charles Kenworthy (United States)

Pregnancy Complications and Outcomes in Women with Moderate and Severe von Willebrand Disease (VWD)

Speaker: Ozlem Turan (United Kingdom)

Alternative Complement Pathway Activation in the Severe Hypertensive Disorders of Pregnancy

Speaker: Reiko Neki (Japan)

Mean Platelet Volume from Adolescent to Adult and during Pregnancy

Speaker: Yue Xu (China)

Deviations in Red Blood Cell Gas Transport Function in Pregnant State

Speaker: Ekaterina Iastrebova (Russian Federation)

Antithrombotic Therapy for Pregnant Woman with Bland-White-Garland Syndrome and Prosthetic Mitral Valves

Speaker: Madina Arslanbekova (Russian Federation)

Scientific Programme

Early Plasma Transfusion and Maternal Outcomes in Women with Persistent Postpartum Haemorrhage: Does the Amount of Resuscitation Fluids Matter?

Speaker: C Caram-Deelder (the Netherlands)

Rotational Thromboelastometry (ROTEM) in Obstetric Population

Speaker: Beatriz Grand (Argentina)

Pregnancy Outcomes in Women with Budd Chiari Syndrome or Portal Hypertension

Speaker: Eva Nicole Hamulyák (the Netherlands)

Risk Factors for Severe Preeclampsia in Obstetric Antiphospholipid Syndrome (OAPS) with Conventional Treatment

Speaker: Gabriela de Larrañaga (Argentina)

F1+2 in Preeclampsia: Is it a Good Hemostatic Marker?

Speaker: Luci Dusse (Brazil)

Maternal Carriage of the Annexin A5 M2 Haplotype Combined with Inherited or Acquired Thrombophilia Would Synergistically Increase the Risk of Suffering Intra Uterine Growth Restriction

Speaker: Federico Aranda (Argentina)

The Impact of Hydroxychloroquine on the Prevention of Severe Preeclampsia in Patients with Obstetric Anti-Phospholipid Syndrome

Speaker: Federico Aranda (Argentina)

Antithrombotic Therapy (Nadroparin Calcium) in the Prevention of Pregnancy Loss in aPL-Positive Women

Speaker: Victoria Bitsadze (Russian Federation)

Impaired Platelet Contractility in Women with a History of Miscarriage

Speaker: Svetlana I. Safiullina (Russian Federation)

Assessment of Endocan as a Marker for Preeclampsia and Its Clinical Forms

Speaker: Luci Dusse (Brazil)

Personalized Control of Anticoagulant and Antiplatelet Therapy for Pregnant Women with a Complicated Obstetric Anamnesis Is Pathogenetically Justified for the Purpose of Prevention of Placenta-associated Complications

Speaker: Svetlana I. Safiullina (Russian Federation)

Disorders in the Fibrinolytic System as a Possible Factor in the Failure of Assisted Reproductive Technologies

Speaker: Svetlana I. Safiullina (Russian Federation)

Reduction of Thromboembolic Disorders in Pregnancy and Postpartum Period: Role of National Pregnancy Heart Team

Speaker: Iuliia Davydova (Ukraine)

Prevalence and Management of Post Partum Hemorrhage in Latin America: An Overview of Systematic Reviews

Speaker: Patricia Casais (Argentina)

Long-term Incidence of Venous Thromboembolic Recurrence After a First Venous Thrombotic Episode During Pregnancy

Speaker: Manal Ibrahim-Kosta (France)

Scientific Programme

Outcomes in Women with Mechanical Heart Valves Anticoagulated with Low Molecular Weight Heparin During Pregnancy

Speaker: Nadine Shehata (Canada)

Hemostasis Disorders in Tunisian Women with Severe Post Partum Haemorrhage : A Case Control Pilot Study

Speaker: Ons Kaabia (Tunisia)

First Direct Evidence in Humans of a Severe Antithrombin Defect Causing Embryonic Lethality

Speaker: Carlos Bravo-Perez (Spain)

Pregnancy Associated Bleeding in Women with Inherited Bleeding Disorders

Speaker: Ons Kaabia (Tunisia)

Women's Experience of Bleeding and Adverse Events Associated with Postpartum Pharmacological Thromboprophylaxis: A Prospective Cohort Study

Speaker: Margaret Donnelly (Ireland)

Fertility Issues in Women with Inherited Bleeding Disorders

Speaker: Ons Kaabia (Tunisia)

The Attitudes of Haemophilia Carriers towards Prenatal Diagnosis and Mode of Delivery

Speaker: Ozlem Turan (United Kingdom)

ABO Blood Groups and Inherited Thrombophilia in Women with Abortion

Speaker: Luca Spiezia (Italy)

Hold Your Breath for 498 (Alternative) Diagnoses in Pregnant Women Suspected of Pulmonary Embolism

Speaker: Ingrid Bistervels (the Netherlands)

Assessment of Post-partum Haemorrhage Risk among Women with Thrombocytopenia: A Cohort Study

Speaker: Sara Arcudi (Italy)

Impact of 399C/T Polymorphism of Tissue Factor Pathway Inhibitor on Risk of Recurrent Pregnancy Loss in India

Speaker: Kamal Kishor (India)

Rituximab before Pregnancy in Refractory Obstetrical Antiphospholipid Syndrome

Speaker: Alessandro Ciavarella (Italy)

Utility of Fibrinogen Levels and Rotational Thrombo Elastometry (ROTEM) in Predicting Post Partum Hemorrhage

Speaker: Jyoti Kotwal (India)

Successful Pregnancy Outcomes in Patients with Protein S Deficiency Treated with Daily Fondaparinux Regimen

Speaker: Aghnia Permatasari (Indonesia)

Five Years of Evaluation of Postpartum Haemorrhage in a Tertiary Portuguese Hospital

Speaker: Sara Ferreira (Portugal)

Family History of Preeclampsia and Hypertension: A Predictor of Preeclampsia in a Resource Limited Country

Speaker: Feriha Fatima Khidri (Pakistan)

Scientific Programme

Reference Ranges for Hemostasis Parameters during Pregnancy and Puerperium

Speaker: Pierre Toulon (France)

Management of Thrombocytopenia in Obstetric Patients: A Retrospective Teaching Hospital Experience

Speaker: Marta Moreno Carbonell (Spain)

Hemophagocytic Lymphohistiocytosis in Pregnancy Evolving towards Fulminant Hepatitis: A Case Report and Complete Literature Review

Speaker: Camille Simard (Canada)

Management of Pregnancy in Severe Factor V Deficiency in Women with Varying Phenotypes

Speaker: Bella Madan (United Kingdom)

Optimizing Tranexamic Acid Dosing for Hemorrhage Prevention in Pregnant Women

Speaker: Homa Ahmadzia (United States)

Role of Thrombin Generation Potential (TGP) in Cesarean Sections and Vaginal Deliveries Puerperium to Guide Thromboprophylaxis. Preliminary Results

Speaker: Paola Turcatti (Uruguay)

On-Demand Poster Session
14:00 - 15:00

Virtual Meeting Room 6

Late-Breaking and COVID-19 Abstracts

COVID-19

Dipyridamole Added to Anticoagulant Prophylaxis: Decline in Poor Outcome of Clinically Severe Ill COVID-2019 Patients

Speaker: Sevgi Kalayoglu Besisik (Turkey)

Clinical and Computed Tomography Characteristics of COVID-19 Associated Acute Pulmonary Embolism: A Different Phenotype of Thrombotic Disease?

Speaker: Lisette F. van Dam (the Netherlands)

The prothrombotic imbalance between VWF and ADAMTS13 in COVID-19

Speaker: Ilaria Mancini (Italy)

Identification of a COVID-19 Subpopulation Responsive to Hydroxychloroquine Using Machine Learning: The IDENTIFY Trial

Speaker: Anna Lynn-Palevsky (United States)

A Low Dose Heparin Protocol Is Associated with Improved Duration of Arterial Line Patency in Critically Ill COVID-19 Patients

Speaker: Lydia Maurer (United States)

Disentangling the Mechanisms behind the Thrombotic Complications of COVID-19 Patients: Insights into Platelet and Endothelial Activation

Speaker: Marina Camera (Italy)

Venous Thrombotic Complications in Cancer Patients with SARS-CoV-2 Infection: Report from the COVID-19 and Cancer Consortium (CCC19) Registry Analysis

Speaker: Rachel Rosovsky (United States)

Scientific Programme

Neutrophil Extracellular Traps Infiltrate Lung Vascular, Interstitial and Airway Compartments in Severe Covid-19

Speaker: Cécile Oury (Belgium)

Prevalence of Pulmonary Embolism in Patients at the Time of Hospital Admission for COVID-19

Speaker: Mitja Jevnikar (France)

Biomarkers of COVID-19 Coagulopathy and D-dimer in a Biracial Cohort Study

Speaker: Debora Kamin Mukaz (United States)

Platelet Activation is Associated with Thrombosis or Death in Patients with COVID-19

Speaker: Tessa Barrett (United States)

Macrovascular Thrombotic Events in a Mayo Clinic Enterprise-wide Sample of Hospitalized COVID-19 Positive Compared to Negative Patients

Speaker: Damon Houghton (United States)

The Acquired Coagulopathy of COVID-19

Speaker: Flora Peyvandi (Italy)

Increased Doses of Low-molecular-weight Heparin in Hospitalized Patients with Covid-19

Speaker: Ida Martinelli (Italy)

The Effect of Anticoagulation on Mortality in COVID-19 Patients: The Drug, the Dose, and the D-Dimer

Speaker: Henny Billett (United States)

Thrombin Generation in Severe COVID-19 Patients Hospitalized in the ICU

Speaker: Maxime G. Zermatten (Switzerland)

Reduction of Venous Thromboembolic Events in Hospitalized Patients with Coronavirus Disease 2019 after Intensification of Thromboprophylaxis

Speaker: Paraskevas Filippidis (Switzerland)

Elevated D-dimers Useful Prediction of Pulmonary Artery Thrombosis in COVID-19 Patients at Initial Presentation to Hospital

Speaker: Adrian Perera (United Kingdom)

Monitoring Unfractionated Heparin Using PTT Versus Anti-Xa in Veno-venous Extracorporeal Membrane Oxygenation Patients with COVID-19 Infection

Speaker: Brandi Thoma (United States)

COVID-19 Pandemic: Dissecting Coagulation apart from Inflammation

Speaker: Jesus Gonzalez-Lugo (United States)

Late-breaking

Elevated BAFF Promote B Cell Survival and Autoantibody Production through Upregulating let-7b in Immune Thrombocytopenia

Speaker: Yang He (China)

Low 1-Year Venous Thromboembolic Recurrence Rates in Patients with and without Thrombotic Risk Factors in Routine Clinical Practice Treated with Edoxaban: The Global ETNA-VTE Study

Speaker: Alexander Cohen (United Kingdom)

Scientific Programme

Differences in Outcomes between Real-World vs Clinical Trial in Atrial Fibrillation and Chronic Kidney Disease

Speaker: Wern Yew Ding (United Kingdom)

The eTHINK Study: Cognitive and Behavioral Outcomes in Children with Hemophilia

Speaker: Christine Mrakotsky (United States)

Phase 2 Study of Efgartigimod, a Novel FcRn Antagonist, in Adult Patients with Primary Immune Thrombocytopenia

Speaker: Adrian C Newland (United Kingdom)

Oral Anticoagulation in Elderly Patients with Atrial Fibrillation: The Murcia AF Project Phase II

Speaker: José Miguel Rivera Caravaca (Spain)

Scientific Programme

Monday, 13. July 2020

Plenary Session
07:40 - 08:30

Virtual Meeting Room 1

PL 03, Plenary Session

Chair: Giancarlo Agnelli (Italy)
Chair: Walter Ageno (Italy)

ISTH 2020 Virtual Congress Welcome	07:40
Speaker: Claire McLintock (New Zealand)	
Unmet Clinical Needs and Future Advances in VTE	08:10
Speaker: Alexander Cohen (United Kingdom)	

Virtual Exhibition
08:00 - 14:00

Virtual Meeting Room 8

Virtual Exhibition

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 1

SOA 07, State-of-the-Art on Diagnostics and OMICs

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Stefano Duga (Italy)

Genome-Wide Polygenic Scores for Common Diseases	08:45
Speaker: Heribert Schunkert (Germany)	
Q&A	09:05
High-Throughput Sequencing Approaches and Database Mining for Profiling the Mutational Landscape and Diagnosing Hereditary Bleeding Disorders	09:10
Speaker: Rosanna Asselta (Italy)	
Q&A	09:30
Genomics on Venous Thromboembolism	09:35
Speaker: Nicholas L. Smith (United States)	
Q&A	09:55

Scientific Programme

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 2

SOA 08, State-of-the-Art on Platelet Disorders and von Willebrand Disease

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Augusto B. Federici (Italy)

Clinical Versus Genetic Approach to the Diagnosis of Platelet Function Disorders	08:45
Speaker: Michele Lambert (United States)	
Q&A	09:05
Impact of Genotyping on VWD Diagnosis	09:10
Speaker: Jeroen Eikenboom (the Netherlands)	
Q&A	09:30
VWF Self Association Role in Hemostasis and Thrombosis	09:35
Speaker: José Aron López (United States)	
Q&A	09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 3

SOA 09, State-of-the-Art on Pediatrics

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Samantha Gouw (the Netherlands)

Risk Factors for First Stroke at Onset and Recurrence in Pediatric Patients	08:45
Speaker: Ulrike Nowak-Göttl (Germany)	
Q&A	09:05
How to Manage Children with Hemophilia: Replacement and Non-Replacement Therapy	09:10
Speaker: Guy Young (United States)	
Q&A	09:30
Immune Eradication of Anti-FVIII Inhibitor: What a Clinician Should Know in the Era of Non-Replacement Therapies	09:35
Speaker: Steven W. Pipe (United States)	
Q&A	09:55

Scientific Programme

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 4

SOA 10, State-of-the-Art on Women's Health

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Ida Martinelli (Italy)

Thrombo-Inflammatory Mechanisms at the Maternal-Fetal Interface	08:45
Speaker: Berend Isermann (Germany)	
Q&A	09:05
Obstetric Antiphospholipid Syndrome	09:10
Speaker: Lai Heng Lee (Singapore)	
Q&A	09:30
Reproductive Issues in Women on DOACs	09:35
Speaker: Jan Beyer-Westendorf (Germany)	
Q&A	09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 5

SOA 11, State-of-the-Art on Coagulation and Natural Anticoagulants

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Coen Maas (the Netherlands)

Factor X Clearance and Amyloid Disease	08:45
Speaker: Olivier D. Christophe (France)	
Q&A	09:05
Contact Activation in Alzheimer's Disease	09:10
Speaker: Sidney Strickland (United States)	
Q&A	09:30
Factor XII as a Modulator of Hemostasis and Wound Healing	09:35
Speaker: Evi X. Stavrou (United States)	
Q&A	09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 6

SOA 12, State-of-the-Art on Vascular Biology

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: Cecile Denis (France)

Scientific Programme

Endothelial Cell Transitions	08:45
Speaker: Peetra Magnusson (Sweden)	
Q&A	09:05
Cell Therapy Targeting Endothelium	09:10
Speaker: Florence Sabatier (France)	
Q&A	09:30
Sepsis: Vascular Endothelial Cell Dysfunction During Sepsis	09:35
Speaker: Steve Kerrigan (Ireland)	
Q&A	09:55

State-of-the-Art Session
08:45 - 10:00

Virtual Meeting Room 7

SOA 13, State-of-the-Art on Venous Thromboembolism

Illustrated SOA Capsules: <https://www.isth.org/page/soair>

Chair: James Douketis (Canada)

Managing DOACs in Emergencies	08:45
Speaker: Cecilia Becattini (Italy)	
Q&A	09:05
New Antithrombotics and New Interventions for VTE Beyond Anti-IIa and Anti-Xa	09:10
Speaker: Stavros Konstantinides (Germany)	
Q&A	09:30
DOACs for Unusual Site Venous Thromboembolism	09:35
Speaker: Nicoletta Riva (Malta)	
Q&A	09:55

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 1

OC 08, Diagnostics and OMICs Oral Communication Session

Chair: Mirko Pinotti (Italy)

Ultra High-throughput Screening Assay to Identify New Antiplatelet Drugs with Discriminative Mode of Receptor-dependent Action	10:15
Speaker: Delia Irene Fernández (the Netherlands)	
Features of Hematopoietic Stem and Progenitor Cells Identified through Single-Cell RNA Sequencing in Immune Thrombocytopenia	10:27
Speaker: Anli Liu (China)	

Scientific Programme

Genetic Dissection of Structural Variants in the Largest Cohort of Patients with Antithrombin Deficiency and Characterisation of the First Complex Structural Variant in SERPINC1 by Long-read Whole Genome Sequencing	10:39
Speaker: Belén de la Morena-Barrio (Spain)	
Platelet-targeted Magnetic Nanoparticles Enhance the Efficacy of Thrombolysis through Induction of Magnetic Hyperthermia	10:51
Speaker: Alan Harper (United Kingdom)	
Characterization of the Protein Profile in Thrombi of Patients with Ischemic Stroke and Identification of Potential Biomarkers as Predictors of Negative Clinical Evolution	11:03
Speaker: Chary Lopez-Pedrerá (Spain)	
Q&A	11:15

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 2

OC 09, Hemophilia and Rare Bleeding Disorders Oral Communication Session 2

Chair: Michael Makris (United Kingdom)

Maternal Microchimerism Protects Hemophilia A Patient from Inhibitor Development	10:15
Speaker: Yeling Lu (China)	
An International Multicenter Study of Bevacizumab for Bleeding in Hereditary Hemorrhagic Telangiectasia (The InHIBIT-Bleed Study)	10:27
Speaker: Hanny Al-Samkari (United States)	
An Insight into Clinical Outcomes in Mild, Moderate, and Severe Hemophilia A (HA): A Preliminary Analysis of the CHESS II Study	10:39
Speaker: Francis Nissen (Switzerland)	
First-in-Human Gene Therapy Study of AAVhu37 Capsid Vector Technology in Severe Hemophilia A: Safety and FVIII Activity Results	10:51
Speaker: Steven W. Pipe (United States)	
HAT and HAT RI: Novel Factor VIII Molecules Addressing Patients' Needs	11:03
Speaker: Peter Herbener (Germany)	
Q&A	11:15

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 3

OC 10, Venous Thromboembolism and Cardioembolism Oral Communication Session

Chair: Cecilia Becattini (Italy)

Association between Initial and Residual Pulmonary Vascular Obstruction and Venous Thromboembolism Recurrence, a Pooled Analysis	10:15
Speaker: Robin Chaux (France)	

Scientific Programme

The ALK Rearrangement is a Major Risk Factor for Venous and Arterial Thrombosis in Non-Small Cell Lung Cancer	10:27
Speaker: Hanny Al-Samkari (United States)	
Accurate and Efficient Non-Invasive Strategy for Early Identification of Chronic Thromboembolic Pulmonary Hypertension after Acute Pulmonary Embolism (InShape II Study)	10:39
Speaker: Duliëtte Boon (the Netherlands)	
High throughput Proteomic Profiling in Cancer-Associated VTE and Link to the Clinical Outcome	10:51
Speaker: Marina Panova-Noeva (Germany)	
Plasma Protein Disulfide Isomerase Levels Predict Thrombosis in Myeloproliferative Neoplasms: A Prospective Cohort Study	11:03
Speaker: Anish Sharda (United States)	
Q&A	11:15

Oral Communication Session
10:15 - 11:30

Virtual Meeting Room 4

OC 11, Women's Health Oral Communication Session

Chair: Maha Othman (Canada)

Outcome of DOAC Exposure during Pregnancy (...and the Problem of Event Reporting...)	10:15
Speaker: Jan Beyer-Westendorf (Germany)	
Comparison of Recommended Postpartum Thromboprophylaxis and of Absolute Risk Thresholds According to the RCOG, ACCP and ACOG Guidelines	10:27
Speaker: Natacha Gassmann (Switzerland)	
Planned Induction versus Spontaneous Delivery among Women Using Prophylactic Anticoagulation Therapy	10:39
Speaker: Amihai Rottenstreich (Israel)	
Evaluation of Platelets Activation and Fibrin Clotting in Post-Menopausal Women with Takotsubo Syndrome	10:51
Speaker: Patrizia Amadio (Italy)	
NETosis in Pregnancy: Role of Different Histones Subtypes	11:03
Speaker: Sylvie Bouvier (France)	
Q&A	11:15

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 1

OC 12, Pediatrics Oral Communication Session

Chair: Maria Elisa Mancuso (Italy)

Scientific Programme

Efficacy and Safety of Dabigatran Etexilate for Treatment of Venous Thromboembolism in Paediatric Patients Aged from Birth to < 2 Years - Results of the DIVERSITY Trial	11:45
Speaker: Jaqueline Halton (Canada)	
Safety and Efficacy of Anticoagulant Therapy in Pediatric Catheter-related Venous Thrombosis (EINSTEIN-Jr. CVC-VTE): A Pre-specified Substudy	11:57
Speaker: Christoph Male (Austria)	
Impact of SERPINC1 Mutation on Thrombotic Phenotype in Children with Congenital Antithrombin Deficiency - First Analysis of the International Society on Thrombosis and Hemostasis (ISTH) Pediatric AT Database and Biorepository	12:09
Speaker: Riten Kumar (United States)	
Risk Factors for Venous and Arterial Thrombosis in the Neonatal Intensive Care Unit (NICU)-A Multicenter Case Control Analysis	12:21
Speaker: Rukhmi Bhat (United States)	
Treatment of Heavy Menstrual Bleeding in a Multidisciplinary Young Women's Bleeding Clinic for Adolescents: An Institutional 2-year Experience	12:33
Speaker: Megan C Brown (United States)	
Q&A	12:45

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 2

OC 13, Platelet Disorders and von Willebrand Disease Oral Communication Session

Chair: Giancarlo Castaman (Italy)

Force-induced Unfolding of the Autoinhibitory Module Activates VWF	11:45
Speaker: Nicholas Arce (United States)	
Genetic Analyses in 391 VWD Patients: Novel VWF Gene Variations, and Important Differences in the Phenotype of Type 1 VWD Patients with- and without - a VWF Gene Mutation	11:57
Speaker: Ferdows Atiq (the Netherlands)	
Combination of New Homozygous MPIG6B and SH2B3 Variants Leads to Early Onset Myelofibrosis, Thrombocytopenia and Abnormal Platelet Function	12:09
Speaker: Marie-Christine Morel-Kopp (Australia)	
The Association between Platelet Count and Perioperative Bleeding Complication in a Cohort of Cirrhotic Patients Undergoing Surgical Excision of Hepatocellular Carcinoma	12:21
Speaker: Gianmarco Podda (Italy)	
Platelet Desialylation Affects Bleeding Tendency in Immune Thrombocytopenic Patients	12:33
Speaker: Irene Marini (Germany)	
Q&A	12:45

Scientific Programme

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 3

OC 14, Vascular Biology Oral Communication Session

Chair: Françoise Dignat-George (France)

A Novel Neutrophil Extracellular Traps (NETs) Assay Predicts DIC and Stratifies Patients with Sepsis for Anti-IL-8 Therapy	11:45
Speaker: Simon Abrams (United Kingdom)	
PAD4-Dependent Assembly of NLRP3 Inflammasome Promotes NET Formation Resulting in Venous Thrombus Progression	11:57
Speaker: Patrick Münzer (United States)	
The Proline-Rich Tyrosine Kinase Pyk2 Contributes to Venous Thrombosis	12:09
Speaker: Ilaria Canobbio (Italy)	
Induction of Innate Immune Memory in Macrophages Profoundly Enhances their Procoagulant and Antifibrinolytic Activity	12:21
Speaker: Seán McCluskey (Ireland)	
Thrombin-PAR1/2 Signaling Axis Modulates TLR3-Mediated Procoagulant, Proinflammatory, and Proadhesive Responses in Vascular Endothelial Cells	12:33
Speaker: Saravanan Subramaniam (United States)	
Q&A	12:45

Oral Communication Session
11:45 - 13:00

Virtual Meeting Room 4

Late-Breaking and COVID-19 Oral Communication Session

Chair: Flora Peyvandi (Italy)

A Novel Adeno Associated Virus (AAV) Gene Therapy (FLT180a) Achieves Normal FIX Activity Levels in Severe Hemophilia B (HB) Patients (B-AMAZE Study)	11:45
Speaker: Pratima Chowdary (United Kingdom)	
Thrombosis, Bleeding, and the Effect of Anticoagulation on Survival in Critically Ill Patients with COVID-19 in the United States	12:00
Speaker: Hanny Al-Samkari (United States)	
Incidence of Venous Thromboembolism in Patients Discharged after COVID-19 Hospitalisation	12:15
Speaker: Matthias M. Engelen (Belgium)	
Higher Incidence of Thrombotic Complications in Hospitalized Patients with SARS-COV-2 Virus versus Influenza Virus Infections	12:30
Speaker: Milou A. M. Stals (the Netherlands)	
Q&A	12:45

Scientific Programme

Plenary Session
13:15 - 13:45

Virtual Meeting Room 1

PL 04, Plenary Session

Chair: Armando D'Angelo (Italy)
Chair: Anna Falanga (Italy)

Guidance or Organ Specific Vascular Patterning
Speaker: Anne Eichmann (United States)

13:15

Scientific Programme

Tuesday, 14. July 2020

Special Session
07:30 - 08:30

Virtual Meeting Room 1

COVID19, COVID-19 and Thrombosis

Chair: Nicola Mutch (United Kingdom)

Coronavirus Mouse Models and Coagulation	07:30
Speaker: Lisa Gralinski (United States)	
The Domino Effect of Inflammation in COVID-19 Microthrombosis	07:50
Speaker: Roberta Gualtierotti (Italy)	
Thromboprophylaxis and COVID-19: The Pandemic Dilemma of Managing Patients Without Any Grade 1A Evidence	08:10
Speaker: Beverley Hunt (United Kingdom)	

Virtual Exhibition
08:00 - 14:00

Virtual Meeting Room 14

Virtual Exhibition

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 1

Bayer AG Supported Symposium

Title: New Insights for Addressing Challenges in the Management of Patients with Cancer-Associated Thrombosis This session is supported by: Bayer AG

Welcome and Introductions	08:45
Speaker: Ajay Kakkar (United Kingdom)	
Addressing Unmet Needs in Cancer-Associated Thrombosis: Insights from the CALLISTO Programme	08:50
Speaker: Alok A. Khorana (United States)	
NOACs for the Treatment of Cancer-Associated Thrombosis: Totality of Data in Perspective	09:05
Speaker: Jeffrey I. Weitz (Canada)	
Changing to Rivaroxaban for the Treatment of Cancer-Associated Thrombosis: Patient-reported Outcomes from the COSIMO Study	09:25
Speaker: Jan Beyer-Westendorf (Germany)	
Live Q&A on Cancer-Associated Thrombosis	09:45
Speaker: Jeffrey I. Weitz (Canada)	
Speaker: Ajay Kakkar (United Kingdom)	

Scientific Programme

Closing Remarks

09:55

Speaker: Ajay Kakkar (United Kingdom)

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 2

Octapharma Supported Symposium

Title: The evolution of FVIII to meet life-long patient needs: New data and future studies with Nuwiq This session is supported by: Octapharma

Welcome And Introduction

08:45

Speaker: Jan Astermark (Sweden)

Making Informed Treatment Decisions In PUPs: Insights From The NuProtect Study

08:50

Speaker: Ri Liesner (United Kingdom)

Inhibitor Management In Haemophilia A - Real-life Experience And Future Studies

09:05

Speaker: Robert F. Sidonio Jr. (United States)

Personalised Approaches To Meet The Life-long Needs Of Patients For Effective Bleed Protection

09:20

Speaker: Linda Sun (Canada)

Elucidating The Role of FVIII In Long-term Joint And Bone Health In People With Haemophilia A

09:35

Speaker: Jess Snedeker (Switzerland)

Concluding Remarks

09:50

Speaker: Jan Astermark (Sweden)

Speaker: Jess Snedeker (Switzerland)

Speaker: Robert F. Sidonio Jr. (United States)

Speaker: Linda Sun (Canada)

Speaker: Ri Liesner (United Kingdom)

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 3

Novo Nordisk Healthcare AG Supported Symposium

Title: Shaping haemophilia care through real-world data: Stepping closer to reality This session is supported by: Novo Nordisk Healthcare AG

Driving clinical care forward: The Canadian Bleeding Disorders Registry (CBDR)

Speaker: Alfonso Iorio (Canada)

Real-world insights on EHLs in haemophilia B from the CBDR

Speaker: Man-Chiu Poon (Canada)

Clinical experience of EHL FVIII in haemophilia A in Germany

Speaker: Robert Klamroth (Germany)

Scientific Programme

Digging deep: Mining trial data for a greater understanding

Speaker: Pratima Chowdary (United Kingdom)

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 4

Pfizer Supported Symposium

Title: From Science Fiction to Reality: a Journey of Evolving Scientific Innovation in Hemophilia B This session is supported by: Pfizer

Welcome and Introduction 08:45

Speaker: Giovanni Di Minno (Italy)

Back to Basics: The Importance of Continued Research Into the Science of Hemophilia B 08:50

Speaker: Stacy E Croteau (United States)

Factoring the Future: Managing the Coagulation "Balancing act" 09:05

Speaker: Andreas Tiede (Germany)

Deep space FIX: Exploring the Hidden Depths of Gene Therapy 09:20

Speaker: John Rasco (Australia)

Panel Discussion 09:40

Speaker: Giovanni Di Minno (Italy)

Speaker: Stacy E Croteau (United States)

Speaker: Andreas Tiede (Germany)

Speaker: John Rasco (Australia)

Speaker: Ian Winburn (United Kingdom)

Meeting Summary and Close

Speaker: Ian Winburn (United Kingdom)

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 5

Grifols Supported Symposium

Title: Update on immune thrombocytopenia: clinical perspectives This session is supported by: Grifols

Welcome & Introduction 08:45

Speaker: Francesco Zaja (Italy)

New insights in ITP: What new guidelines say 08:50

Speaker: Adrian C Newland (United Kingdom)

Clinical approaches to the ITP patient treatment 09:10

Speaker: Francesco Zaja (Italy)

Practical experience with Fostamatinib 09:30

Speaker: Nichola Cooper (United Kingdom)

Scientific Programme

Q&A and Closing Remarks

Speaker: Francesco Zaja (Italy)

09:50

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 6

Daiichi Sankyo Europe GmbH Supported Symposium

Title: Challenges in the Management of VTE: New Evidence in the COVID-19 Era This session is supported by: Daiichi Sankyo Europe GmbH https://www.isth.org/resource/resmgr/ISTH2020_Daiichi_Sankyo_e-in.pdf

Introduction

Speaker: Jeffrey I. Weitz (Canada)

08:45

Cancer-Associated VTE: Are NOACs the Answer?

Speaker: Marcello di Nisio (Italy)

08:50

Insights From Real World Evidence: ETNA-VTE Registry

Speaker: Ander Cohen (United Kingdom)

09:05

Translating Data Into Clinical Practice in the COVID-19 Era

Speaker: Cihan Ay (Austria)

09:20

Discussion and Q&A Session

Speaker: Jeffrey I. Weitz (Canada)

09:35

Summary and Conclusions

Speaker: Jeffrey I. Weitz (Canada)

Speaker: Marcello di Nisio (Italy)

09:55

Supported Symposium
08:45 - 10:00

Virtual Meeting Room 7

COR2ED Independent Accredited Supported Symposium

Title: Current Perspectives on the Treatment of Primary Chronic ITP in Adults This session is supported by: COR2ED. This scientific medical education symposium is hosted by COR2ED based on an independent medical educational grant from Sobi.

Welcome and Introduction

Speaker: Jerzy Windyga (Poland)

08:45

Evolution of Treatment in Chronic Primary ITP in Adults

Speaker: Pål André Holme (Norway)

08:50

Clinical Experience With TPO-RAs

Speaker: David J. Kuter (United States)

Speaker: Vickie McDonald (United Kingdom)

09:08

Current Challenges and Novel Treatment Options in ITP

Speaker: Jerzy Windyga (Poland)

Speaker: Vickie McDonald (United Kingdom)

Speaker: David J. Kuter (United States)

Speaker: Pål André Holme (Norway)

09:28

Scientific Programme

Questions and Conclusions

09:46

Speaker: Jerzy Windyga (Poland)
Speaker: Vickie McDonald (United Kingdom)
Speaker: David J. Kuter (United States)
Speaker: Pål André Holme (Norway)

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 1

F. Hoffmann-La Roche Ltd Supported Symposium

Title: The Evolution of Safety in Haemophilia A: Adapting to an Ageing Population This session is supported by: F. Hoffmann-La Roche Ltd.

Opening Video and Chair's Welcome

10:15

Speaker: Guy Young (United States)

The Future of Haemophilia A Treatment: New Therapies, New Endpoints?

10:16

Speaker: Guy Young (United States)

Interview-style panel discussion

10:26

Speaker: Guy Young (United States)
Speaker: Charles R.M Hay (United Kingdom)

The Changing Face of Haemophilia A: Adapting to an Evolving Patient Population

10:32

Speaker: Charles R.M Hay (United Kingdom)

Interview-style panel discussion

10:47

Speaker: Charles R.M Hay (United Kingdom)
Speaker: Claude Négrier (France)

The Safety Question: Challenges and Considerations

10:53

Speaker: Claude Négrier (France)

Interview-style panel discussion

11:08

Speaker: Claude Négrier (France)
Speaker: Guy Young (United States)

Closing remarks and meeting close

11:14

Speaker: Guy Young (United States)

Panel Q&A via Simulive

11:15

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 2

CSL Behring Supported Symposium

Title: New Standards of Care: Treatment Across the Spectrum of Hemophilia B This session is supported by: CSL Behring

Welcome

10:15

Speaker: Maria Elisa Mancuso (Italy)

Scientific Programme

Raising Standards, Raising Troughs	10:20
Speaker: Maria Elisa Mancuso (Italy)	
Broadening the Spectrum	10:35
Speaker: Cedric Hermans (Belgium)	
The Evidence for rIX-FP	10:50
Speaker: Michael Wang (United States)	
Beyond the Trial Data	11:05
Speaker: Johannes Oldenburg (Germany)	
Close	11:20
Speaker: Maria Elisa Mancuso (Italy)	

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 3

Octapharma Supported Symposium

Title: Managing the complexities of VWD – Clinical experiences with wilate® This session is supported by: Octapharma

Welcome and introduction	10:15
Speaker: Fernando F. Corrales-Medina (United States)	
VWD and surgery - Balancing the need for bleed management with the risk of thrombosis	10:25
Speaker: Mario von Depka (Germany)	
VWF prophylaxis in VWD - Are we protecting our patients enough?	10:40
Speaker: K. John Pasi (United Kingdom)	
Spotlight on women's issues in VWD	10:55
Speaker: Jill Johnsen (United States)	
Towards a better diagnosis of VWD	11:10
Speaker: Fernando F. Corrales-Medina (United States)	
Concluding Remarks	11:25

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 4

Springer Healthcare IME CME accredited Supported Symposium

Title: New Hopes and Opportunities for Hemophilia and other Bleeding Disorders This CME-accredited session is organized by Springer Healthcare IME. This program is made possible thanks to an independent educational grant from Novo Nordisk A/S and Pfizer.

Welcome and Introduction	10:15
Speaker: Steven W. Pipe (United States)	

Scientific Programme

How has our Current Understanding of Hemophilia Driven New Treatment Options	10:20
Speaker: Stacy E Croteau (United States)	
What are these New Treatment Options?	10:30
Speaker: David Lillicrap (Canada)	
What do we know about Anti-TFPI Inhibitors?	10:45
Speaker: Johnny Mahlangu (South Africa)	
Faculty Discussion and Audience Questions	11:15

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 5

Sobi Supported Symposium

Title: Certainty Versus Myths: Increasing Certainty Around Individual Protection Needs This session is supported by: Sobi

Holistic and Personalised Management of People With Haemophilia	10:15
Speaker: Steven W. Pipe (United States)	
New Decade, New Tools Supporting Personalised Treatment	10:25
Speaker: Carmen Escuriola-Ettingshausen (Germany)	
Personalised and Intense Protection for People With Haemophilia	10:50
Speaker: Claude Négrier (France)	
Panel Discussion	11:15
Speaker: Steven W. Pipe (United States)	
Speaker: Carmen Escuriola-Ettingshausen (Germany)	
Speaker: Claude Négrier (France)	

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 6

LFB Supported Symposium

Title: From Protection to Bypass of Factor VIII in Inherited Bleeding Disorders : Insights and Therapeutic Options This session is supported by: LFB

Bringing Novel Therapies to Manage Hemophilia A/B Patients with Inhibitors and Bleedings	10:15
Speaker: Steven W. Pipe (United States)	
Treatment Strategies in von Willebrand Disease - With or Without Factor VIII?	10:40
Speaker: Cedric Hermans (Belgium)	
Revisiting Plasmatic vs. Recombinant Human von Willebrand Factors in the Management of von Willebrand Disease	11:05
Speaker: Sophie Susen (France)	

Scientific Programme

Supported Symposium
10:15 - 11:30

Virtual Meeting Room 7

Boehringer Ingelheim Supported Symposium

Title: Building on a Decade of DOACs: Supporting Safety with Reversal This session is supported by: Boehringer Ingelheim https://docs.boehringer-ingelheim.com/ISTH_Agenda_2020.pdf

Strong Foundations: Dabigatran's Safety Profile in AF and VTE	10:15
Speaker: John Eikelboom (Canada)	
New Developments With DOACs in Pediatric Patients	10:35
Speaker: Leonardo Brandão (Canada)	
Anticoagulation Reversal: is it Needed?	10:50
Speaker: Peter Verhamme (Belgium)	
Case-based Guidance for Reversal in Practice	11:05
Speaker: Richard Whitlock (Canada)	
Panel Discussion and Audience Q&A	11:20
Speaker: Richard Whitlock (Canada)	
Speaker: Peter Verhamme (Belgium)	
Speaker: John Eikelboom (Canada)	
Speaker: Leonardo Brandão (Canada)	

Supported Symposium
11:45 - 13:00

Virtual Meeting Room 1

Roche Supported Symposium

Title: Partnering for Progress: Driving Shared Decision Making in Haemophilia A Care This session is supported by: Roche

Opening video and Chair's welcome	11:45
Speaker: Giancarlo Castaman (Italy)	
Defining a New Normal - Reflecting on Treatment Options for Haemophilia A	11:46
Speaker: Giancarlo Castaman (Italy)	
Partnering for Progress 1	11:57
Speaker: Giancarlo Castaman (Italy)	
Speaker: Rebecca Kruse-Jarres (United States)	
Redefining our Aspirations for Patients - Part 1	12:02
Speaker: Gerard Dolan (United Kingdom)	
Redefining our Aspirations for Patients - Part 2	12:12
Speaker: Gerard Dolan (United Kingdom)	
Partnering for Progress 2	12:23
Speaker: Gerard Dolan (United Kingdom)	
Speaker: Bruno Steiner (United States)	

Scientific Programme

Facilitating Holistic Haemophilia A Care	12:28
Speaker: Bruno Steiner (United States)	
Speaker: Rebecca Kruse-Jarres (United States)	
Partnering for Progress 3	12:39
Speaker: Giancarlo Castaman (Italy)	
Speaker: Rebecca Kruse-Jarres (United States)	
Speaker: Bruno Steiner (United States)	
Closing Remarks	12:45
Speaker: Giancarlo Castaman (Italy)	
Simulive questions	12:46
Speaker: Giancarlo Castaman (Italy)	
Speaker: Gerard Dolan (United Kingdom)	
Speaker: Rebecca Kruse-Jarres (United States)	
Speaker: Bruno Steiner (United States)	

Supported Symposium
11:45 - 13:00

Virtual Meeting Room 2

CSL Behring Supported Symposium

Title: Beyond Clinical Trials: Hemophilia A Care in the Real World This session is supported by: CSL Behring

Welcome	11:45
Speaker: Maria Elisa Mancuso (Italy)	
Advances in Hemophilia A Care	11:50
Speaker: Maria Elisa Mancuso (Italy)	
The Evidence for rVIII-SingleChain	12:10
Speaker: Vinod Balasa (United States)	
Use of rVIII-SingleChain in the Real World	12:30
Speaker: Martin Olivieri (Germany)	
Close	12:50
Speaker: Maria Elisa Mancuso (Italy)	

Supported Symposium
11:45 - 13:00

Virtual Meeting Room 4

Sanofi Genzyme Supported Symposium

Title: The Future of Haemophilia Treatment: Disrupting Expectations This session is supported by: Sanofi Genzyme

Welcome and Introductions	11:45
Speaker: Dan Hart (United Kingdom)	
Health Equity: An Achievable Goal	11:50
Speaker: Mark Skinner (United States)	

Scientific Programme

Factor FVIII Reimagined	12:05
Speaker: Dan Hart (United Kingdom)	
Advancing Possibilities With New Technologies	12:20
Speaker: Johnny Mahlangu (South Africa)	
Translating Innovation	12:35
Speaker: Joe Salas (United States)	
Panel Discussion	12:50
Speaker: Dan Hart (United Kingdom)	

Supported Symposium
11:45 - 13:00

Virtual Meeting Room 5

BioMarin Supported Symposium

Title: Investigational AAV Gene Therapy for Hemophilia: Considerations for Potential Clinical Practice This session is supported by: Biomarin

Welcome and Introductions	11:45
Speaker: Maria Elisa Mancuso (Italy)	
Variability and Durability of Response to AAV Gene Therapies	11:50
Speaker: Glenn F. Pierce (United States)	
Towards Clinical Practice: AAV Gene Therapy Dosing and Patient Monitoring	12:10
Speaker: Maria Elisa Mancuso (Italy)	
Q&A	12:30
Speaker: Maria Elisa Mancuso (Italy)	

Supported Symposium
11:45 - 13:00

Virtual Meeting Room 6

Grifols Supported Symposium

Title: Key questions in the new hemophilia era. Update on concomitant use of FVIII and emicizumab This session is supported by: Grifols

Welcome and introduction -The changing face of immune tolerance induction in hemophilia A with the advent of emicizumab	11:45
Speaker: Manuel Carcao (Canada)	
Concomitant Studies: What about during ITI?	12:00
Speaker: Maria Elisa Mancuso (Italy)	
Concomitant Studies: What about after ITI?	12:15
Speaker: Guy Young (United States)	
Concomitant use in the clinical real practice	12:30
Speaker: Victor Jimenez-Yuste (Spain)	

Scientific Programme

Q&A

12:40

Product Theater
13:15 - 14:00

Virtual Meeting Room 1

Bayer AG Product Theater

Title: Optimizing the Management of VTE with Rivaroxaban in Challenging Clinical Scenarios This session is supported by: Bayer AG

Rivaroxaban for the Patient with VTE and Renal Impairment: Clinical Case 13:15

Speaker: Rupert Bauersachs (Germany)

Rivaroxaban for the Patient with Cancer-Associated Thrombosis: Clinical Case 13:25

Speaker: Mari Thomas (United Kingdom)

When to Extend Anticoagulation Beyond Six Months: Clinical Case 13:40

Speaker: Philip Wells (Canada)

Product Theater
13:15 - 14:00

Virtual Meeting Room 2

Bayer AG Product Theater

Title: Optimizing Hemophilia A Treatment in the Time of COVID-19 and Beyond This session is supported by: Bayer AG

Welcome and Introduction 13:15

Speaker: Snejana Krassova (Switzerland)

COVID-19: Impact on Hemophilia Treatment 13:20

Speaker: Cedric Hermans (Belgium)

Optimizing hemophilia A treatment: Individualized prophylaxis with BAY 94-9027 and the importance of a favorable PK profile 13:35

Speaker: Mark Reding (United States)

Q+A 13:50

Product Theater
13:15 - 14:00

Virtual Meeting Room 3

CSL Behring Product Theater

Title: Advancing Standards of Care in VWD: Challenges, Diagnosis and Treatment This session is supported by: CSL Behring

Welcome 13:15

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Diagnosis and Disease Awareness 13:20

Speaker: Karen van Galen (the Netherlands)

Scientific Programme

Factor Concentrates: Matching Phenotype to Treatment Decisions **13:35**

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Q&A and Close **13:50**

Speaker: Carmen Escuriola-Ettingshausen (Germany)

Product Theater

13:15 - 14:00

Virtual Meeting Room 4

Sobi and Sanofi Genzyme Product Theater

Title: Empowering People With Haemophilia A Throughout Their Life This session is supported by: Sobi and Sanofi Genzyme

Introduction

Speaker: Elena Santagostino (Italy)

One Size Doesn't Fit All in Haemophilia A **13:15**

Speaker: Elena Santagostino (Italy)

Achieve Intense Protection With Personalisation... From Childhood to Adulthood **13:25**

Speaker: Christoph Königs (Germany)

Achieve Intense Protection With Personalisation... To Manage Surgery **13:40**

Speaker: Luigi Piero Solimeno (Italy)

Q&A and Conclusions **13:50**

Speaker: Elena Santagostino (Italy)

Speaker: Luigi Piero Solimeno (Italy)

Speaker: Christoph Königs (Germany)

Product Theater

13:15 - 14:00

Virtual Meeting Room 5

Sobi and Sanofi Genzyme Product Theater

Title: Overcoming Uncertainty in Managing Haemophilia B This session is supported by: Sobi and Sanofi Genzyme

What Makes Haemophilia B Different? **13:15**

Speaker: Giancarlo Castaman (Italy)

Extravascular Distribution of FIX: Scientific Perspective **13:20**

Speaker: Joe Salas (United States)

Treatment Goals in Haemophilia B: Real World Experience **13:35**

Speaker: K. John Pasi (United Kingdom)

Q&A and Conclusions **13:50**

Speaker: Giancarlo Castaman (Italy)

Speaker: Joe Salas (United States)

Speaker: K. John Pasi (United Kingdom)

Scientific Programme

Product Theater
13:15 - 14:00

Virtual Meeting Room 6

Instrumentation Laboratory Product Theater

Title: COVID-19 Conundrums: Coagulopathy and Critical Care Implications for ROTEM(R) Testing This session is supported by: Instrumentation Laboratory

Introduction	13:15
Speaker: Annie Winkler (United States)	
COVID-19 Conundrums: Coagulopathy and Critical Care Implications for ROTEM(R) Testing	13:20
Speaker: Daniel Katz (United States)	
Q&A	13:50
Speaker: Annie Winkler (United States)	

Product Theater
13:15 - 14:00

Virtual Meeting Room 7

Technoclone GmbH Product Theater

Title: Ceveron s100 – a Solution for Challenging Times in Haemostasis! This session is supported by: Technoclone Herstellung von Diagnostika und Arzneimitteln GmbH

Welcome and Introduction	13:15
Speaker: Nikolaus B. Binder (Austria)	
Ceveron s100 - the analyzer	13:20
Speaker: Marco Wolf (Austria)	
TECHNOFLUOR ADAMTS13 Activity A Rapid Quantitative FRET ADAMTS13 Activity Assay	13:30
Speaker: Gary Moore (Austria)	
TECHNOFLUOR FXIII Activity - Fast, Accurate and Precise	13:40
Speaker: Gary Moore (Austria)	
Single Platform Monitoring of Concentrates, EHLs and Non-Replacement Haemophilia Therapies with Clotting, Chromogenic and Thrombin Generation Assays	13:50
Speaker: Gary Moore (Austria)	

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 1

On-Demand Takeda Pharmaceutical Company Limited Supported Symposium

Title: Fit for Purpose: Personalized Prophylaxis for Joint Health and Beyond This session is supported by: Takeda Pharmaceutical Company Limited

Opening Remarks	14:15
Speaker: Giovanni Di Minno (Italy)	

Scientific Programme

Personalized Prophylaxis – Preserving Joint Health and Beyond	14:20
Speaker: Giovanni Di Minno (Italy)	
Trends in Physical Activity and QOL for Patients with Haemophilia	14:35
Speaker: Angela Forsythe (United States)	
Analysis of Ideal Factor Levels for Participation in Physical Activity	14:50
Speaker: Leonard A. Valentino (United States)	
The Application of Personalized Care in Haemophilia: Today and in the Future	15:05
Speaker: Peter L Turecek (Austria)	
Panel Discussion	15:20

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 2

On-Demand Takeda Supported Symposium

Title: Protein C Deficiencies and Their Impact in Critical Care This session is supported by: Takeda

Introduction	14:15
Speaker: Leonardo Brandão (Canada)	
Developmental Haemostasis: A Focus on Protein C	14:20
Speaker: Vera Ignjatovic (Australia)	
Q&A	14:35
Congenital vs Acquired Protein C Deficiencies: Commonalities and Differences	14:40
Speaker: Paul Knoebl (Austria)	
Q&A	14:55
Current Standard of Care for Protein C Deficiencies	15:00
Speaker: Leonardo Brandão (Canada)	
Q&A	15:15

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 3

On-Demand Haemonetics S.A Supported Symposium

Title: COVID-19 patients and viscoelastic testing: what we know so far? This session is supported by: Haemonetics S.A

COVID-19 patients and viscoelastic testing: what we know so far?	14:15
Speaker: Hunter Moore (United States)	

Scientific Programme

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 4

On-Demand Novo Nordisk Healthcare AG Supported Symposium

Title: Spotlight on Women with Rare Bleeding Disorders This session is supported by: Novo Nordisk Healthcare AG

Welcome and Introduction	14:15
Speaker: Ahmad Tarawah (Saudi Arabia)	
FVII deficiency in women: Pregnancy management and outcome	14:20
Speaker: Rezan Abdul-Kadir (United Kingdom)	
Management of female patients with Glanzmann's Thrombasthenia: clinical case and expert recommendations from gulf cooperation council countries	14:40
Speaker: Ahmad Tarawah (Saudi Arabia)	
Pregnancy-related Acquired Hemophilia - remaining alert for rare events	15:00
Speaker: Dan Hart (United Kingdom)	
Panel Discussion	15:20

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 5

On-Demand Sanofi Supported Symposium

Title: State of the art and science in prevention of VTE in medical patients This session is supported by: Sanofi

Welcome & Introduction	14:15
Speaker: Ajay Kakkar (United Kingdom)	
Thromboprophylaxis in acute medically illness: news and controversies	14:20
Speaker: Grégoire Le Gal (Canada)	
Risk-stratified thromboprophylaxis in special patient groups	14:40
Speaker: Ismail Elalamy (France)	
Thrombosis management in critical ill patients: learning from COVID-19 pandemic	14:55
Speaker: Ana Rocha (Brazil)	
Panel discussion	15:10
Conclusion and take-home message	15:25
Speaker: Ajay Kakkar (United Kingdom)	

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 6

On-Demand uniQure Supported Symposium

Title: The Immune System and AAV Gene Therapy: What Every Clinician Should Know This session is supported by: uniQure

Scientific Programme

Chair's Introduction	14:15
Speaker: Annette von Drygalski (United States)	
Reviewing the Immune Response to AAV Gene Therapy	14:20
Speaker: Valder R. Arruda (United States)	
Liver-Directed AAV Gene Therapy: Lessons from a Hepatologist	14:40
Speaker: Graham Foster (United Kingdom)	
A Physician's Perspective on the Immunological Response from Haemophilia Clinical Trials: A Pragmatic Approach	15:00
Speaker: Dan Hart (United Kingdom)	
Close	15:15
Speaker: Annette von Drygalski (United States)	

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 7

On-Demand Kedrion Biopharma Supported Symposium

Title: Optimizing Patient Care in Hemophilia A: A Critical Appraisal This session is supported by: Kedrion Biopharma

Welcome and Introduction	14:15
Speaker: Pier Mannuccio Mannucci (Italy)	
Inhibitor Patients and Inhibitor Eradication	14:20
Speaker: Jerzy Windyga (Poland)	
Speaker: Guy Young (United States)	
Prevention of Bleeds, Joints Protection, Personalization of Treatment	14:40
Speaker: Jerzy Windyga (Poland)	
Speaker: Guy Young (United States)	
Safety Considerations about Replacement and non-Replacement Factors	15:00
Speaker: Jerzy Windyga (Poland)	
Speaker: Guy Young (United States)	
Speaker: Michael Makris (United Kingdom)	
Wrap up and conclusions	15:20
Speaker: Pier Mannuccio Mannucci (Italy)	

Supported Symposium On-Demand
14:15 - 15:30

Virtual Meeting Room 8

On-Demand Takeda Supported Symposium

Title: VWD and TTP in Women: Taking a Patient-centered Approach to Care This session is supported by: Takeda:

Opening Remarks	14:15
Speaker: Michael Laffan (United Kingdom)	
The Science of ADAMTS13 and VWF in Women	14:16
Speaker: Michael Laffan (United Kingdom)	

Scientific Programme

cTTP in Women: Short-and Long-term Complications in Pregnancy and Throughout Reproductive Life	14:21
Speaker: Marie Scully (United Kingdom)	
Panel Discussion - Addressing Women-specific Issues in TTP	14:31
Advances in Care for Heavy Menstrual Bleeding and Pregnancy in VWD	14:46
Speaker: Eugenia Biguzzi (Italy)	
Panel Discussion - Addressing Women-specific Issues in VWD	14:56

Product Theater On-Demand
14:15 - 15:00

Virtual Meeting Room 9

On-Demand CSL Behring Product Theater

Title: Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation This session is supported by: CSL Behring

Urgent Warfarin Reversal for Fast and Sustained Action: A Case-Based Presentation	14:15
Speaker: Ayreh Shander (United States)	

Product Theater On-Demand
14:15 - 15:00

Virtual Meeting Room 10

On-Demand Takeda Product Theater

Title: The Management of Severe Congenital Protein C Deficiency This session is supported by: Takeda

Management of Patients with SCPCD in Turkey	14:15
Speaker: Selin Aytac (Turkey)	
Practical Aspects of Therapy with Protein C Concentrate	14:30
Speaker: Adrian Minford (United Kingdom)	
Q&A and Discussion	14:45

Product Theater On-Demand
14:15 - 15:00

Virtual Meeting Room 11

On-Demand Sysmex Product Theater

Title: Nearing 360° in Haemostasis Testing: Latest Developments From Sysmex This session is supported by: Sysmex www.sysmex-europe.com/cn In case of any questions about the session, please contact: segcoagsupport@sysmex-europe.com

Opening	14:15
Speaker: Ian Mackie (United Kingdom)	

Scientific Programme

Performance Evaluation of CN-6000 a New Automated Haemostasis Analyser. First-Hand Experience From a Haemostasis Lab.	14:17
Speaker: Steve Kitchen (United Kingdom)	
Introduction to the next talk	14:37
Speaker: Ian Mackie (United Kingdom)	
CN-Series Haemostasis Analysers Including an Integrated Chemiluminescent Enzyme Immunoassay Testing Capability.	14:38
Speaker: Chris Gardiner (United Kingdom)	
Closing	14:53
Speaker: Ian Mackie (United Kingdom)	

Product Theater On-Demand
14:15 - 15:00

Virtual Meeting Room 12

On-Demand HYPHEN BioMed Product Theater

Title: Laboratory Updates on Specialized Hemostasis Testing This session is supported by: HYPHEN BioMed

A FVIII Chromogenic Assay System for Measuring EMICIZUMAB and Titrating FVIII Inhibitors in Plasma	14:15
Speaker: Jean Amiral (France)	
Measurement of Edoxaban and its Metabolites with Anti-FXa Assays Comparatively to LC:MS/MS	14:30
Speaker: Claire Dunois (France)	
Optimized LA Clotting Assays Presenting Low Interference with DOACs	14:45
Speaker: Marie Peyrafitte (France)	

Product Theater On-Demand
14:15 - 15:00

Virtual Meeting Room 13

On-Demand Instrumentation Laboratory Product Theater

Title: COVID-19 & Hemostasis: Laboratory and Clinical updates This session is supported by: Instrumentation Laboratory

Introduction of Armando Tripodi	14:15
Speaker: Annie Winkler (United States)	
COVID-19 & Hemostasis: Laboratory and Clinical updates	14:17
Speaker: Armando Tripodi (Italy)	
Introduction of Benilde Cosmi	14:37
Speaker: Annie Winkler (United States)	
COVID-19 & Hemostasis: Laboratory and Clinical updates	14:39
Speaker: Benilde Cosmi (Italy)	
Closing	14:59
Speaker: Annie Winkler (United States)	